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Abstract 
 
Introduction  
Women with diabetes are at increased risk of adverse maternal and fetal outcomes. 
Preconception care can minimise risk of complications and improve outcomes, but current 
provision is inadequate. Mobile technology, particularly smartphone apps, could improve 
preconception care provision but research is lacking in this area.  
Aim  
The study aimed to critically appraise the literature with respect to PCC educational 
interventions and highlight limitations of current interventions, and to develop a 
Preconception and Diabetes Information (PADI) app for women with type 1 or 2 diabetes 
and explore the system’s feasibility and acceptability. 
Methods 
 
A systematic review of the literature and a 2-phase mixed methods study design, (1) 
development and (2) feasibility and acceptability, were used. The app was developed via a 
co-design approach with women with diabetes, healthcare professionals and an app 
development company. A 3-month pre- and post-intervention study assessed preliminary 
outcome estimates (preconception care knowledge, attitudes and behaviours), user 
acceptability was also explored. Data collection methods included focus groups, semi-
structured interviews and questionnaires.   
 
Results  
 
The systematic review showed that PCC educational interventions had a positive effect on 
patient and behavioural outcomes, however, PCC uptake was low and the use of eHealth for 
PCC of women with DM was still in its infancy. The 2-phase mixed methods study design 
indicated a high level of enthusiasm and interest towards a preconception care app that 
could overcome shortfalls in current preconception care service provision. Improvements 
were recorded in knowledge of pregnancy planning and pregnancy-related risks, perceived 
benefits and self-efficacy to seek preconception care, and patient activation measure, 
following the 3-month app usage. Participants found the PADI app acceptable (satisfaction 
rating was 72%), useful and informative. Usage was episodic and influenced by functionality 
(manual data input) and personal factors (pregnancy intention, time/memory and conflicting 
priorities) that participants felt could be overcome via personalisation, automation, improved 
interactivity and daily reminders.  
 
Conclusion  
 
This is the first study to explore the acceptability and feasibility of a preconception care app 
for women with diabetes. It has positive implications in terms of overcoming barriers to 
preconception care provision and uptake, and changing preconception behaviours. In order 
that the contribution of the PADI app can be fully realised, further evaluation is required.  
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1. Chapter 1: Introduction 
 
1.1 Diabetes Mellitus 
1.1.1 Epidemiology 
Diabetes mellitus (DM) is a global public health challenge and one of the most prevalent 
chronic diseases occurring in Western and developing countries (Shaw et al., 2010; 
International Diabetes Federation [IDF], 2017). DM results in high healthcare expenditure, 
costing the National Health Service (NHS) £10 billion pounds every year, due to the 
increased use of health services, higher hospitalisation rates, medication, emergency and 
continuing care (Zhang et al., 2010; Hex et al., 2012). Recent global estimates show that 
425 million people have DM, and this figure is projected to rise to 629 million people by 2045 
(IDF, 2017). The prevalence of DM in women has also risen dramatically. Recent figures 
(IDF, 2017) indicate that 204 million women have DM compared to 199.5 million in 2015. As 
a result of the increased prevalence of DM amongst women of childbearing age, the number 
of high-risk pregnancies (that is, pregnancies that place both mother and baby at increased 
risk of developing complications) will also increase. DM is thus increasingly becoming a 
major issue in the field of women’s health (Wahabi et al., 2010). 
 
1.1.2 Aetiology and diagnosis 
DM is caused by a deficiency in insulin secretion or resistance to the actions of insulin (IDF, 
2017). Abnormalities in carbohydrate, fat and protein metabolism subsequently occur as a 
result of the deficient action of insulin (American Diabetes Association [ADA], 2010). DM is 
diagnosed when a patient has a fasting blood glucose level greater than 7.0mmol/l and a 
two-hour post-prandial glucose level greater than 11.1mmol/l (World Health Organization 
[WHO], 2006). DM is also measured using the glycated haemoglobin (HbA1c), a laboratory 
test which reflects the degree of control of blood glucose over the preceding 2-3 months 
(National Institute for Health and Care Excellence [NICE], 2015). A diagnosis of DM is made 
if the HbA1c level is ≥ 6.5% or 48 mmol/mol (WHO, 2011a). DM is a progressive disease 
associated with macrovascular (e.g. coronary heart disease and stroke) and microvascular 
(e.g. nephropathy, retinopathy and neuropathy) complications, which can lead to premature 
death if not managed properly (Diabetes UK [DUK], 2012; IDF, 2017). DM is best managed 
through diet, exercise, oral medication and insulin injection or pump therapy (ADA, 2010; 
IDF, 2017). 
 
1.1.3 Classification 
DM is mainly classified into two types, Type 1 and Type 2 (WHO, 1999; ADA, 2010). Type 1 
(T1DM) is caused by the auto-immune destruction of the pancreatic β-cells of the islets of 
13 
 
Langerhans and results in an absolute deficiency of insulin (ADA, 2010). Although T1DM 
may occur at any age, it is more common in childhood or adolescence, and accounts for 
about 5-10% of the total number of people with DM (ADA, 2010). In contrast, type 2 (T2DM) 
occurs when the amount of insulin produced by the pancreatic β-cells is insufficient or if the 
body develops resistance to the insulin produced (ADA, 2010; IDF, 2017). This is the more 
common form, affecting about 90-95% of the people with DM (ADA, 2010). Although 
formerly more prevalent in adults, it is now occurring in children and young adults due to the 
rise in obesity, physical inactivity and poor diet (ADA, 2010; Gourdy, 2013; Egan, Murphy 
and Dune, 2015). The risk of developing T2DM increases with age; the risk of developing 
this disease is six times greater among people from black and Asian minority ethnic groups 
(Gourdy, 2013; IDF, 2017). A third type, gestational DM, which occurs or is first diagnosed 
during pregnancy, is caused by glucose intolerance and affects about 7% of pregnancies 
(ADA, 2010). It resolves after delivery but women and their babies are at risk of developing 
T2DM in the future (IDF, 2017).  
 
1.1.4 Diabetes and pregnancy 
DM during pregnancy is of major concern because pre-existent microvascular and 
macrovascular complications can exacerbate as a result of pregnancy, increasing the risk of 
adverse outcomes for both mother and baby (NICE, 2015). Women with DM are at 
increased risk of miscarriage, pre-eclampsia, preterm delivery and maternal death, with the 
risk of perinatal mortality and congenital malformation being five and two times greater than 
that of the general population, respectively (Confidential Enquiry into Maternal and Child 
Health [CEMACH], 2005; Macintosh et al., 2006; McCance, 2011; Knight et al., 2014). The 
risk of congenital malformation and perinatal mortality in women with T2DM is comparable 
and sometimes higher than in women with T1DM (CEMACH, 2007; Temple and Murphy, 
2010; Singh et al., 2013). However, women with T2DM are less likely to plan their 
pregnancies, receive preconception care (PCC), take the recommended 5mg of folic acid or 
attend pre-pregnancy clinics and more likely to be taking teratogens (potentially harmful 
medication to the fetus) at conception (CEMACH, 2007; Murphy, Temple and Ball, 2010; 
NHS Digital, 2016). PCC, which significantly reduces diabetes-related complications during 
pregnancy, is therefore vital for women with DM given the severity of the complications and 
adverse outcomes.  
 
1.2 Preconception care 
Preconception care (PCC) is defined by Bhutta et al. (2011) as any intervention that is 
provided to women (and couples) of reproductive age before pregnancy, regardless of 
14 
 
pregnancy status or desire, to improve the health outcomes of women and their newborn. 
Temple (2010) highlights two distinct components of preconception care: 
1. Preconception counselling, which entails discussion and education. 
2. Preconception care, which entails planning a pregnancy in partnership with healthcare 
professionals.  
 
1.2.1 Preconception counselling and preconception care 
1. Preconception counselling 
This is defined by Temple (2010) as the education of, and discussion with, women of 
reproductive age about pregnancy and contraception. Preconception counselling should be 
an essential element of every consultation in primary and secondary care (outpatients visit), 
and should be provided to women from adolescence (ADA, 2010; NICE, 2015). Temple 
(2010) highlights that it is the responsibility of all healthcare professionals to provide 
preconception counselling, and this ‘discussion’ should include future plans for pregnancy, 
benefits of PCC and how it can improve pregnancy outcomes, as well as contact details of 
the PCC team and how women can access PCC. Women should be advised of the need to 
take folic acid supplements before pregnancy, avoid potentially teratogenic medications such 
as statins and angiotensin-converting enzyme (ACE) inhibitors and use reliable 
contraception until blood glucose levels have been optimised. They should also be informed 
that poor glycaemic control increases the risk of adverse pregnancy outcomes.   
 
2. Preconception care (PCC) 
Temple (2010) asserts that PCC is the additional care needed to prepare women with DM 
for pregnancy, and involves a close partnership between the woman and her diabetes team. 
According to Temple (2010), PCC should ideally begin 6-12 months before conception in a 
woman with DM, however, the time required depends on a number of factors including 
glycaemic control and the presence of complications. PCC includes optimising glucose 
control, prescribing high dose folic acid supplements, reviewing medications to ensure that 
women avoid potentially teratogenic medications and discussing maternal and fetal risks.  
 
1.2.2 PCC and diabetes mellitus 
The benefits of PCC have been well established, hence, national and international 
guidelines are consistent in recommending PCC as the strategy for improving pregnancy 
outcomes in women with DM (Mahmud and Mazza, 2010; Temple, 2011). The endorsed 
PCC components for women with DM include: improving awareness of the risks associated 
with DM and pregnancy, optimising glucose monitoring and blood glucose levels, taking 5mg 
of folic acid one month before and up to twelve weeks into pregnancy, using contraception in 
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order to avoid unplanned pregnancy, stopping teratogenic medications e.g. angiotensin 
converting enzyme (ACE) inhibitors and statins, screening for complications of DM, receiving 
rubella vaccination, maintaining healthy weight and modifying lifestyle (diet, exercise, 
smoking and alcohol cessation) (Scottish Intercollegiate Guidelines Network [SIGN], 2010; 
Canadian Diabetes Association [CDA], 2013; NICE, 2015; ADA, 2017). Table 1.1 details 
NICE guidance in relation to components of PCC for women with DM.  
 
Table 1.1: Components of PCC for women with diabetes mellitus  
Components of PCC Information discussed 
Contraception and planning 
for pregnancy 
 Highlight importance of avoiding unplanned pregnancy from adolescence for 
women with DM. 
 Advise that risks associated with pregnancy in women with DM increase with 
duration of DM. 
 Blood glucose targets, glucose monitoring, medicines for treating DM and 
medicines for complications of DM will need to be reviewed before and during 
pregnancy. 
 Explain extra time and effort is needed to manage DM during pregnancy and that 
she will have frequent contact with HCPs. 
 
Information and advice  Establishing good glucose control before conception and continuing throughout 
pregnancy reduces risk of miscarriage, congenital malformation, stillbirth and 
neonatal death. 
 Information about how DM affects pregnancy and how pregnancy affects DM. 
 Individualised dietary advice. 
 Offer those who have a BMI above 27 kg/m2 advice on how to lose weight. 
 Take folic acid (5mg/day) until 12 weeks gestation. 
 
Monitoring blood glucose, 
HbA1c and ketones 
 Monthly measurement of HbA1c level. 
 Offer blood ketone testing strips and a meter for self-monitoring of blood glucose. 
 Agree individualised targets for self-monitoring of blood glucose. 
 a fasting plasma glucose level of 5-7 mmol/l on waking and 
 a plasma glucose level of 4-7 mmol/l before meals at other times of the day. 
 Advise to keep their HbA1c level below 48 mmol/mol (6.5%), if this is achievable 
without causing problematic hypoglycaemia. 
 Advise those whose HbA1c level is above 86 mmol/mol (10%) not to get 
pregnant.  
 
Reviewing safety of current 
medication 
 Advise to use metformin as an adjunct or alternative to insulin when the likely 
benefits outweigh the potential for harm. 
 Use isophane insulin as the first choice for long-acting insulin. 
 Angiotensin-converting enzyme inhibitors and angiotensin-II receptor antagonists 
should be discontinued. 
 Statins should be discontinued.  
 
Retinal and renal assessment  Offer retinal assessment at first appointment (unless retinal assessment in the 
last 6 months). 
 Advice to defer rapid optimisation of blood glucose control until after retinal 
assessment and treatment completed. 
 Offer renal assessment before discontinuing contraception, if serum creatinine, 
albumin creatinine ratio or estimated glomerular filtration rate (eGFR) is 
abnormal, referral to a nephrologist should be considered.  
 
Adapted from preconception care for women with DM (NICE, 2015) 
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1.2.3 Benefits of PCC and pregnancy planning 
PCC offers the earliest opportunity to reduce risks of complications and adverse outcomes, 
ensuring women enter pregnancy in the best possible health and have the greatest chance 
of giving birth to a healthy baby. There is substantial evidence that PCC is associated with 
improved glycaemic control in early pregnancy and reduction in major congenital 
malformations (Temple, 2011). In a meta-analysis (Wahabi et al., 2010) of 11 cohort studies, 
PCC was associated with a lower risk of congenital malformations [(relative risk; RR: 0.25; 
95% confidence interval; CI: 0.15-0.42)], pre-term delivery (RR, 0.70; 95% CI: 0.55-0.90) 
and perinatal mortality (RR; 0.35; CI: 0.15-0.82). In addition, PCC was found to reduce first 
trimester HbA1c by an average of 2.43% (95% CI: 2.27-2.58). Inadequate PCC and 
pregnancy planning among women with DM can have severe consequences. For example, 
according to the mothers and babies: reducing risks through audits and confidential 
enquiries across the UK (MBRRACE-UK) report (Knight et al., 2014), the four women with 
pre-gestational DM who died had poorly controlled blood glucose levels before and during 
pregnancy; highlighting the importance of PCC advice and optimising glycaemic control. 
 
The babies of women with T1DM and T2DM have an increased risk of developing adverse 
outcomes because high blood glucose levels (hyperglycaemia) in the peri-conception period, 
i.e. the time preceding, including and immediately after conception, exerts a teratogenic 
effect on the fetus (Macintosh et al., 2006; Corrigan et al., 2009; Wahabi et al., 2010). The 
relationship between high blood glucose level and poor pregnancy outcomes have been 
confirmed by several studies. For example, a meta-analysis (Inkster et al., 2006) of 13 
studies involving women with T1DM and T2DM reported a 3-fold increase in malformations, 
spontaneous abortions and perinatal death in pregnancies of women with poor glycaemic 
control. In addition, Bell et al. (2012) found a linear increase in risk of congenital anomaly 
with increase in HbA1c above 6.3% (45 mmol/mol) and for each 1% (11 mmol/mol) increase 
in HbA1c, the risk of a pregnancy being affected by a congenital anomaly increased by 
nearly 30%. Figure 1.1 below shows the association between peri-conceptional HbA1c and 
the risk of congenital malformations.  
 
Glycaemic control is one of the main components of PCC for women with DM; NICE (2015) 
specifically advises women to plan their pregnancy, aim for a target HbA1c of 6.5% 
(48mmol/mol) and avoid pregnancy if HbA1c is greater than 10% (Table 1.1). Optimum 
blood glucose control before conception and during pregnancy can reduce the occurrence of 
miscarriage, fetal malformations and mortality (Wahabi et al., 2010; Temple, 2011; Knight et 
al., 2014). The meta-analysis by Inkster et al. (2006) recorded a reduced risk of congenital 
malformations for every one percent reduction in HbA1c. A second meta-analysis (Guerin et 
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al., 2007), showed a step-wise reduction in the risk of malformations with improved HbA1c, 
i.e., a 12% risk of malformation was recorded for a HbA1c of 12%, 6% risk for a HbA1c of 
9% and three percent risk for a HbA1c of 6%. However, despite the benefits of improved 
glycaemic control, Ludvigsson et al. (2018) found that the rate of malformation in women 
with optimum HbA1c was still twice that of the general population; highlighting that other 
aspects of PCC are equally important for improving maternal and fetal outcomes. 
 
 
Fig 1.1 Association between peri-conception HbA1c in women with pre-existing DM 
and the risk of a pregnancy affected by major congenital anomaly.  
 
CEMACH (2007) found an association between adverse pregnancy outcome and unplanned 
pregnancy (odds ratio [OR] = 1.8) and no contraceptive use in the 12 months prior to 
pregnancy (OR = 2.3). Women with DM are thus advised to plan their pregnancy and use 
effective contraception until their HbA1c is stable at recommended levels (CEMACH, 2007; 
NICE, 2015). CEMACH (2005) defines planned pregnancies as pregnancy which was 
desired before conception, for which contraception was stopped, and the woman attempted 
to achieve optimal blood glucose before conception. All other pregnancies are regarded as 
unplanned. In a qualitative study of 29 women with DM, Murphy et al. (2010a) found that 
70% of women were not using reliable contraception prior to conception, and none of the 
women in the study, including those who experienced an adverse outcome, specifically 
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considered the implications of an unplanned pregnancy. Evidence shows that many 
unplanned pregnancies occur from failure to use contraception or use it properly, and 
unplanned pregnancy combined with uncontrolled DM at conception contributes to the high 
burden of maternal and fetal mortality and morbidity (Negrato et al., 2012; McCance, 2011; 
NICE, 2015).  
 
Safe and effective contraception is important to minimise complications and adverse 
outcomes for all women with DM. There are 15 different methods of contraception for 
women with DM to choose from: combined hormonal contraception (combined oral 
contraceptive pill, patch and vaginal ring), progestogen-only methods (pills, injection and 
implants), intrauterine devices (copper IUD and levonorgestrel-releasing intrauterine system 
IUD), sterilisation (female and male), barrier methods (male and female condom, diaphragm 
and vaginal ring), natural family planning (cervical mucus assessment method and devices 
for measuring hormones) and emergency contraception (oral-progestogen only pills and 
copper IUD) (UK MEC, 2009; FPA, 2010). The IUD may be particularly suited to women not 
planning a pregnancy in the next one year, while for women without vascular disease, the 
combined hormonal contraception is considered safe. Women who have longstanding DM, 
hypertension, microvascular or cardiovascular complications, who smoke, have a BMI of ≥ 
35Kg/m2 should avoid estrogen-containing contraception as the progestogen only methods 
may be more suitable (Gourdy, 2013). 
 
NICE (2015) recommends that women receive PCC education incorporating contraception 
use to prevent unplanned pregnancies, from adolescence. The choice of contraception 
needs to be based on women’s own preferences and any risk factors such as nephropathy, 
neuropathy or retinopathy (Gourdy, 2013; WHO Medical Eligibility Criteria, MEC, 2015). 
Choosing a safe and reliable contraception for a woman with DM requires careful 
consideration and the chosen method must not induce risks such as thromboembolic and 
cardiovascular complications (UK MEC, 2009). Thus, HCPs need to refer to the WHO MEC 
for Contraceptive Use (WHO MEC, 2015). It is recommended that women planning a 
pregnancy start taking folic acid 3 months before stopping contraception (Blumer et al., 
2013).  
 
Folate deficiency has been identified as a risk factor for abruption placentae, pre-eclampsia, 
spontaneous abortion and stillbirth (Scientific Advisory Committee on Nutrition, SACN, 2009; 
Gaskins et al., 2014). Three cohort studies (Hasan et al., 2009; Byrne, 2011; Gaskins et al., 
2014) found that folic acid intake during pregnancy may be associated with a reduction of 
20-60% in the risk of miscarriage or spontaneous abortion in the general population. 
19 
 
Additionally, the intake of folic acid one month before pregnancy was found to reduce the 
risk of neural tube defects (NTDs) by 72% in the general population (De-Regil et al., 2010).  
 
Compared to women in the general population, women with DM have a higher risk of having 
babies with NTDs such as spina bifida and anencephaly (King, 2011), hence, it is 
recommended that all women with DM should be prescribed a higher dose of folic acid 
(NICE, 2015). NICE (2017) distinguishes between the folic acid dosage for non-diabetic 
women and those with DM planning a pregnancy, and recommends that the former consume 
0.4 mg of folic acid daily, while women with DM consume a higher dose of 5mg daily until the 
twelfth week of pregnancy to prevent NTDs. Roland et al. (2005), in a study of 535 women 
with T1DM and T2DM, confirmed that folic acid was associated with a significant reduction in 
the risk of malformations (odds ratio, (OR): 0.3; 95% CI: 0.09-1.0; P = 0.04).  
 
Other PCC requirements that contribute to improving pregnancy outcomes include: a review 
of women’s medication, rubella vaccination, screening for complications, smoking and 
alcohol cessation and weight management. Medication review is important because there 
are increasing numbers of women of reproductive age with DM using statins and ACE 
inhibitors (which can cause fetal abnormalities and impair the renal function of the fetus) to 
reduce risk of cardiovascular and renal complications e.g. hypertension, kidney disease and 
nephropathy (Temple, 2011). These medications should be stopped and replaced with safer 
alternatives before conception. Women should also be advised to avoid illicit drugs and over-
the-counter medication as these can adversely affect the fetus (Seshadri et al., 2012).   
 
Rubella vaccination should be arranged if the woman is not immune, to prevent congenital 
rubella syndrome (CRS) (Mason et al., 2014). Smoking cessation reduces the occurrence of 
low birth weight (LBW), congenital malformations, miscarriage, preterm delivery and stillbirth 
while alcohol cessation reduces the incidence of fetal alcohol syndrome (FAS) (Seshadri et 
al., 2012). Women should be screened for diabetic complications, including retinopathy and 
nephropathy, which can deteriorate during pregnancy; evidence suggest an association 
between nephropathy and fetal malformations, pre-eclampsia and pre-term delivery (Bell et 
al., 2012; Ringholm et al., 2012). Women with severe diabetic retinopathy are advised to 
postpone conception until treated and stable for at least 6 months. Satisfactory blood 
pressure is important (<130/80 mmHG), and thyroid function status should be assessed and 
managed prior to conception as hypothyroidism may reduce fertility, increase the risk of 
miscarriage and affect fetal brain development (Blumer et al., 2013).  
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Obesity is associated with an increased risk of adverse outcomes and attaining a healthy 
weight (body mass index, BMI 18.5 to 24.9 kg/m2) reduces the risk of birth defects, 
miscarriage, perinatal and maternal morbidity and mortality (Gardiner et al., 2008; 
Papachatzi et al., 2013). NICE (2015) also advises that women with a BMI over 27 kg/m2 
should be supported to reduce their weight. PCC targets all the factors of poor pregnancy 
outcomes, hence, in order to reduce complications and adverse outcomes, it is vital that 
women with DM receive PCC education (preconception counselling) and understand the 
need for pregnancy planning. 
 
1.2.4 Limitations of current PCC service provision 
A recent National Pregnancy in Diabetes (NIPD) audit (NHS Digital, 2016) reported 
significant variations between services in meeting the NICE guideline recommendations for 
pregnancy planning. Only 8% of women achieved HbA1c ≤ 6.5% (48mmol/mol), took folic 
acid and stopped teratogenic medications. One-third of women with T2DM took folic acid in 
75% of services and those from lower socio-economic groups were the least prepared for 
pregnancy. The audit concluded that the low awareness of pregnancy planning and risks 
was due to the failure of the primary care referral pathways and specialist diabetes services 
in providing PCC education. Furthermore, although current guidelines (CEMACH, 2007; 
NICE, 2015) recommend the use of contraception until a stable HbA1c level is achieved, as 
many as two-thirds of women with DM do not recall discussing contraception with their 
healthcare professionals (HCPs), are unsure of suitable contraception options or are not 
using reliable contraception before pregnancy (Cartwright et al., 2009; Murphy et al., 2010a). 
Consequently, despite contraception being freely available in some parts of the world, such 
as the UK, women with DM are less likely to be using contraception than women without DM 
(Shawe, 2008; Vahratian, 2009; Gourdy, 2013). 
 
It is evident that despite information on clinical guidance being readily available to HCPs, the 
scarcity of information on how to best implement PCC services hinders progress (Hughes et 
al., 2016). Thus, PCC service provision has remained inadequate and fragmented with less 
than 50% of women with DM receiving PCC advice (CEMACH, 2007; Murphy et al., 2010b; 
Egan et al., 2016). Two-thirds of all pregnancies are still unplanned despite the knowledge 
that babies of women with unplanned pregnancies are more likely to be small for gestational 
age, admitted to the neonatal intensive care unit and to have a longer stay in hospital 
(Holmes et al., 2017). Moreover, various barriers including inadequate resources to provide 
PCC, busy clinics, unsupportive HCPs, lack of trust in HCPs, lack of transport, distance to 
travel, childcare requirements and time constraints further inhibit the extent to which women 
engage in PCC (Infanti et al., 2014; Singh et al., 2010; Spence et al., 2010). Women with 
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DM thus have a poor understanding of pregnancy-related risks and the consequences of 
having an unplanned pregnancy to themselves or their baby (McCorry et al., 2012; Dean et 
al., 2013; Xaverius et al., 2013; O’Higgins et al., 2014). These inadequacies in PCC service 
provision are not specific to a particular country but adversely affect the health of women 
with DM globally, of especially those in developing countries which face the greatest barriers 
to PCC (World Health Organisation [WHO], 2012a; WHO, 2013).  
 
The slow progress in this field is also due to the location of the PCC services (Murphy et al., 
2010). Ideally, PCC services should be provided in both primary and secondary care. 
However, the predominance of PCC services in specialist hospitals means that many 
women, particularly those with T2DM cared for in primary care, lack adequate access to 
PCC (Murphy et al., 2010b; Steel et al., 2015). Although Klinke and Toth (2003) argue that 
PCC should be provided by general practitioners (GPs) in primary care; this approach has 
been deemed opportunistic and dependent on the number of women attending the practice 
(Shannon et al., 2014; Hughes et al., 2016). PCC service provision in primary care has been 
further criticised by Earle et al. (2017), who note that GPs do not fully understand the need 
for PCC in women with DM.  
 
The lack of clarity regarding PCC responsibility by HCPs in secondary care further 
contributes to the aforementioned slow progress within the field (CEMACH, 2007; Hughes et 
al., 2016). King (2011) maintains that PCC should be provided by a specialist 
multidisciplinary team with the appropriate competency as described in Skills for Health 
(2010). Yet, there are ongoing arguments amongst specialists regarding the HCP best 
placed to provide PCC. In the UK, secondary care clinicians, such as the diabetes specialist 
nurse (DSN) (Scott, 2005) and midwives (Hughes et al., 2016; Chief Nursing Officers, 2010) 
are deemed to have PCC responsibility, while in the USA, it is the gynaecologic and 
obstetric clinicians who assume this responsibility (Schwarz et al., 2011). However, van 
Heesch et al. (2006) note that midwives do not view themselves as having a role in PCC due 
to inadequate knowledge and time constraints. Indeed, a general decline in HCPs’ input in 
PCC has been highlighted with several studies concluding that many HCPs are not 
adequately trained to provide PCC (Charron-Prochownik and Michel, 2006; CEMACH, 2007; 
Shannon et al., 2014; Earle et al., 2017). Undeniably, the deficiencies in PCC service 
provision for women with DM has become a significant public health issue (Hughes et al., 
2016; Shannon et al., 2014). There is therefore an urgent need for more effective PCC 
service provision.  
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1.3 Rationale for the study 
Given the undeniable need for a PCC educational (preconception counselling) resource for 
women with DM, various initiatives have been developed to improve awareness and 
encourage women to seek PCC. The READY-Girls (reproductive-health education and 
awareness of diabetes in youth for girls) is one example of an educational program, which 
used CDs (Charron-prochownik et al., 2008; Fischl et al., 2010) and DVDs (Charron-
prochownik et al., 2013), to improve reproductive health awareness in young women with 
DM in America. Another educational program, available both in DVD and website format, 
titled “Women with diabetes – things you need to know (but maybe don’t), has been 
developed for women with DM in the UK (Holmes et al., 2012, 2013). The DVD is currently 
being used as a preconception counselling resource by diabetic teams in Northern Ireland. 
 
Other PCC initiatives for women with DM include a preconception leaflet in East Anglia, UK 
titled EASIPOD (East Anglia study for improving pregnancy outcomes in women with DM) 
which was mailed annually to all women aged 16-45 years identified from specialist and 
primary care diabetes registers (Murphy et al., 2010b). PROCEED (preconception care in 
diabetes for Derby and Derbyshire) is a multi-faceted initiative that uses various means, 
including mass media (television, radio and newspaper), websites and social media (twitter) 
to improve PCC awareness in women with DM and HCPs (King, 2013). Diabetes UK also 
has a web page that hosts information and short video clips on PCC (e.g. Rebel Rebel) to 
encourage women to plan their pregnancy. However, despite these initiatives, a systematic 
review of 18 qualitative studies carried out by Earle et al. (2017) highlighted that women with 
DM were unaware of available educational resources; sub-optimal levels of PCC awareness 
and experiences were also recorded across studies.   
 
1.3.1 Women’s views and experiences of PCC 
Women with DM, of reproductive age, face various challenges particularly when 
contemplating pregnancy and several factors influence their decision to seek (or not seek) 
PCC prior to pregnancy. For example, the nature and quality of existing relationship with 
HCPs play an important role. Women who had a good relationship described the positive 
emotional and practical consequences of this positive patient-provider relationship which 
encouraged them to seek PCC and plan their pregnancy, while those who did not were less 
likely to seek PCC (The diabetes and pregnancy group, 2005; Murphy et al., 2010a; 
Charron-prochownik et al., 2006b). For women who desired PCC advice, several constraints 
including busy clinics, lack of staff continuity, unfamiliar HCPs, poor patient-provider 
relationships, stereotypes held by HCPs and embarrassment (for younger women) made it 
difficult to be pro-active in seeking advice (Spence et al., 2010; O’Higgins et al., 2014).  
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The diabetes and pregnancy group (2005) in France, carried out a survey of 138 women, 
and noted that inadequate knowledge of PCC and pregnancy-related risks contributed to low 
rate of PCC uptake in French women with T1DM. Spence et al. (2010) also found that lack 
of awareness about the rationale for planning pregnancy played a major role in the poor 
uptake of pre-pregnancy care services in the UK. Two other UK studies (Lavender et al., 
2009; O’Higgins et al., 2014) found that the general apathy towards PCC was influenced 
both by a lack of information and emphasis from HCPs on the importance of PCC. 
Inadequate information and preparation for pregnancy contributed to women’s emotional 
burden, making them more anxious and afraid of a pregnancy complicated by DM (Lavender 
et al., 2009; McCorry et al., 2012).  
 
It has been established that advice of PCC and risks alone is not effective in preventing 
unplanned pregnancy, the way such information is provided is also important (Murphy et al., 
2010a). Spence et al. (2010) found that some women were told to plan without information 
on why and how. In addition, women who reported receiving PCC felt that glycaemic control 
was prioritised by HCPs, hence, women focused on controlling their blood glucose levels 
which is important to reduce adverse outcomes. However, the discussion had an adverse 
effect on women’s psychological well-being and they reported feeling anxious and fearful 
afterwards (Griffiths et al., 2008). Lavender et al. (2009) also reported that women advised to 
avoid pregnancy, due to the potential risks, chose to ignore this advice and went ahead to 
conceive. Findings also suggested that women who knew about PCC did not attend because 
they were either discouraged by HCPs paternalistic and authoritarian behaviour or had a 
past negative PCC experience. Earle et al. (2017) highlighted that women want to feel 
empowered with information and supported from preconception to pregnancy, and the 
authoritarian approach used by some HCPs only led to fear, resistance, resentment and 
non-compliance with directives.  
 
The need for HCPs to focus on positive aspects of pregnancy rather than only on the 
problematic aspects for women with DM has been highlighted (O’Higgins et al., 2014; Earle 
et al., 2017). Several studies have reported that PCC information framed in a motivating, 
positive and supportive way was more likely to be heard by women and translated into action 
(Egan et al., 2016, Earle et al., 2016, Spence et al., 2010). It has also been noted that 
women with DM need support and reassurance about PCC and pregnancy, whilst coping 
with the various challenges of DM. To encourage uptake of PCC by women with DM, 
O’Higgins et al. (2014) suggest establishing PCC as something every woman with DM will 
do irrespective of pregnancy plans. Given the various challenges of traditional PCC, it is 
24 
 
evident that there is still a long way to go before PCC becomes the norm for women with 
DM. Hence the use of more ubiquitous technology, such as a mobile phone, to supplement 
traditional PCC could help improve awareness, coverage and uptake.   
 
1.3.2 Potential of mobile phone use for PCC 
Concerns have been raised that the current ad-hoc nature of PCC service provision, 
absence of written hospital policies, poor patient-provider relationships, negative PCC 
experiences and lack of agreement both regarding PCC remit and the most effective 
strategies to encourage the uptake of PCC services could be detrimental to the health of 
women (WHO, 2012a, 2013; Shannon et al., 2014; Murphy et al. 2010a). Emphasis is 
therefore being placed on developing and testing alternative approaches to PCC provision, 
and moving away from a PCC model that is traditionally provided by HCPs within a clinic 
setting. Innovative strategies for improving PCC provision through eHealth technology 
(DVDs and CD-ROMs) have been found to be effective ways of changing behaviours and 
improving knowledge of PCC (Charron-Prochownik et al., 2008; 2013; Fischl et al., 2010; 
Holmes et al., 2012). However, they are now outdated and offer limited scope to the many 
women without access to computers and DVD players, who increasingly rely on smartphone 
apps to access health information (Tripp et al., 2014; Chen and Mangone, 2016; 
Krishnamurti et al., 2016). Thus, the use of more contemporary technologies for PCC, such 
as smartphone applications (apps), need to be explored in line with the WHO eHealth 
strategy (2012), NHS Five Year Forward View (2014) and the Personalised Health and Care 
2020 framework (National Information Board [NIB] 2014), which seek to promote patients’ 
use of smartphones and apps for self-management and access to the information needed in 
order to avoid complications.  
 
Mobile health, the medical and public health practice that is supported by mobile devices 
(WHO, 2011b), is one way to improve the provision of PCC. Mobile health (mHealth) is a 
component of eHealth, the cost-effective and secure use of information and communication 
technology, ICT, in support of health and health-related fields (WHO, 2005). According to the 
International Telecommunications Union (ITU, 2010), 90% of the world’s population now own 
a mobile phone, and almost half of the 7.4 billion mobile devices currently in use are 
smartphones with the capacity of computers and the internet (Eng and Lee, 2013; 
Derbyshire and Dancy, 2013; Silva et al., 2015; Klasnja and Pratt, 2012). The capacity of 
smartphones to help improve PCC awareness has been recognised by the World Health 
Organisation (2013) and other researchers (O’Higgins et al., 2014; Hughes et al., 2016). 
Smartphones have now overtaken laptops and desktop computers as the device used to 
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access the internet (Ofcom, 2016; Deloitte, 2016). Although smartphones are currently more 
common in developed countries, global smartphone subscriptions are projected to increase 
from 3.2 billion in 2015 to 6.6 billion in 2021, covering 70% of the world’s population 
(Ericsson Mobility Report, 2016). The smartphone is thus the most popular mobile device 
and is technologically advanced, easily accessible, mobile and has the potential to influence 
a large population (Tripp et al., 2014; Pew Research Center, 2016). Smartphone 
functionalities are facilitated by apps. 
 
Apps are software programs designed to run on smartphones, increasingly being used in 
order to facilitate the cost-effective delivery of health interventions (Hebden et al., 2012; 
Derbyshire and Dancy, 2013). In a qualitative study by O’Higgins et al. (2014), women with 
DM of reproductive age suggested the development of a mobile app to help provide PCC 
education, increase knowledge of diabetes and pregnancy, and improve PCC uptake. Thus, 
the smartphone app, an adjunct to traditional PCC, has the potential to serve as an 
intervention medium to deliver PCC education and improve awareness. Advancement in 
technology has made it possible for health information to be incorporated into easily 
accessible digital formats, such as a smartphone app, and this is rapidly changing the health 
education and information paradigm (Willcox et al., 2015). Evidence suggests that apps can 
help improve women’s knowledge of family planning and contraception, reduce body mass 
index (BMI), connect young teenage women with contraceptive information and reproductive 
health services and increase antenatal care attendance (Carter et al., 2013; Gilliam et al., 
2014; Chen and Mangone, 2016; Krishnamurti et al., 2017).  
 
There is increasing evidence that mHealth interventions, particularly apps, can successfully 
change behaviours and improve outcomes (Zhao et al., 2016; Irvine et al., 2015; Carter et 
al., 2013; Kirwan et al., 2013; Gustafson et al., 2014). The scarcity of studies using 
pervasive technology, e.g. mobile apps to support PCC behaviour change for women with 
DM reflects a gap in the evidence base. Insufficient PCC understanding, perceived lack of 
support, negative PCC experiences and poor patient-provider relationships are some of the 
most frequently cited barriers to PCC uptake and contributors to unplanned pregnancy 
(Murphy et al., 2010a; Earle et al., 2017). Hence, for meaningful change to occur, it is 
important that the PCC information is provided in a supportive way and with positive 
intervention language. Few PCC educational interventions in the literature (Egan et al., 
2016; Holmes et al., 2012; 2013) make reference to the use of supportive approach for 
women with DM, yet, this has been extensively discussed in the qualitative literature 
(Spence et al., 2010; O’Higgins et al., 2014; Earle et al., 2017). For example, Holmes et al. 
(2013) suggest emphasising the benefits of performing relevant behaviours, such as using 
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contraception and quitting smoking, in a non-authoritarian manner. Hence, the use of a 
(hybrid) mobile app to educate women about pregnancy and contraception, and support 
them to optimise blood glucose levels before and during pregnancy, while making use of a 
supportive approach and positive intervention language, is warranted.  
 
Apps have contributed to healthy behavioural changes in a number of areas including 
medication management, diet control, physical activity, lifestyle improvement, smoking 
cessation and diabetes management (Zhao et al., 2016). Apps have also been successfully 
used in order to improve diabetes self-management and monitoring (Kollmann et al., 2007; 
Cafazzo et al., 2012; Kirwan et al., 2013). With traditional methods of PCC provision, such 
as face-to-face methods, failing to sufficiently engage women with DM in PCC, a 
smartphone-based intervention could provide an alternative means of improving activation, 
changing behaviours and reducing barriers to seeking PCC. However, the use of mHealth 
technology for PCC is still in its infancy and to date, no study has examined the use of a 
smartphone app for PCC among women with DM. In order for this type of technology in PCC 
to develop, research into its acceptability and feasibility is therefore needed.  
 
1.4 Aim of the study 
The aim of the study was to develop a Preconception and Diabetes Information (PADI) app 
for women with T1DM and T2DM and explore the system’s feasibility and acceptability. 
 
1.5 Research questions 
The research questions addressed in this study are outlined below; research question 1 is 
addressed in Chapter 2 while research questions 2 to 7 are informed by the issues and gaps 
highlighted in the literature (as discussed in Chapter 2), and the qualitative findings (as 
discussed in Chapters 6 and 7). 
 
1. What are the current methods and limitations of providing PCC educational interventions, 
and what is the relationship between PCC educational interventions and patient and 
behavioural outcomes? 
2. What are the views and experiences of women with T1 or T2DM and healthcare 
professionals (doctors and nurses) in relation to PCC? 
3. What are the views and experiences of women with T1 or T2DM and healthcare 
professionals (doctors and nurses) regarding the use of the PADI app in practice? 
4. What are the factors that inhibit/facilitate the use of the PADI app? 
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5. What is the acceptability of the overall app, as measured by satisfaction, usefulness, 
ease of use and attitudes towards the receipt of the intervention? 
6. What are the preliminary estimates of the effect of the PADI app on PCC knowledge, 
attitudes and behaviours?  
7. What are the suggestions for future app development? 
 
1.6 Rationale for research approach and methodology 
A systematic review of the literature and feasibility study using mixed methods were deemed 
the most appropriate approach to answer the research questions and develop an 
understanding regarding the acceptability of the PADI app intervention. Systematic reviews 
are used to identify, evaluate and summarise the findings of relevant individual studies, 
demonstrate gaps in the literature and provide justification for the research (University of 
York, 2009). Feasibility studies are used in order to assess whether the study can be done 
or whether the intervention is acceptable to the target population and shows potential of 
being successful (Orsmond and Cohn, 2015). A co-design approach with healthcare 
professionals, women with DM and a digital agency was used to develop and test the app in 
order to ensure that it meets the needs of women with DM and that its content is appropriate 
and acceptable (Steen et al., 2011; Whittaker et al., 2012; Mummah et al., 2016). Thus, 
feasibility studies incorporating several stages of user feedback can help identify and solve 
problems of intervention acceptability, compliance, delivery, recruitment and retention (Craig 
et al., 2008; Mummah et al., 2016).   
 
1.7 Personal interest  
I first became interested in DM while studying Endocrinology as part of my undergraduate 
degree in Physiology. During this time, I completed an independent research project titled 
‘The Effect of Oestrogen on Fasting Blood Glucose, Blood Electrolyte Composition and 
Bleeding Time in Albino Rats’. This enabled me to gain an in-depth understanding of the role 
of oestrogen in blood glucose homeostasis and insulin sensitivity, which stimulated my 
interest in diabetes research. Furthermore, while studying for a Master’s degree in 
International Health and Management, I developed a keen interest in maternal and women’s 
health research, particularly in issues surrounding maternal mortality and PCC.  
 
Since graduating in 2011, I have been interested in diabetes research and how it affects 
women’s health. This is of particular importance to me because coming from a developing 
country, Nigeria, I have witnessed the negative consequences (e.g. maternal mortality) 
resulting from inadequate PCC awareness, as well as the geographic and financial barriers 
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to maternal health services, particularly for women with DM. Even though maternal mortality 
has declined, many women still experience adverse outcomes arising from the failure to plan 
their pregnancies (WHO, 2012a; WHO, 2013). The problem is further exacerbated in women 
with DM of reproductive age and they experience increased adverse outcomes of 
pregnancy, compared to the background population (NICE, 2017). This problem is not 
specific to a particular region but is of global public health concern.  
 
Although DM is a matter of growing concern that affects maternal and child health, PCC has 
been shown to be an effective strategy to combat this challenge (Wahabi et al., 2010). PCC 
is also cost-effective and reduces the cost of care per patient by facilitating early visitations 
to antenatal care clinics, less hospitalisation for complications and a reduced occurrence of 
congenital abnormalities (Egan et al., 2016). However, an optimal approach to reaching 
more women with DM with PCC information has not been found. Technology may offer a 
potential solution to this problem. My interest in the use of ICT for PCC stems from the 
realisation that this is a technological age and that technology is affecting all spheres of life, 
including healthcare (WHO, 2012b). ICT is being used on a global scale in order to improve 
access to care and mitigate the current challenges faced by healthcare systems, particularly 
the shortage of healthcare workers, variable quality of care and the barriers of traditional 
face-to-face care. Mobile phone technology in particular provides an innovative approach to 
healthcare and is helping to eliminate geographic and financial barriers to health in 
developed and developing countries.  
 
Mobile phones are available worldwide, and an increase has been experienced in the growth 
of mobile apps. Hence, I intend to explore the incorporation of health education intervention 
into a smartphone (app). Mobile phone use for health (mHealth) is bridging the gap between 
the rich and the poor, thereby rendering care more accessible to hard-to-reach populations 
and low-income/disadvantaged communities. Therefore, I am hopeful that the use of mobile 
technology can increase access to PCC for women; a PCC mobile app intervention can be 
easily scaled up and adapted into a sustainable PCC programme that can be used by 
women in both developed and developing countries. My desire to contribute towards 
providing equitable access to PCC for women in developed and developing countries, 
combined with a strong interest in health education especially women’s health and DM, are 
the main motivating factors that led me to conduct this research.   
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1.8 Structure of thesis 
This thesis is organised into eight chapters. The first chapter introduces the study and 
provides a justification as to why it should be conducted. Background information is provided 
about the burden of DM and its associated complications, benefits of PCC for women with 
DM and current challenges, and the potential of a smartphone app to increase PCC 
knowledge and awareness amongst women with DM. The study aim and research 
questions, along with a rationale for the research approach and methodology are then 
provided.  
 
Chapter 2 systematically reviews the literature with respect to the methods currently being 
used to provide PCC education, and examines the relationship between PCC educational 
interventions (including the use of technology as an intervention tool) on patient and 
behavioural outcomes. Any existing gaps in the literature from which the research questions 
are formulated are highlighted. Additionally, recommendations for future research are made.  
 
Chapter 3 discusses behaviour change and the normalisation process theory, the two 
theoretical frameworks used in the study. It also discusses the research design, 
epistemological approach of the study and the philosophical basis of mixed methods 
research. The use of a mixed methods study design and the ethical considerations of the 
study are addressed. Practicalities and access issues are considered. 
 
Chapter 4 discusses the PADI app development and rationale for the app content. The 
sample selection, research setting and app development process are addressed. The 
rationale for the methods of data collection (focus groups and interviews) and the 
instruments used in order to collect the data are presented. Subsequently, the methods of 
data analysis are reported.  
 
A discussion of the methods used in the feasibility study is presented in Chapter 5. It also 
discusses the rationale for the methods of data collection (questionnaires, interviews and 
software log of activity) and the instruments used in order to collect the data. The methods of 
data analysis are presented.  
 
The results are presented sequentially in Chapters 6 and 7. Chapter 6 focuses on phase 
one, namely the development of the PADI app. The results from the analysis of the data sets 
collected from the focus group and interviews with HCPs and women with DM are reported.  
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Chapter 7 focuses on the second phase of the study, namely the feasibility and acceptability 
of the PADI app intervention. The results from two (pre and post-PADI app intervention) 
questionnaires and user experience interviews are presented.  
 
Chapter 8 discusses the reported findings in relation to the literature, provides a critical 
review of the methodology and identifies study strengths and limitations. The contribution of 
the study to the body of knowledge is presented. Recommendations and suggestions for 
additional research are made, followed by a conclusion of the main points. 
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 2. Chapter 2: Review of the literature 
2.1 Overview 
Rapid technological advancement has created new opportunities to improve PCC 
awareness and health outcomes, therefore it was important to understand how technology 
was being used in order to support PCC services for women with DM. Hence, this review 
aimed to evaluate and quantify the impact of different methods of PCC provision for women 
with DM. The literature review was conducted using a systematic approach and two 
guidelines: the National Health Service (NHS) Centre for Reviews and Dissemination (CRD) 
guidelines for conducting reviews in healthcare (University of York, 2009) and the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) (Moher et al., 2009).  
  
The literature review answered the following questions: 
 What are the current modes of delivery for providing PCC education to women with 
DM? 
 What is the relationship between PCC educational interventions (including eHealth 
technology) and patient and behavioural outcomes? 
 What are the limitations in current PCC practice and gaps in the literature? 
 
2.2  Search strategy 
A systematic approach was used to search the literature for relevant articles. The review 
was limited to studies conducted between January 2003 and December 2017 to reflect 
current and emerging trends in the design and conduct of PCC interventions for women with 
DM. This restriction was also applied because smartphones were first introduced in 2003 
and formed the focal point of this research. The reviewed literature drew on a wide range of 
evidence. The following electronic databases were searched: MEDLINE, Embase, 
Cumulative Index to Nursing and Allied Health (CINAHL), PsycINFO, Maternity and Infant 
Care, British Nursing Index (BNI), Web of Science, Scopus and ScienceDirect.  
 
Both medical subject headings (MESH) and key words were used in various combinations 
when searching the databases. The following keywords were used: ‘preconception care’, 
‘education’, ‘counselling’, ‘diabetes’, ‘pregnancy outcomes’, ‘knowledge’, ‘behaviour change’, 
‘birth defects’, and ‘women’. The strategy used for the search was developed to meet the 
specific requirements of each electronic database, and in accordance with their subject 
headings or search structure. The search structure for MEDLINE is presented below: 
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1 pre#concept* care OR pre#concept* OR pre#concept* counse*ing OR 
pre#concept* education OR pre#pregnan* care OR pre#pregnan* plan* OR 
pre#pregnan* OR pre#concep* adj1 care 
2 diabetes OR diabetes mellitus OR diabet* OR type 1 diabetes OR type 2 
diabetes OR insulin dependent diabet* OR non#insulin dependent diabet* OR 
IDDM OR NIDDM 
3 anomal* OR congenital anomal* OR malformation* OR birth defect* OR health 
outcome* OR pregnancy outcome* OR obstetric outcome* OR adverse adj1 
outcome* OR knowledge OR attitude OR behaviour change 
4 maternal OR maternal health OR mother* OR gestation OR pregnan* OR 
wom*n OR infant OR f*tus OR neonat* OR newborn* OR child 
5 1 AND 2 AND 3 AND 4 
 
The truncation symbol was used in the middle of a word in order to capture both American 
and British spellings of the word and at the end to capture various forms of the word. The 
Boolean operators OR and AND were applied to combine terms and give the search a 
precise focus. In addition to electronic databases, the reference lists of retrieved articles, 
reviews and related articles were hand-searched for potentially relevant papers. Other 
relevant databases, for example, Google Scholar, NHS Evidence and Cochrane Library 
were also searched in order to identify any existing papers and reviews related to the topic. 
No language or geographical restrictions were applied in order to refine the search.  
 
2.2.1 Study selection 
The titles, abstracts and full papers were initially screened by the researcher and verified by 
the study supervisors (NC and JS). The search protocol included the identification of 
potentially relevant articles, the screening of the identified papers based on their titles and 
abstracts, the examination of the full text of potentially relevant studies for eligibility, and the 
application of the inclusion criteria in order to select the studies included in the review.  
 
The search yielded 2,702 hits, most of which were duplicates and studies not relevant to the 
review. These articles were exported into RefWorks (reference management software) in 
order to allow for duplicates to be identified and excluded. The titles and abstracts of 1,437 
articles were then screened against the inclusion criteria and the potentially eligible studies 
identified, while those that failed to meet the inclusion criteria were excluded. After excluding 
1,411 articles that did not meet the eligibility criteria, 26 full text articles were selected for 
critical review, of which 14 met the eligibility criteria (Figure 2.1).  
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The criteria for including studies in the literature review were informed by the PICOS 
(population of interest, intervention, comparator, outcomes assessed and included studies) 
method (University of York, 2009). For the study to be included in the literature review, the 
following inclusion criteria were applied.  
 
Inclusion criteria 
 Women of reproductive age with pre-existing T1DM or T2DM and not pregnant at the 
time of the PCC intervention.  
 PCC interventions including but not limited to education, counselling, or advice on the 
use of folic acid, insulin therapy, glycaemic control, screening for diabetes complications, 
contraception use, and blood glucose monitoring.  
 Studies utilising a standard care comparator group or where the intervention group 
serves as the control (pre-post studies).  
 Studies reporting on maternal and neonatal outcomes, and knowledge and attitudes 
towards PCC.  
 Quantitative studies, or more specifically, randomised controlled trials, before and after 
studies, and observational studies (cohort, cross-sectional and case control).  
 
Exclusion criteria 
Articles were excluded if there was an agreement that the article met one or more of the 
following exclusion criteria:  
 Did not contain any human data.  
 Contained no original data (in the case of a commentary, meeting abstract or 
editorial). 
 The population of interest was not women with DM.  
 Did not assess the impact of a PCC educational intervention. 
 
2.2.2 Data abstraction and quality assessment 
 
Data abstraction 
The data were subsequently extracted by the researcher and checked by the supervisors 
(NC and JS) for accuracy and completeness. The researcher was not masked to the articles’ 
authors, journals, or institutions. The data extracted include the following: general 
information (e.g. author, title of study, country in which the study was conducted and year of 
publication), eligibility (type of study, participants, type of intervention, outcome measure and 
comparator), population (from which the sample was recruited) and setting (in which the 
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intervention was delivered), description of the intervention (e.g. duration, dose, type of 
intervention, mode of delivery and theoretical basis), outcomes / results (e.g. statistical 
techniques used, length of follow-up, results of study analysis and details of outcome 
measurements), study limitations and any mitigation strategies (see Appendix 1 for a copy of 
the data extraction form).   
 
Quality assessment 
 
The quality of the reviewed studies was assessed using a modified version of the Effective 
Public Health Practice Project (EPHPP) quality assessment tool for quantitative studies, 
which was developed by EPHPP, Canada (Thomas et al., 2004; Sanderson et al., 2007). It 
contains summary judgments and an accompanying dictionary that increases 
standardisation and minimises subjectivity in the study quality assessment. This tool 
includes items on selection bias, study design, minimising confounders, blinding, data 
collection, and withdrawals and dropouts (see Appendix 2 for a copy of the EPHPP quality 
assessment tool). Each of these six aspects of quality received a score out of 3 to make up a 
total score of 18. The studies were given a rating out of 18, and the quality of the evidence 
was graded as strong (rating≥ 14), moderate (rating 7-13), or weak (rating 1-6). Although 
less weight was given to studies of poorer quality, no papers were excluded based on their 
quality.  
 
2.2.3 Narrative synthesis 
In this review, the main focus was on extracting data on intervention descriptions (study 
design, samples and intervention overviews), outcome measures and the examinations of 
the effectiveness of interventions. The results are presented as a narrative summary. 
 
2.3 Search results 
The 14 included studies evaluated two categories of PCC health education delivery in use 
for women with DM, namely health education provided by health care professionals (HCPs; 
n=9) and health education using eHealth technologies (CD-ROMs and DVDs; n=5). Of the 
included studies, nine focusing on PCC health education delivery by healthcare 
professionals were found to investigate the effect of PCC education on maternal and child 
health outcomes (Murphy et al., 2010b; Tripathi et al., 2010; Temple et al., 2006a, 2006b; 
Neff et al., 2014; Boulot et al., 2003; Galindo et al., 2006; Kekäläinen et al., 2016; Egan et 
al., 2016). Four studies focusing on the use of eHealth technology for the PCC of women 
with DM (Charron-Prochownik et al., 2008, 2013; Fischl et al., 2010; Holmes et al., 2012) 
investigated the effect of the eHealth technology on knowledge and attitude towards PCC, 
and one study (Holmes et al., 2017) investigated the effect of eHealth technology on 
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maternal and child health outcomes. Of the 14 included articles, one study discussed its 
findings in two articles (Temple et al., 2006a, 2006b). Hence, 14 articles reporting 13 studies 
were included. 
 
2.3.1 Study characteristics 
The summary characteristics of the reviewed articles are presented in Table 2.1 and include 
the focus, content, outcome measures and study design of the interventions. All studies 
involved evaluating the effect of a PCC educational intervention provided to women with DM 
either face-to-face or via eHealth PCC. The evidence identified was all quantitative in nature 
and included two retrospective and eight prospective cohort studies, three randomised 
controlled trials (RCTs) and one before and after study. Eight studies included women with 
both T1DM and T2DM, and six studies focused on women with T1DM. In all studies, except 
two (Holmes et al., 2012; 2017) where health education was delivered in women’s homes, 
health education was delivered in clinical settings; highlighting the current emphasis on the 
PCC received within a healthcare (clinic) setting. 
 
Women were recruited from specialist and primary care diabetes clinics. Timing, frequency 
and the intervention duration for some studies were not specified (Holmes et al., 2012; 
Tripathi et al., 2010; Neff et al., 2014; Boulot et al., 2003; Galindo et al., 2006; Kekäläinen et 
al., 2016; Egan et al., 2016) . Follow-up periods ranged from 3 months to 12 years. Most 
studies were observational (Murphy et al., 2010b; Tripathi et al., 2010; Temple et al., 2006a, 
2006b; Neff et al., 2014; Boulot et al., 2003; Galindo et al., 2006; Kekäläinen et al., 2016; 
Egan et al., 2016; Holmes et al., 2017), with data collected from medical, pregnancy and 
birth records, or databases. Of the included studies, four (Charron-Prochownik et al., 2008; 
Fischl et al., 2010; Holmes et al., 2012; Charron-Prochownik et al., 2013) used previously 
validated and reliable questionnaires. Although the methods of data collection were different 
for the face-to-face and eHealth PCC studies, there was consistency in the findings and 
methods of data collection used within each category. Sample sizes ranged from n=58 to 
n=680. All studies, except one (Holmes et al., 2012), had a separate intervention and control 
group.  
 
All studies were conducted in developed country settings (United States, n=3; United 
Kingdom, n=6; France, n=1; Spain, n=1; Finland, n=1; and Republic of Ireland, n=2), 
highlighting the increased prioritisation of PCC for women with DM in these countries. 
Studies, which adopted eHealth for the PCC of women with DM, were based in either the 
United States (n=3) (Charron-Prochownik et al., 2008, 2013; Fischl et al., 2010) or in the 
United Kingdom (n=2) (Holmes et al., 2012, 2017), perhaps reflecting the increasing use of 
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information and communication technology (ICT) to support PCC service provision in these 
countries. All (n=14) studies provided robust evidence of the impact of PCC education on 
maternal and child health outcomes, as well as on the knowledge and attitudes to PCC. 
Their findings were based on a rigorous quantitative analysis.  
 
2.3.2 Study quality 
Studies varied but were either of moderate or high quality, as shown in Table 2.1 below. Of 
the included studies, four had a rating of ≥ 14 (Fischl et al., 2010; Charron-Prochownik et al., 
2013; Murphy et al., 2010b; Holmes et al., 2017) and ten were rated between 7-13 (Charron-
Prochownik et al., 2008; Holmes et al., 2012; Tripathi et al., 2010; Temple et al., 2006a, 
2006b; Neff et al., 2014; Boulot et al., 2003; Galindo et al., 2006; Kekäläinen et al., 2016; 
Egan et al., 2013). All studies used appropriate study designs, namely, randomised 
controlled trials, before and after, and cohort studies, but lacked details on blinding and 
allocation concealment. Although small sample sizes (Charron-Prochownik et al., 2008; 
Fischl et al., 2010; Holmes et al., 2012), selection bias (Charron-Prochownik et al., 2008; 
Holmes et al., 2012; Kekäläinen et al., 2016), and confounding (Holmes et al., 2012; Boulot 
et al., 2003; Galindo et al., 2006) were the underlying weaknesses in most studies, these 
were acknowledged and addressed by the authors. 
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Figure 2.1. PRISMA flowchart of included studies  
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Table 2.1 Summary characteristics and quality assessment of reviewed articles 
Author or 
country 
Study population Methods or focus Intervention Findings Quality 
assessme
nt 
1. Evaluation of PCC Educational Interventions Provided by Healthcare professionals 
 
Boulot et al. 
(2003) - France 
435 pregnant women 
with DMa. 
 
T1DMb, n=289 
(intervention =140/289, 
48.5% received the 
intervention, control=149). 
T2DMc, n=146 
(intervention= 
35/146, 24% received 
the intervention, 
control=111). 
Prospective 
cohort study. 
 
To determine if 
PCCd interventions 
improved 
pregnancy 
outcomes in 
women with DM. 
Oral PCC educational intervention delivered by health care 
professionals (HCPse; diabetologists). 
 
Advice regarding blood glucose optimisation, DM 
complications, dietary modification, self-monitoring of blood 
glucose levels, and insulin therapy. 
Information was collected on HbA1ci >8% in the first 
trimester. 
 
The duration of the intervention was not specified. The face-
to-face time with the women was not indicated. 
 
Significantly lower no. of 
women with HbA1c >8% in 
the intervention group 
compared with the control 
group (4.3% vs. 55%; 
P<.001 and 2.9% vs. 
27.9%; P<.001) for T1DM 
and T2DM, 
respectively). 
(9/18) 
Galindo et al. 
(2006) - Spain 
 
127 Women with 
T1DM and T2DM. 
 
Intervention, n=15/127, 
12% received the 
intervention, control, 
n=112. 
Prospective 
cohort study. 
 
To investigate 
the effect of DM 
on the 
pregnancy 
outcome. 
Oral PCC educational intervention delivered by health care 
professionals (HCPs). 
 
Advice regarding the self-monitoring of blood glucose levels 
and the intensification of insulin therapy. 
 
The duration of the intervention was not specified. 
 
The face-to-face time with the women was not indicated. 
3/15 (20%) of pregnancies 
in the intervention group 
and 14/112 (12.5%) in the 
control group resulted in 
congenital malformations. 
1 spontaneous abortion 
was recorded in the 
intervention group 
compared with 9 in the 
control group. 
(9/18) 
Temple et al. 
(2006a, 2006b) - 
the 
United Kingdom 
 
290 pregnancies to 
women with T1DM. 
 
Intervention, 
n=110/290, 37.9% 
received the 
intervention, control, 
n=180. 
Prospective 
cohort study. 
 
To investigate 
the relationship 
between PCC 
and obstetric 
outcomes in 
women with 
T1DM. 
Oral PCC educational intervention provided by HCPs 
(doctors, dieticians and DSNsf). 
 
Advice regarding blood glucose monitoring, glycaemic 
control, initiation of folic acid supplements after stopping 
contraception, smoking cessation, and avoidance of 
teratogens, such as ACEg inhibitors and statins. Targets 
were set for pre- and postprandial blood glucose levels.  
 
The intervention group attended a PCC centre at intervals of 
1-3 months. 
 
There were lower 
spontaneous abortion 
rates (5.7% vs. 14.0%; 
P=.06), adverse 
pregnancy outcomes 
(2.9 vs. 10.2; P=.03), and 
premature delivery (5.0% 
vs. 14.2%; P=.02) rates in 
the intervention group 
compared with the control 
group. 
 
(13/18) 
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Author or 
country 
Study population Methods or focus Intervention Findings Quality 
assessme
nt 
Murphy et al. 
(2010b) - the 
United 
Kingdom 
680 women with T1DM 
and T2DM. 
 
Intervention, n=181/680, 
26.6% received the 
intervention, control, 
n=499. 
Prospective 
cohort study. 
 
To investigate 
the association 
between PCC 
and obstetric 
outcomes. 
Oral PCC educational intervention delivered by HCPs 
(doctors, nurses and midwives). 
 
Structured education regarding PCC. 
 
The content of the intervention was not described in the 
paper. 
 
The frequency of the face-to-face time with the women 
ranged from 1 to 7. 
The intervention group 
presented significantly 
earlier for PNCh 6.7 vs. 
7.7 weeks; P <.001), and 
was unlikely to be taking 
ACE inhibitors (1.1 vs. 
4.6%; P =.05) and statins 
(0 vs. 7.6%; P<.001) at 
conception compared with 
the control group. 
 
HbA1c improved in the 
intervention group and 
was sustained through the 
first trimester (6.9% vs. 
7.6%; P<.001). 
(14/18) 
Tripathi et al. 
(2010) - the 
United 
Kingdom 
588 women with T1DM 
and T2DM. 
 
Intervention, n=240/588, 
40.8% received the 
intervention, control, 
n=297. 
Prospective 
cohort study. 
 
To investigate 
the association 
between PCC 
and obstetric 
outcomes, as 
well as 
pregnancy 
planning 
indicators. 
Oral PCC educational intervention provided by HCPs.  
 
Counselling regarding PCC. 
 
The content of the intervention was not described. 
 
The duration of the intervention was not specified. 
 
The face-to-face time with the women was not indicated. 
The PCC intervention led 
to significant 
improvements in HbA1c 
before (ORj 1.91, 95% CI 
1.10 to 3.04; P =.002) and 
during pregnancy (OR 
2.05, 95% CI 1.39 to 3.03); 
P<.001), and in the folic 
acid intake (OR 4.88, 95% 
CI 3.26 to 7.30; P <.001) 
in the intervention group 
compared with the control 
group. 
(11/18) 
Neff et al. (2014) - 
the Republic of 
Ireland 
505 women with 
T1DM. 
 
Intervention, n= 
70/505, 14% received 
the intervention, 
control, n=394. 
Retrospective 
cohort study. 
 
To analyse the 
effect of PCC on 
obstetric 
outcomes. 
Oral educational intervention provided by HCPs (DSNs, 
endocrinologists, dieticians). 
 
Advice regarding insulin therapy, discontinuation and the 
replacement of teratogens, such as ACE inhibitors and 
statins, intake of 5mg of folic acid and retinal assessment. 
 
The face-to-face time with the women was not indicated. 
 
PCC education led to 
better HbA1c (6.9 vs. 
7.8%); P <.001 and earlier 
presentation for PNC [(6 ± 
2 vs. 8 ± 6 weeks; P 
<.001) in the intervention 
group compared with the 
control group. 
 
 
(13/18) 
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Author or 
country 
Study population Methods or focus Intervention Findings Quality 
assessme
nt 
Kekäläinen et al. 
(2016) - Finland 
 
145 pregnancies to 
women with T1DM. 
 
Intervention, n=96/145, 
66% received the 
intervention, control, 
n=49. 
Retrospective 
cohort study.  
 
To evaluate the 
effect of 
pregnancy 
planning on 
glycaemic 
control and 
pregnancy 
outcomes. 
 
Oral educational intervention provided by HCPs (doctors). 
 
Advice regarding glycaemic control, screening for diabetes 
complications and hypertension, medication review, and folic 
acid supplementation. 
 
The face-to-face time with the women was not indicated. 
 
The intervention group had 
significantly lower HbA1c 
before conception (7.06% 
vs. 9.11%; P <.001) which 
was sustained throughout 
pregnancy (6.37% vs. 
7.28%; P <.001).  
 
The congenital 
malformation rate was 
lower (2.5% vs. 11.1%; P 
<.001) in the intervention 
group compared with the 
control group. 
(12/18) 
Egan et al. (2016) 
- Ireland  
414 women with T1DM and 
T2DM. 
 
Intervention, n=149/414, 
36% received the 
intervention, control, 
n=265. 
 
T1DM, n=111/269 (41%) 
received the intervention, 
T2DM, n=38/146 (26%) 
Prospective cohort 
study. 
 
To investigate the 
effect of a pre-
pregnancy 
educational 
programme on the 
risks of adverse 
pregnancy 
outcomes.  
Oral PCC educational intervention delivered by HCPs 
(endocrinologist, DSN and dietician). 
 
Structured pre-pregnancy care programme involving patient 
education, medication review, assessment and treatment of 
diabetes complications and thyroid function status, intake of 
5mg of folic acid, intensive glucose monitoring with 
preconception target HbA1c of <6.1%. Particular focus on 
the positive aspects of pregnancy.  
 
The face-to-face time with women was not indicated.  
The intervention group 
were less likely to smoke 
(8.7 vs. 16.6%, P=.03) or 
take teratogens at 
conception (0.7 vs. 6.0, 
P=.008) compared to the 
control group. 
First (6.8% vs. 7.6%, P 
<.001), second (6.2% vs. 
6.6%, P <.001) and third 
trimester HbA1c (6.1% vs. 
6.5%, P=.001) remained 
significantly improved, 
compared with the control 
group.  
(13/18) 
2. Evaluation of PCC educational intervention delivered via eHealth technology 
 
Charron- 
Prochownik et 
al. (2008) - the 
United States 
53 adolescent girls with 
T1DM (16-19.9 years). 
 
Intervention, n=37 (lCD-
ROM- 17, book-20), 
control, n=16. 
Randomised 
controlled trial. 
 
To develop and 
assess the clinical 
feasibility of a PCC 
programme for 
young women with 
DM. 
PCC educational intervention provided via the eHealth 
application. 
 
The READY-Girls programme was developed by the authors. 
The CD-ROM contained information on DM and its effects on 
reproductive health, sexuality, puberty and pregnancy; 
advantages of PCC; sessions on decision-making and 
communication skills development.  
 
The knowledge 
(F2,40.1=3.77; P= .03) and 
perceived benefits 
(F2,40.1=3.48; P=.04) of 
PCC significantly improved 
by the end of the study. A 
significant increase in the 
intention to seek PCC and 
(12/18) 
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The intervention participants watched a CD-ROM and 
received a comprehensive session on the content of the CD-
ROM at their routine clinic visit. This lasted for about an hour.  
utilise effective family 
planning (F1,37=5.75; P 
=.02) was recorded. 
Author or 
country 
Study population Methods or focus Intervention Findings Quality 
assessme
nt 
Fischl et al. (2010) 
- the United 
States 
88 adolescent girls with 
T1DM (13-19.9 years). 
Intervention, n=43, control, 
n=45. 
Randomised 
controlled trial. 
 
To assess the 
effectiveness of 
PCC on 
behavioural and 
cognitive 
outcomes. 
PCC educational intervention provided via eHealth 
application. 
The READY-Girls preconception care programme was used 
to promote the benefit of PCC. 
 
The intervention participants watched an educational CD-
ROM, read a book, and received a nurse consultation over 3 
consecutive clinic visits at intervals of 3 months. 
Knowledge (F=32.34;  
P <.001) and perceived 
benefit of PCC (F= 9.70; 
P=.003) increased by the 
end of the study. 
 
A significant improvement 
over time in the actual 
initiation of the PCC 
discussion with the 
diabetes health care team 
(F= 14.6; P<.001). 
(16/18) 
Holmes et al. 
(2012) - the United 
Kingdom 
97 women with DM (16-40 
years). 
 
T1DM, n=89, T2DM, n=8. 
Before and after 
study. 
 
To determine if an 
educational mDVD 
increases knowledge 
and changes the 
attitudes of women 
toward PCC. 
PCC educational intervention provided via the eHealth 
application. 
 
The authors developed and explored the use of a DVD to 
raise awareness of pregnancy planning and prevention of 
unplanned pregnancies. 
 
Women watched an educational DVD with information on 
pregnancy planning, contraception use, pregnancy 
complications, and PCC advice. 
 
The number of times they watched the DVD or the duration of 
the intervention was not reported. 
 
Significant improvement in 
self-confidence to use 
contraception to prevent 
unplanned pregnancies 
and access PCC (OR 3.3, 
CI 1.9, to 4.7; P<.001). 
 
Significant reduction in 
perceived barriers to PCC 
(OR -0.7, CI -1.2 to -0.2); 
P=.01). 
(12/18) 
Charron- 
Prochownik et 
al. (2013) – the 
United States 
 
109 adolescent girls with 
T1DM and T2DM (13-19 
years). 
 
Intervention, n=51, control, 
n=58. 
Randomised 
controlled trial. 
 
To examine the 
long-term effect of 
the READY-Girls 
programme on PCC 
knowledge and 
behaviour. 
PCC educational intervention provided via the eHealth 
application. 
 
The authors developed and explored the use of a DVD to 
raise awareness of pregnancy planning and prevention of 
unplanned pregnancies. 
 
Women watched an educational DVD with information on 
pregnancy planning, contraception use, pregnancy 
complications and PCC advice. 
 
Increased intention 
(F6,82.4= 2.56; P = .03) to 
initiate the diabetes 
discussion with HCPs. 
 
Significant increase in the 
intention to seek PCC and 
plan a pregnancy 
(F6,534=2.58; P=.02). 
16/18 
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 aDM: diabetes mellitus, bT1DM: type 1 diabetes mellitus, cT2DM: type 2 diabetes mellitus, dPCC: preconception care  
 eHCPs: Health care professionals, fDSN: Diabetes specialist nurse, gACE: angiotensin-converting enzyme, hPNC: prenatal care  
 iHbA1c: glycosylated haemoglobin, jOR: odds ratio, kREADY-Girls: Reproductive-health education and awareness of diabetes in youth for girls, lCD-
ROM: compact discs with read-only memory, mDVD: digital video discs. 
 
 
 
 
 
 
 
 
DVD-1 lasted an average of 36.3 mins ± 6.2, DVD-2: 25.4 
mins ± 7.4 and book: 20.4 mins ± 4.0.  
 
Author or 
country 
Study population Methods or focus Intervention Findings Quality 
assessme
nt 
Holmes et al. 
(2017) - the 
United Kingdom 
248 women with T1DM and 
T2DM.  
 
Intervention, n=135; 
watched DVD subgroup, 
n=58 (43%), Control, 
n=114. 
Prospective cohort 
study. 
 
To evaluate the 
effect of a regional 
implementation of a 
preconception 
counselling DVD 
into routine diabetes 
care on pregnancy 
planning indicators.  
The authors explored the use of a DVD resource to prepare 
women with DM for pregnancy. 
 
Women of childbearing age across Northern Ireland were 
given the educational DVD by their HCPs either face-to-face 
in clinics or by post.  
 
The DVD intervention contained three sections as follows: (1) 
things you need to know — information on contraception, 
risks, reasons for planning and a pre-pregnancy checklist; (2) 
things you might not know — support team, blood glucose 
target, ketoacidosis, hypoglycaemia and diet; (3) things you 
may want to know — information on 1st, 2nd and 3rd trimester, 
delivery and post-delivery.  
 
The DVD duration was 45 minutes. 
Women who watched the 
DVD were less likely to 
smoke at conception (1.9% 
vs. 20.6%, P=.02) 
compared with the control 
group. 
 
The intervention 
participants were also 
more likely to be taking 
5mg of folic acid (92.7% 
vs. 75%, P=.05) and have 
improved preconception 
HbA1c (7.3% vs. 8.2%, 
P=.02) compared with the 
control group.  
(14/18) 
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2.4 Findings 
The 14 articles reporting on 13 studies were grouped into two main categories based on 
their mode of PCC health education delivery: 
 
A. Evaluation of the PCC education provided by HCPs (n=9) 
B. Evaluation of the PCC education provided via eHealth technology (n=5).  
 
2.4.1 Evaluation of the PCC education provided by HCPs 
 
PCC education traditionally provided in clinical settings by health care professionals is 
associated with positive maternal and child health outcomes (Murphy et al., 2010b; Tripathi 
et al., 2010; Temple et al., 2006a, 2006b; Neff et al., 2014; Boulot et al., 2003; Galindo et al., 
2006; Kekäläinen et al., 2016; Egan et al., 2016). An overview of the interventions, outcome 
measures, and their effects are described in the following two points. 
 
1. Maternal health outcomes 
2. Child health outcomes 
 
2.4.1.1 Maternal health outcomes 
Of the included studies, two prospective cohort studies (Boulot et al., 2003; Galindo et al., 
2006) explored the effect of a PCC educational intervention on the levels of glycosylated 
haemoglobin (HbA1c). Boulot et al. (2003) assigned women with T1DM and T2DM to either 
an intervention group (n=175), where they received the PCC education before conception 
(PCC uptake was 48.5% in women with T1DM and 24% in women with T2DM), or to a 
control group (n=360) receiving standard care. The 435 women were recruited from tertiary 
perinatal centres. The results showed that the educational intervention was effective in 
enabling more women in the intervention group to attain HbA1c <8%. The intervention 
participants had improved HbA1c in the first trimester with a significantly lower number of 
women with T1DM (4.3% vs. 55%) and T2DM (2.9% vs. 27.9%) having HbA1c >8% 
compared with those in the control group (P<.001). 
 
In this study (Boulot et al., 2003), it can be seen that the PCC education played an important 
role in the improvement of glycaemic control and contributed to more women in the PCC 
group having HbA1c below 8% and closer to the recommended threshold. The results 
further indicated that glucose optimisation preconception and in the first trimester was 
achievable through PCC for both women with T1DM and T2DM. A similar study by Galindo 
et al. (2006) in Spain included women with both T1DM and T2DM. The intervention group 
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(n=15) received preconception counselling (uptake = 12%), whereas the control group 
(n=112) only presented to medical care when pregnant. Although Galindo et al. (2006) did 
not set out to measure the effect of a PCC intervention on maternal HbA1c, the intervention 
group had significantly improved HbA1c (<7%) compared with those in the control group 
(P=.02). 
 
Another prospective cohort study conducted in the United Kingdom (Temple et al., 2006a, 
2006b) considered the effect of PCC education on maternal HbA1c, spontaneous abortion, 
preterm deliveries, and gestational age at presentation for prenatal care. The educational 
intervention was provided to women of reproductive age attending the pre-pregnancy care 
centre (uptake = 37.9%). Statistically significant differences were found among the 
intervention participants who had improved and sustained HbA1c (6.5% vs. 7.6%; P<.001) 
throughout pregnancy, presented earlier for prenatal care (6.6 vs. 8.3 weeks; P<.001), fewer 
spontaneous abortions (5.7% vs. 14.0%, P=.06), and preterm deliveries (5.0% vs. 14.2%, 
P=.02). The results suggested that PCC was associated with a significant reduction in 
obstetric risks and improvement in glycaemic control.  
 
Temple et al. (2006a, 2006b) also found that in later pregnancy, the difference in HbA1c 
between the intervention and control groups became less pronounced, for example (5.5 vs. 
5.8%) in the 28th week and (5.6 vs. 5.8%) in the 32nd week of pregnancy, respectively. The 
reason for these comparable results was unclear from the study. However, the optimised 
HbA1c observed in the control group (in later pregnancy) may have been due to improved 
knowledge, skills and confidence to manage diabetes or improved diabetes care during 
pregnancy (Holmes et al., 2017). 
 
Two other prospective cohort studies (Murphy et al., 2010b; Tripathi et al., 2010) reported 
the effects of PCC education on HbA1c, gestational age at presentation for prenatal care, 
and folic acid intake in women with T1DM and T2DM. Murphy et al. (2010b) provided PCC 
education to women with T1DM and T2DM in a diabetes specialist clinic (uptake = 26.6%). 
During the 3-year study period by Murphy et al. (2010b), all women who received a 
structured education programme were assigned to the intervention group (n=181), while 
those who did not, were assigned to a control group (n=499). Significantly more women in 
the intervention group took 5mg of folic acid before conception (88.2% vs. 26.7%, P<.001), 
had significantly improved and sustained HbA1c values (6.9% vs. 7.6%; P<.001), and an 
earlier date of presentation for prenatal care compared with those in the control group (6.7 
vs. 7.7 weeks; P<.001).  
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The role of PCC education in promoting healthy preconception behaviours and pregnancy 
planning was also explored by Tripathi et al. (2010), who assigned women receiving PCC 
counselling to the intervention group (n=240; 40.8%) and those who did not, to the control 
group (n=297). The results showed that participants receiving the intervention had 
significantly improved and sustained levels of HbA1c (≤7% vs. >7%) 3 months before 
conception (P=.002) and during the first trimester of pregnancy (P<.001), higher rates of folic 
acid intake 3 months before pregnancy (P<.001), and presented earlier for prenatal care (≤8 
weeks vs. >8 weeks; P=.001) compared with the control group. 
 
Additionally, three recent studies (Neff et al., 2014; Egan et al., 2016; Kekäläinen et al., 
2016) reinforced the benefits of PCC education on HbA1c and pregnancy outcomes. Neff et 
al. (2014), in a retrospective cohort study, recruited women with T1DM from specialist 
diabetes centres and assigned to the intervention group those who received health 
education (n=70; 14%), while those in the control group had received standard care (n=394). 
The intervention participants had significant improvements to HbA1c <7% (6.9% vs. 7.8%; 
P<.001) and earlier prenatal care presentation (6±2 weeks vs. 8±6 weeks; P<.001) 
compared with those who received standard care. However, the effect on the rate of 
spontaneous abortion (10% vs. 16%, P=.12) or preterm delivery (15% vs. 15%, P=.46) was 
not found to be statistically significant. According to Neff et al. (2014), the significantly higher 
maternal age and weight in the intervention group may have reduced the effect of the 
intervention, and thus led to comparable results.  
Furthermore, the intervention group had HbA1c of 6.3% at delivery, indicating that 
educational PCC interventions can enable women to optimise their blood glucose levels and 
sustain this throughout pregnancy. This result is supported by Kekäläinen et al. (2016), who 
in another retrospective cohort study also allocated women with T1DM who received the 
PCC education (n=96; 66%) to the intervention group and those who did not, to the control 
group (n=49). Statistically significant differences were observed in the intervention group, 
who had improved and sustained HbA1c (7.1% vs. 9.1%; P<.001) and reduced adverse 
pregnancy outcomes (17.7% vs. 34.7%, P=.06).  
Similarly, Egan et al. (2016) in a prospective cohort study provided a pre-pregnancy care 
programme to women with T1DM and T2DM in specialist diabetes clinics across the Irish 
Atlantic seaboard. During the 8-year study period, women who received a standardised 
educational programme were assigned to the intervention group (n=149; 36%) and those 
who did not, to the control group (n=265). The results showed that the participants receiving 
the intervention had an increased folic acid intake (97.3% vs. 57.7%, P<.001), and also had 
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significantly improved preconception (7.4% vs. 8.1%, P=.002) and first trimester (6.8% vs. 
7.6%, P<.001) HbA1c, which was sustained throughout pregnancy. Although improvements 
in HbA1c for the intervention group remained statistically significant when compared to the 
control group, second (6.2% vs. 6.6%, P< .001) and third (6.1 vs. 6.5%, P=.001) trimester 
HbA1c for all participants had improved. Egan et al. (2016) also found similar miscarriage 
and pre-term delivery rates (P=.09) amongst the intervention and control groups. This 
supports the findings by Neff et al. (2014) indicating that a significantly higher maternal age 
may have lessened the effect of the PCC intervention, and the HbA1c levels of <7% 
maintained by both groups in the second and third trimesters may have contributed to the 
lower and comparable rates of adverse outcomes. 
 
2.4.1.2 Fetal health outcomes 
Boulot et al. (2003) demonstrated that women with T1DM who received PCC education had 
significantly lower rates of perinatal mortality and congenital malformation (P<.005) 
compared to those in the control group. Furthermore, women with DM whose HbA1c was > 
8% in the first trimester had double the risk of developing adverse fetal outcomes, such as 
perinatal mortality (P<.005), congenital malformation (P<.01), and preterm delivery (P<.005). 
Additionally, six further studies (Murphy et al., 2010b, Temple et al., 2006a, 2006b, Galindo 
et al., 2006, Kekäläinen et al., 2016, Egan et al., 2016) reported similar findings. Temple et 
al. (2006a, 2006b) and Egan et al. (2016) found that women who received a PCC 
educational intervention experienced a significantly reduced risk of adverse outcomes 
(including shoulder dystocia, stillbirths, and neonatal death) compared with those receiving 
standard care (P=.03; P=.007), respectively.  
 
Similarly, Murphy et al. (2010b) and Kekäläinen et al. (2016) found that the intervention 
participants experienced a significant reduction in congenital malformations compared with 
those in the control group (P=.009; P=.001), respectively. Furthermore, Egan et al. (2016) 
observed that the babies of the intervention participants had significantly reduced 
admissions to the neonatal intensive care unit (44.3% vs. 62.0%, P=.002) compared with the 
control group. Galindo et al. (2006) further identified a positive relationship between the 
increase in maternal HbA1c levels (>7%) and the occurrence of fetal malformations. 
Additionally, Tripathi et al. (2010) and Neff et al. (2014) found a significant association 
between the lack of preconception care education and the increased risk of adverse fetal 
outcomes (P=.03).  
 
Across all reviewed studies, PCC education was associated with improved HbA1c and 
reduced maternal and fetal adverse outcomes. However, most studies (n=8) reported low 
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levels of PCC uptake, ranging from 12% (Galindo et al., 2006) to 36% (Egan et al., 2016), 
amongst women with DM. 
 
 
2.4.2   Evaluation of the PCC education provided via eHealth technology 
Low levels of PCC uptake among women with DM have elicited interest in the use of 
multimedia technologies, such as CD-ROMs and DVDs as an intervention tool for PCC 
education.  
Four studies (Charron-Prochownik et al., 2008, 2013; Fischl et al., 2010; Holmes et al., 
2012) investigated the effect of eHealth technology on knowledge and PCC behaviours while 
one recent study (Holmes et al., 2017) investigated the effect of the eHealth intervention on 
maternal and child health outcomes. Charron-Prochownik et al. (2008), in an RCT, 
developed and used an interactive computer programme (CD-ROM) to promote PCC 
knowledge. Adolescent girls with T1DM, recruited from one diabetes clinic, were randomised 
to receive the 3-month CD-ROM intervention (n=37) or standard care (n=16). The outcomes 
were assessed using self-completed questionnaires at baseline, immediately following the 
CD-ROM viewing and at 3 months after the intervention. Significant improvement in 
knowledge (P<.05), perceived benefits (P=.04), and reduced barriers to seeking PCC 
(P=.01) were reported in the intervention participants. 
An RCT by Fischl et al. (2010), which lasted 9 months, similarly used an interactive CD-
ROM to deliver PCC health education. Adolescent girls with T1DM, recruited from two 
university-based diabetes clinics, were randomised to either the intervention group (n=43), 
where they watched 2 CD-ROMs, read a book, and met with a nurse for counselling, or 
standard care (n=45). This was conducted over three consecutive clinic visits at intervals of 
3 months. During the first visit, they viewed a CD-ROM containing information on diabetes 
and its effect on reproductive health, sexuality, puberty and pregnancy. The second visit 
involved viewing a CD-ROM containing tasks to improve communication skills related to 
seeking preconception counselling and the third visit involved reading a print version of the 
CD-ROM. After the final session, they met with a nurse to discuss issues relating to PCC. 
Compared with those receiving standard care, the intervention participants had significantly 
improved knowledge and perceived benefits of PCC (P<.001), reduced barriers to seeking 
PCC (P<.001), and an increased intention to initiate the PCC discussion with health care 
professionals (P<.001). The effect on the intention to use contraception was not significant 
(P=.10). 
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A UK, before and after, study by Holmes et al. (2012) sought to explore whether an 
educational DVD would improve PCC knowledge and behaviour. The participants were 
recruited from two National Health Service (NHS) hospitals. The intervention involved 
women watching the contents of a DVD and the outcomes were assessed pre- and post-
DVD intervention. Postal questionnaires were used in order to assess the beliefs and 
attitudes associated with preventing unplanned pregnancies and seeking preconception care 
before and after watching the DVD. Women with T1DM and T2DM (n=97) who watched the 
contents of the DVD individually in their homes showed a significant increase in perceived 
benefits and attitudes to contraceptive use (P=.001), receiving PCC (P=.003), knowledge of 
pregnancy planning (P<.001), and pregnancy-related risks (P<.001). There was a significant 
improvement in self-efficacy, that is participants’ self-confidence to use contraception to 
prevent an unplanned pregnancy and access PCC (p < 0.001), and knowledge of pregnancy 
planning and pregnancy-related risks (p<0.001).  
 
Charron-Prochownik et al. (2013), using an RCT, assessed the long-term effect (12 months) 
of an educational DVD on knowledge and attitudes to PCC in adolescent girls with T1DM 
and T2DM. The participants, recruited from two hospitals, received the intervention over 
three consecutive (clinic) visits. They viewed DVD-1 containing the PCC information at 
baseline, DVD-2 with exercises on the application of the information in DVD-1 at three 
months and read a book version of DVD-1 at six months. Participants, who were randomised 
to receive the intervention (n=51), demonstrated a significant increase in PCC knowledge 
(P=.001), and in their intention to discuss PCC and contraception with health care 
professionals (P=.03, P=.003), compared with those in the control group who received 
standard care (n=58). 
 
Finally, a more recent cohort study by Holmes et al. (2017) conducted across all five 
diabetes-antenatal clinics in Northern Ireland evaluated the effect of a preconception 
counselling DVD on the pregnancy planning indicators for women with T1DM and T2DM. 
Women who received and watched the educational DVD (n=58) were allocated to the 
intervention group and those who did not (n=114), to the control group. Women who 
received and watched the DVD at home were more likely to plan their pregnancies (87.5% 
vs. 64.7%, P=.001), take folic acid (80.7% vs. 42.3%, P<.001) and have improved HbA1c 
(6.7% vs. 7.4%, P<.001), which was sustained throughout pregnancy. Lower rates of 
miscarriage (1.7% vs. 14.0%, P=.01) and admission to the neonatal unit (26.8% vs. 32.6%, 
P=.05) were also recorded for the intervention group compared with the control group.  
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2.5 Methodological issues  
Research tools 
Nine studies exploring PCC education provided by healthcare professionals (Murphy et al., 
2010b; Tripathi et al., 2010; Temple et al., 2006a, 2006b; Neff et al., 2014; Boulot et al., 
2003; Galindo et al., 2006; Kekäläinen et al., 2016; Egan et al., 2016) and one study on 
eHealth technology (Holmes et al., 2017) used similar methods of data collection, e.g. 
medical records, pregnancy or birth records (both vital statistics and hospital records). There 
was also consistency in study findings, which increases the reliability of the data collection 
methods.  
 
The four research studies evaluating PCC education delivered via eHealth technology 
(Charron-Prochownik et al., 2008, 2013; Fischl et al., 2010; Holmes et al., 2012) utilised 
questionnaire surveys. The research tool (a theory-based reproductive health and diabetes 
instrument) was replicated across all four studies and the findings were similar, despite 
having been conducted in different settings (clinic and home) and on different dates. This not 
only increases the reliability of the data collection tool and quality of evidence, but also 
indicates that the instrument should be appropriate for this study. 
 
Reliability and validity 
All studies evaluating PCC education provided by healthcare professionals (Boulot et al., 
2003; Temple et al., 2006a, 2006b; Galindo et al., 2006; Murphy et al., 2010b; Tripathi et al., 
2010; Neff et al., 2014; Kekäläinen et al., 2016; Egan et al., 2016) and the study evaluating 
eHealth technology (Holmes et al., 2017) adopted a predominantly observational approach. 
They did not address the issue of reliability and validity within their studies. However, some 
confidence can be placed in the evidence generated for the following reasons: there was 
agreement in the results obtained across studies and the majority used appropriate 
statistical techniques in the form of logistic regression to confirm the association between 
PCC education and outcomes, thereby ruling out the effect of confounding factors. This 
increases confidence that the impact of the PCC educational intervention was more likely to 
be causally related to the outcomes, rather than to confounding factors.  
 
The other four studies on eHealth technology (Fischl et al., 2010; Charron-Prochownik et al., 
2008, 2013; Holmes et al., 2012) addressed reliability and validity through the use of a valid 
and reliable questionnaire. There was consistency in the use of the same instrument, that is, 
the Reproductive Health Attitude and Behaviour (RHAB) questionnaire. The role of 
confounders were minimised in three studies (Fischl et al., 2010; Charron-Prochownik et al., 
2008, 2013) where randomisation was used in order to reduce selection bias and 
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confounding. It is not evident whether Holmes et al. (2012) controlled for confounders (such 
as maternal age, weight, diabetes type, duration and diabetes complications), which may 
undermine the internal validity of the study. However, the overall findings across the four 
studies were similar and consistent, which increased the reliability of the findings. 
  
Sampling 
The studies on PCC educational interventions delivered by healthcare professionals utilised 
relatively large sample sizes (range: 127-680) (Murphy et al., 2010b; Tripathi et al., 2010; 
Temple et al., 2006a, 2006b; Neff et al., 2014; Boulot et al., 2003; Galindo et al., 2006; 
Kekäläinen et al., 2016; Egan et al., 2016). While the studies on educational interventions 
delivered via eHealth technology utilised smaller sample sizes (range: 58-248) (Charron-
Prochownik et al., 2008, 2013; Fischl et al., 2010; Holmes et al., 2012, 2017). Thus, the 
demonstration of statistical significance in studies utilising sample sizes under 100 (Charron-
Prochownik et al., 2008; Fischl et al., 2010) should be interpreted with caution. However, the 
successful use of smaller samples in the eHealth PCC studies, for demonstrating knowledge 
and behaviour change, suggested that similar studies can be conducted using smaller 
samples.  
 
Sample size calculation was mentioned in only two studies (Holmes et al., 2012, 2017). By 
not reporting sample size considerations, it is difficult to determine whether the authors 
considered the risk of type 1 or type 2 errors within their results. Furthermore, the small 
sample size and lack of power calculations in these educational PCC intervention studies 
limit the extent to which the study results can be generalised to a wider population of women 
with DM. Furthermore, the use of observational cohort design in several studies (Murphy et 
al., 2010b; Tripathi et al., 2010; Temple et al., 2006a, 2006b; Neff et al., 2014; Boulot et al., 
2003; Galindo et al., 2006; Kekäläinen et al., 2016; Egan et al., 2016; Holmes et al. 2017) 
may increase potential for selection bias. Additionally, due to the difficulty in recruiting 
women with T2DM, a lower representation of T2DM women was evident across all studies 
(Boulot et al., 2003; Holmes et al., 2012, 2017; Egan et al., 2016, Murphy et al., 2010b), 
which could in turn reduce the generalisability of the findings.  
 
Location of the data collection 
The interventions were all carried out in developed countries (as mentioned in section 2.3.1); 
the extent to which the findings can be applicable to other settings such as developing 
countries is limited. Also in recent times, the US and the UK appear to be channelling more 
effort into this area of research (see section 2.3.1). It is worth highlighting that the nature of 
PCC service provision in the UK has been described as fragmented and ranked poorly in 
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comparison to other European countries, such as the Netherlands (Murphy et al., 2010b). In 
terms of the use of eHealth technology for PCC, studies have only been conducted in the 
USA (n=3) and UK (n=2). The small number of studies using eHealth technology for PCC 
reflects the slow rate of eHealth adoption in this area of practice.  
 
Description of interventions  
The studies evaluating the PCC educational interventions provided by healthcare 
professionals were predominantly cohort studies (Boulot et al., 2003; Galindo et al., 2006; 
Temple et al., 2006a,b; Murphy et al., 2010b; Tripathi et al., 2010; Neff et al., 2014; 
Kekäläinen et al., 2016; Egan et al., 2016). These studies generally lacked information on 
the use of underlying theoretical models and on the duration of the PCC interventions 
provided in healthcare settings, while most studies assessing eHealth technological 
interventions (Fischl et al., 2010; Charron-Prochownik et al., 2008, 2013; Holmes et al., 
2012, 2017) adopted the expanded health belief model (EHBM) of behaviour change and 
provided information on the duration of the eHealth interventions. The majority of authors 
provided explicit descriptions of their interventions, thereby improving clarity with reference 
to the content of the interventions and the reliability, as studies can be replicated more 
easily.  
 
Description of outcomes 
Ten cohort studies, i.e. nine studies on PCC education provided by HCPs and one study on 
PCC education provided via eHealth technology, measured patient (maternal and child) 
outcomes: women’s HbA1c level (prior to pregnancy, and in the first, second and third 
trimesters), obstetric complications (including miscarriage or spontaneous abortions and 
preterm deliveries), gestational age at the first presentation for prenatal care, adverse 
outcomes (including congenital malformations, stillbirth, and neonatal death), pregnancy 
planning indicators (including folic acid intake and avoidance of teratogenic medications), 
and rate of admission to neonatal intensive care units (NICU). Four studies using eHealth to 
provide PCC education (Fischl et al., 2010; Charron-Prochownik et al., 2008, 2013; Holmes 
et al., 2012) measured behavioural outcomes: knowledge of PCC (pregnancy planning and 
pregnancy-related risks) and attitudes (including benefits, barriers and self-confidence to 
seek PCC). The authors were consistent in the outcomes measured, which in turn increased 
the reliability of the review result.  
 
2.6 Summary 
The review summarised and critically appraised the literature on current methods for 
providing PCC education to women with T1DM and T2DM. The effect of PCC educational 
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interventions (including the use of eHealth technology) on patient and behavioural outcomes 
were identified and examined in each case. Although the evidence was consistent across 
studies, only a limited number of robust controlled studies on PCC educational interventions 
for women with DM were found. The studies were generally of moderate quality, with only 
four assessed as high-quality (Murphy et al., 2010b; Fischl et al., 2010; Charron-Prochownik 
et al., 2013; Holmes et al., 2017). The methodological issues identified in these studies, 
including selection bias and confounding, call for caution in interpreting their findings. 
 
The reviewed evidence suggested that educationally-based PCC is instrumental to the 
achievement and maintenance of optimised HbA1c by women with T1DM and T2DM. The 
influence on preconception and first trimester HbA1c is of significance because fetal 
development (organogenesis) occurs before many women realise that they are pregnant. 
Optimised HbA1c during the early developmental stages contributes to a reduction in 
adverse pregnancy outcomes, which may help explain the significant reduction in perinatal 
mortality, preterm delivery and spontaneous abortions in the reviewed studies. Furthermore, 
the ability to achieve and maintain optimised HbA1c from preconception to delivery is of 
particular importance to women with T1DM for whom diabetes management and glycaemic 
control, are often difficult (Murphy et al., 2010b).  
 
PCC educational interventions also played an important role in motivating women with T1DM 
and T2DM to plan their pregnancy, take 5mg of folic acid, stop smoking and avoid 
teratogenic medications. Kekäläinen et al. (2016) observed that improved pregnancy 
planning amongst the intervention group reduced their rate of congenital malformation to that 
of the general population. Despite these positive benefits, the inadequacy in traditional PCC 
education in meeting the needs of women with DM was widely recognised (Murphy et al., 
2010; Tripathi et al., 2010; Boulot et al., 2003; Galindo et al., 2006; Kekäläinen et al., 2016). 
The PCC uptake was below 50% in all studies except one (Kekäläinen et al., 2016), and 
challenges across studies in terms of how to improve awareness and encourage women to 
seek PCC prevailed.  
  
eHealth technologies have shown considerable promise in terms of helping to deliver 
preconception health education that increases knowledge and supports behaviour change 
(Fischl et al., 2010; Charron-Prochownik et al., 2008, 2013; Holmes et al., 2012). This review 
highlighted their potential to empower women with DM to make informed reproductive health 
decisions that will reduce unplanned pregnancies and adverse outcomes. The study by 
Holmes et al. (2017) further demonstrated the role of eHealth PCC in improving HbA1c and 
pregnancy planning, and in reducing the rates of miscarriage and admissions to the NICU.  
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2.7 Gaps in the literature 
 
There are gaps within the literature with respect to knowledge and understanding, 
methodology and theory, each of which is explored below: 
 
a. Gaps in knowledge and understanding 
Preconception care education and its incorporation into eHealth technology (such as 
multimedia and mobile technology) appear promising as effective strategies for promoting 
the knowledge of PCC, and maternal and child health outcomes. Several researchers 
(Charron-Prochownik et al., 2008, 2013; Fischl et al., 2010; Holmes et al., 2012, 2017) 
utilised multimedia technology (CD-ROMs and DVDs) for the PCC education of women with 
DM. However, none of them utilised mobile technology, particularly smartphones (mobile 
phones with the capacity of internet and computers) or apps (applications designed to run on 
smartphones, which are increasingly being used to provide health education) in order to 
address the issue of inadequate PCC. Therefore, the scarcity of research that uses 
smartphone apps for PCC combined with the limitations of traditional PCC, underscore the 
need for research in this area. Furthermore, because it is unknown whether app use for PCC 
education is feasible and acceptable, a feasibility study is required.  
 
The review revealed that more women with T1DM (managed in specialist hospitals) than 
T2DM (managed in primary care within communities) received PCC advice. A lack of 
awareness of the PCC services provided predominantly in hospitals has been highlighted as 
a key reason for their low attendance rates at PCC clinics and uptake of PCC services 
(Murphy et al., 2010b). This highlights the need to use a more universal type of technology, 
such as smartphone apps, in order to reach women with both types of DM. Furthermore, 
only four out of fourteen educational interventions supported healthy behavioural changes 
through knowledge optimisation, and just two (Holmes et al., 2012; Egan et al., 2016) used 
positive intervention language. This highlights the need for the development of a PCC app, 
utilising a supportive approach, in order to optimise PCC knowledge and support healthy 
behavioural changes.  
 
Studies evaluating the effect of the PCC educational interventions provided by HCPs did not 
measure educational outcomes, thus it is unknown whether the PCC education had any 
effect on women’s PCC knowledge. Very few studies (n=4) also explored knowledge or 
attitudinal change as part of their investigations and only two included women with T1DM 
  
54 
 
and T2DM. This calls for a future study exploring knowledge and attitudes to PCC before 
and after the intervention, and that includes women with T1DM and T2DM.  
 
b. Gaps in methodology  
Although studies using eHealth for PCC were predominantly quantitative in nature, two 
(Charron-prochownik et al., 2008; Holmes et al., 2012) sought participant input prior to 
developing the technology (i.e. mixed methods research approach was used to some 
extent). However, in-depth user experience was not addressed. It is important for future 
eHealth studies to seek participant input prior to development and assess patient 
satisfaction. Clearly, there is a need for a feasibility study using mixed methods and a co-
design approach. 
 
c. Gaps in theory  
The review also revealed that most studies in this field (excluding those that used eHealth 
technology to provide PCC education) utilised an observational approach and were highly 
clinically oriented. As a result, they were not underpinned by theory or located within a 
conceptual framework.  
 
The issues and gaps highlighted within the review formed the basis of the research 
questions developed within the mixed methods study as described in Chapter 1.5. The next 
chapter presents the theoretical framework underpinning the app intervention and study. 
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3. Chapter 3: Theoretical framework and study design 
3.1 Theoretical framework overview 
The role of preconception care (PCC) in reducing risks of pregnancy-related complications 
and adverse outcomes was demonstrated in the previous chapters, which also showed the 
inadequacy in current PCC uptake and slow eHealth adoption rate in this field. Despite the 
global increase in smartphone-based health app usage (Eng and Lee, 2013; Silva et al., 
2015), there is a dearth of evidence exploring how this technology can be used to support 
improved PCC behaviours. Predicted increases in the number of women with DM of 
childbearing age means that there is an urgent need to adopt a more innovative approach.  
This section will discuss the theoretical frameworks used (Figure 3.1). The rationale for the 
PADI app intervention developed and used in the study, and anticipated benefits will be 
explained.  
3.2 Normalisation process theory (NPT) 
New technological interventions that address behaviour change are more likely to result in 
significant effect on health and care when they are implemented and ‘normalised’ into 
practice (Murray et al., 2010). However, technological health innovations are often faced with 
implementation challenges after development, resulting in a gap between new technology 
and its recommendation to patients (Grol and Grimshaw, 2003; Woolf, 2008). Hence, the 
use of theoretical frameworks, such as knowledge to action (KTA), implementation of 
change model, PARIHS (promoting action on research implementation in health services) 
model and normalisation process theory (NPT), have been recommended (Rycroft-Malone, 
2004; Graham et al., 2006; Grol and Wensing, 2013; May et al., 2009; Murray et al., 2010). 
These implementation theories map onto the broader field of implementation science (IS) — 
the study of techniques to promote the integration of research findings and innovations into 
health policy and practice (Eccles and Mittman, 2006; May et al., 2011; Murray et al., 2010).  
 
Normalisation process theory (NPT) developed by May et al. (2009) and noted to be 
particularly useful for behaviour change interventions, was deemed the most useful 
framework to guide the feasibility study and support the early development stages of the 
PADI app. The framework helps to optimise development, evaluation and implementation of 
eHealth interventions, and bridge the translational gap between research and practice (May 
et al., 2007, 2011; May and Finch, 2009; Murray et al., 2010; Morrison and Mair, 2012). 
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FRAMEWORK 1          FRAMEWORK 2 
(Normalisation process theory)        (Expanded Health Belief Model)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.1 The two frameworks (NPT and EHBM) underpinning the PADI app development and study 
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NPT is a well-established theory, adopted and used by over 200 studies to guide 
intervention implementation. It also helps researchers to recognise factors that promote or 
inhibit the integration of new technology into routine practice; it explains how interventions 
will work, become sustainable and ingrained into everyday practice such that it ‘disappears’ 
from view (i.e. becomes normalised). NPT seeks to identify component parts for 
understanding and evaluating the process (implementation) that would enable an 
intervention, such as the PADI app, not only to be incorporated and normalised into 
everyday work of individuals and groups (embedded), but also sustained in practice 
(integration) (Murray et al., 2010).  
 
NPT has four constructs that enable early consideration of factors that may affect adoption 
and implementation of an intervention at the individual, clinician and organisational level. 
The constructs highlight crucial areas of consideration prior to developing a new technology 
and help to ensure that (1) the technological intervention would be easy to understand, 
meaningful and beneficial to participants and healthcare organisations (coherence/sense 
making), (2) the target user groups would see the intervention as a good idea and be 
committed to investing time, energy and work into its implementation (cognitive 
participation/engagement), (3) it will fit with existing working practices and skill set, and 
target user groups would be prepared to do the work needed for the intervention to happen, 
e.g. using it in routine practice (collective action), (4) participants can appraise the 
interventions and contribute feedback which can be used to improve the intervention 
(reflexive monitoring). In order to give the app the best chance of being accepted and 
adopted by women with DM, healthcare professionals and healthcare organisations, it was 
important that this study addressed the issues raised within the NPT constructs. It was 
envisaged that this would be achieved by using NPT to guide the intervention development 
and study design (as described in chapter 4, phase 1 development). Table 3.1 below 
describes the four NPT constructs in more detail.  
 
Using NPT to guide the intervention development  
Adoption of new innovations in practice affects both patients and HCPs because it 
constitutes a new way of receiving care and / working. Hence, Presseau et al. (2009) 
highlight clinician time-constraint and patient preference as potential barriers to adoption and 
acceptance of a new technology. In order to identify potential factors (barriers and 
facilitators) that could affect adoption or acceptance of the PCC app, a co-design approach 
with HCPs and women with DM would be used (see Chapter 4). This approach would help to 
ensure that target user groups are involved in the development of the app and that their 
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views (including any concerns) regarding the app use in practice are explored. It is 
recognised that interventions which are difficult to understand or fit into normal daily practice 
would not appeal to HCPs or policy makers (Mair et al., 2008; Murray et al., 2010), hence 
this co-design approach would help to optimise the intervention content, features and 
design. An exploratory study would be an appropriate approach to elicit participants’ views 
and inform the app development 
 
Table 3.1 Normalisation Process Theory (NPT) constructs 
NPT construct and components Topic areas to consider and explore within 
the framework and study 
Coherence: Sense-making work that people do when they 
are faced with operationalising a new technology. 
 
Differentiation:  
Understanding how a set of practice differs from each other, 
e.g. face-to-face consultation and use of eHealth.   
 
Communal specification: 
People working together to build a shared understanding of 
the aims, objectives and benefits of a set of practice or a 
way of working.  
 
Individual specification:  
Understanding specific tasks and responsibilities around a 
set of practice or way of working.  
 
Internationalisation:  
Understanding the value, benefit and importance of a set of 
practice or way of working.  
 
 
 
 
 
The value attributed to introducing a new eHealth 
intervention, i.e. the PCC app and the meaning it makes 
to participants. 
 
Is the intervention easy to understand and describe? 
 
Is it different from other interventions?  
 
Does it have a clear purpose and do participants have a 
shared sense of its purpose? 
 
Are the benefits likely to be valued by women with DM 
and HCPs?  
 
Cognitive participation: relational work that people do to 
build and sustain a community of practice around a new 
technology.  
 
Initiation:  
A core problem, and whether or not key participants are 
driving a new set of practice forward. 
 
Enrolment:  
Participants may need to organise or reorganise themselves 
in order to contribute to the work involved – rethinking 
relationships.  
 
Legitimation:  
Ensuring participants believe that they can make a 
contribution.  
 
Activation: 
Identifying the actions and procedures required to sustain a 
new practice.  
 
 
 
 
 
The commitment made by participants. 
 
Are HCPs and women with DM likely to think that it is a 
good idea? 
 
Can they see the point of the intervention easily? 
 
What kind of skills and experience do participants have 
with regards to using apps and technology for 
healthcare? 
 
Will HCPs and women with DM be prepared to invest 
time, energy and work into it? This includes undergoing 
any training or investing time needed to deliver the 
intervention? 
Collective action: operational work that people enact to 
make a new technology function; previously referred to as 
normalisation process model (NPM). 
 
Interactional Workability (IW):  
How an e-health intervention might affect interactions 
between people and practices.  
 
 
Effort invested in the intervention by participants.  
 
How will providing the PCC app intervention affect the 
work of HCPs? Do they think it would promote or impede 
their work? 
 
What effect will it have on the support they offer to 
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Relational Integration (RI):  
How the intervention might affect the existing knowledge and 
relationships.  
 
Skill Set Workability (SSW): 
How the intervention might affect the current division of 
labour. This reveals the degree to which the e-health 
initiative will fit with existing working practices, skill set and 
perceived job role. 
 
Contextual integration (CI):  
How the intervention might affect the organisation in which it 
is set.  
women? 
 
Do they think it would change (i.e. enable or impede) 
interactions between HCPs and women with DM? 
Is the work compatible with their current working 
practices? 
 
How would the intervention impact on their workload, and 
what impact will there be on resources such as time? 
 
How does it fit with the overall goals of their 
organisations, their capacity to undertake the 
implementation and wider policy agenda?  
Reflexive monitoring: appraisal work that people do to 
assess and understand how a new technology affects them 
and others. 
 
Systematisation: Participants may seek to determine how 
effective and useful it is for them and others.  
 
Communal appraisal: Participants work together to evaluate 
the worth of a set of practices- is it working? 
 
Individual approval: Participants work experientially to 
appraise its effect on them and the context (an intervention 
that is complicated to use or adds to HCPs’ workload may 
well have low uptake even if beneficial to patients). 
 
Reconfiguration: Modifying, redefining or changing a 
technology to make it workable in practice.  
 
 
 
Perceptions of benefit to patients and HCPs.  
 
How do users perceive use of the intervention, is it likely 
to be perceived as advantageous for patients? 
 
What may be required to make the intervention workable 
in practice? Can users contribute feedback about the 
intervention and is there room for the intervention to be 
adapted or improved following user experience? 
 
Using NPT to guide the study design 
Mair et al. (2012) note that many eHealth implementation efforts are unsuccessful due to 
inadequate consideration of the wider issues, outlined in the NPT constructs, which affect 
implementation of technological innovations in healthcare setting. Hence, the first phase of 
the study would be designed to ensure that important contextual issues that can affect future 
implementation of the PADI app, are incorporated in early discussion of the app 
development. To achieve this, a qualitative approach incorporating focus groups and 
interviews would be adopted (see Chapter 5); the discussion would explore whether 
participants (HCPs and women with DM) perceive the PCC app intervention as potentially 
useful to women with DM and healthcare organisations (general practices and NHS 
hospitals) that provide PCC, and if they would be willing to recommend and adopt it within 
their respective healthcare organisations. It would also be important to understand how the 
app would fit into routine practice, affect current PCC service provision and if it would be 
consistent with existing work practices (see Chapter 6, for phase 1 results).   
 
It was also envisaged that exploring user experience, following development and preliminary 
testing of the app, would provide useful feedback that could inform future development of the 
app intervention. This warranted the inclusion of a qualitative component to the quantitative 
behaviour change intervention. Hence a mixed methods research methodology, with 2 
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phases, would enable the development of the app via a co-design approach, and 
establishment of intervention feasibility and acceptability.  
 
3.3 Behaviour change intervention for women with DM 
Based on the theory of behaviour change (Expanded Health Belief Model), this study aimed 
to develop an intervention that would address a number of factors associated with PCC and 
shortfalls in service provision that women with DM experience (Earle et al., 2017; O’Higgins 
et al., 2014; Infanti et al., 2014). It has been recognised that insufficient access, a lack of 
information, poor clinician knowledge and PCC uptake, contribute to inadequate pregnancy 
planning and blood glucose control, which can contribute to increased prevalence of 
preventable obstetric complications (O’Higgins et al., 2014; Earle et al., 2017). In addition, 
teratogenic medications (e.g. ACE inhibitors and statins) which should be avoided before 
pregnancy are increasingly used for hypertension, reno-protection and cardiovascular risk 
reduction in patients with DM.  
Many women with DM are also not sufficiently aware of the benefits of health promotion (e.g. 
folic acid intake, physical activity and healthy diet) and health checking behaviours 
(attending screening for microvascular complications), or the need to avoid health risk 
behaviours (e.g. inadequate blood glucose control, smoking and alcohol consumption) 
before and during pregnancy (McCorry et al., 2012; Dean et al., 2013; Xaverius et al., 2013; 
O’Higgins et al., 2014). Hence, as most women tend to seek medical care after conception 
(Galindo et al., 2006; Frayne et al., 2016), a more innovative means of providing PCC 
information and changing behaviours, is paramount.  
Improved PCC awareness and behaviours in women with DM is vital to reducing pregnancy 
related risks (Earle et al., 2017; Holmes et al., 2012), and smartphone apps provide a 
platform through which health behaviours of individuals and groups can be changed 
(Prestwich et al., 2018). According to Handel (2011), a recognised benefit of mobile health 
apps is that they support patient-centred models of healthcare, which emphasise patient 
involvement and self-management. Consequently, app-based interventions that support 
people to make healthy behavioural changes such as quitting smoking, achieving healthy 
weights, reducing alcohol consumption and eating healthier diets have increased rapidly 
(Free et al., 2011; Gustafson et al., 2014; Zhao et al., 2016). The need for women with DM 
to become more actively involved in PCC and have the confidence to involve the diabetes 
team in pregnancy planning to help achieve a healthy pregnancy and baby, have been 
highlighted (ADA, 2003; Wouters, 2005). Hence, a PCC app, underpinned by the expanded 
health belief model (EHBM), would be instrumental in providing health education needed to 
change behaviours and support women to become more proactive in planning a pregnancy. 
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3.3.1 The expanded health belief model (EHBM) 
The PCC app intervention was designed to alter cognitive factors embedded within the 
constructs of the Expanded Health Belief Model (EHBM), a social cognitive model used to 
predict health behaviours. The EHBM is underpinned by six main constructs that are 
believed to influence behaviour change (Figure 3.2): Perceived Susceptibility, Perceived 
Severity, Perceived Benefits, Perceived Barriers, Cues to Action, and Self-Efficacy (Burns, 
1992; Charron-Prochownik et al., 2001). 
 
 
 
 
 
1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Expanded Health Belief Model (EHBM) constructs 
 
 
  
1. Perceived Susceptibility 
2.  
Perceived Severity 
3. Perceived Benefits 
4. Perceived Barriers 
5. Cues to action 
6. Self-efficacy 
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Perceived susceptibility is the perception of vulnerability to reproductive health problems e.g. 
pregnancy-related complication while perceived severity is the belief of the seriousness of 
the problem. Perceived benefits is one’s opinion that a behaviour change e.g. seeking PCC 
will promote positive reproductive health, and perceived barriers is the assessment of 
obstacles that may deter a behaviour change (Janz and Becker, 1984). Cues to action are 
people, actions, or things that trigger a change in behaviour (Stretcher and Rosenstock, 
1997).  Self-efficacy is the belief or confidence in one’s own ability to perform effective 
reproductive health behaviours e.g. using contraception to prevent an unplanned pregnancy 
(Bandura, 1977; Charron-Prochownik et al., 2001).  
 
The EHBM proposes that knowledge improves attitudes (perceived benefits and self-efficacy 
minus barriers) which then increases likelihood of a behaviour change. Motivational cues 
(ability to make informed decisions and discuss PCC with a HCP) also contribute to 
behaviour change. It was anticipated that the PCC app intervention would help improve 
knowledge and attitudes, and result in behaviour change particularly regarding optimising 
blood glucose levels, seeking PCC and preventing unplanned pregnancy. According to 
Charron-prochownik et al. (2001), several major constructs of the EHBM correlate with 
reproductive health behaviours in women with DM. In a study by Janz et al. (1995), the 
construct of perceived benefits was found to be most influential. Women who received PCC 
were more knowledgeable and perceived greater benefits of PCC for themselves and their 
babies. For eHealth PCC studies, similar findings were noted. Compared to the standard 
care group, the intervention group had greater perceived benefits of reproductive health and 
PCC along with fewer barriers to seeking PCC (Charron-Prochownik et al., 2008, 2013; 
Fischl et al., 2010; Holmes et al., 2012). The use of EHBM in several eHealth studies 
exploring PCC, helped inform the decision to use it in this study.  
 
3.3.2 The preconception and diabetes information (PADI) app intervention  
 
The aim of PCC is to optimise each woman’s health before pregnancy in order to decrease 
risks during pregnancy and improve birth outcomes (Frayne et al., 2016). Evidence suggests 
that women’s PCC knowledge and attitudes are key factors that contribute to inadequate 
PCC uptake and pregnancy planning (Spence et al., 2010; Earle et al., 2017). For example, 
despite the established effects of folic acid (De-regil et al., 2010), less than one-third of all 
women take or aware of the importance of preconception folic acid. Additionally, the 
literature suggests that patients with DM who are more knowledgeable about PCC, are more 
likely to plan their pregnancies, seek PCC and to have improved health outcomes (Holmes 
et al., 2012; 2017).  
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National and international guidelines (NICE, 2015; Frayne et al., 2016) have identified 
healthy behaviours which when adopted before and during pregnancy reduce risks of 
complications and adverse outcomes. These include use of contraception to avoid 
unplanned pregnancy, folic acid supplementation, registering for prenatal care in the first 
trimester, smoking and alcohol cessation, attaining a healthy weight, absence of infection 
(e.g. human immunodeficiency virus and sexually-transmitted infections), optimal blood 
glucose control, avoidance of teratogenic and over-the-counter medications, as well as 
discussing pregnancy intentions with the healthcare team.  
 
For most people, behaviour change occurs gradually over time with the individual 
progressing from one stage to the other and for many health behaviours, initiation does not 
lead to significant benefits unless these changes are maintained over an extended period of 
time (Prestwich et al., 2018). Poor rates of adherence to behaviours highlight the need for 
improved self-management strategies (Handel, 2011); one way to improve self-management 
is through remote access to health information, via smartphone apps (Calvillo et al., 2013; 
Zhao et al., 2016). Apps are also useful for educating, supporting and encouraging patients 
to adopt healthier behaviours in order to improve health outcomes (Mertz, 2012; Prestwich et 
al., 2018).  
The PADI app would therefore be developed to improve the PCC that women with DM 
receive. It was anticipated that providing comprehensive PCC information and advice via a 
smartphone application would help improve the process by which women with DM receive 
PCC information and advice.  
 
The PADI app would provide information and advice on the topics, outlined in figure 3.3 
below (subject to changes according to results from the research process). This would be 
done in order to increase awareness regarding pregnancy planning and pregnancy-related 
risks; encourage women to prepare for pregnancy (e.g. stop smoking, have BMI in normal 
range, take 5mg folic acid), optimise blood glucose levels before and during pregnancy, 
collaborate with diabetes team during pregnancy planning and make informed reproductive 
health decisions that would reduce risk of complications and adverse outcomes (e.g. using 
contraception until recommended HbA1c is attained).  
 
The intervention would use a supportive approach, and also provide social support, 
instruction on how to perform the behaviours, and self-monitoring of blood glucose (SMBG) 
function. The PCC app intervention would therefore aim to empower women with the 
knowledge and confidence to take control of their health, plan their pregnancies, adopt and 
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maintain behaviours that would increase the likelihood of a healthy pregnancy and baby. 
Furthermore, it was envisaged that a feasibility study would help provide preliminary 
information on intervention acceptability, satisfaction, and effect on knowledge, attitudes and 
behaviour.  
 
 
 
 
  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.3 PADI app information topics 
 
Summary 
The preceding section has discussed the behaviour change theory which underpinned the 
PADI app intervention and the normalisation process theory used to guide the intervention 
development and study. The rationale for the PADI app content and the predicted 
mechanism of behaviour change (based on the EHBM) have been discussed. A mixed 
methods research approach, encompassing an initial qualitative study followed by a 
quantitative and qualitative strand, are identified as the most appropriate research 
methodology to support the two theoretical frameworks used in this study.  
 
2. Pregnancy and diabetes 
3. Blood glucose management 
 4. Pregnancy preparation (e.g. taking folic acid, and discussing pregnancy intentions and 
medications with diabetes team) 
5. Lifestyle modification (e.g. physical activity, diet, weight, smoking and alcohol 
cessation) 
 
6. Regular chronic care monitoring (e.g. HbA1c 
and microvascular complications) 
7. PCC checks (e.g. vaccination 
and infections) 
1. Contraception use 
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3.4 Study design overview 
A mixed methods feasibility study with two phases, phase 1 (PADI app development) and 
phase 2 (feasibility and acceptability of intervention), was used in this study. Phase 1 
explored participants’ PCC views and experiences, as well as their opinions regarding the 
development and use of the Preconception and Diabetes Information (PADI) app, while 
phase 2 provided information regarding preliminary intervention estimates, experiences and 
satisfaction with the app content and functionality. The mixed methods study design is 
discussed in detail in Chapter 4 and 5. This section explores the epistemological approach of 
the study and the philosophical basis of the mixed methods research, specifically focusing 
on a feasibility study. The specific mixed methods research approach used, as well as the 
stages of intervention development and evaluation are then considered. Finally, the ethical 
considerations of the study and practicalities issues are discussed.  
 
3.5 Epistemology 
There are three main approaches to research — quantitative, qualitative and mixed 
methods. Debates about these three research approaches date back to ancient Western 
philosophy and are still ongoing (Johnson et al., 2007). On the one hand, there are those 
(e.g. Socrates and Plato) who believe in singular/universal truths, others who believe in 
multiple/relative truths (e.g. sophists such as Georgia and Protagoras), and those who 
believe in mixtures of the two extremes (e.g. Aristotle’s golden mean and Hume’s moderate 
scepticism) (Johnson et al., 2007). These debates continue to affect how we gain knowledge 
— our expectations and view of knowledge, and the methods we use to gain knowledge.  
 
Generally, mixed methods research is an approach to knowledge that considers multiple 
perspectives and viewpoints (including quantitative and qualitative research) (Johnson et al., 
2007; Creswell and Plano-Clarke, 2011). The distinction between quantitative and qualitative 
research lies in the philosophical assumptions of each, i.e. post-positivism and 
constructivism respectively, and the methods they use to investigate a particular area of 
interest. Quantitative research is based on the assumption that behaviour can be explained 
using objective facts that are independent of the researcher; it uses hypotheses to examine 
the relationship between variables in order to establish cause and effect (Scotland, 2012; 
Creswell, 2014). Post-positivists employ methods that enable the replication and comparison 
of groups e.g. experiments and surveys (Creswell, 2014). In contrast, qualitative research 
follows the notion that multiple realities exist, it is subjective and based on interactions with 
people (Guba and Lincoln, 1994; Creswell, 2014). Qualitative researchers make sense of 
data and interpret the meanings people make of the world, thus the constructivist generates 
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theory and patterns of meaning by using focus groups, observations and unstructured or 
semi-structured interviews (Creswell, 2014). 
 
Despite the acceptance of mixed methods research (MMR) as a distinct methodology, many 
unresolved questions exist about the philosophical assumptions underpinning this approach 
(Creswell, 2014; Johnson et al., 2007). These philosophical assumptions are ‘a set of beliefs 
that guide inquiries’ (Creswell and Plano-Clarke, 2011) and perspectives used to look at the 
world (Bowling, 2009). Philosophical assumptions are also referred to as worldviews or 
paradigms. Advocates of mixed methods have therefore proposed the following paradigms 
for MMR: Transformative-emancipatory, Pragmatism, Critical Realism and Dialectics. 
However, pragmatism has remained one of the most commonly used paradigms because it 
offers the best opportunities for answering research questions and enhancing knowledge on 
a specific research topic (Johnson and Onwuegbuzie, 2004; Bryman, 2007; Creswell and 
Plano-Clarke, 2011; Johnson et al., 2007; Morgan, 2007; Tashakkori and Teddlie, 2010). 
 
Proponents (Morgan, 2007; Creswell, 2014; Creswell and Plano-Clarke, 2011) argue that in 
pragmatism, the world is not seen as ‘an absolute unity’, thus in mixed methods research, 
various approaches to data collection and analysis are considered, rather than an absolute 
subscription to one method alone (such as quantitative or qualitative). Hence, this study 
upholds the pragmatic paradigm and does not embrace any one system of philosophy and 
reality in particular, as there is freedom of choice in utilising both qualitative and quantitative 
methods and assumptions in developing and testing the PADI app intervention (Creswell, 
2014). Furthermore, Johnson et al. (2007) argue that pragmatism provides an 
‘epistemological justification’ and logic for mixing approaches and methods in research 
because the combination of methods and ideas helps to adequately frame, address and 
answer different research questions. This paradigm supports the use of both qualitative and 
quantitative research questions in this study (see Chapter 1).  
 
As a philosophical underpinning for mixed methods, the ultimate value of pragmatism lies in 
the incorporation of different methods, paradigms, as well as approaches to data collection 
and analysis, while investigating a research topic. Thus, due to the multi-faceted, complex 
and dynamic nature of health service research, it is evident that neither constructivism nor 
post-positivism alone should constitute the sole approach to scientific enquiry. However, in 
accepting pragmatism, there is a danger of over-prioritising research questions such that 
they become more important than either the method or philosophical assumption that 
underlie the methods. Yet, it is evident that agreeing with only one view will not provide the 
most informative, complete, balanced and useful research results nor will it provide an in-
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depth understanding of the research problem or topic (Johnson et al., 2007; Tashakkori and 
Teddlie, 2010; Creswell and Plano-Clarke, 2011).  
 
A key criticism of the pragmatic approach is that mixing quantitative and qualitative methods 
can be deemed inappropriate (Greene, 2008; Mertens, 2012), especially with reference to 
philosophical assumptions. Pragmatism has nevertheless gained popularity as a 
philosophical perspective because it is the foundation for the rejection of the incompatibility 
thesis and addresses the dualism that drives the ‘paradigm wars’ (Bryman, 2006, 2007; 
Biddle and Schafft, 2015). It provides support for building a practical, multi-perspective and 
flexible research philosophy. Greene and Caracelli (1997) acknowledge that while 
philosophical differences exist between various methods of inquiry, these philosophical 
perspectives are independent and can be mixed (using appropriate methods) to achieve the 
best combination for a given scientific enquiry. With this in mind, mixed methods was 
deemed the best research approach for this study.  
 
3.6 Mixed methods research approach 
Mixed methods, often referred to as a new methodology, the origin of which dates back to 
the late 1980s and early 1990s, has been in use in medicine and epidemiology since the 
mid-19th century (Maxwell, 2016). It came into existence from the efforts of several writers 
from different disciplines, who searched for means to systematically and coherently combine 
qualitative and quantitative methods into a distinct type of research. Creswell and Plano-
Clarke (2011) however link the origin of mixed methods to Campbell and Fiske (1959), who 
discussed the need to include multiple forms of quantitative data in studies investigating 
behavioural characteristics, and Denzin (1978), who advocated the use of multiple data 
sources, both qualitative and quantitative in nature, in the conduct of scholarly studies. The 
evolution of mixed methods research (MMR) over the years has largely been due to the 
growing complexity of research problems and the need for more evidence-based research in 
applied settings (Creswell, 2014; Creswell and Plano-Clarke, 2011).  
 
The Medical Research Council (MRC) guidance on the development and evaluation of 
complex health interventions highlights the importance of incorporating both qualitative and 
quantitative methods within a single study to enhance its findings (Craig et al., 2008). 
However, the evidence derived from the reviewed literature in Chapter 2 indicated that there 
was a scarcity of mixed methods research exploring the use of technology for the PCC of 
women with DM. This was an important element of consideration during the formulation of 
the research questions and study design. The MMR approach is of particular benefit in 
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mHealth development and feasibility studies where the research questions are best 
answered by a combination of two or more approaches (Mummah et al., 2016).  
 
3.6.1 Embedded sequential mixed method approach 
 
An embedded design is a mixed methods approach where a second method is embedded or 
nested within a primary research method (Creswell, Plano Clarke, 2011). In this design, the 
researcher may add a quantitative (supplemental) strand / phase, such as an intervention, to 
a larger qualitative design such as an exploratory study. The purpose of including the 
quantitative data are tied to but different from the purpose of the qualitative data.  
 
In an embedded sequential design (Figure 3.4), the qualitative and quantitative strands are 
implemented in two distinct phases, with data collection and analysis of one type of data 
occurring after the collection and analysis of the other data type. In line with the principles of 
embedded MMR design, the researcher will begin by collecting and analysing qualitative 
data (i.e. focus groups and interviews) to understand the participants, establish a need for 
and inform the intervention. Using these results, the researcher will develop a relevant 
intervention (i.e. the PADI app) and test it with a quantitative (before and after study) design. 
Following the quantitative phase, a qualitative phase will also be conducted to enhance 
understanding of the quantitative phase and obtain participants’ feedback in order to improve 
the intervention (Creswell, Plano Clarke, 2011). The two methodologies used in this 
embedded design are distinct and will be implemented independent of each other; the data 
collection and analysis will also be kept separate.  
 
The point of integration, i.e. the explicit interrelating of the study’s quantitative and qualitative 
strand, is a point within the process of MMR where the quantitative and qualitative strands 
are mixed (Morse, Niehaus, 2009; Creswell, Plano Clarke, 2011). According to Creswell and 
Plano Clarke (2011), mixing occurs at four points during an MMR study: design, data 
collection, data analysis or interpretation. The researcher will only mix / bring the two strands 
together during the discussion (interpretation) of the results. This is the only point in the 
research process where mixing will occur. Mixing during interpretation occurs when the 
quantitative and qualitative strands are mixed during the final step of the research process, 
after the researcher has collected and analysed both sets of data. It involves drawing 
inferences / conclusions that reflect what was learned from the combination of results (see 
Chapter 8).  
 
Mixed methods research helps to improve an intervention, facilitate the interpretation of 
study findings and identify interventions that are more likely to be effective in larger future 
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studies (O’Cathain et al., 2013). Hence, MMR would help provide a detailed justification as 
to why the PADI app intervention does or does not work (Mummah et al., 2016; Whittaker et 
al., 2012). In order to ensure success, health interventions should undergo various stages of 
development and evaluation, as discussed below.  
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Fig 3.4 Embedded mixed methods research (Adapted from Creswell and Plano Clarke, 2011)
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3.7 Stages of intervention development and evaluation  
To ensure that an intervention is as effective as possible, the MRC guidelines recommend 
that the development of the intervention should be based on available evidence and theory, 
followed by feasibility and pilot testing, along with a large-scale evaluation using RCT and 
implementation (Craig et al., 2008). More recently, development and evaluation frameworks 
(Whittaker et al., 2012; Mummah et al., 2016) have been specifically developed for mobile 
app interventions and these supports, build on and extend the MRC framework (Craig et al., 
2008).  
 
Furthermore, Craig et al. (2008) argue that the various stages are not necessarily linear or 
cyclical, as this is dictated by the design of the study in question. Nevertheless, the authors 
recommend following a systematic approach and the PADI app intervention started with the 
development phase. A combination of all three evidence-based frameworks was therefore 
used to inform the PADI app development (Table 3.2). 
 
Table 3.2 PADI app development and evaluation process 
 
Stages  Components 
Development   Identification of evidence base and theory. 
 In-depth understanding of the target population (via interviews and 
focus group discussions). 
 Develop prototype and gather feedback.  
 Build an initial intervention incorporating app analytics.  
Feasibility and acceptability  Conduct a small-scale evaluation (with or without randomisation) to 
test potential efficacy. 
 Analyse app usage behaviour. 
 Assess usability and satisfaction. 
 Conduct interviews to understand user experience. 
 Test recruitment, data collection and intervention delivery. 
Evaluation*  Conduct RCT to assess efficacy of intervention. 
 Further gather and interpret data from app analytics, 
questionnaires and interviews. 
Implementation*  Publish findings to advance knowledge. 
 Implement intervention. 
 Analyse usage data. 
 Continue to refine product to increase usability.  
* Beyond the scope of this study (future work) 
 
3.8  Ethical considerations  
This research used the three main ethical principles on which the standards of ethical 
conduct in healthcare are based: principle of beneficence, respect for autonomy and justice 
(Holloway and Wheeler, 2010; Babbie, 2013). These principles helped to ensure that the 
rights of the research participants were protected. Each principle is discussed below:  
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a) The Principle of Beneficence  
This principle requires researchers to act for the benefit of the study participants. It helps to 
ensure that participants do not experience any harm during the study and instead benefit 
from it. The World Medical Association (WMA, 2013) maintains that the risks must be kept to 
a minimum and should be carefully weighed against the benefits for the individual. The NHS 
Research Ethics Committee considered the study to entail low risk, burden or intrusion for 
participants.  
Furthermore, should any sensitive issues arise, or should the participant become distressed, 
actions to reduce or eliminate the risk, such as stopping the interview, seeking verbal 
consent to continue or referring the participant to appropriate counselling services, would be 
taken (Ryan et al., 2009). However, no physical, psychological or emotional risk pertaining to 
the involvement in the study was identified during phase 1 (PADI app development) or phase 
2 (feasibility and acceptability of intervention). Additionally, all participants were given the 
opportunity to ask questions before, during and after the study; the researcher’s contact 
details (email and telephone number) were also provided to the participants in order to 
enable them to discuss any concerns.  
Ethics approval was obtained from the National Research Ethics Service (NRES) Committee 
East Midlands-Derby (see Appendix 3), the University of Surrey Ethics Committee (the study 
sponsor) (see Appendix 4) and the Research Governance Committee at the three NHS 
hospitals (see Appendices 5 to 7). Each hospital also supported the researcher’s application 
to obtain an honorary research contract.  
b) Respect for Autonomy  
This involves respecting the decision-making capacities of individuals. It is achieved by 
allowing the participants in a research study to make an independent, free and informed 
choice without pressure or coercion. This principle of respect for autonomy ensures that 
researchers consider the effect their actions and choices will have on the study participants 
involved in the research (Holloway and Wheeler, 2010).  
The decision of an individual to participate in research must be completely voluntary and 
should be based on a full understanding of what the research entails (Gray, 2012; Ryan et 
al., 2009). The Department of Health (DH, 2005) highlights these as pertinent features of 
research that is conducted for the benefit of individuals, patients, healthcare professionals 
and the general public. The DH also emphasises the protection of participants’ dignity, 
rights, safety and wellbeing as the primary consideration of any research. Holloway and 
Wheeler (2010) further affirm that informed consent is at the centre of all research and 
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appropriate arrangements should be made for obtaining informed consent. Details of how 
informed consent was obtained in this study are provided below.  
Obtaining Informed Consent 
Informed consent involves ensuring that potential participants have sufficient information 
about the study before deciding whether or not to participate (Holloway and Wheeler, 2010; 
Babbie, 2013). This was achieved by preparing and presenting participants with a written 
participant information sheet (PIS) (see Appendix 8). For participants to be able to make an 
informed decision regarding participation, the PIS contained information regarding the 
research study and sponsoring body/institution, purpose of the research, benefits of taking 
part and any risks involved. It also outlined the participants’ level of involvement, assurance 
of confidentiality, liberty to withdraw at any time and the names of the people to contact for 
further questions or problems (Holloway and Wheeler, 2010; Ryan et al., 2009). 
The PIS for healthcare professionals and women with DM (for phases 1 and 2 of this study) 
were designed with this in mind, and were friendly, simply worded and easy to understand 
(see Appendix 8). Participants were given a copy of the PIS at least one week before 
providing written consent to participate and were given the opportunity to ask any questions 
about the study. Participants were advised that they do not have to participate in the study 
and that they can withdraw from the study at any time without prejudicing their care. Once 
the participant consented to take part in the study, a consent form was signed by both the 
participant and the researcher (see Appendix 9). A copy of this was kept in the research 
portfolio. The design of the consent form allowed participants to take part in some or all 
research activities and included tick-boxes, where they could indicate what they will/would 
not do. 
c) The Principle of Justice   
This principle requires the researcher to be fair to the study participants and preserve their 
right to privacy. It is the researcher’s duty to protect the privacy of the participants. In this 
study, precautions were taken to ensure anonymity and confidentiality of data, in line with 
the Data Protection Act (1998) and the Declaration of Helsinki (WMA, 2013).  
Confidentiality is recognised as the basis of the patient-practitioner-researcher relationship, 
as without it, trust in any encounter would be undermined. Information can thus only be 
given to a third party with the consent of the research participant. The DH (2005) upholds the 
need for everyone involved in the research to be aware of their ethical and legal duties and 
to ensure that systems are put in place to protect confidentiality. Participants were assured 
that the information obtained in interviews and questionnaires would be confidential, 
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anonymised and that any identifying features would be removed (Crinson and Leontowitsch, 
2006). 
The questionnaires and audio recording were coded and anonymised and did not include 
the participants’ name or address. Numbers were assigned to each participant and used 
instead in order to collect correct and comprehensive information about each participant. 
The audio recordings were only heard by the researcher. The content of the audio recording 
was transferred to a secure hard drive and stored in a locked cabinet within a locked office, 
and all electronic data were password-protected on a university computer. The data from the 
questionnaires and interviews will be held for a period of 10 years and destroyed afterwards, 
in accordance with the University's policy.  
Ethical principles were followed during the conduct of the study in order to ensure that the 
rights of the participants were protected and that they were informed about the research 
prior to commencement. Care was taken to ensure that they consented to participate freely 
and that they were made aware of their right to say no or withdraw from the study without 
prejudice to their future care or employment.  
3.9 Practicalities and access 
 
Prior to the commencement of data collection at the study sites, it is important that 
researchers seek and gain permission for entry to the setting and access to participants 
(Holloway and Wheeler, 2010; Harding, 2013). Gaining access ensures that the setting can 
be observed, individuals at the site can be spoken to, necessary documents can be 
disseminated, and potential participants can be approached or interviewed.  
 
In order to obtain access to the three hospital sites and general practice (GP) used in the 
study, several meetings were organised between the researcher, supervisors and key 
personnel at each site (Holloway and Wheeler, 2010; Babbie, 2013). In addition to the 
Research and Development (R & D) manager, relevant members of staff also included 
consultants, nurses and GPs, whose patients were later recruited into the study. These 
meetings were used to discuss the nature of the research, study design and data collection 
methods. Furthermore, it created an opportunity for the researcher to familiarise herself with 
the study setting (Holloway and Wheeler, 2010). Additionally, ongoing communication was 
maintained between the researcher, diabetes nurse and other HCPs through the use of e-
mail and telephone contact. 
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However, despite being granted access to study sites and permission to recruit participants 
(Appendices 5-7), the researcher experienced challenges in recruiting women with DM, who 
met the inclusion criteria (as discussed in Chapter 4 and 5), from clinic settings. Very few 
women informed the consultant/diabetes nurses that they were planning a pregnancy. It was 
therefore important for the researcher to consider alternate sources of recruitment, such as 
social media, which has become a new and powerful method for recruiting participants, 
especially women, for health research studies (Fenner et al., 2012; Topolovec-Vranic and 
Natarajan, 2016). Furthermore, Liu et al. (2016) argue that people with DM are increasingly 
using Twitter for health conversations and peer support, making it an ideal platform to recruit 
women with DM. Following an amendment to the study protocol, all participants for phase 1 
and the majority of study participants for phase 2 (as described in section 4.4 and 5.4) were 
subsequently recruited via Twitter.  
 
Summary  
 
The preceding section has presented the overall study design, epistemological approach of 
the study, the researcher’s pragmatic stance, the justification of the mixed methods 
feasibility study and the stages of the PADI intervention development and evaluation. The 
ethical principles guiding the study, and practicalities and access issues were also 
presented. 
The next chapter explores phase 1 methodology and the PADI app development process. 
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4. Chapter 4: Phase 1 Methodology and App Development  
4.1 Overview 
This chapter explores phase 1 methodology and the PADI app development process. The 
co-design and iterative approach used to develop the app will be explained. Following this, 
the study setting and sample selection are considered. The methods of data collection (focus 
groups and interviews), tool development and analysis are then described.  
 
4.2 Development of the PADI app 
A co-design approach with healthcare professionals (HCPs), women with DM and Netsells 
Ltd. (an award-winning digital agency with expertise in building cutting edge mobile 
applications based in York, UK) was specifically used to inform and develop the PADI app’s 
content and features (Sanders and Stappers, 2008; Steen et al., 2011). Co-design has been 
described as a collaborative activity between researchers and study participants, with the 
participants taking on the role of experts in forming ideas and concepts based on their 
personal or professional experiences (Sanders and Stappers, 2008). Focus groups and 
interviews were used to identify the views, needs, preferences and expectations of the target 
population regarding the PADI app in line with the guidelines (Craig et al., 2008; Whittaker et 
al., 2012; Mummah et al., 2016); Figure 4.1 below shows the phase 1 flowchart. Evidence 
has shown that involving participants in intervention development facilitates a better fit 
between a product and the end users’ needs or preferences, resulting in more successful 
innovations and end user satisfaction (Steen et al., 2011; Liem and Sanders, 2013). The 
development process of the PADI app is outlined below.  
 
PADI app design and prototype development  
Following participants’ input regarding the PADI app features and content, the app design 
was then discussed with the app developer (Netsells) in July 2016, which then created 
wireframes (a visual guide representing the skeletal framework of the app) (Experience UX, 
2017). The wireframes were used to detail the app layout, prioritise components and 
determine how the app screens would link together. They took into account the functionality 
of the screen, content, layout, app behaviour and sequencing of the app’s function. The 
output of the wireframe work was then used to create an initial prototype, a design model of 
the final user interface (UI), which gave the first detailed impression of how the UI or app 
screens would look and work.  
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Figure 4.1 Phase 1 flowchart 
 
The PADI app prototype was designed to provide a series of informational pages (see 
Chapter 3) and a place to submit and view blood glucose readings by day, week and month. 
However, this initial design output highlighted (to the researcher and supervisor) potential 
usability issues regarding layout, colours and navigation. The prototype was then revised 
several times to ensure that the final UI was simple, user-friendly and attractive. PADI was 
developed in both Swift (programming language for iOS) and Java (Android development 
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language) (Android Authority, 2018) in order to run on Apple’s iOS and Google’s Android 
platforms.  
 
An application programming interface (API) was also developed to allow the storage and 
retrieval of user data records. The API routine connected the PADI app to Netsells’ remote 
server and along with the creation of user accounts, allowed authentication with the data in 
the database. The API was developed using the Hypertext Preprocessor (PHP) framework 
Laravel, one of the most popular programming languages for web application back-end 
development (Bean, 2015). The resulting app design and content (prototype) was tested by 
Netsells to ensure optimal functionality before being released for further testing. The 
prototype was subsequently presented to a selection of participants [patients (n=4), HCPs 
(n=3), supervisors (n=2), researchers (n=4) and members of the public (n=2)], to test the full 
app functionality over the course of 14 days and provide feedback. 
 
This pre-testing involved two cycles of feedback (see Figure 4.2) and led to minor textual 
changes in the informational content, the addition of a weight management section, a 
modification of the blood glucose (BG) diary to include the PCC target range (4-9mmol/l) and 
a pop-up feature that alerts and redirects participants to the BG management page, and the 
correction of an error in the graphical display of the BG readings. The pre-testing was 
considered complete when the changes made were tested by the participants and their 
needs satisfied. The final PADI app (Figure 4.3) therefore contained pregnancy planning 
information, a BG diary with graphical display and reminders, and built-in app analytics to 
collect app usage data in line with the guidelines (Mummah et al., 2016). Figure 4.3 below 
shows the PADI app development process. Following this stage, the app was further tested 
for 3 months in order to determine the system’s feasibility and acceptability (see Chapter 5).  
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Figure 4.3 Screenshots of the Final PADI app 
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Figure 4.3 Screenshots of the final PADI app   
Blood glucose diary showing daily blood 
glucose reading 
Blood glucose diary reminder 
Graphical display of average blood 
glucose levels 
  
83 
 
Reflection on app development process 
The app development took 5 months (July-November 2016) and during this time, close 
liaison was maintained with the app development team at Netsells Ltd; it was important that 
meetings were held regularly to discuss progress, problems or feedback. To ensure that 
discussions held with the app development team were productive, the researcher ensured 
that she was familiar with the app development process and related technical terminology 
but used lay language to communicate her research to the development team. It was agreed 
from the outset, that regular progress reports would be sent to the researcher to keep her 
updated and ensure timely completion of the app.  
 
Before the app development commenced, the researcher and development team had 
several in-depth discussions about the app and its content. However, the prototype 
development took longer than anticipated because the app development team and 
researcher struggled to reconcile their varying perspectives of the app. Hence, the first set of 
prototypes, even after being revised a few times, had usability issues (see section 4.2). 
Hence, after going back and forth a number of times, it became evident to the researcher 
that in order to move forward with development, she had to create a schematic diagram of 
how she expected the app and its content (including the welcome screen, menu screen, 
home page, information pages and diary) to look and function. This was then communicated 
to the development team who immediately understood the direction in which the researcher 
wanted the app design to take.  
 
The developers took this design onboard and changed the prototype. Both the researcher 
and the development team agreed that the final design was indeed more contemporary and 
usable. Having the researcher’s design to work with gave the developers direction and 
facilitated the app development. This experience enabled the researcher to understand the 
importance of maintaining frequent communication, receiving regular update reports and 
developing a visual representation of the app (i.e. abstract ideas have to be made concrete) 
in order to expedite the development process and prevent time lost by going back and forth 
during the early development stage.  
 
4.3 Research setting 
The research settings for phase 1 of the study included one general practice and the 
diabetes clinic of two NHS hospitals, based in the South of England. These sites were 
selected as they provide specialist diabetes services to women in Surrey, Sussex and 
Hampshire. Participants were also recruited via social media (i.e. Twitter).  
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Phase 1 participants were recruited between February and September 2016. The data 
collection and analysis were completed in September 2016.  
 
4.4 Sample selection 
A purposive sampling strategy was used in order to ensure the adequate representation of 
clinicians and women with DM for this phase of the study (Patton, 2002; Creswell and Plano-
Clarke, 2011). The study sample comprised a total of 36 participants: phase 1 (19 
participants; 10 women with DM and 9 HCPs) and phase 2 (17 women with DM).  
 
The number of participants was guided by previous studies using a co-design approach to 
develop mHealth apps and their sample varied from nine to fourteen participants (Cafazzo et 
al., 2012; Krishmanurti et al., 2017; Reade et al., 2017). For this study, a total of 19 
participants, comprising HCPs (n=9) and patients (n=10), were recruited in order to ensure 
that the sample was sufficiently large if anyone decided to withdraw from the study, and to 
increase confidence that the data generated was comprehensive. Furthermore, although 
Guest et al. (2006) and Cafazzo et al. (2012) found that data saturation occurred after the 
analysis of twelve interviews, Francis et al. (2010) concluded that saturation is reached after 
thirteen to fifteen interviews. The larger sample size used in this study was to ensure data 
saturation and that no new findings emerged. For participants to be included in phase 1 of 
this study, they either had to be healthcare professionals involved in diabetes care or women 
of reproductive age (18-45 years) with T1 or T2DM. 
 
Clinicians were recruited from two NHS hospitals and one GP practice in the South of 
England. A lead research nurse facilitated the recruitment of clinicians (n=7) from one NHS 
hospital. HCPs, who indicated interest in participating in the study, provided the nurse with 
their contact details, which were then passed to the researcher. The researcher, with the 
help from supervisors, further identified and recruited two other HCPs from one NHS hospital 
and GP practice. The researcher then sent them the healthcare professional information 
sheet, discussed the study with them and answered any questions. A signed consent form 
was then obtained.  
 
A consultant at one of the NHS hospitals facilitated the recruitment of women with DM for 
this phase by handing out study information packs (comprising the invitation letter, 
information sheet and consent form) to patients attending the diabetes clinic, however no 
participants were recruited from this site after several months. Following this delay in 
recruitment, an amendment form was sent to the NHS Research Ethics Committee and 
  
85 
 
approval was obtained; all patients for phase 1 (n=10) were then recruited via social media 
(i.e. Twitter). A tweet was sent out via the University of Surrey and School of Health 
Sciences Twitter account, inviting eligible participants to contact the study researcher if they 
were interested in taking part in the study. Women who expressed interest in taking part 
provided the researcher with their contact details. The researcher then contacted the 
participants, sent them a participant information sheet and provided them with an opportunity 
to ask questions. A signed consent form was then obtained.  
 
4.5 Data collection  
The method used in the first phase of the research was qualitative in nature, using interviews 
and focus groups. Specifically, an exploratory approach was used in order to explore 
participants’ perceptions about PCC and experience of app use, as well as their views, 
needs, expectations and attitudes towards the use of a PCC mobile app. This approach was 
vital in order to develop a PCC mobile app intervention that was acceptable, feasible and 
relevant to women with DM and HCPs (Yardley et al., 2015; Mummah et al., 2016).  
 
Qualitative research is used to provide insight into people’s different experiences and 
viewpoints (Marks and Yardley, 2004; Krueger, 2015). It was therefore necessary to use 
data collection methods that allowed participants to talk freely, as this often provides a more 
accurate insight into individuals’ inner thoughts and feelings (Harding, 2013). This phase of 
the study used both focus groups and interviews, the two most widely used methods for 
gaining insight into participants’ perspectives and experiences (Marks and Yardley, 2004; 
Harding, 2013). These methods of data collection have also been recommended for use in 
mHealth studies during the development of smartphone apps (Jurascio et al., 2015; 
Mummah et al., 2016; Whittaker et al., 2012).  
 
4.5.1 Focus groups 
Wilkinson (2011) described focus groups as ‘a way of collecting qualitative data which 
usually involves engaging a small number of people in an informal discussion about a 
particular topic or set of issues’. Focus groups were first used in the 1940s by Robert Merton 
and colleagues (Krueger, 2015; Silverman, 2014) and have gained recognition over the past 
20 years as a qualitative data collection method in the field of healthcare research (Marks 
and Yardley, 2004; Holloway and Wheeler, 2010). The advantages of the focus group 
include flexibility, production of quick responses and low cost (Babbie, 2013).  
 
This method of data collection was deemed relevant to the current research because as 
Krueger (2015) argues, focus group discussions are particularly useful for exploring people’s 
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knowledge and experiences and can be used to examine what people feel or think about an 
idea or product, that is, they are used in order to gather opinions. The participants in a focus 
group discussion (FGD) have certain characteristics or experiences in common and are thus 
similar in a way that is important to the researcher. The ideal group size is between five to 
eight people (Krueger, 2015), although smaller sizes of three to four people have been 
reported (Barbour, 2007).  
 
Focus groups however have some challenges, such as the difficulty associated with 
assembling these types of groups (Babbie, 2013). For example, in this study, women with 
DM were geographically dispersed and available at different times, therefore an FGD was 
not feasible and individual semi-structured interviews were used. Furthermore, due to 
difficulties in arranging a mutually convenient time for all HCPs to attend the FGD, one FGD 
comprising three participants and six individual semi-structured interviews were conducted 
with this professional group. 
 
4.5.2 Semi-structured interviews 
Interviews have become the most common method of data collection in qualitative research 
(Holloway and Wheeler, 2010) and are referred to as the gold standard (Barbour, 2008). 
Interviews are flexible and adaptable (Robson, 2011). Interviews provide an opportunity for 
the researcher to listen to the views and experiences of one participant for an extended 
period of time and to ask questions using probes in order to further explore ideas. 
Furthermore, a researcher can formulate questions based on participants’ responses, rather 
than asking only pre-formulated questions. The significance of this is that emergent issues 
can be examined in subsequent interviews. Each interview is therefore different in terms of 
wording and sequencing, however, distinct patterns common to all interviews in a study 
emerge during the analysis (Holloway and Wheeler, 2010).  
 
Interviews can be structured, unstructured or semi-structured. The semi-structured 
approach, also known as a focused interview, is the most popular method in health and 
social care research (Hancock et al., 2009). This approach was used to interview the 
remaining phase 1 participants (six HCPs and ten women with DM). Semi-structured 
interviews provide more in-depth access to participants’ views, understandings, experiences 
and opinions, and as such can achieve a level of depth that may not be available to other 
methods (Babbie, 2013; Silverman, 2014). Thus, the semi-structured interview was used to 
explore participants’ perceptions and experiences in relation to PCC service provision, 
mobile app use and the PADI app development. The flexibility involved in semi-structured 
interviews allowed the researcher to adjust the interview in order to meet the study 
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objectives. She was also able to prompt the participants for more information, and they in 
turn explored their thoughts and exerted more control over the interview as their ideas took 
precedence. Furthermore, the meanings of words and phrases were followed up and 
clarified. 
 
Semi-structured interviews can be conducted face-to-face whereby the researcher and 
participant meet. Although this interaction can be affected by bias, such as the researcher’s 
appearance, gender or ethnicity, face-to-face interviews facilitate attention to non-verbal 
behaviours and to the rapport between the researcher and the participant (Bowling, 2009; 
Holloway and Wheeler, 2010). Alternatively, telephone interviews are used as an alternative 
to face-to-face interviews when interviewing busy professionals and patients with limited 
availability. Telephone interviews are an effective means of interviewing and are particularly 
useful when the participants are geographically dispersed, such as the women with DM in 
this study. A limitation of telephone interviews however is that the researcher may not get to 
know or deeply interact with the participants. However, this method also has several 
advantages including immediate response, anonymity of participants and effective use of 
time (Holloway and Wheeler, 2010). Bowling (2009) adds that data collected via telephone 
interviews are as accurate as the face-to-face method. Hence, both face-to-face and 
telephone interviews were used.  
 
4.5.3 Tool development and piloting 
Tool development 
Two separate topic guides informed by the literature (Holmes et al., 2012, 2013; Charron-
Prochownik et al., 2006a) were developed for phase 1: one for the healthcare professionals 
(HCPs) and a second one for women with DM (see Appendix 10). These ensured that 
specific areas were covered but it was also possible to probe into and clarify emerging 
information within the FGD and interviews. The guides incorporated questions on PCC 
knowledge and attitudes, as well as app development.  
 
The women with DM/patient interview guide was developed from previously published semi-
structured interview questions by Charron-Prochownik et al. (2006a). The questions 
addressed items pertaining to awareness and the understanding of diabetes and PCC, 
complications associated with pregnancy, the prevention of complications with PCC and the 
use of contraception. The section on app development contained questions relating to the 
acceptability and use of apps in general and PCC in particular; these were formulated by the 
researcher. Similar questions were used in a recent formative research on app development 
(Cai et al., 2017). Similarly, the healthcare professional topic guide was developed based on 
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the research conducted by Holmes et al. (2012, 2013). The guide contained questions 
related to the aspects of diabetes, PCC and pregnancy planning that women with DM need 
to be aware of, as well as questions on the use of a PCC app in practice.  
 
Marks and Yardley (2004) note that care should be taken in preparing the schedule in order 
to ensure that it is engaging, uses appropriate vocabulary, provides opportunities for various 
views to be expressed, and allows the participants to raise points not already covered in the 
schedule. In developing the schedules, questions were designed to be open-ended and 
follow a logical sequence, while probes that elicited more detailed information were also 
included.  
 
Piloting  
Piloting is vital for identifying potential problems and reducing the likelihood of collecting 
flawed data (Harding, 2013). Four researchers were interviewed and used to pilot the HCP 
and patient schedules, while one woman with DM and one HCP also piloted the patient and 
HCP topic guides, respectively. Following this, and a discussion with the academic 
supervisors, adjustments were made to the flow and wording of the HCP and patient 
interview guide.  
 
4.5.4 Data collection process 
Conducting the focus group 
An FGD was conducted with three HCPs, i.e. one DSN and two diabetes research nurses. 
They were contacted well in advance and sent reminders a few days before the discussion. 
The HCP topic guide was used to guide the FGD, with the researcher acting as the 
moderator/facilitator of the group, asking questions, keeping the discussion flowing and 
encouraging group members to fully participate and interact with each other. As Krueger 
(2015) notes, ‘the researcher’s function is that of a moderator, a listener, and an observer, 
and in the end, an analyser of the discussion’. An assistant moderator (a fellow PhD student) 
took notes during the discussion, kept track of the order of speakers and recorded key 
issues. The researcher also made notes that helped guide the discussion.  
 
According to Kitzinger (1995), it is important for the participants in an FGD to feel at ease, 
therefore the setting has to be comfortable and the atmosphere should be relaxed. The FGD 
was conducted in the diabetes centre of an NHS hospital in the South of England (i.e. the 
HCPs’ workplace). The small group sat in a semi-circle and the digital audio recorder was 
placed in the centre and used to record the discussions, which lasted 50 minutes. The FGD 
participants responded to the researcher and to each other. The FGD in this study used a 
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semi-structured approach in order to give participants the opportunity to express themselves 
freely, while also covering all areas of interest to the researcher. The FGD was also 
analysed as an interview, as recommended by Krueger (2015), in keeping with the study 
objectives seeking to understand various perspectives.  
 
Conducting the semi-structured interviews 
 
Healthcare professionals 
The semi-structured interviews with the professional group, comprising six HCPs (three 
doctors and nurses), took place mainly via face-to-face method and one telephone interview. 
These interviews took place at a time that was convenient for the participants. The face-to-
face interviews were conducted in the diabetes centre at one NHS hospital in the South of 
England or the workplace of the HCPs. Similarly to the FGD, all participants were contacted 
well in advance and sent reminders a few days before the discussion. The HCP topic guide 
was used to guide the discussion with the researcher acting as the interviewer. The 
interviews were audio-recorded and lasted between 30 and 50 minutes. During the 
interviews notes were taken recording key topic headings, responses and any factors of 
interest, such as interruptions, notes on the setting and impressions of the process. 
Silverman (2014) suggests recording what the researcher sees and hears, the researcher’s 
behaviour and how the researcher is being treated.  
 
Women with DM 
The individual interviews with the patient group, comprising ten women with DM, were 
mostly conducted by phone, and took place at a time that was convenient for all participants. 
One interview, with one of the youngest women who was a student, was conducted face-to-
face in a quiet meeting room at the University in the South of England. Participants were 
contacted one to two weeks in advance and were sent reminders a few days before the 
interview. The patient interview schedule was used to guide the interviews, which were 
audio-recorded and lasted between 20 and 30 minutes.  
Prior to commencing the interview, it is important for the interviewer to establish and 
maintain rapport with the participants (Fox, 2006; Hennink et al., 2011) in order to generate 
rich data that are relevant to the research questions. It is more difficult to establish rapport 
during telephone interviews (Braun and Clarke, 2013; Harding, 2013); hence, the researcher 
took time at the beginning of each interview to engage in everyday conversation and explain 
the reason for the interview, including the project aim and how the interview data will be 
handled. Hennink et al. (2011) recommend that the interview should feel like a conversation 
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to the participant, but stress that it is not a two-way conversation and that the interviewer’s 
role is to obtain information and views.  
The interviewing style used was aimed at building and maintaining rapport by relating to 
participants on a personal level and asking questions using the conversational style as 
recommended by Fox (2006) and Hennink et al. (2011). Furthermore, if participants 
encountered difficulties in answering certain questions, prompts were used sensitively to 
encourage further elaboration and dialogue regarding the topic. To further establish rapport, 
the researcher offered to answer questions at the end of the study as recommended by 
Harding (2013), and participants were encouraged to contact the researcher (via email or 
telephone) with any other questions or ideas that they may have.  
 
Recording the data 
The discussions (one focus group discussion and sixteen interviews) were digitally recorded 
and all participants consented to the audio recording. It was important to obtain an accurate 
recording of the discussion that could be played several times in order to facilitate the 
accurate conversion of the recordings from audio to a text-based format (transcription). 
Participants who may initially be self-conscious and concerned about the recording 
instrument quickly forget about it within a few minutes.  
 
4.5.5 Data management and analysis 
Qualitative data analysis (QDA) has been described as an iterative, complex and non-linear 
process that also employs a systematic, orderly and structured approach (Holloway and 
Wheeler, 2010). The analysis of data commenced immediately after conducting the first 
focus group discussion and interview with HCPs and patients; data collection therefore 
occurred alongside the analysis. An early commencement of the analysis enabled the 
researcher to identify areas that required more information, questions that were not fully 
answered and which needed adapting or pursuing in future interviews. Krueger (2015) adds 
that analysing data while the collection is ongoing provides an opportunity for the researcher 
to learn and improve. Initial findings were also explored in subsequent interviews. The audio 
recordings generated from the FGD and interviews were listened to repeatedly in order to 
gain familiarity with the dataset’s content before drafting the transcripts. 
 
All data generated were transcribed verbatim by the researcher as soon as possible after the 
discussion with the two groups of participants. This is particularly important in a focus group 
discussion in order to remember who made each comment (Krueger, 2015). Bazely and 
Jackson (2013) recommend that researchers complete the transcription process themselves 
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in order to build familiarity with the data. The researcher transcribed the data by first listening 
to the entire discussion and interviews in order to grasp the overall content and then listening 
and transcribing the entire audio recordings using Microsoft Word. Krueger (2015) notes that 
the researcher represents the voice of the study participants and as such needs to clearly 
communicate their feelings about a topic while accurately representing the different voices 
and views. The recordings were therefore listened to again while reading the transcript in 
order to ensure transcription accuracy.  
 
Furthermore, Harding (2013) argues that transcription involves interpretation because 
spoken language requires punctuation to be added, period, dashes, etc., which reflects the 
transcriber’s interpretation of what was said. By the end of the transcription process, the 
researcher had become very familiar with the data and had started to note down initial 
analytic ideas; hence, Braun and Clarke (2013) perceive transcription as part of the analytic 
process. The transcribed data were then prepared for coding and analysis by using the QSR 
NVivo 10 computer software package.  
 
QSR NVivo was used as a data handling management system for the data collected from 
the FGD and semi-structured interviews. NVivo was used because it allows large volumes of 
data to be handled with speed, facilitates the exploration of relationships between codes, 
and aids interpretation (Bazely and Jackson, 2013). The use of NVivo for conducting the 
qualitative data analysis is supported by Babbie (2013) and Braun and Clarke (2013). The 
transcripts of the sixteen interviews and one FGD were imported into NVivo as ‘sources’ 
followed by the process of thematic analysis as discussed by Braun and Clarke (2006, 
2013). 
 
Thematic analysis 
Thematic analysis (TA) is defined as a method for identifying, analysing and reporting 
patterns (themes) within the data (Braun and Clarke, 2006, 2013). However, TA often goes 
further than this and interprets various aspects of the research topic and describes the 
dataset in rich detail. Gibson and Brown (2009) report that TA has three main aims, namely 
to examine commonalities by collating all the materials across a dataset that have something 
in common, identifying differences across datasets and examining relationships by exploring 
how different parts of the analysis fit together and contribute to the overall understanding of 
different issues.  
 
As a method, TA has received criticism in relation to the fact that looking at similarities and 
differences removes most of the background detail and generates accounts that can be 
  
92 
 
distant from the experience of individuals. However, this has been rejected by Gibson and 
Brown (2009), who argue that thematic analysis is a means of linking different experiences 
and ideas together and comparing and interrelating different features or examples of the 
data. TA was previously seen as a poor method because it was not a ‘named’ method of 
analysis in the same way as other methods, e.g. grounded theory (Meehan et al., 2000). 
Additionally, there was lack of agreement about what it entailed and how to conduct it 
(Boyatzis, 1998; Tuckett, 2005). Moreover, it was not characterised as a method but as a 
tool to be used across different methods. Thus, TA was a poorly demarcated, rarely 
acknowledged, yet widely used qualitative analytic method until 2006, when Braun and Clark 
introduced it as a distinct method for analysing data.  
 
TA has since become a widely accepted method that has been used in researching various 
topics including experiences of online gaming, living with multiple sclerosis and mobile app 
development (Robinson et al., 2013; Jurascio et al., 2015). One of its strengths is that it is a 
flexible approach that can be used within any paradigm and theoretical framework. In using 
TA, it is important for the researcher to be interpretive in order to identify themes that go 
beyond the surface meaning of the data and link to broader concerns (Braun and Clarke, 
2013). Thematic analysis comprises six stages: reading and familiarisation with the data, 
generating initial codes, searching for themes among codes, reviewing themes, defining and 
naming themes, and writing (finalising the analysis). 
 
Producing the findings  
Coding is the initial process of grouping and labelling data so that they reflect broader 
perspectives, from which emerging themes and patterns are identified. A code draws 
attention to a commonality or difference within a dataset (Gibson and Brown, 2009). The 
data were analysed by reading the narrative and then assigning labels based on the 
meaning elicited from the narrative. Rapley (2011) emphasises the importance of engaging 
with every line of text and of highlighting categories or taking note of what is of interest to the 
researcher. Tagging and naming selected texts (extracts) within the data led to the 
identification of initial topics organised using a system of nodes (codes) in NVivo. 
 
After the initial coding process, the transcripts and recordings were read and listened to 
again for emphasis and meaning that were subsequently incorporated into the transcripts. 
Codes were further identified by summarising, selecting and interpreting the narrative data 
(Harding, 2013). The list of codes were then revisited and refined, and decisions were made 
about which category each code belonged to. This led to codes being moved or merged, 
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sub-categories being developed and/or new categories being created. The categories then 
became the themes for analysis, with the codes sorted into the different themes and the 
coded data extracts collated within the relevant themes. The aim of this process was to find 
all possible themes and sub-themes. Krueger (2015) refers to a theme as ‘an idea that can 
be seen running through different responses’.  
 
According to Patton (2002), the researcher has an obligation to ‘fairly represent the data and 
communicate what the data reveal given the purpose of the study’. The analyses of data in 
this phase resulted in the identification of commonalities and differences in the views and 
experiences of both groups of participants in relation to PCC, use of technology for 
healthcare and the development and feasibility of an app for PCC. Braun and Clarke (2013) 
note that a theme is significant when it comes up numerous times, however, a higher 
frequency does not mean that the theme is more important to understanding the data. A 
researcher’s judgement is the key tool in determining which themes are more crucial to 
answering the research questions. Essentially, each theme should tell a story about the 
content and meaning of the data using extracts from the coded and collated data (Braun and 
Clarke, 2013).  
 
TA can be inductive or deductive and this study incorporated both approaches (Braun and 
Clarke, 2013). The themes in this phase were determined by both multiple readings and 
interpretations of the raw data (inductive approach) and the research questions outlined by 
the researcher (deductive approach). Although a mixed inductive and deductive approach 
was used to elicit themes, the approach was largely inductive because the researcher was 
committed to examining the data without the constraint imposed by existing literature or 
preconceptions (Moses and Knutsen, 2007; Braun and Clarke, 2013). This approach was 
used in analysing the transcripts generated from both groups of participants (HCPs and 
women with DM).  
 
The transcripts of the discussions with HCPs and women with DM were initially coded 
separately, however, while writing up the analysis (i.e. at the final TA stage), it emerged that 
the themes from both datasets were thematically consistent. Braun and Clarke (2013) 
acknowledge that writing is a deep analytic and interpretative work that is undertaken in 
order to make sense of and interpret the patterns identified within the data. Writing is 
therefore the process through which the analysis of data reaches its final form. Hence, a 
decision was made to present the findings from HCPs and women with DM together (see 
Chapter 6). Examples of coded interview transcripts, HCPs and women with DM, are shown 
in Appendix 11. 
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4.5.6 Validity and reliability: trustworthiness 
Qualitative research, frequently criticised for lacking scientific or methodological rigour and 
analytical transparency, needs to be systematic and organised in order to improve validity 
and reliability (Noble and Smith, 2015). Validity in qualitative research refers to the integrity 
and relevance of the research methods undertaken and the accuracy with which the findings 
reflect the data (Long and Johnson, 2000). In this study, several strategies were employed in 
order to promote validity (credibility). For example, the research instruments were piloted to 
ensure that the study questions made sense to the participants; Guest et al. (2012) note that 
piloting facilitates the collection of valid data. Themes and interpretations were supported 
with verbatim quotes directly connecting the researcher’s interpretation with participants’ 
actual words (Creswell, 2014; Guest et al., 2012).  
 
A common critique of qualitative research is that the reported data are selected to support 
the author’s conclusions or further an agenda. Hence, Guest et al. (2012) recommend 
presenting data that contradict common themes in order to prevent ‘analytic cherry-picking’. 
Creswell and Plano-Clarke (2011) argue that in real life, evidence for themes is expected to 
diverge and include more than only positive information. Similarities and differences across 
themes were included in order to ensure the representation of different perspectives. A clear 
description of the research process, i.e. recruitment, methods of data collection, analyses 
and findings, was also provided to increase research transparency (Guest et al., 2012; Noble 
and Smith, 2015).  
 
Reliability in qualitative research indicates that the researcher’s approach is consistent 
across different researchers, projects or analytical procedures (Noble and Smith, 2015). 
Several strategies were used to ensure the reliability (dependability) of the findings including 
checking the transcripts for errors and constantly comparing the data with the codes. In 
order to further promote rigour in the research process, portions of the interview data were 
independently coded by two other PhD students, and data workshops were held to discuss 
the coding and codebook; any discrepancies were discussed and resolved. The data were 
also discussed and reviewed with the PhD supervisors. Guest et al. (2012) note that 
reviewing both coding and summaries in this way facilitates coding reliability and provides 
checks on individual biases. 
 
Summary 
Chapter 4 has provided an account of the methodology and app development process for 
phase 1 of this study. First, a description of the co-design and iterative approach used to 
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develop the PADI app was provided. This chapter also discussed the research setting, 
sample selection and development of data collection tools, as well as the methods of data 
collection (focus groups and interviews) and analysis. For each method, the rational for its 
use, as well as the strengths and weaknesses were provided. The data collection methods 
were followed by the data analysis method, i.e. thematic analysis. The research was 
designed and conducted so that reliability and validity issues were addressed. Measures 
were taken to reduce the effect of researcher bias that may be inherent in qualitative 
research and to ensure that the findings were an accurate and true account of the topic 
under investigation. These measures involved a comprehensive description of the research 
procedure, a rich description of data with verbatim quotes, checking the accuracy of 
transcripts against codes and inter-coder agreement. The next chapter explores Phase 2 of 
the study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
96 
 
5. Chapter 5: Phase 2 Methodology 
 
5.1 Overview 
A mixed methods approach was used to explore the PADI app’s feasibility and acceptability 
in phase 2 of this study. This chapter begins with a description of the feasibility and 
acceptability of the PADI app. Following this, the study setting and sample selection are 
considered. The methods of data collection (questionnaires, semi-structured interviews and 
software log of activity), tool development and data analysis are then described.  
 
5.2 Feasibility and acceptability of the PADI app intervention 
Feasibility studies, research conducted on a small scale in order to ascertain whether the 
study can be done (National Institute for Health Research [NIHR], 2014), have been 
explicitly recommended by the Medical Research Council (Craig et al., 2008) as a 
prerequisite for the development and evaluation of complex interventions (i.e. interventions 
with several interacting components). They provide evidence as to whether an intervention 
should be further tested for efficacy (Bowen et al., 2010). Thabane et al. (2010) argue that 
feasibility testing prior to the main trial increases the likelihood of trial success. Conducting a 
feasibility study before a large trial has several advantages which include: providing 
preliminary data for the primary outcome measure, determining the integrity of the study 
protocol, testing data collection instruments, e.g. questionnaires, determining recruitment, 
retention and consent rates, and exploring intervention acceptability (Craig et al., 2008; 
Lancaster et al., 2002; Thabane et al., 2010). Additionally, several researchers have 
recommended using feasibility studies in order to determine the demand for an intervention; 
the practicality of conducting the intervention; the usability, implementation and potential 
efficacy of the intervention (Bowen et al., 2009; Arain et al., 2010; Mummah et al., 2016). 
 
Feasibility studies have been conducted in numerous clinical and public health areas, such 
as critical (Arnold et al., 2009) and cancer care (Kearney et al., 2006), pain (Martorella et al., 
2014) and diabetes management (Cafazzo et al., 2012), lifestyle modification e.g. diet, 
weight and smoking cessation (Whittaker et al., 2008; Knight-Agarwal et al., 2015; Hebden 
et al., 2012), promotion of PCC awareness (Charron-Prochownik et al., 2008) and 
pregnancy-related risks (Krishnamurti et al., 2017). The feasibility aspect of this study was 
therefore designed to explore study processes (intervention design, recruitment and 
retention), acceptability, experiences of app use, satisfaction, app usage behaviour and 
usability (problems and opportunities for improvement) and provide preliminary outcome 
estimates. 
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Examining the feasibility and acceptability of the intervention 
Current guidelines (Craig et al., 2008; Whittaker et al., 2012; Mummah et al., 2016) 
recommend conducting a small-scale evaluation (with or without randomisation) in order to 
test the app intervention following development; hence, a pre- and post-intervention design 
with two data collection points, at the beginning and after 3 months of app usage, explored 
the feasibility of the PADI app. According to Orsmond and Cohn (2015), this helps ascertain 
whether the interventions show promise of being successful with the intended population. 
The 3-month intervention time frame was informed by previous studies that have developed 
eHealth interventions for PCC, pregnancy and diabetes (Charron-Prochownik et al., 2008; 
Cafazzo et al., 2012; Krishmanurti et al., 2017). Following this, semi-structured interviews 
were conducted with participants who used the app for 3 months in order to explore their 
views and experiences and ascertain the intervention’s acceptability (see Figure 5.1 for 
phase 2 flowchart).    
 
5.3 Research setting 
The research settings for phase 2 of the study included the diabetes clinics of two NHS 
hospitals, based in the South of England. These sites were selected as they provide 
specialist diabetes services to women in Surrey, Sussex and Hampshire. Participants were 
also recruited via social media (i.e. Twitter).  
 
Phase 2 participants were recruited from December to March 2017. The data collection and 
analysis were completed in July 2017.  
 
5.4 Sample selection 
A purposive sampling strategy was used in order to ensure the adequate representation of 
women with DM in this phase of the study (Patton, 2002; Creswell and Plano-Clarke, 2011). 
The study sample comprised a total of 36 participants: phase 1 (19 participants; 10 women 
with DM and 9 HCPs) and phase 2 (17 women with DM).  
 
Women with T1 and T2DM were recruited from two NHS hospitals in the South of England 
and via social media (i.e. Twitter). For a feasibility study, a sample size of 12 participants is 
recommended (Julious et al., 2005), and has been used by various mHealth studies 
(Whittaker et al., 2012; Tatara et al., 2013; Robinson et al., 2013; Knight-Agarwal et al., 
2015). The target sample for this phase was (n=12); a total of (n=17) participants with T1 
and T2DM were recruited to allow for loss due to follow up (estimated at 20%) (National 
Institute of Health [NIH], 2014).  
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Potential participants, who attend the diabetes outpatient clinics at the two district general 
hospitals, were approached by a member of the healthcare team when they came for their 
clinic appointments and asked whether they were planning a future pregnancy and were 
willing to speak to the researcher about participating in the study. They were then 
approached by the researcher who explained the study to them, provided them with an 
information sheet and asked them to contact her if they were willing to participate. Those 
who agreed to participate in the study were recruited.  
 
Additionally, patients were recruited via social media. A tweet was sent out via the University 
of Surrey and School of Health Sciences Twitter account as well as by other researchers 
and organisations involved in diabetes research, e.g. Diabetes UK, Women with Diabetes 
and the College Diabetes Network (CDN), inviting eligible participants to contact the study 
researcher if they were interested in participating in the study. If women indicated interest, 
they provided the researcher with their contact details. The researcher then contacted them, 
sent them an information sheet, explained the study to them and provided them with an 
opportunity to ask questions. All participants who indicated interest were screened for 
eligibility using the following inclusion criteria: 
 
Inclusion criteria 
 Woman of reproductive age (18-45 years) with T1 or T2DM. 
 Diagnoses of diabetes by a healthcare professional for more than 6 months. 
 Currently not pregnant but planning a pregnancy (in the next 5 years or want children 
at some point in the future).  
 Owns an iOS or Android smartphone. 
 
The (n=17) women with T1 and T2DM who met the inclusion criteria and provided written 
informed consent were enrolled in the study, given the link to the free app download (from 
Apple and Google Play stores) and asked to download the app on their smartphones. 
Participants who were recruited from clinics (n=2) received a face-to-face demonstration of 
the key components and functionality of the PADI app by the study researcher, while the 
same information was communicated to those recruited via Twitter (n=15) remotely (via 
email and telephone). They were asked to use the app for 3 months for PCC and the self-
monitoring of blood glucose levels, and to contact the researcher if they had any questions 
or experienced any problems during app usage.  
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Fig 5.1  Phase 2 flowchart 
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5.5 Data collection for phase 2 (feasibility and acceptability of intervention) 
As mentioned in section 5.1, phase 2 of this study adopted a mixed methods approach. The 
quantitative method is discussed first, followed by the qualitative method and software log of 
activity. 
 
5.5.1 Patient questionnaire  
Two questionnaires (a pre-intervention questionnaire and a post-intervention questionnaire 
completed after the 3-month intervention) were used to collect data in order to answer the 
following research question:  
 
What are the preliminary estimates of the effect of the PADI app on PCC knowledge 
and attitudes and the Patient Activation Measure? 
 
Questionnaires are one of the most useful, popular and accepted quantitative methods in 
health research. They are mainly used in survey research, but are also widely adopted in 
experimental research (Babbie, 2013). They ensure respondents are asked the same 
question without interviewer bias in order to identify the respondents’ true opinion or position 
(Neuman, 2006; Bowling, 2009). It determines the extent to which the respondents in a study 
hold a particular attitude or perspective (Babbie, 2013). In this study, questionnaires were 
used because they were deemed to be the most practical means of assessing an individual’s 
feelings, self-management levels, attitudes and behaviours (Marks and Yardley, 2004).  
 
The ordering of questions (within a questionnaire) has been identified as an important factor 
that can affect responses. According to Babbie (2013), demographic questions are best 
placed at the end of the questionnaire and the use of open- and closed-ended questions 
increases the flexibility of the questionnaire design, making it more interesting. Therefore, a 
mix of closed-ended and open-ended questions was included in the two questionnaires 
used, with demographic questions placed at the end of the pre-intervention questionnaire. 
The questionnaires also had clear instructions for completion so as to guide the 
respondents. A copy of each questionnaire is provided in Appendix 12.   
 
Question types 
A mix of questions was used: 
Closed-ended questions 
Closed questions give respondents a set of answers and ask them to select the most 
applicable option from a pre-determined list (Parahoo, 2006). Closed questions are popular 
because they can provide uniformity and are analysed more easily. Yes/No and 
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True/False/Not Sure questions/statements were used. Likert scales (a composite measure 
made up of standardised response categories to determine the intensity of different items) 
with five categories were also included.  
 
Open-ended questions 
Open questions, with space for free comments, offer respondents the opportunity to write 
their opinion and provide their own answers to questions and statements (Oppenheim, 
2000). This was considered especially useful to gather feedback regarding the participant’s 
experience in terms of app use and suggestions for improvement. 
 
A number of disadvantages to using questionnaires have been identified. For example, the 
researcher has no control over the conditions or order in which the questionnaire is 
completed (Neuman, 2006; Bowling, 2009). Furthermore, although questions were adapted 
from existing questionnaires in the literature, the choice of questions remains subjective and 
may not be appropriate for the respondent (Kent, 2001), hence, the researcher piloted the 
questionnaire with one woman with DM and one DSN prior to the study. Other 
disadvantages of questionnaires include their rigid structure, simplification of complex issues 
and an inability of respondents to express their views about a topic or express themselves 
freely.  
 
However, these limitations were overcome by incorporating open-ended sections into the 
questionnaire and collecting qualitative data using semi-structured interviews (as discussed 
in section 5.5.5). The two questionnaires used in this study were also worded in simple, 
everyday language in order to make them easy to understand and questions were asked 
without ambiguity, double-barrelled statements or double negatives. This was important as 
participants may not ask for clarifications while completing the questionnaires (Neuman, 
2006; Babbie, 2013).  
 
5.5.2 Methods of questionnaire administration 
There are three main methods of administering the questionnaire and eliciting responses. 
They are self-administered questionnaires, questionnaires completed by the interviewer and 
telephone questionnaires. Two types of self-administered questionnaires, mail and online, 
were used in this study as participants were geographically dispersed.  
 
Mail questionnaire 
The most common form of self-administered questionnaires is the mail questionnaire, 
whereby a questionnaire is sent to a respondent, accompanied by a letter of invitation and a 
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self-addressed, stamped (reply-paid) envelope for returning the questionnaire. This method 
can however be affected by low response rates (Babbie, 2013), which can be partially 
overcome by sending reminder questionnaires. Incentives, such as gift certificates, money or 
prize draws, although not adopted in this study, have been shown to have a positive effect 
on the response rate (Petrolia and Bhattacharee, 2009). This method was found to be less 
successful compared to the online questionnaire, which is rapidly becoming a popular 
method of collecting questionnaire data. 
 
Online questionnaire 
Technological advancement has caused an explosion of interest in the internet as a tool for 
collecting questionnaire data (Couper and Miller, 2008). Some questionnaires are 
administered via email while others are conducted via websites (Babbie, 2013). 
Respondents may either receive an email with the questionnaire attached or one directing 
them to a website where they can complete the questionnaire. Online questionnaires are 
easy and convenient as participants can choose when to complete the questionnaire. This 
approach also increases reach and accessibility, and it is thus ideal for geographically 
dispersed participants. Online questionnaires are also cheaper to conduct. However, given 
that there may be some concerns over anonymity, researchers using this approach must 
ensure that all identifying features are kept separate from the returned questionnaires. This 
method has lower non-response rates when compared to the more conventional mail survey 
(Denscombe, 2009).  
 
5.5.3 Questionnaire development 
Two booklets, 7-9 pages in length were developed for this aspect of the study. The first page 
of the questionnaire contained information about the study, how long it will take to complete 
(10 - 15 minutes) and simple instructions on how to complete the questionnaire.  
 
It contained five ‘Yes/No’ questions with further open-ended questions and fifteen 5-point 
Likert scale statements, designed to assess participants’ knowledge of reproductive health. 
There were twenty ‘True/False/Not Sure’ questions designed to assess their knowledge of 
PCC and thirteen 5-point Likert scale statements to assess their levels of activation. 
Questionnaire 1 contained an additional ten demographic information questions. 
Questionnaire 2 comprised all the questions (minus the ten demographic information 
questions) plus two additional sections aimed at evaluating respondents’ satisfaction with the 
app. A simple visual scale asked respondents to rate the app from 0 to 100, while a free text 
section asked them to provide additional information regarding their experience of app usage 
and suggestions for improvement.  
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The two questionnaires, used to assess patients’ reproductive health, attitudes and 
behaviour (RHAB), knowledge of PCC and level of patient activation, were developed from 
the following instruments (Charron-Prochownik et al., 2006b; Hibbard et al., 2005; Holmes et 
al., 2012). Section one (comprising 20 questions exploring reproductive health, attitudes and 
behaviour) was divided into six scales: cues to action (five questions), perceived 
susceptibility (four questions), perceived benefit (two questions), perceived barriers (two 
questions), self-efficacy (three questions) and outcome expectations (four questions). 
Section two comprised 20 questions on knowledge of pregnancy planning (11 questions) 
and pregnancy-related risks (9 questions) and section three had 13 patient activation 
measure (PAM) questions. The rationale and description of the choice of instruments are 
provided below.  
 
Reproductive Health Attitudes and Behaviour (RHAB) multi-dimensional reproductive health 
and diabetes instrument 
The RHAB is a validated theory-based instrument that measures the decision-making factors 
related to reproductive health and preconception care behaviours in women of reproductive 
age with DM. This instrument was adapted by Charron-Prochownik et al. (2006b) from the 
‘Pregnancy and Diabetes Interview Schedule’ previously created and validated by Janz et al. 
(1995). The psychometric properties of the 48-item RHAB questionnaire were tested in a 
population of 87 adolescent women with DM and found to have acceptable levels of validity 
and reliability (Cronbach’s alpha = 0.65 - 0.83). It has since been used in several eHealth 
PCC studies designed to improve PCC behaviours (Charron-Prochownik et al., 2008, 2013; 
Fischl et al., 2010; Holmes et al., 2012). Hence, it was used in this study to measure 
changes in PCC beliefs and attitudes at baseline and following the PADI app intervention.  
 
Charron-Prochownik et al. (2006b) identified unplanned pregnancies in women with DM as a 
complex problem and observed that various interconnected factors such as demography, 
psychology, behaviour and social characteristics contribute to poor pregnancy planning 
behaviours in this group of women. They concluded that preconception behaviours can be 
explained by the health belief model (HBM), theory of reasoned action (TRA) and social 
cognitive theory (SCT), thus, the RHAB examines constructs of these three social cognition 
models. The RHAB was developed for use in young women with DM in America, hence, it 
was modified in terms of language in order to make it more applicable to a UK study 
population. For example, contraception was used in place of birth control, in line with another 
UK study (Holmes et al., 2012). Furthermore, as the target behaviour is PCC, the instrument 
centred on achieving normal blood glucose levels, obtaining PCC and using effective 
contraception to prevent unplanned pregnancies.  
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Questionnaire length is a key factor that contributes to participants’ response burden (the 
effort required to answer a questionnaire) (Rolstad et al., 2011); increased response burden 
may result in lower questionnaire completion, response rates and data quality (Rolstad et al., 
2011). To avoid participant response burden, an abridged (20-item) version of the 48-item 
RHAB questionnaire was used. The items in the abridged RHAB questionnaire used in this 
study were taken directly from the RHAB scale and contained the following six constructs: 
cues to action (motivation to seek PCC), perceived susceptibility (women’s belief of their 
personal susceptibility to problems, such as unplanned pregnancies and pregnancy-related 
complications), perceived benefits (benefit of receiving PCC and using contraception to 
prevent an unplanned pregnancy), perceived barriers (barriers to seeking PCC), self-efficacy 
(self-confidence to get PCC and use contraception to prevent an unplanned pregnancy), and 
outcome expectations (participants’ belief that the outcomes are influenced by their own 
decisions to use contraception and seek PCC).  
 
It was important to maintain the content validity (the degree to which the instrument 
measures the intended idea) by using it in a population that was similar to the original 
authors and other researchers that have used the RHAB (Charron-Prochownik et al., 2006b; 
Charron-Prochownik et al., 2008, 2013; Fischl et al., 2010; Holmes et al., 2012; Komiti et al., 
2013). Questionnaire content was also reviewed by the study supervisors to ensure that it 
was valid for use in this population before being piloted. These steps were taken to ensure 
that the abridged questionnaire was comparable to other studies using the RHAB.    
 
Preconception care knowledge instrument 
This part of the instrument consisted of items from Holmes et al. (2012). The research team 
at Queens University, Belfast adapted the knowledge (K) questionnaire for use in women 
with DM in the UK from a validated instrument (Charron-Prochownik et al., 2006c) with 
acceptable levels of validity and reliability (Cronbach’s alpha = 0.65-0.83). The instrument 
was used to evaluate PCC knowledge and rate the levels of understanding specific to an 
educational DVD content in 97 women with DM, of reproductive age, before and after 
receiving an educational DVD intervention. The Knowledge (K) questionnaire aligned with 
the PADI app content. It was therefore used in this study to assess respondents’ knowledge 
and understanding of PCC based on the information provided in the PADI app before and 
after the educational PADI app intervention.  
 
Specifically, participants’ knowledge of pregnancy planning and pregnancy-related risks was 
assessed. In this section, women were asked to report their knowledge of PCC using 
True/False/Not Sure. Of the 20 statements, 11 were True (T) and 9 were False (F). 
  
105 
 
Individual pre- and post-PADI app knowledge responses were expressed as percentage of 
participants correct. The overall knowledge of pregnancy planning and risks, and perceived 
understanding of how diabetes affects pregnancy were evaluated.  
 
Patient activation measure (PAM) 
Patient activation has been identified as an important determinant of health behaviour, and a 
good predictor of self-care and improved outcomes (Greene et al., 2005; Hibbard and 
Gilburt, 2014). It is a behavioural concept, concerned with patients’ involvement, 
participation and active engagement in their own health (Hibbard et al., 2005; Hibbard and 
Gilburt, 2014). According to NHS England (2016), patient activation is of particular 
importance to people living with long-term conditions (LTCs). Individuals with LTCs who 
report higher levels of patient activation are more likely to engage in positive health 
behaviours and to manage their health conditions more effectively (Hibbard and Gilburt, 
2014). Hence, healthy behavioural changes and adherence to difficult medical and/or 
lifestyle programmes are also more likely to be consistent and longer lasting in those 
patients with a high level of activation (Mukoro, 2012). Patient activation can be improved by 
(eHealth) educational interventions (Solomon et al., 2012), and the best way to assess the 
extent of behaviour change is to measure the level of patient activation before and after an 
intervention using the patient activation measure (PAM) (Solomon et al., 2012).  
 
During tool development, the PAM was appraised with respect to content, appropriateness 
and psychometric properties. The overall suitability to support the research design and 
answer the research questions was also considered. The PAM was deemed to be a suitable 
scale for measuring patients’ self-beliefs, confidence to manage health-related tasks and 
knowledge of the condition (Dixon, Hibbard and Tusler, 2009). It is a 13-item instrument, 
incorporating elements of self-efficacy and readiness to change, and the most widely used 
measure of activation (Hibbard et al., 2005; Hibbard and Gilburt, 2014).  
 
The PAM is a validated measure that provides consistent and accurate means of assessing 
changes in patients’ level of activation over time. It was originally developed by Hibbard et al. 
(2004) as a 22-item scale, and subsequently as a 13-item short form (Hibbard et al., 2005). 
A convenience sample of 1,515 patients with and without LTCs were used to establish the 
validity and reliability of the 22-item PAM. Good internal reliability (Cronbach’s alpha = 0.84 - 
0.89) has been consistently demonstrated in studies that have explored the psychometric 
properties of the 13-item PAM in different populations, languages and settings across the 
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world (Brenk-Franz et al., 2013; Rademakers et al., 2012; Fujita et al., 2010; Maindal et al., 
2009; Steinsbekk, 2008; Solomon et al., 2012; Hibbard et al., 2005).  
 
The results have consistently demonstrated that individuals with improved PAM are 
significantly more likely to engage in a wide range of health behaviours, such as eating 
healthy diets, exercising regularly, quitting smoking, attending screenings, regular check-ups 
and immunisation (Hibbard et al., 2004, 2005; Greene and Hibbard, 2012; Mosen et al., 
2007). They are also more likely to seek health information from a variety of sources 
including reliable websites (Fowles et al., 2009). Higher activation in patients with DM is 
particularly associated with improved diabetes self-management and blood glucose levels 
(HbA1c), adherence to medication, regular foot and eye checks, improved quality of life 
(QOL), lower use of emergency rooms and hospitalisation (Mosen et al., 2007; Rask, 2009; 
Greene and Hibbard, 2012; Remmers et al., 2009).  
 
The PAM segments respondents into 4 levels of activation (reflecting a developmental 
progression from the passive receipt of care toward greater activation) (Greene and Hibbard, 
2012). Level 1: Patients who do not feel in control of their own health and care, level 2: 
patients who have low confidence in their ability to manage their health, level 3: patients who 
have some experience and success in making behavioural changes and level 4: patients 
who have made most of the behavioural changes and can maintain these over time. Level 1 
is the lowest, while level 4 is the highest. The degree of certainty attached to the PAM that 
an increase in PAM levels will lead to improved behaviours, healthcare engagement and 
outcomes (Hibbard et al., 2004, 2005) constituted an important factor of consideration during 
the instrument development.  
 
5.5.4 Data management and analysis  
Microsoft Excel© was used for the organisation, collation and recording of the data from 
each participant. The processing of the questionnaire was consistent, and a clear record of 
the returned questionnaires was kept. Each participant was assigned a study number and 
the same number was used throughout the study to allow the data on demographic 
information, knowledge and attitudes to PCC and PAM to be collated. A coding 
manual/schedule was developed in Excel and used during the data entry process. The 
responses were assigned numerical codes and recorded in the codebook. The data were 
then entered into the Statistical Package for the Social Sciences (SPSS) version 23 prior to 
conducting the quantitative analysis. Data were summarised using frequencies and 
descriptive statistics.  
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The narrative data from the open-ended questions were analysed and grouped into 
categories, labelled and assigned numerical codes. The data gathered from the closed 
questions were analysed using SPSS. All demographic data were expressed as n (%) for 
categorical variables and mean ± standard deviation (SD) for continuous variables. The 
mean, SD, median, interquartile range (UQ - LQ) and range (maximum-minimum) 
descriptive statistics were produced for each preliminary outcome estimate. Comparisons 
between the pre- and post-intervention questionnaires allowed for any differences to be 
established. The data analysis methods for the RHAB, knowledge of PCC and PAM items 
are provided in detail below. 
 
Reproductive Health Attitudes and Behaviour (RHAB) instrument 
This section contained six sections, as already described. All questionnaire measures 
(theoretical constructs) were based on 5-point Likert scales, where Not at all = 1, A little = 2, 
Somewhat = 3, A moderate amount = 4 and A lot = 5; 1 = the lowest score and 5 = the 
highest score. The frequency of responses was examined by combining the number of 
people selecting the same scores (Pallant, 2010). This was summarised using tables and 
figures. All responses were expressed as numbers and percentages (n, %).  
 
The total RHAB scores represented the sum of the items within each construct. Perceived 
susceptibility was determined by summing up the four Likert-type items; the perceived 
benefit of PCC, the sum of two Likert-type items; the perceived barriers to PCC, the sum of 
two Likert-type items; self-efficacy, the sum of three Likert-type items and of the outcome 
expectations, the sum of four Likert-type items. For example, in order to obtain the total 
score for perceived susceptibility, which is a 4-item scale, using a response scale from 1 to 5 
(not at all to a lot), the minimum value would be 4 and the maximum value would be 20. If a 
participant answered 1 to every item, the overall score would be 1 x 4 = 4. If a participant 
answered 5 to each item, that score would be 5 x 4 = 20. The cumulative responses to each 
construct were collated in order to determine any changes in participants’ overall attitudes 
and behaviours pre- and post-PADI app intervention. Higher summative scores show a 
stronger level of belief in the construct.  
 
Preconception care knowledge 
Questions specific to the PADI app content regarding pregnancy planning and pregnancy-
related risks were scored as correct or incorrect. Individual pre- and post-PADI app 
knowledge responses were expressed as percentage of participants correct. The results 
were presented using a table.  
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Patient activation measure (PAM) 
The PAM was based on 5-point Likert scales, where Strongly disagree = 1, Disagree = 2, 
Agree = 3, Strongly agree = 4 and Not Applicable (N/A) = 5. The frequency of responses 
was examined by combining the number of people selecting the same scores. This was 
summarised using figures and expressed as (n, %).  
 
The total PAM score was further calculated by adding up the responses to the 13 questions. 
If all questions were answered and no N/A is used, the raw score range is between 13 and 
52. If there is at least one item including an N/A response, the total score will then be divided 
by the total number of items completed by the participant and multiplied by 13. The raw 
score is then transformed to a scale from 0-100 with the aid of a nomogram provided by 
Hibbard et al. (2005) to give the PAM score. Higher PAM scores indicate higher patient 
activation. On the basis of the PAM score, participants were segmented into one of four 
activation levels (as already described in section 5.5.3).  
 
Statistical analysis 
Comparisons between pre- and post-intervention (for the RHAB, PCC knowledge and PAM) 
scores were carried out using Wilcoxon-signed rank test, the non-parametric alternative to 
the t-test, because the data was from a non-random sample with scores that were not 
normally distributed and sample size < 30. The effect size (strength of the difference arising 
from the impact of the intervention) of the measures was reported using Cohen’s criteria 
(Cohen, 1988): 0.1=small effect; 0.3=medium effect and 0.5=large effect. It has been 
recommended that cut-off points for smaller samples (n≤20) be set to P = 0.10 or 0.15 rather 
than the conventional 0.05 to compensate for the small sample size (Stevens, 1996; Pallant, 
2013). However, for this feasibility study, results could be considered significant when P ≤ 
0.05.  
 
Internal consistency (the degree to which all the items making up the scale measure the 
same underlying constructs) for the pre- and post-intervention questionnaires were also 
analysed to demonstrate their reliability. Internal consistency was measured using 
Cronbach’s coefficient alpha; values range from 0-1, with higher values indicating higher 
reliability (Pallant, 2013). Scales with few items (e.g. less than 10) are more likely to have 
low values.    
 
5.5.5 Semi-structured interviews  
The sample for this phase was obtained from the participants recruited for the intervention 
phase (Creswell, 2014), and consisted of (n=6) participants who consented to being 
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interviewed. This sample size is considered adequate to gain an in-depth understanding of 
user experiences and usability issues (Nielsen, 1993, 2012).  
 
The semi-structured style of interview, via the telephone, was selected as the best means of 
generating data regarding participants’ experiences of app use because participants were 
geographically dispersed across the UK and North America. Furthermore, this method has 
been recommended for collecting feedback regarding participants’ views and experiences of 
app use (Whittaker et al., 2012; Mummah et al., 2016). It has also been used by several 
mHealth intervention studies (Robinson et al., 2013; Fjeldsoe et al., 2012; Cai et al., 2017; 
Milward et al., 2017) to explore the intervention’s usability, acceptability, benefits, 
challenges, usefulness and recommendations for improvement. Moreover, semi-structured 
interviews provide insight into participants’ engagement with technology that may not be 
captured by quantitative methods (Yardley et al., 2016).  
 
As initially discussed in section 4.5.2, the strength of this medium of interviewing is the 
flexibility to adjust or tailor the interview to the goals of the study. Thus, based on the 
answers given to the previous questions, subsequent questions can be formulated and 
explored. In this phase, the questions were standardised using a topic guide in order to 
ensure that specific areas were covered but with room to probe into issues and clarify 
emerging information.  
 
Tool development and piloting 
The interview schedule was developed from review of relevant literature and the work of 
Hebden et al. (2012). Themes and topics with pre-established questions were employed to 
guide the direction of the discussion with the women. During the development of the 
schedule, it was important for questions to be open-ended, logical, and sequential, and 
probes to elicit more detailed information were included. One woman with DM and one HCP 
piloted the interview schedule. A copy of the interview schedule is provided in Appendix 10. 
 
Data collection process 
The interviews, which took place from April to July 2017, were conducted with six 
participants over the phone. For semi-structured interviews to be successful, it is important 
to gain participants’ trust (Denzin and Lincoln, 2005). Frequent interaction with the 
participants during recruitment helped to build rapport and participants were encouraged to 
contact the researcher with any questions regarding the study. Furthermore, the interviewing 
style was intended to maintain rapport and questions were asked in a manner that ensured 
participants felt like they were involved in a discussion (Hancock et al., 2009). When 
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participants encountered difficulty in answering certain questions, probes were used 
sensitively to encourage elaboration on the topic.  
 
Recording interview data  
The interviews, lasting between 20 and 30 minutes, were digitally recorded for transcription 
and all participants consented to the audio recording of the interviews. This was important in 
order to obtain an accurate record of the interview, which can be repeatedly played at a later 
stage to aid transcription. 
 
Data management and analysis  
The audio recordings generated from the six interviews were listened to repeatedly in order 
to gain familiarity with the dataset’s content prior to drafting the transcripts. The analysis 
started while the data collection was ongoing.  
 
Interview data were transcribed verbatim using Microsoft Word as soon as possible after the 
interview with the participants. The digitally recorded interviews were listened to several 
times in order to ensure that the transcripts contained reliable information. Data were 
prepared for coding and analysis by using NVivo 10, as already described in section 4.5.5. 
The analysis used a largely inductive approach to generate the following three themes: 
feasibility and acceptability of the intervention, engagement with the intervention and future 
development of the intervention. See Appendix 11 for a coded transcript sample. 
Trustworthiness was ensured, as already described (see section 4.5.6).  
 
5.5.6 Software log of activity 
A software log of activity enables the collection of patient engagement data. According to 
Yardley et al. (2016), it is important to understand engagement with mobile health 
interventions in order to develop interventions that are effective and meet users’ needs. 
Analytics data provide an opportunity to measure various aspects of engagement, such as 
how frequently participants access the app, the time spent on the app, the number and type 
of pages visited, the features used, and the response to notifications or reminders (Yardley 
et al., 2016; Taki et al., 2017). The app analytics built into the PADI app specifically 
measured the software log of activity.  
 
All (n=17) phase 2 participants were included in the software log of activity. The logging of 
app data was conducted at the end of the 3-month intervention period and was used in order 
to demonstrate the uptake and utilisation of the PADI app. This set of data was stored on a 
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secure server that was only accessible to Netsells (the app development company), who 
ensured the secure transfer of data to the researcher for analysis purposes. The recorded 
data were examined to identify how often participants engaged with the app, i.e. frequency 
of app use, and location of users who interacted with the app.  
 
User engagement with app interventions can be measured in several ways including user 
experience interviews (Yardley et al., 2016). Although this form of data collection is 
subjective, it enables researchers to reliably explain usage patterns generated via the 
software log of activity. A strength of the software log of activity is that it can be collected 
without any user burden. However, a drawback of this method of data collection is that it can 
be difficult to interpret the data generated. Yardley et al. (2016) also note that this method 
does not measure user engagement with behaviour change, and qualitative research is 
needed to explain the observed differences in usage patterns. Therefore, in line with the 
recommendations by Yardley et al. (2016), the software log of activity was used to 
supplement the user experience interviews.  
 
Summary 
Chapter 5 has discussed the methodology used in phase 2 of this study. First, a description 
of the feasibility and acceptability of the PADI app was provided. This chapter also discussed 
the research setting, sample selection and development of data collection tools, as well as 
the methods of data collection and analysis used in phase 2 of this study. Questionnaires 
and semi-structured interviews were the methods of data collection used in phase 2. For 
each method, the rationale for its use, as well as the strengths and weaknesses were 
provided. The data collection methods were followed by the data analysis methods, i.e. 
descriptive statistics and statistical analysis for quantitative data and thematic analysis for 
qualitative data.   
 
The research was designed and conducted so that reliability and validity issues were 
addressed. Measures were taken to reduce the effect of researcher bias that may be 
inherent in qualitative research (as already described in Chapter 4, section 4.5.6).  
 
The next two chapters (6 and 7) present the findings from phases 1 and 2 of the study.  
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6. Chapter 6: Phase 1 results and preliminary discussion 
 
6.1 Overview of chapter: PADI app development  
 
This chapter presents the findings from analysis of data collected during phase 1 to direct 
development of the PADI app (that is, focus group and interviews). An initial overview of the 
participants will be followed by a thematic analysis of the views and experiences of women 
with diabetes and healthcare professionals regarding PCC, development and use of the 
PADI app in practice. In addition, findings are concurrently discussed in the context of ‘in 
line’ with other studies. Further discussion in context of App development is found in Chapter 
8. 
 
6.1.1 Demographic profile 
 
A total of 19 participants comprising healthcare professionals (HCPs, n=9) and women with 
diabetes mellitus (DM; n=10) took part (Table 6.1).   
 
Table 6.1 Participants descriptive table 
 
Healthcare professionals 
 
No Identifier Role Setting No of years 
in 
profession 
Provided 
PCC as part 
of role 
1.  HCP1 Nurse  Secondary care 32 No 
2.  HCP2 Nurse  Secondary care 43 No 
3.  HCP3 Nurse  Secondary care 14 No 
4.  HCP4 Doctor Primary & Secondary 
care 
44 Yes 
5.  HCP5 Doctor Secondary care 19 Yes 
6.  HCP6 Doctor Secondary care 11 Yes 
7.  HCP7 Nurse  Secondary care 13 Yes 
8.  HCP8 Nurse  Primary care: general 
practice 
32 Yes 
9.  HCP9 Nurse Secondary care 5 Yes 
Women with DM 
 
No Identifier Diabetes mellitus 
type & duration 
(years) 
Geographical location Age (years) Received 
PCC advice 
10. P1 Type 2 (5) Scotland 43 No 
11. P2 Type 1 (17) Wales 22 No 
12. P3 Type 1 (21) England 40 No 
13. P4 Type 1 (11) England 23 No 
14. P5 Type 1 (28) Northern Ireland 39 Yes 
15. P6 Type 1 (24) England 29 Yes 
16. P7 Type 1 (29) England 40 No 
17. P8 Type 1 (15) Northern Ireland 35 Yes 
18. P9 Type 1 (27) Northern Ireland 29 Yes 
19. P10 Type 1 (23) Ireland 43 Yes 
  
113 
 
HCPs included nurses (n=6, diabetes specialist and research nurses) and doctors (n=3, 
general practitioner, obstetrician and endocrinologist). Participants had extensive experience 
in the care of patients with DM with the majority (n=8) having over 10 years [range 5-44 
years]. Most of the HCPs (n=7) worked in the hospital (secondary care) setting providing 
specialist diabetes services while (n=2) worked in general practice (primary care), in the 
South of England. Most participants (n=6) provided PCC as part of their role (Table 6.1). 
Women with DM were geographically dispersed across England, Scotland, Wales and 
(Northern) Ireland (Table 6.1). The average age of participants was 34 years and majority 
(n=9) had T1DM with an average diabetes duration of 22 years. Five women reported that 
they had received PCC. Of the five women who had not received any PCC, three reported 
an unplanned pregnancy and one had experienced two miscarriages.   
 
6.2 Findings 
 
Three main themes emerged from the analysis: current state of PCC, adoption of technology 
and technology-assisted PCC. Each theme comprised of two or more sub-themes and was 
organised using sub-sections as shown in Table 6.2 below. 
 
Table 6.2  Themes and subthemes 
 
 Main themes 
 
Sub-themes Sub-sections 
 
1. 
 
 
 
Current state of PCC 
Understanding of PCC  Understanding of blood glucose 
control 
 Understanding of folic acid intake 
Preconception care service provision   Provision of advice 
 Inconsistency in advice 
 Factors hindering PCC provision 
Women’s experiences of receiving 
PCC advice 
 Missed opportunities and 
inadequate information 
 Dissatisfaction with HCPs’ 
attitudes 
 
 
2. 
 
 
Adoption of technology 
Use of technology for healthcare 
information 
 
 
 
Mobile apps trump all 
 
 Perceived benefits regarding use 
of a PADI app 
Acceptability and feasibility of a PADI 
app 
 Potential for integration  
 
 
 
3. 
 
 
Technology-assisted 
PCC 
PADI app development  Intervention content 
 Self-monitoring functions 
 Reminders 
 Intervention language 
Factors affecting implementation  Cost and organisational support 
 Facilitating content and design 
factors  
 Hindering content and design 
factors 
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6.3 Current state of PCC 
 
This theme illustrates the current PCC situation, explores participants’ understanding of 
PCC, clinicians’ provision of PCC advice and women’s experiences of receiving PCC.  
 
6.3.1 Understanding of PCC 
Understanding of PCC varied between participants (n=19) with healthcare professionals 
(HCPs) being understandably more aware of PCC and pregnancy-related complications than 
women, whose understanding of the same issues was limited and sometimes non-existent. 
For example, HCPs were of the opinion that PCC helped to improve diabetes control and 
reduce risk of complications during pregnancy while women believed diabetes control was 
the main focus of PCC, as shown below. 
 Preconception care is, care provided to women planning to become pregnant all in an attempt 
to optimise their health status before they become pregnant … just to make sure that their diabetes is 
under control … and they don’t have complications for which pregnancy would be a contraindication. 
(HCP5, interview 2)  
 It’s just really getting ready for your pregnancy more than anything else and the care which 
the hospital can offer you. Also, there really isn’t much, it’s all … working on HbA1c I think for most 
people. [P5, 39 years]   
The emphasis on blood glucose control in women’s discussion of PCC was in line with the 
qualitative study by Earle et al. (2017) in which glycaemic control was the focus of concern 
for those who attended PCC. The authors explained that many women with DM struggled 
with attaining good control and often sought extra support when hoping to get pregnant or in 
early pregnancy.   
As well as diabetes control, HCPs recognised the importance of identifying and managing 
complications, and medication reviews as vital PCC strategies for a healthy pregnancy and 
baby; however, their concerns regarding potential complications and need to minimise them 
were not expressed by women. For example, while one HCP stressed the need for women 
to see their HCPs to get screened for complications and discuss current medications as part 
of PCC, all women lacked sufficient understanding of potential complications or how to 
minimise them.  
 It’s organising patients so that they’re in the best possible shape when they are planning a 
pregnancy and making sure that any complications have been identified so they can be dealt with 
before entering pregnancy, and that all medication is appropriate for use in pregnancy. [HCP6, 
interview 3] 
 No, I don’t really know much at all … not really much about the PCC, diabetes itself I do have 
a bit of understanding of but not in a sort of preconception way [P1, 43 years] 
Similar to this study, Earle et al. (2017) also found that women (with and without prior 
pregnancies) had insufficient understanding of risk of complications. In contrast, Chuang et 
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al. (2010) found that knowledge gaps were particularly significant for women without prior 
pregnancies compared to women with prior pregnancies.  
Other women in the study also reported a lack of understanding of PCC for women with DM. 
For example, one woman felt PCC meant family planning and a second woman believed it 
involved monitoring fertility, having ovulation calendars and taking multi-vitamins, as shown 
in the data extract below. 
 I’m thinking like vitamins. Kind of just all of the general things that women do when they would 
like to conceive like planning out, not planning out, but having like a calendar for ovulation, stuff like 
that, vitamins, just being healthy in general. I can’t think of anything specific for diabetes though just 
because I don’t know anything. [P4, 23 years] 
Different levels of PCC understanding were reported by participants (both HCPs and 
women); with women specifically having limited understanding of PCC, how to optimise their 
health before pregnancy and reduce risk of pregnancy-related complications. Several 
studies in the literature (Spence et al., 2010; Lavender et al., 2010; O’Higgins et al., 2014; 
Murphy et al., 2010a; Shawe et al., 2008) also found that women with DM lacked sufficient 
understanding of PCC and how to prepare for pregnancy. Earle et al. (2017) further reported 
that the dominant message that seemed to be provided and taken on board by most women 
was that high blood glucose levels could cause complications in pregnancy.  
6.3.1.1 Understanding of blood glucose control 
Participants, both HCPs and women, were generally aware of the need to improve blood 
glucose control before pregnancy. Several authors (Berg and Sparud-Lundin, 2009; Chuang 
et al., 2010; Collier et al., 2011; Griffiths et al., 2008; King and Wellard, 2009; Shawe et al., 
2008) also found that many women were aware of the need to address blood glucose levels 
prior to pregnancy. However, some women lacked understanding of the rationale for 
optimising preconception blood glucose (BG) levels or the need to maintain this good control 
especially in early pregnancy. The rationale was however fully understood by HCPs who 
were keen to highlight the various complications that can affect pregnancy in women with 
diabetes if their BG levels were uncontrolled. For example, one doctor explained how 
pregnancy generally exacerbated existent diabetes complications and disrupted glycaemic 
control. Although women agreed that diabetes control was needed before pregnancy, in-
depth understanding of the subject was lacking, as noted below. 
 So, diabetes and all the hormones involved make the pregnancy affect diabetes by making 
diabetes control more difficult, then there are the complications that you can get microvascular, macro 
vascular complications from diabetes, that can be exacerbated by a pregnancy. [HCP6, interview 3] 
 I know about like the importance of controlling your blood sugars and having HbA1c of a 
certain range before conceiving and things but nothing, I don’t really know too much on the subject. 
[P2, 22 years] 
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Other HCPs (n=3) reported that the woman’s level of diabetes control prior to pregnancy 
influenced the development of microvascular complications, for example nephropathy (renal 
disease) and retinopathy (eye disease), which would ideally require assessment and 
management prior to conception. However, none of the women in the study (n=10) 
mentioned that microvascular complications could worsen due to uncontrolled diabetes or 
that attending retinal and renal screening could help in identifying and managing pre-existing 
complications before pregnancy.  
HCPs (n=5) also highlighted that poor glucose management before and during pregnancy 
could cause several problems for women with DM and their fetus, including macrosomia and 
shoulder dystocia which could impact the mode of delivery and increase the need for a 
caesarean section. They emphasised that these complications and adverse outcomes all 
had detrimental effects on the health of both the woman and baby. A doctor in secondary 
care described some of the obstetric problems caused by poor diabetes control, in the 
extract below. 
 The main issues relate to baby becoming very big [macrosomia]… still birth or intrauterine 
deaths also from poorly controlled diabetes, and when the babies are very big, they pose problems at 
delivery … a good proportion are delivered by caesarean section and for those that have a natural 
birth, there is risk of difficulty in delivering their shoulders [shoulder dystocia] and that ofcourse poses 
problem, injuries to the baby in the form of lack of oxygen, fractures or/and nerve injuries. [HCP5, 
interview 2] 
Two women agreed that uncontrolled diabetes during pregnancy could result in adverse 
outcomes; however, their understanding was limited to either the ‘baby growing too big’ or 
‘possibility of a miscarriage.’ This agrees with the study by Spence et al. (2010) which found 
that some women’s knowledge of pregnancy-related risks was that women with DM ‘have 
really big babies.’ It was apparent that most women did not realise the extent of pregnancy-
related risks or the effect that high blood glucose levels could have on their pregnancy and 
the likelihood of experiencing pregnancy-related complications, as noted below. 
 I don’t really know much. I mean I’m sure it’s more difficult to control your blood glucose levels 
but yeah I’m not really sure. [P4, 23 years] 
 Not really, no … because I think it’s not something that I know of personally, it’s not 
something I know much about [P1, 43 years] 
HCPs highlighted that priority should be given to blood glucose management as this helped 
to prevent complications. Yet, despite a general awareness of the need for optimised 
diabetes control among participants, many women were still unaware of basic PCC 
information such as the risks of uncontrolled diabetes to the woman or her baby and 
importance of planned pregnancy. This is in line with O’Higgins et al. (2014) who found that 
although women with DM knew that glucose control was crucial for a safe and healthy baby, 
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they still had inadequate understanding of the risks of poorly controlled DM on pregnancy 
outcomes.  
6.3.1.2 Understanding of folic acid intake 
The role of folic acid in preventing birth defects was recognised by some clinicians and 
women. For example, a clinician in secondary care and a woman with DM highlighted the 
need for a higher dose of folic acid in order to help with the baby’s development, reduce the 
risks of disabilities, such as spina bifida, and improve the likelihood of a healthy baby. 
HCPs explained how the recommended folic acid dosage for women with DM was higher, 
noting that whereas women with DM needed 5mg folic acid (the higher dose), other women 
were advised to take the lower dose of 400 µg. Although HCPs seemed to understand the 
importance of folic acid, there was uncertainty regarding timing and duration. This 
uncertainty was also evident among the women. 
 Ladies with diabetes need to be on 5mg of folic acid rather than the 400 microgrammes that is 
readily available over the counter, so they need to go ask for it be specifically prescribed. [HCP6, 
interview 3] 
 Well I don’t know a huge amount about that [folic acid] other than I know you are supposed to 
take it for a while before you conceive ideally and then continue to take it during pregnancy. I think 
that’s to do with the baby’s spine development but I haven’t been told any more details about that …Is 
it 5 mg or something like that rather than 4 or something, I think I’m not a 100% sure. [P6, 29 years]. 
 
This is similar to the findings of Earle et al. (2017) whereby some women who recognised 
the need to take folic acid were unsure as to how long to take it before becoming pregnant, 
and some reported taking it only during pregnancy.  
 
Knowledge gaps were significant for women in the study and they reported not being given 
adequate folic acid information. For example, another woman who learnt about the 
importance of folic acid supplementation as part of a course in dietetics, acknowledged 
receiving insufficient information on the recommended dosage for women with DM, as 
shown below. 
 Well, I don’t really know too much about it. I know obviously about the importance of like folic 
acid supplementation because that’s just a topic I’ve just covered now myself in University … I don’t 
really know too much on the subject. [P2, 22 years] 
Spence et al. (2010) and Shawe (2008) acknowledged that very few women with DM knew 
that the recommended folic acid dose was higher than the general maternity population or 
that over-the-counter folic acid may not provide them with levels required by women with DM 
(which was only available on prescription in the UK).  
This insufficient knowledge of folic acid could lead to misconceptions. For example, a 
woman who reported being prescribed folic acid by a HCP during two prior pregnancies that 
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sadly ended in miscarriage, wrongly associated folic acid with this negative pregnancy 
outcome. 
 It’s something that I was sort of told to take when I was expecting my daughter, but I didn’t 
actually take it ... I think partly because in my own mind, I had miscarried twice before I had my 
daughters and both times I had taken folic acid. So it was something in my head telling me “don’t take 
it, try and do something different.” but it was a coincidence that I wasn’t taking it and I had my 
daughters. [P1, 43 years].  
Inadequate awareness of PCC and folic acid in particular may be the reason why it was 
linked to miscarriage by this participant who further reported not knowing why the folic acid 
was prescribed. This finding is supported by other studies (Spence et al., 2010; Earle et al., 
2017) which found that very few women were aware of the rationale for folic acid use. It has 
also been noted that although previous pregnancy loss may encourage some women to 
seek PCC, this was not the case for most women (Earle et al., 2017).  
 
Overall, all HCPs noted that PCC could help to reduce risk of complications and negative 
pregnancy outcomes while women agreed that health optimisation before pregnancy was 
important. Two participants, a secondary care nurse and woman, recognised that pregnancy 
in women with DM was high-risk, highlighting the need for all women with DM to receive 
PCC to help improve their health, before pregnancy.  
 I mean it’s still appalling— maternal death, preeclampsia, intrauterine death, still births, early 
miscarriage, but getting the preconception in there reduces all these various risks so much. [HCP7, 
interview 4] 
 You want to go into [pregnancy] being as healthy as possible because so much can happen 
during pregnancy especially when you are type 1 so you want to start it being as healthy as possible. 
[P5, 39 years] 
However, one woman concluded that seeking PCC was not prioritised by many women with 
DM due to insufficient understanding of PCC or its benefits and deemed it “something that’s 
not really thought about that much.” [P1, 43 years]. This is in line with the argument, by 
Lavender et al. (2010), that inadequate understanding could lead to apathy towards PCC 
because women did not understand how important it could be to them.  
6.3.2 Preconception care service provision 
6.3.2.1 Provision of advice 
HCPs’ accounts of providing PCC advice were different from women’s views of being given 
advice. HCPs (n=6) whose roles involved PCC reported giving advice to all women with DM 
of childbearing age during clinic consultations. They reported using these routine 
appointments to encourage women to discuss their pregnancy intentions and attend 
medication reviews before conception. Although most women (n=9) acknowledged that they 
had frequent contacts with their diabetes health care team e.g. endocrinologists, general 
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practitioners (GPs), diabetes specialist nurses (DSNs), dieticians, and psychologists either 
via telephone, email or face-to-face, only half (n=5) reported receiving PCC advice from their 
healthcare team. 
 Any woman of childbearing age, I’ll always ask them if they are planning to have children, and 
then, people know that they can come to me and talk to me about when they are planning, so that we 
can make the necessary arrangements, do the necessary investigations, change the medications 
around. [HCP6, interview 3]  
 I see a pre-pregnancy consultant at my hospital and I also see the diabetes specialist nurses 
and I have email contacts and phone contacts with them pretty much all the time if I need it and I also 
see a psychologist. [P5, 39 years] 
 
HCPs highlighted close monitoring of women with DM as being instrumental to identifying 
potential complications. They also noted that the possibility of women being on teratogenic 
medications such as statins and ACE inhibitors that could adversely affect the fetus during 
pregnancy was an issue of key concern and underscored the importance of pre-pregnancy 
care. A nurse in secondary care reported using these consultation time to help women 
optimise their blood glucose levels, encourage intake of folic acid, identify and prevent use of 
harmful medications in pregnancy.   
 It’s so important and generally it can be just taking time to get their control good, getting them 
onto folic acid. Yeah and especially ladies with type 2, younger age and women having babies later, 
you’ve got the risks that they might be on tablets that they shouldn’t be on for the pregnancy and 
that’s kind of a key thing. [HCP7, interview 4] 
This secondary care nurse identified high risk categories of women for whom PCC is 
essential, as younger women, those with T2DM and older women (over 35 years). But, 
participants (n=5) whose ages spanned between 22-43 years could not recall receiving any 
PCC advice from their care team. Despite being classified as ‘high risk’, some younger aged 
women who were students (n=2) did not receive any PCC advice and could not understand 
why they were overlooked despite being of childbearing age, as shown below. 
 Given perhaps that I’m a student maybe my diabetes team don’t look at me as being of 
childbearing age … but I have never had any like any particular input [PCC advice] from my care 
team … I don’t know whether it’s just the healthcare team I’m with necessarily, but I would have 
thought that being like a 22 year old female, they would have like warned– like talked more to me 
about [PCC], and like the importance of it. [P2, 22 years] 
In terms of providing PCC advice to younger women with DM, Spence et al. (2010) reported 
that young nulliparous women felt that pregnancy advice was often withheld until they 
reached the appropriate age, which frustrated women as they believed there was no 
appropriate age when it came to discussing pregnancy plans. Women further felt that 
pregnancy advice was often provided in a manner that confirmed certain preconceived ideas 
and social stereotypes held by their HCPs; for example, they were more likely to be asked 
about pregnancy plans once they were engaged or married.  
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Hence, for half of the women (n=5), contacts and consultations with their diabetic team did 
not involve provision of PCC advice. Furthermore, it was important for all women of 
reproductive age to receive PCC (including contraception) advice as absence of PCC 
information could impact on whether or not women planned their pregnancies. Three women 
(n=3) who did not receive any PCC advice prior to conception reported having unplanned 
pregnancies, as noted below.  
 My first pregnancy was a massive shock … I just happened to do a test one day and it was 
positive and that was that, so I didn’t actually have anything pre-gestation at all. [P7, 40 years] 
 
6.3.2.2 Inconsistency in advice 
Provision of PCC advice and services in primary and secondary care was inconsistent and 
lacked standardisation amongst HCPs. For example, Spence et al. (2010) reported wide 
variability in knowledge of recommended blood glucose target range among women with DM 
(including those who received PCC). In this study, women (n=5) who received PCC provided 
different accounts of the PCC advice received from their respective HCPs, as shown below.  
 It’s [PCC] to try and maintain your HbA1cs at a reasonable rate below 7, also to make sure 
preconception to be off other prescriptions, medications and to have a healthy diet. [P9, 29 years] 
 My consultant she has spoken to me about pregnancy and … that you need to keep your 
blood sugars in a good range, your HbA1c … below 6.5 for a while before conceiving or thinking 
about conceiving and to speak to your diabetes team if that is something that you are planning to do 
so they can offer extra support. [P6, 29 years] 
 
It was not clear whether any of the women were given advice on contraception, medication 
reviews or attending screening for complications. Three clinicians in secondary care 
acknowledged that although women with poor glucose control were asked to delay 
pregnancy, they were often advised to speak to their GP about contraception, as this was 
not seen as the responsibility of clinicians in secondary care. 
 It [contraception] isn’t our remit but we would say if you are planning- you know someone’s 
HbA1c isn’t good and we want them to delay … we would usually say, “see your GP for adequate 
contraception to have a- or suggest having a coil fitted” but we don’t actually do contraception. [HCP2, 
FG1] 
This HCP’s response suggested that secondary care clinicians tended to focus on other 
aspects of PCC such as glucose control, lifestyle modification, medication review and 
screening for complications. This view was supported by this doctor’s account of what her 
PCC advice contained. 
 Try and get as fit as you possibly can, try and eat as healthily as you possibly can, and don’t 
drink too much alcohol, and really try to avoid alcohol, stop smoking, let’s look at your medication, see 
what pills and portions you are on, let’s have a look at the diabetes complications that you already 
have, let’s make sure you get screened for it and so make sure your medication is as good as 
possible. [HCP6, interview 3] 
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On the other hand, contraception appeared to be of particular importance to HCPs in primary 
care (n=2). For example, one primary care nurse highlighted discussing contraception, in 
addition to other PCC needs with women of childbearing potential during clinic consultations.  
 Just as I see people for reviews … I would talk through their contraception, their [pregnancy] 
plans, folic acid. [HCP8, interview 5] 
This was supported by another primary care doctor who reported also providing 
contraception and folic acid advice to women with DM. It was noted that primary care 
clinicians, e.g. GPs, had a duty to encourage women to avoid unplanned pregnancies by 
using contraception and to consume 5mg folic acid in preparation for a pregnancy.  
 We always had a sort of thing that either the patient should be taking the contraceptive pill or 
5mg folic acid, one or the other just to make sure that at the point of conception they would have on 
board 5mg folic acid. [HCP4, interview 1] 
Murphy et al. (2010) highlighted the significance of contraceptive services in relation to PCC, 
arguing that contraception advice was particularly relevant for younger women for whom 
pregnancy may seem a long way off. However, none of the (n=5) women in the study who 
received PCC reported that they received contraception advice as part of PCC. These 
shortcomings in PCC service provision may be due to various factors which are presented 
below.  
6.3.2.3 Factors hindering PCC provision 
Effective PCC provision was reported to be hindered by a number of factors including level 
of involvement in PCC provision, service configuration and lack of pregnancy planning.  
Level of involvement in PCC provision 
Clinicians’ job roles influenced their level of PCC knowledge and awareness. Some nurses 
(n=3) who were not directly involved in providing PCC advice explained that they had limited 
knowledge of PCC and the issues and challenges facing women with DM, as shown in the 
focus group discussion below. 
 I don’t know. I presume that they will have to be advised that they will have more frequent 
monitoring than they would do normally … I don’t know, you probably know, [to Assistant Moderator] 
do they have amniocentesis that is different to anyone else because they have diabetes? But that’s 
not preconception, that’s when they’ve conceived but pre-pregnancy, I don’t know if there is anything 
else they do. [To HCP3] You don’t know either? [HCP2, FG1] 
 I don’t have that kind of experience myself, sorry … Well, if they are type 1 probably they 
know about their disease quite well because they have been living with it for a long time, so usually 
they are quite well informed [about diabetes and pregnancy]. [HCP3, FG1] 
 I mean we are mostly talking about the type 1 patients aren’t we? … You won’t get many type 
2 who get pregnant because usually the type 2 are the older age group so you’re mostly talking about 
type 1 patients. [HCP2, FG1] 
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This finding agrees with the study by Mortagy et al. (2010) in which there was a contrast in 
perspective between GPs with and without specialist interest in DM, while the former were 
more informed and involved in providing PCC education, the latter were uncertain as to their 
role and involvement in PCC of women with DM. However, it was of concern that most GPs 
saw T2DM as a disease of the elderly rather than something that might affect women of 
childbearing age. Hence, as Earle et al. (2017) highlighted, this view may have a bearing on 
the service GPs provide and the emphasis they place on providing PCC or referring women 
to specialist PCC centres.  
The criteria for allocating PCC responsibility was not clear from discussions however it 
emerged that PCC responsibility was given to some clinicians but not others, who were 
equally in contact with women with DM of reproductive age. This meant that clinicians 
without PCC responsibility who came in contact with women planning a pregnancy referred 
them to other clinicians, as noted below. 
 If I came across someone who was planning a pregnancy if they had diabetes then they 
would be referred into the hospital to the specialist. [HCP2, FG1] 
 
Service configuration 
The different configuration in services for women with T1 and T2DM also affected PCC 
provision and uptake. PCC services were reported to be mostly provided in secondary care 
which catered for T1DM. While most T1DM women received their PCC advice at the 
hospitals, T2DM women who were mainly seen in primary care missed out of receiving 
important PCC advice. A secondary care nurse noted that lack of PCC for women with 
T2DM, particularly poor diabetes control and lack of folic acid in the first few weeks of 
pregnancy, increased the risk of complications and adverse outcomes. 
 So those first 12 weeks of organ forming can be– you can miss them before the lady realises 
she is pregnant and then they’ve had awful control, they haven’t had their folic acid.’ [HCP7, interview 
4] 
Mersereau et al. (2011) acknowledged that lack of knowledge and awareness was a barrier 
to PCC for women with T2DM, and they were the least knowledgeable about the risks of DM 
and pregnancy. HCPs who provided PCC were therefore concerned about the inequality in 
PCC service provision amongst women with DM. A primary care doctor reported that despite 
the increase in pregnancies to women with T2DM, many of them were unlikely to receive 
PCC compared to those with T1DM. 
 We are seeing more patients that are going into pregnancy with type 2 DM, and I think those 
are the patients that sometimes get missed … and our patients with type 1 DM … will get their 
preconception/conception advice at the hospital [HCP4, interview 1] 
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This indicated that some GP practices did not provide PCC advice to women with T2DM. 
The inadequate provision of advice to T2DM women was supported by a nurse in secondary 
care who stressed that many T2DM women, referred to her for PCC by their GPs, did not 
attend their PCC appointments and often conceived without adequate pregnancy 
preparation. 
  There is all these ladies who aren’t getting [PCC] and if a GP rang me and said “oh my lady 
is type 2, she wants to get pregnant”, I would be like “oh that’s great, when is she coming to have a 
chat with me?” we make ourselves so accessible, but it doesn’t happen and the type 2 ladies do tend 
to have quite poor control when they conceive.  [HCP7, interview 4] 
Across several studies (Chuang et al., 2010; Griffiths et al., 2008; King, Wellard, 2009; 
McCorry et al., 2012; Mersereau et al., 2011; O’Higgins et al., 2014; Shawe 2008; Spence et 
al., 2010; Woolley et al., 2015), there was uncertainty between clinicians in primary and 
secondary care as to who was responsible for the delivery of PCC and the practitioner best 
placed to provide it. According to Mortagy et al. (2010), secondary care clinicians highlighted 
seeing many pregnant women with T2DM who had uncontrolled blood glucose levels and 
noted that as key members of the multidisciplinary team, the GP’s role was crucial yet 
missing particularly with regards to providing PCC advice to young women with T2DM.  
In addition, Murphy et al. (2010) acknowledged that better integration between DM care and 
PCC services was needed across primary and secondary care, stressing that failure to 
provide a more coordinated care will have devastating consequences for women. 
 
Lack of pregnancy planning  
HCPs reported that many women with DM did not plan their pregnancies or disclose their 
pregnancy intentions to their healthcare teams. They felt that this limited their ability to 
provide effective PCC especially as antenatal care only provided a short window for HCPs to 
help women reduce risks of complications and adverse outcomes. 
 We all know that, well I wouldn’t like to say how many pregnancies are planned and the 
patients take your advice before hand? … You still get women, who become pregnant and then think 
about it afterwards and so you are sort of scrambling about to do what you can, and some women 
genuinely don’t know that they are pregnant, some women don’t make plans beforehand obviously. 
[HCP4, interview 1] 
HCPs further noted that many women did not discuss their pregnancy plans with their 
healthcare teams because they were uncertain and anxious about pregnancy. Women 
therefore preferred to wait until they had established that the baby was healthy, usually after 
the first trimester, before discussing their pregnancy with their diabetic team. They explained 
that women did not respond well to being asked about their pregnancy intentions during 
consultations, making it an uncomfortable subject for both HCPs and women.  
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 I think some women don’t tell you they are planning a pregnancy because they don’t want a 
lecture and the Spanish inquisition, sort of thing … because you don’t know how long it’s going to 
take, the pressure, you just keep it quiet don’t you? You don’t tell anyone till you’ve had your 12 
weeks scan and everything is ok …. A lot of women don’t like every time they come being asked if 
they are planning to get pregnant. I mean even without diabetes, “oh, are you gonna have little ones 
soon?” and they are like “go away”. Can you imagine having that every time? But unfortunately it’s so 
important that it has to be mentioned. [HCP7, interview 4] 
Mersereau et al. (2011) described the contrasting perspectives of HCPs and women with 
DM with regards to pregnancy planning. According to the authors, HCPs believed women 
with DM were often in denial and not compliant or proactive in managing their DM. Women 
on the other hand reported that they wanted their lives to be as normal as possible despite 
having DM, and wanted to feel the joy of preparing for pregnancy or being pregnant which 
they noted would not happen if they involved HCPs; women desired normalcy in the context 
of such a high-risk and medicalised experience. 
6.3.3 Women’s experiences of receiving PCC advice 
Only two women expressed satisfaction with the level of PCC advice and support received 
from their diabetes team. The majority of women felt their experience of receiving PCC was 
sub-optimal due to several factors including missed opportunities, inadequate PCC 
information and HCPs’ attitudes.  
6.3.3.1 Missed opportunities and inadequate information 
Women reported that various opportunities such as clinic appointments or consultations 
which they believed could be used by HCPs to provide comprehensive PCC advice were 
often not properly utilised. Half of the women (n=5) recalled numerous encounters with their 
HCPs in which they were told about their sub-optimal blood glucose control but without 
accompanying PCC targets to aim for should they decide to conceive, as shown in the data 
below. 
 So, preconception I didn’t get any advice at all which really isn’t good enough … I could 
remember several appointments with the consultant at the hospital [and] them always saying “oh your 
levels are too high” but never ever giving me, “if you keep below this number things will be better.” 
[P3, 40 years] 
Majority of women in one qualitative study (McCorry et al., 2010) attributed their limited 
knowledge of PCC and pregnancy-related risks to a lack of information from HCPs. Similarly 
in Lavender et al. (2010), women reported having vague chats with HCPs which left them 
with no clue about where or how to access PCC. 
 
Women in the study reported being given fragmented advice by HCPs which did not provide 
them with adequate knowledge to make changes; thus this advice was not well received. For 
example, one woman reported constantly being told by her diabetes team to avoid a 
pregnancy but without adequate explanation, as noted below. 
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 It was every time I showed up at the clinic “do not get pregnant, do not get pregnant 
accidentally” that kind of sermon … “let us know when you want to get pregnant”… they didn’t tell me 
why just that “when you do get pregnant its very dangerous” but not going into details which I think 
would have helped. [P10, 43 years] 
 
In two other studies (Lavender et al., 2010; Spence et al., 2010), women reported being 
advised not to get pregnant or have any more children (due to risks) but were not told why, 
and interpreted it as HCPs wanting control or dictating if and when they can have children. 
Consequently, the women did not seek PCC, engage with HCPs to plan their pregnancy or 
adhere to the HCPs’ advice.    
PCC advice was limited and much emphasis seemed to be on reducing the likelihood of 
complications by attaining good blood glucose control. However, some women were still not 
sufficiently aware of the implications of having HbA1c levels outside the target range and 
began pregnancy with sub-optimal blood glucose control, as shown below. 
 It was about 9 or 10 then … but I don’t remember any diabetic consultant suggesting that 
before I became pregnant or asking you know if I was thinking of becoming pregnant or anything like 
that. [P3, 40 years] 
 
Participants reported generally not getting enough information from HCPs. They believed 
opportunities to provide PCC advice were often missed and vital preconception information 
such as the need to take 5mg folic acid at least 3 months before conception or the HbA1c 
target to aim for, were sometimes not provided.  
 Some diabetes care teams don’t tell girls that they need to be on the 5 [mg folic acid] instead 
of the 4 [µg folic acid] and they don’t tell them to try and get their HbA1c in good order or their basal 
rates checked which I think is a bit silly really … in clinics they are just given so little information. [P5, 
39 years] 
 
 
6.3.3.2 Dissatisfaction with HCPs’ attitudes 
 
Women with DM were able to achieve healthy pregnancy outcomes especially with effective 
PCC provision, however this message was reported to be downplayed and HCPs seemed to 
focus more on complications. This approach to PCC provision was met with disapproval, as 
noted below. 
 I think it’s scare-mongering in a way, if you don’t do this, baby is going to be that. [P3, 40 
years] 
Several studies in the literature (Collier et al., 2011; Griffiths et al., 2008; King and Wellard, 
2009; Mersereau et al., 2011; Murphy et al., 2010; Shawe, 2008) have highlighted that HCPs 
often focused on the risks and negative outcomes of DM and pregnancy rather than on the 
opportunities for change. These literature suggest that the focus of information and advice 
given to women with DM was quite negative and this negativity hindered the patient/provider 
relationship and the likelihood of women seeking PCC. Some studies (Griffiths et al., 2008 ; 
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McCorry et al., 2012) have reported that instead of being informed and supported, some 
women felt fearful and anxious after receiving advice from their HCPs which deterred them 
from further seeking PCC. This view was echoed by another woman who believed that 
HCPs had an unsupportive attitude towards pregnancy in women with DM and stated that 
women were often only told about adverse outcomes of pregnancy, for example. 
 A lot of diabetes management come from like scare tactics and from what I gather with 
pregnancy that can be the same, so it’s all like “oh you are gonna do this otherwise you are gonna 
give birth to some deformed child” which is quite negative. [P5, 39 years].  
Participants were unhappy with HCPs judgemental attitudes and highlighted that this 
discouraged women with DM from disclosing their pregnancy intentions or seeking PCC 
advice from their HCPs. Several studies (King, Wellard, 2009; Lavender et al., 2010; 
O’Higgins et al., 2014; Shawe, 2008; Woolley et al., 2015) have highlighted that HCPs adopt 
communication styles that are perceived by women to be authoritarian and paternalistic. 
Shawe (2008) stressed that this style of communicating was a form of social control, which 
made women feel judged, nagged, undermined, intimidated and less receptive to advice or 
care. Earle et al. (2017) highlighted that this style of communicating was intended 
(erroneously) to be informative and to encourage behaviour change but Spence et al. (2010) 
noted that it made women see HCPs as unsupportive to their needs.  
 
Participants reported that dissatisfaction with HCPs’ attitudes often caused women with DM 
to seek health information from other sources, as noted in this quote below. 
 Particularly in diabetes I think sometimes it’s very difficult because people often feel reluctant 
to be honest with healthcare professionals because they feel that they are judged a lot of the time and 
sometimes I think people don’t always want to go to somebody who is medical to find things out. [P7, 
40 years] 
 
Women were reported to also be critical of HCPs in three other studies (O’Higgins et al. 
2014; Richmond, 2009; Woolley et al., 2015), noting that HCPs often did not appreciate the 
work it took to manage DM during pregnancy or while preparing for pregnancy. Women 
desired to have more control over their pregnancy or plans for pregnancy and wanted HCPs 
to focus more on their pregnancy and not just on the DM. Lavender et al. (2010) thus 
proposed that HCPs should seek to normalise the experience of pregnancy for women with 
DM to ensure that they have a positive experience by balancing their need for safety with 
that of enjoyment.  
It appeared that women were reticent to approach HCPs for PCC advice due to their 
attitudes and approach to PCC service provision. Women’s report of seeking health 
information via other sources, warranted further exploration, the findings of which are 
presented below. 
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6.4 Adoption of technology 
This section will discuss participants’ views and experiences regarding the use of interactive 
technology available via the Internet and smartphones, experience of using apps, benefits 
and perceived acceptability of the PADI app.  
6.4.1 Use of technology for healthcare information 
All women with DM (n=10) reported using technology as a supplement to information 
received from HCPs and to fill knowledge gaps. The benefits of using technology for health 
information were also recognised by HCPs especially as they believed that it would make 
information readily accessible. This was felt to be particularly important due to current clinic 
time constraints, mainly office hours, and the challenges that this created for women who 
were working and had to make child care arrangements in order to attend.  
Women also reported limited availability of some HCPs due to their heavy work load, busy 
clinics and time constraints. Thus, many women were disinclined (unless absolutely 
necessary) to travel to and from clinics because they felt that ‘sometimes you can’t always 
access healthcare professionals when you need them.’ [P7, 40 years] This agrees with the 
study by Spence et al. (2010) which cited busy clinics as a barrier to seeking PCC. 
HCPs recognised that current PCC practice, which used traditional leaflets and face-to-face 
engagement, required women to travel to clinics to receive advice. A nurse noted that with 
advancement in technology, women could access PCC information from the comfort of their 
own homes which could help to reach women planning a pregnancy but who do not present 
to medical care until already pregnant, as noted below.  
 What I’m trying to do is gather leaflets from all around that companies have made… and see 
which ones we are happy giving out … that’s another piece of paper and also the lady’s got to come 
in and engage with us to get it. But actually, if you are thinking of getting pregnant you might google 
things at home first and rather than us meeting a lady when she is already pregnant but now to get in 
there with preconception care. [HCP7, interview 4] 
HCPs felt that increased access to health information would reduce patients’ travel to 
hospital and encourage women to discover information themselves, become independent 
and less reliant on healthcare professionals. This mapped onto interactional workability 
which is concerned with the effect of technology on people and practices. Furthermore, 
HCPs and women believed many patients were inclined to turn to technology (including the 
Internet, smartphones and apps) for support due to its wide reach, convenience and impact, 
as shown in the data extracts below. 
 We are in the realm of technology and so it’s become part and parcel of a lot of activities and 
service provision, so it’s something which more or less brings a lot of information to the doorstep of 
the patients. [HCP5, interview 5] 
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 If I had a specific question … I might I suppose read articles on the Internet that has to do 
with healthcare. [P6, 29 years] 
 
Other women agreed and reported using the Internet for seeking healthcare information 
which they accessed via the smartphone. The internet was reportedly used to supplement or 
substitute face to face care. Spence et al. (2010) found that women who wanted more 
information or had negative experiences with HCPs or healthcare turned to ICT. Search 
engine Google, also known as Dr Google, was a popular source of health information that 
was frequently visited by patients in the study. The portability of smartphones meant that 
information could easily be accessed anywhere and anytime, and women in the study 
reported using their phones to seek information from ‘Dr Google’ as shown in the extract 
below. 
 I google quite a lot of things, I know. Dr Google in all things. I have practically got my phone 
glued to my hands … if I need to know, if like something comes to mind that I want to think of, it’s 
usually my phone that I tend to use. [P2, 22 years] 
Another woman supported this view and added that she consulted Dr Google for information 
when she was not feeling well, and Google in turn provided her with both a diagnosis and 
remedy to the problem. In addition to diagnosis of various conditions, the Internet was also 
consulted by participants for reproductive health advice. For example, one woman reported 
that she would rather consult the internet for information on contraception than discuss it 
with a member of her healthcare team.  
 I will just look online probably on the NHS website or something. I don’t think I will bother 
asking anyone in relation to that [contraception]. [P5, 39 years] 
 
Women reported using social media sites including Facebook and Twitter to access health 
information or consult diabetes charities with an online presence such as Diabetes UK and 
juvenile diabetes research fund (JDRF), and the smartphone made accessing these sites 
very convenient. They also noted using support groups on social media for information and 
support regarding PCC and pregnancy. These support groups were very useful for providing 
practical advice rather than text-book knowledge as done by HCPs and was an opportunity 
for women to learn from the lived experiences of others. 
 Well there are online groups like on Facebook which are geared towards pregnancy and pre-
pregnancy … they give you advice on a more practical level, people who have been there and done it 
rather than just the hospital reading from a book or from what they know. [P5, 39 years]  
 
Furthermore, women in the study who consulted search engines for information noted that 
PCC information, especially for women with DM, was lacking. One woman expressed 
concern about the lack of available information given that PCC was very important to women 
with diabetes.    
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 When you google it … there doesn’t seem to be much out there about like preconception 
especially with diabetes because obviously, it needs to be tightly controlled, your blood sugar and 
things, but there doesn’t seem to be much. [P2, 22 years] 
In line with this study, Earle et al. (2017) reported that women who used the Internet as a 
source of information when planning pregnancy were surprised by the lack of information 
and stressed the need for PCC information for women with DM to be made more readily 
available and easily accessible.  
6.4.2 Mobile apps trump all 
Participants, HCPs (n=4) and women (n=10), mentioned using apps on their smartphones 
daily to manage different aspects of their lives. Participants noted the benefits of using apps, 
citing that it made information easily accessible and helped to improve knowledge. Their use 
ranged from personal to professional and they reported using various gaming, banking, 
communications, music, shopping, social media, information, pregnancy and health apps.  
Participants generally expressed a liking for technology and apps in particular due to their 
usefulness and convenience. Apps were therefore reported to be used by health-based 
charities for handling daily activities and participants for seeking information on specific 
subjects that they might want to find out more about, as noted in the extracts below. 
 So I use a smartphone to use twitter and Facebook and Instagram for the Charity and also 
personally ... I use a lot of them … social media apps, communications apps for talking to patients 
and things, banking, mobile phone apps, oh, there are so many, things like planning meetings, count 
downs, making picture collages … things like that. [P5, 39 years] 
 
 I’ve got an app on geography, I’m trying to improve my knowledge on maps and stuffs but 
actually having it on my phone … I can just do it. I have got a book of maps somewhere in my house 
but to go and find it or the time you know, you could play on the app [HCP7, interview 4] 
All participants, HCPs and women, agreed that apps were pervasive and commonly used by 
women of reproductive age for various activities. They reported that women with DM of 
childbearing age were tech-savvy and found, downloaded and used apps to manage 
different aspects of their reproductive and diabetes health. Participants noted that apps were 
popular tools for health and diabetes management, and were used for monitoring diet, 
exercise and blood glucose levels, as shown below. 
 You can use an app almost for everything now. So you enter your details and then you can 
keep track of your period and everything. So you can also add all the other things that you need to 
check, so [if] its blood glucose or if you have to do some other tests. [HCP3, FG1] 
 I use 2 apps mainly- I use my Fitness Pal to like calculate foods and keep track of what I’m 
eating. I use the Carb and Cal app too for obviously when I need to estimate carbohydrate intake. [P2, 
22 years] 
App use appeared to be ingrained into women’s daily lives and even women who described 
themselves as being non tech-savvy (n=3), still used different apps on a daily basis. 
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Furthermore, women in the study generally used numerous apps for different purposes and 
had wide ranging experience of using apps. They all mentioned that they were more likely to 
use an app that was simple and beneficial, as noted below.   
 So I use an iPhone where I use the kind of regular Facebook, Instagram, twitter, I have my 
bank apps, I have the train line apps, I have a libraries app that I use, I have a weather app but again 
I’m not a huge app person … I am not a big techy person but if something is easy to use and helpful, 
then it would be something I would use regularly. [P9, 29 years]  
 
6.4.2.1 Perceived benefits regarding use of a PCC mobile app 
Many women with DM were savvy users of technology especially mobile phones, and the 
use of a PCC app sat comfortably within their skill set workability (the degree to which the e-
health initiative fits within existing skill set). There was a consensus among participants 
(clinicians and women) that apps were generally easy to use and appealed to women of 
different age groups. It was felt by participants that an app with PCC information would be of 
benefit to women with DM who were planning a pregnancy as they were motivated to stay 
healthy in order to achieve good pregnancy outcomes, as shown in the extracts below. 
 I think it’s a great idea to be honest. I mean everything now is apps and technology, and there 
is nobody who doesn’t know, even my mum knows how to use an iPhone and she is nearly 60 so it 
would be a great idea. [P8, 35 years] 
 I think great because that’s what people use … most women can intuitively work through 
[apps] regardless of age and stage … I’m working with a girl … she wants to start a pregnancy in the 
best possible shape both physically and biochemically… if there was any kind of sophisticated [PCC] 
app for her, that’s the sort of person who would benefit from it. [HCP8, interview 5]  
Two studies (Collier et al. 2011; King and Wellard, 2009) in the literature explained that 
women with DM were often concerned about the health of their unborn baby or baby-to-be; 
the desire for a healthy baby motivated them to be as healthy as possible and ensure the 
best outcomes for their baby.  
 
Another nurse in secondary care noted the usefulness of the Internet and apps in providing 
healthcare information. A PCC app could be used to enhance the experience of women and 
their partners as it would enable them to jointly access the information in the app and keep 
themselves informed on issues related to diabetes and pregnancy. 
 So you would kind of hope the lady or her partner or someone will be like “well hang on if you 
are gonna be doing this [pregnancy], do a bit of research” and google, and the internet and apps is 
the way forward, definitely. The partners are very involved, want to know about their ladies’ diabetes 
and want to know how it’s going to affect them and their babies. So actually it’s something their 
partners as well can look at with them which will improve their experience generally. [HCP7, interview 
4] 
Most clinicians (n=7) recognised the challenge involved in persuading women to discuss 
their pregnancy intentions and/or establish rapport with their healthcare team prior to 
pregnancy. One nurse stated that a PCC app had the potential to increase engagement with 
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HCPs via knowledge optimisation, so that women were fully informed about PCC and could 
approach their healthcare providers with confidence. Women agreed that the convenience of 
a PCC app would not only appeal to a large number of women with DM but also had the 
potential to increase PCC uptake.  
Phoning someone up and asking things you might think you ought to know can be a bit 
embarrassing and put you off whereas if you just look it up, at least it will give you the confidence 
when you then go and speak to someone like a healthcare professional. [HCP7, interview 4] 
 
 You might actually get more women actively seeking it [PCC], if that sort of thing was 
available… if I was gonna have another baby, I think I would be more likely to look it up like that now 
than see the diabetic specialist or whatever, I think I would probably do that first. [P3, 40 years] 
Hence, relational integration (how the intervention might affect the existing knowledge and 
relationships) and interactional workability (the degree to which the proposed technology 
enables or impedes interaction between HCPs and patients) were generally positive. 
Furthermore, a doctor felt that a PCC app would help inform women of the importance of 
working with their healthcare providers in order to attain good pregnancy outcomes, as 
shown the data extract below. 
It would bring about the engagement with the service providers so that they know they should 
work together for their own benefit. So, I think it’s a really good thing and if they’ve got the app by 
them, to be looking at, at their leisure which is even more important, rather than going to see–, it’s 
even more appealing, in that sort of sense. [HCP5, interview 2] 
 
HCPs and women reported that a PCC app also has the potential to address the constraint 
of current PCC service provision because it precludes the need to constantly travel to a 
hospital to receive information, thereby reducing patient travel to hospital. A nurse in 
secondary care further noted that many women were occupied (with work and child care) 
and constantly going to the hospital during preconception and pregnancy left them with a 
negative experience. 
I think it’s useful, I think that it’s something that is accessible at all times, you don’t need to 
have an appointment or anything similar it’s just something that is there, available all the time. [P7, 40 
years] 
 
The women appreciate not being dragged to a hospital every 5 minutes … they’ve got other 
things going on. Yeah and pregnancy and preconception is meant to be a lovely healthy time isn’t it, 
you don’t want to associate it with always being at a hospital, almost gives you the impression that 
you are ill. [HCP7, interview 4]  
 
Additionally, it was reported by women and HCPs that women with DM had a close 
relationship with their phones, and a PCC app with information on diet, blood glucose 
control, folic acid, etc. would be an ideal way for women to receive pertinent PCC advice. 
Most importantly the need to make PCC information more accessible to women with DM was 
highlighted, as shown below. 
 I can literally see the point, I’ve got quite a few … girls with type 1 … they are all in their 20’s 
and they all use phones all the time. So that would be a good way to communicate with them … diet, 
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GIs, reminders and general information, folic acid, all sorts of stuff could be useful on apps. [HCP8, 
interview 5] 
 I think it’s brilliant, I mean you look at anybody now if you are outside or anywhere, getting a 
coffee, everybody’s got a phone in their hands … I think people would [use it] because they need the 
help. [P8, 35 years] 
6.4.3 Acceptability and feasibility of a PCC mobile app 
Overall, views on use of a PADI app were positive. Most HCPs (n=7) and all women (n=10) 
acknowledged that women with DM needed PCC advice. Although the use of an app for 
PCC was a novel approach, they agreed that the incorporation of PCC information within an 
easily accessible and highly accessed platform had the potential to improve provision of 
PCC information.  
 So women do need [PCC] advice and if you are going to put it in an app and it’s something 
that’s easily accessible then yeah I guess it’s a good idea. [HCP4, interview 1] 
 It [PCC]’s not something that I know of personally, it’s not something I know much about so to 
be able to have an app to go into and get information from, I think is really important. [P1, 43 years] 
Another woman reported the urgent need for a PCC app and noted that for women who 
were not provided with PCC information by their healthcare team, a PCC app was an ideal 
way to deliver relevant PCC information. 
 I think it’s probably the best way to get information across to people like myself who obviously 
haven’t been informed of like the importance of preconception especially in diabetes … I think it’s a 
good idea. To get the message out there is better than– to have some understanding is more 
important than having no understanding.  [P2, 22 years] 
Participants, women and HCPs, expressed confidence in women’s ability to engage and 
interact with the app, and to use it effectively for PCC. It was noted, by HCPs and women, 
that a PCC app could easily be integrated into women’s lives and would provide a handy, yet 
discrete way for women to access PCC information. Participants further admitted that this 
medium of providing PCC was preferred to the use of leaflets, as noted in the data extracts 
below.  
 I think it’s a brilliant idea. Easy to access, you’ve got the information there so it’s something 
you can discreetly look at on your phone. It’s not like you are sitting there with a textbook on diabetes 
and pregnancy. It’s just something people could look up when they are commuting on the train, 
standing in the post office for an hour, they can look at their app which would make it a lot easier for 
ladies to look up things. [HCP7, interview 4] 
  I think more women would use something like that these days. I don’t think a lot of women 
now would go and sort of pick up leaflets … If there was an app they could download, I think they 
probably would. [P3, 40 years]  
It was also thought by participants, HCPs and women, that a PCC mobile app would be 
easier to update compared to traditional leaflets and hence increase confidence that the 
information provided was  up-to-date and relevant, for example; 
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 If you were gonna pick up a leaflet, it could have been printed years ago, couldn’t it? But I 
guess it’s easy to update an app. [P3, 40 years]  
 I mean NICE guidelines have just updated so that’s kind of put- so many things are now 
wrong– leaflet information out there. Yeah, I think an app is a lovely idea. [HCP7, interview 4]  
Women noted the difficulties in accessing PCC information via the traditional means such as 
healthcare professionals or leaflets, noting that whilst access to both could not always be 
guaranteed, a PCC app would provide a readily available repository of information which 
could help address shortcomings of current PCC practice.  
 I think having something there that I know that I can always reach for and look at if I am 
suddenly having any question or a concern or I’m looking for more information because you can’t 
always call a doctor and you can’t always go look on a pamphlet or search online. [P4, 23 years]  
 It would be good to have somewhere to go to get information specifically for diabetes and 
preconception. [P9, 29 years]   
6.4.3.1 Potential for integration  
The majority of clinicians (n=7) recognised the potential benefit of a PCC app and indicated 
that they would recommend the app when developed to women with DM. For example, a 
nurse in primary care and a doctor in secondary care were quite enthusiastic about 
integrating the app into their consultations and recommending it to women in their care. This 
indicated that the PADI app will easily fit into HCPs’ existing working practices and skillset, 
therefore skillset workability was positive.  
 Yeah. Definitely, yes. Just as I see people for reviews, and I always talk to anybody in the 
range where I think they might possibly be thinking about having a baby, I would talk through their 
contraception, their plans, folic acid, control and what are you using to monitor, would you like 
anything else that’s out there? So yeah, most definitely. [HCP8, interview 5] 
 Yeah … we are in the realm of technology and if obviously it will help with her preconception 
care, and then the subsequent pregnancy, yes, why, yes. [HCP5, interview 2] 
Furthermore, another nurse who previously worked in primary care stated that she was likely 
to suggest a PCC app (if one existed) to women with DM who approached her with 
pregnancy intentions because of her insufficient expertise and knowledge of PCC. 
 If I knew about this kind of app when I was working at the GP and I have some patients that 
“oh you know that I’m type 1 and I’m thinking about having a baby”, probably I would suggest because 
… maybe my knowledge is not enough. [HCP3, FG1] 
HCPs (n=4) reported the need for women with DM to be made aware of the existence of the 
app and noted recommendations by HCPs (particularly GPs) as effective ways of raising 
awareness of the app. Two nurses in secondary care felt that recommendations by a HCP 
would encourage women to use the app, as indicated in the focus group discussion below.  
 So you have to make aware … so kind of advertising or saying that there is this kind of 
opportunity because otherwise how can the patient know if no one will tell them. You have to really 
think, “ok, I want an app because I am diabetic and I am planning to have a baby,” so you have to 
specifically search for that one, it’s not a usual search … But if it’s someone else that is your 
  
134 
 
healthcare professional will suggest it, probably you will use it, because it’s someone that you 
consider- [HCP3, FG1] 
 Yeah, yeah, absolutely, more your GP. [HCP1, FG1] 
Advertisements was another way of raising awareness of the PADI app and ensuring that it 
got to the right audience. Another nurse in secondary care suggested placing 
advertisements in general practices within the community in order to reach women with DM 
(especially those with T2DM) who received their care in GP surgeries; 
 It’s something that could be advertised in like a poster up in the GP surgery, do you have 
diabetes? Are you planning to get pregnant? Look at it. It’s out there. [HCP7, interview 7] 
Apart from primary care, the app also had a place in secondary care. Some clinicians (n=3) 
stated that the app was likely to be adopted within their organisations as they were often 
keen to trial new innovations that would contribute to patients’ health improvement, thus 
increasing the likelihood of contextual integration (CI). CI is concerned with the degree to 
which the app fits (integrates) with the overall goals and structure of the organisation, and 
the capacity of the organisation to undertake the implementation. Adoption however 
depended both on appraisal of the app’s usefulness and user acceptance, as shown below.  
 I don’t see why not … I guess sometimes with a lot of things we seem to trial things in the 
hospital, get feedback and then kind of launch them. [HCP7, interview 5]  
Two HCPs, a doctor and nurse, however expressed concern about the use of an app for 
PCC information. The doctor acknowledged that an app may have a possible role in PCC 
but stressed that PCC provision involved medical interventions that could only be provided 
by a healthcare professional within a clinic setting, thus giving rise to some reluctance in 
accepting an app for PCC, as shown below.  
 I really don't know because I’m personally not convinced that it is necessarily going to be the 
answer that it’s going to solve a lot of women's problems. I think if someone knows they need PCC, 
they need to come really to the [clinic] it’s not something that can be delivered via an app, its 
medications review, complications review screening that can’t be done by an app and has to be done 
by a person… because actually the stuffs that you need, you need nurses and doctors for. [HCP6, 
interview 3] 
The nurse on the other hand, noted that an app might introduce bias and possibly result in a 
digital divide whereby women with smartphones have better access to PCC while those 
without smartphones will be unable to access the PCC information, as shown below. 
 It would be population-biased because I can’t suggest it to all my ladies because I know that 
not all of the ladies can afford to have a mobile phone let alone a smartphone. So we are going back 
to postcodes, lotteries- the people that can afford things get better quality care, allegedly. [HCP9, 
interview 6] 
These concerns may affect confidence in the applicability of a PCC app to women with DM. 
However, all women (n=10) recognised the need, benefits and usefulness of a PCC app, 
and the majority of clinicians (n=7) reported that the proposed app appeared feasible to be 
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integrated into their practices and recommended to their patients. They were willing to use 
the app in their practices and expressed interest in seeing the proposed app when 
completed. 
6.5 Technology-assisted PCC 
This section will address the development of the proposed PADI app and the app’s potential 
for adoption and implementation following development.  
6.5.1 PADI app development 
6.5.1.1 Intervention content  
HCPs and women provided suggestions for the app content. The majority of HCPs (n=8) 
suggested including information on importance of pregnancy planning, pregnancy-related 
risks for the woman and baby, and general health advice for the preconception period. 
Although some women expressed limited knowledge when asked about PCC content, this 
formed the basis of their suggestions which were mainly for more accessible PCC 
information and awareness of pregnancy planning and risks. The need for PCC education in 
general, and information on blood glucose control, diet, diabetes and pregnancy, and 
supplementation were particularly emphasised (see Appendix 13 for full list of suggested 
app content). For example; 
They have to know the impact the disease would have on their pregnancy, and the impact, of 
the pregnancy on their disease. They have to know of lifestyles that would improve their health status, 
so avoid smoking, excessive alcohol intake, be advised that they take folic acid, healthy diet in 
general, exercise, so it’s more of health promotion together with their specific medical needs … 
compliance with treatment, adherence to healthy lifestyle and avoiding pregnancy if they are not in the 
right sort of health status. [HCP5, interview 2] 
 Well considering I don’t really have much, I have never been told much information on it. 
Anything really, anything that’s relevant to me, to my age, my condition, … just getting the message 
across to people … When you realise this can happen to you, then I think that’s the best way, for me 
personally anyways, it’s the best way to get the message across and relay the importance of it and 
how things can and things do go wrong with, like obviously an unplanned pregnancy in diabetics [P2, 
22 years] 
For majority of clinicians (n=8), having comprehensive PCC information in the PADI app 
would not only improve women’s knowledge and confidence (relational integration) but also 
the patient-clinician interaction (interactional workability). Furthermore, because many 
women already used apps for managing many aspects of their health (including SMBG; self-
monitoring of blood glucose), a PCC app which incorporated SMBG functions would fit within 
their competence boundaries and satisfy the skill-set workability condition for 
implementation.  
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6.5.1.2 Self-monitoring of blood glucose (SMBG) functions 
Monitoring of blood glucose levels was an important component of PCC and diabetes self-
management, and most participants (n=17) felt that the addition of a built-in blood glucose 
diary to the app would be of added benefit to women planning a pregnancy. Two 
participants, a primary care doctor and woman, highlighted that an information app may not 
encourage engagement but a built-in diary would make the app more useful and reduce the 
burden involved in using two separate apps, to self-monitor and receive PCC advice.  
  To me I’m not really sure if using an app would be any different than like giving someone a 
brochure … I would prefer having a brochure rather than having an app if it’s … just for providing 
information. But if it was to be something like tracking your blood glucose levels, providing information 
… I think that would be more useful than just providing information in like my experience of using 
apps. [P4, 23 years].  
 A lot of them do that separately. But having something all in one place, I mean it’s that thing 
about keeping it as simple as possible and you know easily accessible [HCP4, interview 1] 
Another woman agreed with this view while noting the advantage of using one app for both 
PCC and blood glucose monitoring.  
 That would be something that you want to keep track of anyways so if it was on the app it 
would be better than having two or three different things on your phone. [P9, 29 years]  
Women reported using several apps for their blood glucose management including iBGStar, 
Monster and mySugr, and felt that a diary built into the PCC app would help women stay 
focused, improve self-monitoring and keep their glucose levels on track as they plan for 
pregnancy. Other women in the study (n=3) commented on the mobility and convenience of 
entering and monitoring glucose levels that the app would provide and noted that this would 
be especially beneficial. It was also suggested that the diary utilise a graphical display of 
information rather than plain display of numbers, as this would be easier to visualise and 
help identify trends in blood glucose readings, for example. 
I think it would be a great idea because if you have your phone in your hand it’s so easy to 
pull up your app and enter your levels … with the app you are just entering everything quickly and it’s 
easy to see … if you have graphs you can see your levels going up and down. [P8, 35 years] 
 
Furthermore, the relevance of good control to fertility was noted by another woman who 
highlighted that aiming for optimised control should be a target for women planning a 
pregnancy in order to improve their chances of conception, and a PCC app with a diary 
would contribute to helping women achieve optimised levels. 
 From what I have heard if your blood glucose is high, then it’s more difficult to get pregnant so 
I feel like that would probably be more of a priority to try and lower your blood glucose … I think that’s 
more of like a goal setting thing in my mind … if you know it’s out of range, there are things you can 
do to bring it down. [P4, 23 years] 
The built-in diary also had the capacity to provide both healthcare professionals and patients 
with information regarding patients’ BG levels. The PADI app could easily be incorporated 
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into existing patterns of activities which further demonstrates its potential to fulfil the 
condition for contextual integration. For example, a nurse in secondary care commented that 
it would be especially useful to women who received their care in general practice as it may 
come to replace their existing blood glucose diaries.   
 I can see that some of them can be quite excited about the idea … in primary care, it could 
well have a place because then maybe they are not using the latest monitor, they are only using the 
one that the GP sent them because it is the cheapest on the market, so an app that may take over 
that role may be very, very beneficial. [HCP1, FG1]  
Clinicians (n=5) also suggested in the long-run, having the diary connected to the patients 
metres to reduce user burden.  
6.5.1.3 Reminders 
 
Some HCPs (n=3) and the majority of women (n=8) agreed that a reminder should be added 
to the app to remind users of pre-pregnancy activities and BG readings. Opinion was split 
over the type of reminder to be included. For example, some participants (HCPs, n=2 and 
women, n=4) recommended using notifications to remind women about pre-pregnancy 
activities such as assessments to go for and supplements to take, as shown in the data 
extracts below. 
I think it’s then reminders that this is a cardiovascular disease- diabetes, so how’s the blood 
pressure … have you had your cholesterol checked this year? It’s all the broader stuff as well 
because people just think sugar for diabetes and actually it’s good to get those reminders that these 
other things need to be done. [HCP8, interview 5] 
 I think that’s a good thing to have because I think sometimes … people go in with good 
intentions but obviously if like it takes a while to get pregnant or whatever, they can lose interest 
which is obviously a bit alarming because especially with diabetics, you need to maintain looking after 
yourself and obviously like supplementations and all things like that so having reminders and like 
notifications and things would be a good thing to include. [P2, 22 years] 
Caution was however advised by some women regarding the use of reminders for things 
such as pre-pregnancy activities, appointments and BG reading to avoid putting women 
under pressure, as reported to be done by healthcare professionals. They suggested 
avoiding anything that would make women feel under pressure, as shown below. 
 I would be a bit wary about it because it could be a bit annoying because again you do feel a 
bit nagged by healthcare professionals and stuff so you wouldn’t want the app to come across too 
naggy. [P6, 29 years] 
 
Other participants (HCP, n=1 and women, n=4) expressed preference for a built-in reminder 
to monitor BG levels. A doctor reported that it was preferable to have a reminder that 
allowed women with both T1 and T2DM to have control over the SMBG function and a 
woman noted that having such a reminder within the app would help increase engagement 
with the blood glucose diary.  
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 Well I know it’s very individual because if you’ve got somebody with type 2 they are not going 
to need to monitor as often, but certainly, people, women with type 1 are going to be monitoring more 
often … but you could put something into your app that would just alarm the person to test however 
many times you decide they need to test. [HCP4, interview 1] 
 Reminders for anything, that’s always good in that it keeps people using things … a reminder 
sort of alarms, to remind you to do things. The diary is great if it could run sort of hand in hand with 
the reminder. I know when I had to do mine on a regular basis sort of 3x a day, it would have been 
handy just to have something to sort of remind me to do it. [P1, 43 years] 
Women also indicated that it would be more useful for women trying to improve their glucose 
control to have a built-in reminder for BG levels, stressing that it would alert them to take 
their readings and encourage better self-monitoring. It was also important that the diary 
could be adjusted, that is turned off or on, depending on user preference. 
 
6.5.1.4 Intervention language 
Some participants, clinicians (n=4) and women (n=4), suggested using positive and 
encouraging language to provide the PCC information to women in order to improve their 
knowledge of PCC, including pregnancy planning and risks, and the benefits of adopting 
healthy preconception behaviours, as shown in the data extracts below. 
 It’s important the ladies know [of pregnancy-related risks and complications], definitely, but at 
the same time it’s kind of saying these risks can be reduced. It is possible, that’s why we want 
preconception care … so like giving all the information but I guess in a positive way … Giving the 
ladies a bit of knowledge is power and a bit of positivity like actually this is fine “I need to get my sugar 
sorted, I need my folic acid. Actually I want this baby and I can do the best I can by getting my 
preconception sorted.” [HCP7, nurse]  
 I think like a positive spin on things would be important so like positive reinforcement as 
opposed to” if you don’t do this, this would happen”, more like “if you do this, this would help your 
baby develop safely”, or “this would help you feel better or this would increase your chances of 
conceiving” … making sure that the app, although provided education it wasn’t too negative and it 
was more from a positive point of view I think that’s probably the most important thing. [P6, 29 years] 
Several studies (King, Wellard, 2010; Shawe, 2008; Spence et al., 2010) have reported that 
many women perceived having DM as ‘hard work’ particularly in terms of the physical and 
emotional effort required to achieve and maintain good blood glucose levels. The pressures 
faced by women with DM especially those with T1DM regarding their control was highlighted 
by another woman who further stressed the importance of using a supportive approach 
within the PADI app.   
  Obviously things don’t always go right particularly when you’ve got type 1 day to day wise, 
and we often hear about ourselves being poorly-controlled, “oh you must be doing something wrong” 
… and sometimes that’s very difficult to hear … and anything that would be a [PCC] mobile app would 
be beneficial to not come across as anything that was making people feel that they were under 
pressure to do anything, that this was the best option, it needs to be something positive. [P7, 40 
years] 
 
In line with this study, Earle et al. (2017) stressed that focusing on positive changes that 
women might make when planning a pregnancy was more likely to encourage women to 
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engage more with the support being offered. Similarly, Collier et al. (2011) reported that 
women were more receptive to care, and advice provided using a positive approach, and 
this approach encouraged them to find out more about various aspects of preparing for 
pregnancy. It was agreed by women and HCPs that a positive and supportive approach to 
PCC would promote women’s confidence and increase the app’s potential to be 
recommended and incorporated into clinical consultations and used by women. 
6.5.2 Factors affecting implementation 
All participants (n=19) recognised a number of factors, including cost and organisational 
support, as well as facilitating/hindering content and design factors, that could facilitate, or 
hinder acceptance, recommendation and adoption of the app once developed. 
6.5.2.1 Cost and organisational support 
Cost was perceived to be both a facilitator and a barrier to adoption and implementation, and 
a woman stated in a matter of fact way that ‘a lot of people won’t pay for apps’ [P5, 39 
years]. Furthermore, a nurse in secondary care highlighted that cost would play a role in the 
overall uptake of the app and noted that ‘the way to meet most people would be for the app 
to be free … or at least very [affordable].’ [HCP7, interview 7] This was supported by other 
women with DM (n=5) which highlighted the need for the PADI app to be affordable in order 
to encourage uptake.  
Furthermore, HCPs noted that in light of the financial constraints facing the NHS, cost would 
affect the ability of NHS organisations to adopt and integrate the app into routine care, as 
noted in the data below. 
 Every hospital is struggling financially, we are leasing resources and various things so I must 
admit generally if there is a cost … but apart from that, the reason we do this job or we work in a 
hospital is to make a difference and improve things with people so from that side of things … people 
still want to drive things forward and improve care. [HCP7, interview 7] 
However, HCPs felt that cost was not the only factor to consider with regards to adopting 
new technology such as a PCC app, the app also had to have the backing of the hospital 
stakeholders including other healthcare professionals. This organisational support for the 
app was crucial to allow HCPs, especially nurses in secondary care, freely recommend the 
app, promote and publicise it both within and outside their respective NHS organisations, as 
noted below. 
 So if it provided the information and kind of everything else and the hospital are happy then 
I’d be happy to have posters up. We have a meeting where we meet with the GPs and the diabetes 
leads in the area, it would be presented there, and everything … but generally as long as my hospital 
and my team, antenatal team were happy, I would be happy to, because it’s helping benefit women. 
[HCP7, interview 5] 
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6.5.2.2 Facilitating content and design factors 
Informative and up-to-date information  
Clinicians reported that they were very cautious about recommending technology to patients 
and highlighted the need for the app to contain accurate, relevant and evidence-based 
information that was accepted by the target user group. 
 I think if it’s well produced and if you’ve got something that has been researched, that’s 
sound, that the patients like, that is recognised, and that it’s got accepted advice, then I think we 
would. I mean, in general, I recommend websites to patients but you have to be careful, you have to 
be very careful about what you do recommend. [HCP4, interview 1].  
Other clinicians (n=2) reported that they would carry out quality assurance checks on the 
app before recommendation, as noted below. 
 If there was an app, I would download it and have a look at it and make sure I was happy, but 
if it was relevant and up to date, yeah, I don’t see a problem ... being updated, not just being put out 
there but if you are providing information that is, it’s not medical as such but it’s so important, it’s also 
important to make sure that its updated. [HCP7, interview 4]  
Efficiency 
Women further noted that an app that was efficient and helped to expedite access to PCC 
information had a clear advantage over Internet search engines such as Google. Thus, this 
utility could promote the PADI app’s uptake and engagement, as noted below.  
 I think for me, the biggest thing that I would want to use an app for is if it’s providing me with 
something that I can’t get otherwise. So you can google for hours preconception care for type 1 
diabetes or type 2 diabetes but if all that information was neatly packaged in an app, I think that would 
be nice. [P4, 23 years] 
Simplicity and ease of use 
Participants, clinicians and women, noted that simplicity in design and delivery of information 
was a very important factor for promoting adoption. They felt that it was vital that the app 
used easy to understand language while at the same time providing essential PCC 
information, and by so doing, maximise benefit for women, as noted below. 
 I think if it was like user friendly, not too overpowering but delivers the key information points 
needed like the absolute importance of supplementation, the importance of blood glucose control, the 
effect of not having blood glucose control. So, that delivered the key messages in a simple way. [P2, 
22 years 
 It’s so much easier to read kind of either bullet points or short paragraphs rather than just an 
essay … so just making it memorable what they are reading. [HCP7, interview 4] 
This opinion was supported by another woman. 
 So easy to use, I mean, that’s a trademark of a good app anyway and gives you the 
information you need to help you with your preconception care in a way that you can understand it. 
[P10, 43 years] 
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Relevant content and features 
In addition to provision of advice via a static app, it was important for the PADI app to 
contain other features that were considered relevant to women with DM and thus more 
engaging. For example, a PCC app that was compatible with patients’ existing app usage 
activities and that tied in with women’s self-management practices such as blood glucose 
monitoring was more likely to be recommended by clinicians and used by women with DM, 
as noted below. 
 I think if the right things are on it. That it has all their [blood glucose] readings, it has one 
place that they could go to get all the readings and [PCC] advice that they may need. [HCP1, FG1] 
 I guess just depending what was on it really, if I thought it was going to be useful for me, that 
would motivate me, if I thought it was gonna educate me then I’d be interested … so if I thought, “oh 
this is quite handy because I can keep track of my blood sugar or I can keep all the information in one 
place” … that would motivate me to get the app [P6, 29 years] 
Attractiveness 
Participants connected the look of an app to its potential usability i.e. the more appealing it 
looked, the more likely it was to attract users who would consider downloading and using it. 
Women recommended avoiding the ‘clinical’ look of medical or health apps and making use 
of nice bright colours and ensuring that although the app was for promotion of women’s 
health, it still looked interesting, as shown below. 
 I think women tend to go for things that can be quite cute … Although you want it simple, you 
don’t want it boring or plain … I think possibly if it was sort of like a clinical thing, I think if it looks, 
although I know it’s educational and sort of towards healthcare and things, I think if it doesn’t look too 
interesting then you kind of tend to bypass. [P1, 43 years] 
6.5.2.3 Hindering content and design factors:  
Missing health promotion information 
For HCPs, it was important that the app contained vital information on PCC including 
assessments (retinal, renal, thyroid) and the absence of this vital information would be a 
barrier to recommendation, as noted below. 
 What will not make me recommend it is if it does not address the general aspects of care 
such as the health promotion aspect of care because they are key to the control … If it does not 
appreciate that there should be baseline investigations … I’m talking of the eye examination, I’m 
talking of kidney assessment, and I’m talking of at least thyroid function because the thyroid T test I’m 
pretty sure can easily be missed. [HCP5, interview 2] 
Complexity 
It was reported by HCPs and women that user engagement would reduce if the app was 
difficult to use. They agreed that a complex app would hinder recommendation and uptake, 
as shown in the data below. 
 If it’s too complicated. The things that put patients off, whatever it may be, for whatever 
reason, if it’s too complicated, too fiddly and it’s not easy to use, with easy instructions. [HCP1, FG1] 
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 I want something not too complicated. I think if it gets too sort of complicated or technical, it 
can put people off depending on your own level of using things like that. [P1, 43 years] 
 
6.6 Phase 1 findings and the expanded health belief model (EHBM) 
 
Although women with DM had limited understanding of PCC and pregnancy-related risks, 
both healthcare professionals (HCPs) and women with DM recognised that women who had 
DM were more vulnerable and susceptible to reproductive health problems, such as 
pregnancy-related complications. They also believed that when these problems occur, they 
could be severe, e.g. having uncontrolled blood glucose levels during pregnancy could lead 
to major complications such as miscarriage and macrosomia, and lack of folic acid could 
affect the baby’s development and result in an NTD such as spina bifida.  
 
There was a perception amongst participants, HCPs and women with DM, that receiving 
PCC advice and optimising one’s health before pregnancy was beneficial. More specifically, 
the use of a mobile app for PCC was recognised as an opportunity to reduce barriers to PCC 
service provision and uptake and, improve access to PCC information. It was also 
highlighted that providing pertinent PCC information to women, via the PADI app 
intervention, could help improve their knowledge, independence and self-efficacy. 
Knowledge optimisation in turn could enable them to seek PCC and take actions that 
increase the likelihood of a healthy pregnancy and baby, e.g. discussing pregnancy plans 
with HCPs. Hence, the PADI app could motivate women to adopt healthy preconception 
behaviours.   
 
The additional app components, such as blood glucose diary and reminder, could also 
encourage women to monitor blood glucose levels before and during pregnancy. An easy-to-
use PCC app that provides information using simple and positive intervention language, and 
that contains relevant content and features could be instrumental in ensuring that women 
understand the need to plan their pregnancy and seek PCC in order to reduce risk of 
complications. The app could also serve to remind women of the benefits of seeking PCC, 
reassure them that they can have healthy babies with PCC, and signpost them to available 
PCC resources and HCPs that they can contact for PCC. Table 6.3 below shows how phase 
1 findings fit with the EHBM.  
 
 
 
 
  
143 
 
Table 6.3 Phase 1 findings and the EHBM constructs 
Constructs Themes  
Perceived susceptibility Understanding of PCC 
Perceived severity Understanding of PCC 
Perceived benefits minus barriers Understanding of PCC; Use of technology for 
healthcare information; PADI app development 
Self-efficacy PADI app development; factors affecting 
implementation 
Cues to action PADI app development; factors affecting 
implementation.  
 
6.7 Summary of key findings 
This chapter presented analysis of data from discussions, conducted between March to 
October 2016, with nine HCPs and ten women with DM, and the key findings that emerged. 
It provided detailed insight into what information HCPs would like women to know before 
pregnancy, as well as the information women themselves would like to see in a PCC app 
developed specifically for women with DM. Suggestions from both HCPs and women with 
DM were used to inform the design and development of the PADI app [see Chapter 4 and 
Appendix 14 for app screenshots]. 
Phase one findings highlighted the views and experiences of participants regarding PCC and 
use of the PADI app in practice. It showed that PCC information delivery for women with DM 
was inconsistent and limited with various factors, including service configuration, lack of 
pregnancy planning and HCPs’ judgemental attitudes, hindering effective provision and 
uptake. Challenges in current PCC service provision placed women at a disadvantage with 
regards to receiving information, and majority reported sub-optimal PCC experiences and 
general dissatisfaction with current PCC approach. Findings also indicated that a PADI app, 
incorporating PCC information and SMBG functions, would be highly feasible and 
acceptable to participants. Women and HCPs recognised the gaps in current PCC service 
provision and highlighted that an app could increase PCC knowledge, accessibility and 
uptake. HCPs highlighted the PADI app’s potential to improve engagement with HCPs, 
confidence to seek PCC and pregnancy outcomes, and were willing to recommend and 
integrate it into clinical consultations.  
Findings suggested that the app has potential to be implemented into routine healthcare 
practice given its capacity to confer an interactional advantage between patients and HCPs, 
improve knowledge and confidence, and fit within users’ skill set and clinicians’ work 
practices. Concerns regarding the applicability of the app to women with DM could pose as 
potential barriers to recommendation and integration by some HCPs. Yet, many women 
were reticent to approach HCPs with pregnancy intentions despite insufficient awareness of 
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PCC. Hence, highlighting the need for a change in current approach to PCC information 
delivery and the PADI app is one way to achieve this. 
Participants’ views regarding factors that could affect implementation of the PADI app were 
also explored. Overall, participants identified only very few factors that would prevent women 
in the study from using the app once developed however uptake and user engagement can 
be hindered if the app is complex, expensive or negative. For clinicians, complexity and cost 
were key points to consider during development that could affect uptake, in addition to up-to-
date and relevant information. Furthermore, for a PADI app to be adopted by women with 
DM, recommended by clinicians and embedded into routine care, organisational, content 
and design factors have to be taken into consideration during development of the PADI app. 
By so doing, promote the potential for adoption and implementation.  
The results of the feasibility testing of the PADI app with women with T1 or T2DM forms the 
focus of the next chapter. 
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7. Chapter 7: Phase 2 results 
 
7.0 Overview of chapter: Intervention 
This chapter presents the results from analysis of data collected in Phase 2, feasibility and 
acceptability of the PADI app intervention, from questionnaires and interviews. Presentation 
of questionnaire data in section 1 is followed by a thematic analysis of the views and 
experiences of women with DM regarding the PADI app use in section 2. 
 
7.1 Section 1: Quantitative results 
 
This section presents an analysis of the data collected from two questionnaires, 
administered at pre-intervention (Questionnaire 1) and post-intervention (Questionnaire 2). 
Data relating to recruitment, retention and a descriptive overview of participants are 
presented, followed by a preliminary evaluation of the effects of the app intervention on 
participants’ knowledge and attitudes to preconception care (PCC), and patient activation 
measure (PAM). The pre- and post- PADI app intervention results are presented separately 
followed by a brief comparison of results. This study was not powered to detect statistical 
changes therefore results should be interpreted with caution.  
 
7.2 Eligibility, recruitment, retention and attrition levels 
Between December 2016 and March 2017, 38 women with T1 and T2DM expressed interest 
in joining the study (three responded to an invitation received during a visit to an NHS 
hospital and 35 to a twitter advert). Two (5%) were later excluded as they had completed 
their families and therefore were not eligible for inclusion and 19 (50%) declined participation 
after receiving further study information. Reasons for non-participation included work/time 
constraint (5/19, 26%), personal reasons (2/19, 11%) and a lack of financial reward (1/19, 
5%). Most (11/19, 58%) however did not give a reason.  
Seventeen (45%) women were therefore recruited (using the inclusion criteria described in 
chapter 4) exceeding the recruitment target of 12 participants. All participants returned the 
pre-intervention questionnaire, and were provided information on how to download and use 
the app. Hence, all (n=17) recruited participants received the PADI app intervention. Of the 
17 participants who enrolled into the study, one left the study after one month and 16 were 
sent the post-intervention questionnaire. Eleven (65%) completed and returned 
Questionnaire 2, however, five did not respond to the post-intervention questionnaire 
invitations. The attrition rate (the percentage of participants who did not complete the study) 
was estimated at (6/17) 35%. The reasons given for leaving the study included work/time 
constraint (n=1) and no longer planning a pregnancy (n=1). Four other participants did not 
give a reason and could not be contacted despite several attempts. Figure 7.1 shows the 
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flow of participants through the study, loss to follow up, and number of participants who 
completed the study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.1  Study flow diagram 
 
7.3 Sample 
The sociodemographic characteristics of the 17 women who completed the pre-intervention 
questionnaire are outlined in Table 7.1 and demographics data are expressed as n (%) for 
categorical variables and mean ± SD for continuous variables.  
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7.3.1 Characteristics of participants  
 
Participants were geographically dispersed across North America (n=4, 24%) and UK (n=13, 
76%). All participants were white, with the majority married or living with partner (n=11, 
65%). Age ranged from 20 to 43 years (range =23). The majority of participants (n=16, 94%) 
had type 1 DM, were employed (n=14, 82%) and had a first or higher academic degree 
(n=11, 65%). Most women (n=12, 70%) reported plans for a pregnancy in the near future 
(i.e. next year or in 1-5 years). Table 7.1 below shows the demographic characteristics of the 
(n=17) study participants.  
 
Table 7.1a Demographic data 
Characteristic n Percentage 
Total sample 17 100% 
Demographic characteristics   
Age (years) 31.3 ± 6.7 
 
 
Marital status 
     Married/living with partner 
     Single (never married) 
 
11 
  6 
 
65% 
35% 
Diabetes type 
    Type 1 
    Type 2 
 
16 
  1 
 
94% 
  6% 
Diabetes duration 
    Less than 1 year 
    Over 5 years 
 
 1 
16 
 
 6% 
 94% 
Race or ethnic group 
     White British 
     Irish 
    Any other white background 
 
  9 
  2 
  6 
 
53% 
12% 
35% 
Geographical location 
    United Kingdom  
    America 
    Canada 
 
13 
  2 
  2 
 
76% 
12% 
12% 
Highest educational qualification 
   Higher degree (M.Sc or PhD) 
   First degree (B.Sc) 
   Other diplomas  
   A / AS / S levels 
   Other academic qualifications  
   None of these qualifications 
 
  6  
  5  
  2  
  2  
  1  
  1  
 
35% 
30% 
12% 
12% 
  6% 
  6% 
Employment status 
     Employed full-time/part time 
     Full-time homemaker 
     Student 
 
14  
  1  
  2  
 
82% 
  6% 
12% 
Currently considering or planning to have children 
    In less than 1 year 
    In 1-5 years 
    Over 5 years 
    Do not know/unsure 
 
  6  
  6  
  3  
  2 
 
35% 
35% 
18% 
12% 
Previously had a pregnancy that ended in: 
    Miscarriage 
    Ectopic pregnancy 
    Other (e.g. termination or preterm birth) 
 
  1  
  1  
  2  
 
  6% 
  6% 
12% 
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Table 7.1b Demographic characteristics for responders and non-responders at 3 
months 
Demographic characteristics Responders 
(n=11) 
 
Non-responders 
(n=6) 
Age (years) 
 
31 ± 6.6 31.83 ± 7.5 
Education  
   Higher degree (M.Sc or PhD) 
   First degree (B.Sc) 
   Other diplomas  
   A / AS / S levels 
   Other academic qualifications  
   None of these qualifications 
 
6 (35.3) 
2 (11.8) 
1 (5.9) 
2 (11.8) 
0 (0) 
0 (0) 
 
0 (0) 
3 (17.6) 
1 (5.9) 
0 (0) 
1 (5.9) 
1 (5.9) 
Race or ethnic group 
     White British 
     Irish 
    Any other white background 
 
4 (23.5) 
2 (11.8) 
5 (29.4) 
 
5 (29.4) 
0 (0) 
1 (5.9) 
Marital status 
   Married/living with partner 
   Single/never married 
 
8 (47.1) 
3 (17.6) 
 
3 (17.6) 
3 (17.6) 
Employment status 
     Employed full-time/part time 
     Full-time homemaker 
     Student 
 
9 (52.9) 
1 (5.9) 
1 (5.9) 
 
5 (29.4) 
0 (0) 
1 (5.9) 
Currently considering or 
planning to have children 
    In less than 1 year 
    In 1-5 years 
    Over 5 years 
    Do not know/unsure 
 
 
6 (35.3) 
2 (11.8) 
2 (11.8) 
1 (5.9) 
 
 
0 (0) 
4 (23.5) 
1 (5.9) 
1 (5.9) 
 
Age was similar for responders and non-responders. However more responders than non-
responders had a first or higher degree (n=8, 47.1% vs n=3, 17.6%), were non-British (n=7, 
41.2% vs n=1, 5.9%), married or living with partner (n=8, 47.1% vs n=3, 17.6%), employed 
(n=9, 52.9% vs n=5, 29.4%) and planning to have a baby in <1 year (n=6, 35.3% vs 0, 0%).  
 
7.4 Findings from pre- PADI app intervention questionnaire 
The study findings from the pre-intervention questionnaire are presented below in relation to 
the following research question:  
 
What is the effect of the PADI app on attitudes and knowledge of PCC and patient 
activation measure (PAM)? 
 
Attitudes and knowledge of PCC and patient activation were assessed using a pre- and 
post-intervention questionnaire. The pre-intervention questionnaire comprised of three 
sections and had a total of 53 items including Yes/No, True/False/Not Sure and Likert type 
questions.  
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7.4.1 Section one:   Reproductive health attitude and behaviour (RHAB)  
The RHAB comprised 20 questions exploring reproductive health, attitudes and behaviour 
which were divided into the following six areas: cues to action, perceived susceptibility, 
perceived benefit, perceived barriers, self-efficacy and outcome expectations.  
 
7.4.1.1 Cues to action (motivation to seek PCC) 
This section contained both closed ended and open ended questions. Cues to action include 
motivation to seek PCC. Figure 7.2 shows the number of women who reported that they had 
received cues to action prior to the intervention.  
 
Figure 7.2 Women’s cues to action pre- intervention 
 
A high number of women in the study reported that they had previously received PCC advice 
(n=15, 88%) and discussed how diabetes affects pregnancy (n=13, 76%) with a healthcare 
professional (HCP) (figure 7.2). However, the number who received contraception advice 
from a HCP was <50% (n=8, 47%). The proportion who discussed PCC and contraception 
use with others (partner, friends, family, colleagues, etc) was also low (n=6, 35%). 
 
Content analysis of free-text data from the open-ended questions showed specific HCPs e.g. 
doctors (endocrinologist or diabetes consultant) and diabetes specialist or practice nurses, 
and others (family, colleagues, friends and partners) who provided advice and this 
information acted as cues to action.  
 
Women reported receiving advice on how DM affects pregnancy from doctors (consultant, 
n=4; GP, n=1), nurses (n=4), both nurses and doctors (n=3). PCC advice was also received 
from doctors (consultant, n=3; obstetrician/gynaecologist, n=2 and GP, n=1), nurses (n=3), 
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both nurses and consultants (n=4). Furthermore, women reported discussing contraception 
with doctors (obstetrician, n=2; GP, n=1) and nurses (n=2).  
 
Apart from cues received from HCPs, five (29%) women noted discussing PCC with family, 
partners, colleagues and friends while four (24%) received contraception advice from family, 
friends, and school. This indicated that women used a network of friends and families to 
access information, and perhaps consulted HCPs occasionally especially regarding 
contraception.   
 
The other five areas of the RHAB contain Likert-type questions with the response ranging 
from (1) not at all to (5) a lot (Table 7.2). The results are presented in detail below. 
 
7.4.1.2 Perceived susceptibility  
 
Perceived susceptibility was assessed to determine women’s belief of their personal 
susceptibility to problems such as unplanned pregnancy and pregnancy-related 
complications. Of the 17 participants, 10 (59%) indicated that they were either a little or not 
worried at all about having an unplanned pregnancy and 12 (71%) were a little or not worried 
about developing a sexually transmitted infection. Furthermore, 8 (48%) reported that they 
felt moderately or very susceptible to a pregnancy-related complication while 10 (59%) were 
moderately or very worried that their baby could develop health problems.  
 
7.4.1.3 Perceived benefits and barriers to seeking PCC 
With regards to perceived benefits, there was a very high level of agreement amongst 
participants (n=16, 94%) that having blood glucose levels in the normal range (Mdn=5, 
IQR=0) and seeking PCC improved the chances of having a healthy baby (Mdn=5, 
IQR=0.5). 
 
With regards to barriers, 11 (64%) participants reported that they would find seeking PCC 
not at all or a little difficult while 9 (53%) would find following the PCC advice given by a HCP 
not at all or a little difficult.  
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Table 7.2 Responses to the pre- intervention RHAB questionnaire 
 
 
 
Reproductive health, attitudes and behaviour  
(RHAB) question 
Pre- intervention (n, %) 
Total n=17 
Not at all/  
A little 
1 & 2 
Somewhat 
3 
A moderate 
amount/  
A lot 
4 & 5 
Median (LQ-
UQ) 
Perceived susceptibility  
How much do/did you worry that you could become 
pregnant? 
10 (59) 5 (29) 2 (12) 2 
(1.5-3) 
How much do/did you worry that you could catch a 
sexually transmitted infection (eg HIV/AIDS)? 
12 (71) 3 (18) 2 (12) 2 
(1-3) 
How much do/did you worry that you could develop health 
problems if you become pregnant? 
3 (18) 6 (35) 8 (48) 3 
(3-4.5) 
How much do/did you worry that if you become pregnant 
your baby could develop health problems? 
4 (24) 3 (18) 10 (59) 4 
(2.5-5) 
Perceived benefits  
Would having blood sugar levels in the normal range  
(4.0-7.5 mmol/l) before becoming pregnant improve your 
chances of having a healthy baby? 
0 (0) 1 (6) 16 (94) 5 
(5-5) 
Would seeking preconception care improve your chances 
of having a healthy baby? 
0 (0) 1 (6) 16 (94) 5 
(4.5-5) 
Perceived barriers  
How difficult do you think it would be to seek 
preconception care  
11 (64) 2 (12) 4 (24) 
 
2  
(1-3.5) 
How difficult do you think it would be, to follow the 
preconception care advice given by a health professional 
(e.g attending retinal screening)? 
9 (53) 4 (24) 4 (24) 2  
(2-3.5) 
Perceived self-efficacy 
How confident are you that you could get PCC before 
getting pregnant. 
1 (6) 3 (18) 13 (76) 4  
(3.5-5) 
How confident are you that you could change your  insulin, 
medication and diet to keep your blood sugar levels in 
normal range, even if you are not yet pregnant, but 
planning a pregnancy. 
1 (6) 4 (24) 12 (71) 4  
(3-4) 
How confident are you that you could delay becoming 
pregnant until your blood sugar levels are within the 
normal range. 
0 (0) 3 (18) 14 (82) 4  
(4-4) 
Outcome expectations 
Would you say that getting PCC would help you get normal 
blood sugar levels? 
1 (6) 4 (24) 12 (71)  4  
(3-5) 
Would you say that getting PCC would help you 
understand how diabetes affects pregnancy? 
1 (6) 2 (12) 14 (82) 4  
(4-5) 
Would you say that getting PCC would help you decide 
what contraception method to use? 
6 (36) 2 (12) 9 (53) 4  
(2-4.5) 
Would you say that getting PCC would help you prevent an 
unplanned pregnancy? 
4 (24) 3 (18) 10 (58) 4  
(2.5-5) 
 
 
 
7.4.1.4 Perceived self-efficacy 
 
Self-efficacy was assessed to determine participants’ confidence to get PCC and use 
contraception to prevent an unplanned pregnancy. 14 (82%) were moderately or very 
confident that they could delay becoming pregnant until their blood glucose levels were in 
the normal range. 13 (76%) respondents reported that they were moderately or very 
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confident that they could get PCC before becoming pregnant. 12 (71%) felt moderately or 
very confident that they could change their insulin, medication and diet in order to keep their 
blood sugar levels in normal range when planning a pregnancy.  
 
7.4.1.5 Outcome expectations of PCC 
 
This assessed the level of participants’ belief that outcomes were the result of their own 
decisions regarding using contraception and seeking PCC. 14 (82%) participants indicated 
that getting PCC would be moderately or very helpful in understanding how diabetes affects 
pregnancy and 12 (71%) reported that getting PCC would be moderately or very helpful in 
getting normal blood sugar levels. Furthermore, 9 (53%) reported that getting PCC would be 
moderately or very helpful in deciding what contraception method to use while 10 (58%) 
agreed that getting PCC would be moderately or very helpful in preventing an unplanned 
pregnancy.  
 
7.4.1.6  Total Reproductive health and attitudes (RHAB) summative scores 
The cumulative responses to each construct were collated to determine participants’ overall 
attitudes and behaviours pre- intervention (Table 7.3). Higher summative scores show a 
stronger level of belief in the construct.   
 
 
Perceived benefits and self-efficacy were highest pre-intervention, indicating that participants 
already had a strong belief in the benefits of PCC and their own confidence to seek PCC 
before pregnancy. Furthermore, barriers to seeking PCC was lowest showing that 
participants’ perception of the level of difficulty in accessing and adhering to PCC advice was 
low, pre-intervention.  
 
Table 7.3 Summary of beliefs and attitudes associated with preventing an unplanned 
pregnancy and seeking PCC pre-intervention 
 
 
Questionnaire 
Measures 
 
Possible scale 
range 
Pre- intervention attitudes 
Total (n=17) 
Mean & Standard 
deviation 
Median  
(LQ-UQ) 
Range  
(Min-Max) 
Susceptibility 
 
4-20 
 
11.53 ± 3.17 12 
(9-14) 
13 
(5-18) 
Benefit 
 
2-10 
 
9.47 ± .94 10 
(9-10) 
3 
(7-10) 
Barriers 
 
2-10 
 
4.94 ± 2.14 4 
(3.5-6) 
8 
(2-10) 
Self-efficacy 
 
3-15 
 
12 ± 1.62 12 
(11.5-13) 
7 
(8-15) 
Outcome 
expectations 
4-20 
 
15.1 ± 3.72 16 
(11.5-18) 
13 
(7-20) 
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7.4.2 Section two: Preconception care (PCC) knowledge 
 
PCC knowledge was assessed using 20 True (T; 11)/ False (F; 9) statements. Individual pre- 
intervention knowledge responses were expressed as percentage of participants correct 
(Table 7.4). Overall knowledge of pregnancy planning and pregnancy-related risks were 
evaluated.  
 
7.4.2.1 Pregnancy planning 
Pre-intervention pregnancy planning knowledge scores were highest for two items: speaking 
to a healthcare professional about medication (100%, n=17) and quitting smoking (100%, 
n=17), and lowest for items regarding recommended folic acid dosage for women with DM 
(n=6, 35%) and suitability of all insulin during pregnancy (n=1, 6%).  
 
7.4.2.2 Pregnancy-related risks 
Similarly, with regards to knowledge of risks, scores of 100% were recorded for four items: 
(1) high blood glucose levels during pregnancy and maternal problems, (2) high blood 
glucose levels during pregnancy and fetal problems, (3) women having control over the 
baby’s health and (4) being able to have a healthy baby (n=17, 100%). However, the lowest 
score was recorded for the risk of miscarriage in women with DM (n=8, 47%).  
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Table 7.4 Knowledge of PCC: correct answers pre-intervention  
 
 
Knowledge statement 
Correct 
response 
Pre-
intervention no 
of participants 
correct (n=17) 
Pre-
intervention 
% of 
participants 
correct 
Knowledge of Pregnancy Planning 
1. Women who are planning a pregnancy should discuss medication 
use with a healthcare provider 
T 17 100 
2. Women who are planning a pregnancy should stop smoking T 17 100 
3. Before becoming pregnant, ideally your HbA1c should be below 
6.5% (48.0 mmol/mol) 
T 16 94 
4. Women with diabetes cannot use hormonal contraception  F 16 94 
5. Women with diabetes have very limited choices of contraception F 15 88 
6. Women with diabetes should take folic acid daily when planning a 
pregnancy 
T 14 82 
7. Women who are planning a pregnancy should stop drinking alcohol T 13 77 
8. All over the counter drugs are safe and can be taken by women with 
diabetes who are planning a pregnancy 
F 12 71 
9. If you have Type 2 diabetes and are planning to become pregnant 
you may need to change from tablets to injections of  insulin  
T 7 41 
10. Women with diabetes should take the same amount of folic acid as 
all other women planning a pregnancy  
F 6 35 
11. All insulin are suitable for use during pregnancy 
 
F 1 6 
Knowledge of Pregnancy-related Risks 
12. High blood glucose levels during pregnancy do not increase the risk 
of problems for the mother 
F 17 100 
13. High blood glucose levels during pregnancy do not increase the risk 
of problems for the baby 
F 17 100 
14. Women with diabetes have little control over the health of their baby F 17 100 
15. Chances of a woman having a healthy baby increase as she 
improves her health prior to conception 
T 17 100 
16. Women with diabetes can have a healthy baby 
 
T 16 94 
17. Blood glucose levels before pregnancy can affect the health of the 
baby 
T 16 94 
18. Women with diabetes have an increased risk of having a large baby 
making delivery more difficult 
T 16 94 
19. Women with diabetes do not have an increased risk of having a 
baby with birth defects 
F 12 71 
20. Women with diabetes have an increased risk of miscarriage T 8 47 
 
 Pre intervention responses (scored as correct and incorrect). Three possible responses: true, false, not sure. 
Question adapted from Holmes et al. (2012) 
 
7.4.3 Section three: Patient activation measure (PAM)  
 
Patient activation measure (PAM-13) was used to assess participants’ level of activation 
(Hibbard et al. 2004, 2005). The 13 item scale has five possible response options ranging 
from 1) disagree strongly 2) disagree 3) agree 4) agree strongly and 5) not applicable (N/A). 
Participants need to answer 10 out of the 13 questions for a valid score. All participants 
answered the 13 questions.  
 
Pre-PADI app intervention data showed that the majority of responses clustered around 
agree or agree strongly. Figure 7.3 below shows the number of participants who agreed or 
strongly agreed with each PAM statements.  
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Figure 7.3 Participants’ response to the PAM items pre-intervention 
 
All (n=17, 100%) participants agreed or strongly agreed with the following four PAM 
statements  ̶  
1: When all is said and done, I am the person who is responsible for taking care of my 
health, 2: Taking an active role in my health care is the most important thing that affects my 
health,  
3: I am confident I can help or reduce problems associated with my health and  
7: I am confident that I can follow through on medical treatments I may need to do at home.  
 
Most participants (≥11, 65%) also agreed or strongly agreed with other PAM statements 
except for item 9: I know what treatments are available for my health problems where 10 
(59%) disagreed or strongly disagreed and 7 (41%) agreed or strongly agreed with the 
statement.  
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7.4.3.1 Total pre- intervention PAM score  
 
The total PAM score was calculated and used to segment participants into one of four levels 
of activation (as described in Chapter 5). Level 1: = <47.0; Level 2 = 47.1–55.1, Level 3 = 
55.2–67.0, and Level 4 = >67.1. At baseline, 11 participants (64.7%) were at level 4, four 
participants (23.5%) at level 3, two participants (11.8%) at level 2 and none were at the 
lowest level of activation (level 1). The pre-intervention mean and standard deviation were 
44.7 ± 4.3, and the scores ranged from 37 to 51 (range =14).  
 
7.5 Findings from post- PADI app intervention questionnaire 
After the intervention, participants were sent a follow-up questionnaire. In addition to the 
three sections contained in the pre-intervention questionnaire, the post intervention 
questionnaire contained an additional satisfaction rating scale and open-ended section 
where participants could comment on their experience of using the PADI app or provide 
suggestions for improvement. 11 participants completed the post intervention questionnaire.  
 
7.5.1 Section one:   Reproductive health attitude and behaviour (RHAB)  
7.5.1.1 Cues to action (motivation to seek PCC) 
All (n=11, 100%) women who completed the post-intervention questionnaire reported that 
they had discussed diabetes and pregnancy, and PCC with a HCP during the intervention. 
More than half (n=6, 54.5%) discussed contraception with a HCP, while 7 (63.6%) discussed 
PCC and 4 (36.5%) discussed contraception use with others (family, partners, colleagues 
and friends).  
 
Content analysis of free text comments from questionnaire 2 showed that in addition to 
doctors (consultants and GPs, n=5) and nurses (n=1), participants also discussed PCC with 
other PCC team members including dieticians (n=3). Likewise, DM and pregnancy was 
discussed with doctors (consultants and GPs, n=4), nurses (n=2) and other PCC team 
members (n=2). Contraception was also discussed with doctors (consultants and GPs, n=3; 
obstetrician, n=1) and nurses (n=1).  
 
The other five RHAB areas contain Likert-type questions with responses ranging from (1) not 
at all to (5) a lot (Table 7.5). The results are presented below. 
 
7.5.1.2 Perceived susceptibility 
After the intervention, most respondents reported that they were a little or not worried about 
having an unplanned pregnancy (n=8, 73%) and developing a sexually transmitted infection 
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(n=10, 91%). Furthermore, only a small number of participants (n=3, 27%) considered 
themselves or their baby (n=4, 36%) moderately or very susceptible to developing 
complications and health problems.  
 
7.5.1.3 Perceived benefit and barriers to seeking PCC   
 
With regards to perceived benefits, there was agreement amongst nearly all participants 
(n=10, 91%) that having blood glucose levels in the normal range improved the chances of 
having a healthy baby (Mdn=5, IQR=0). Likewise, all participants (n=11, 100%) indicated 
that seeking PCC would improve the chances of having a healthy baby (Mdn=5, IQR=1). 
  
With regards to barriers, a small number of respondents (n=3, 27%) reported that they would 
find it moderately or very difficult to seek PCC and only one (9%) felt that following the PCC 
advice given by a HCP would be moderately or very difficult. 
 
7.5.1.4 Perceived self-efficacy 
 
Nearly all participants reported that they were moderately or very confident that they could 
get access to PCC before becoming pregnant (n=9, 82%) and change their insulin, 
medication and diet to keep their blood sugar levels in normal range when planning a 
pregnancy (n=10, 91%). Furthermore, 8 (73%) participants were moderately or very 
confident that they could delay becoming pregnant until their blood glucose levels were in 
the normal range.  
 
7.5.1.5 Outcome expectations of PCC 
 
Most participants (n=9, 82%) reported that getting PCC would be moderately or very helpful 
in their understanding of how diabetes affects pregnancy. Opinions were however divided 
over the capacity of PCC to help influence choice of contraception, achieve normal blood 
glucose levels and prevent unplanned pregnancy.   
 
For example, 3 (27%) respondents felt that getting PCC would be of no or little help, 3 (27%) 
indicated that PCC would be of some help while 5 (45%) reported that PCC would be 
moderately or very helpful in deciding what contraception method to use. Likewise, 5 (45%) 
participants reported that PCC would be of no or little help, 3 (27%) thought that PCC would 
be of some help while 3 (27%) felt that PCC would be moderately or very helpful in 
preventing an unplanned pregnancy. 
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Table 7.5 Responses to post-intervention RHAB questionnaire  
 
 
 
Reproductive health, attitudes and behaviour 
(RHAB) question 
Post- intervention (n, %) 
Total n=11 
Not at all/  
A little 
1 & 2 
Somewhat 
3 
A moderate 
amount/  
A lot 
4 & 5 
Median 
(LQ-UQ) 
Perceived susceptibility  
 
How much do/did you worry that you could become 
pregnant? 
8 (73) 2 (18) 1 (9) 1  
(1-3) 
How much do/did you worry that you could catch a 
sexually transmitted infection (eg HIV/AIDS)? 
10 (91) 1 (9) 0 (0) 1  
(1-2) 
How much do/did you worry that you could develop health 
problems if you become pregnant? 
4 (36) 4 (36) 3 (27) 3  
(2-4) 
How much do/did you worry that if you become pregnant 
your baby could develop health problems? 
2 (18) 5 (46) 4 (36) 3  
(3-4) 
Perceived benefits  
Would having blood sugar levels in the normal range  
(4.0-7.5 mmol/l) before becoming pregnant improve your 
chances of having a healthy baby? 
0 (0) 1 (9) 10 (91) 5  
(5-5) 
Would seeking preconception care improve your chances 
of having a healthy baby? 
0 (0) 0 (0) 11 (100) 5  
(4-5) 
Perceived barriers  
How difficult do you think it would be to seek preconception 
care  
7 (64) 1 (9) 3 (27) 2  
(1-4) 
How difficult do you think it would be, to follow the 
preconception care advice given by a health professional 
(e.g attending retinal screening)? 
7 (64) 3 (27) 1 (9) 2  
(1-3) 
Perceived self-efficacy 
How confident are you that you could get PCC before 
getting pregnant? 
0 (0) 2 (18) 9 (82) 4  
(4-5) 
How confident are you that you could change your insulin, 
medication and diet to keep your blood sugar levels in 
normal range, even if you are not yet pregnant, but 
planning a pregnancy? 
0 (0) 1 (9) 10 (91) 4  
(4-5) 
How confident are you that you could delay becoming 
pregnant until your blood sugar levels are within the normal 
range? 
0 (0) 3 (27) 8 (73) 4  
(3-5) 
Outcome expectations 
Would you say that getting PCC would help you get normal 
blood sugar levels? 
2 (18) 3 (27) 6 (54) 4  
(3-5) 
Would you say that getting PCC would help you 
understand how diabetes affects pregnancy? 
1 (9) 1 (9) 9 (82) 4  
(4-5) 
Would you say that getting PCC would help you decide 
what contraception method to use? 
3 (27) 3 (27) 5 (45) 4  
(2-4.5) 
Would you say that getting PCC would help you prevent an 
unplanned pregnancy? 
5 (45) 3 (27) 3 (27) 3  
(1-4) 
 
 
7.5.1.6  Total reproductive health and attitudes (RHAB) summative scores 
The cumulative responses to each construct were collated to determine participants’ overall attitudes 
and behaviours post- PADI app intervention (Table 7.6). High summative scores indicate a strong level 
of belief in the construct.   
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Table 7.6 Summary of beliefs and attitudes associated with preventing an unplanned 
pregnancy and seeking PCC post-intervention 
 
 
Questionnaire 
Measures 
 
Possible scale 
range 
Post- intervention attitudes 
Total (n=11) 
Mean & Standard 
deviation 
Median  
(LQ-UQ) 
Range  
(Min-Max) 
Susceptibility 
 
4-20 
 
9.18 ± 2.60 9  
(8-10) 
10 
(6-16) 
Benefit 
 
2-10 
 
9.55 ± .93 10  
(9-10) 
3 
(7-10) 
Barriers 
 
2-10 
 
4.27 ± 2.24 3  
(3-7) 
6 
(2-8) 
Self-efficacy 
 
3-15 
 
12.55 ± 1.81 12  
(12-14) 
6 
(9-15) 
Outcome 
expectations 
4-20 
 
15.1 ± 3.72 16  
(11.5-18) 
13 
(7-20) 
Perceived self-efficacy and benefits were highest post-intervention, indicating increased belief in 
benefits of PCC and confidence to seek PCC while perceived barriers remained low. 
 
7.5.2 Section two: Preconception care (PCC) knowledge 
 
Women’s knowledge of pregnancy planning and risks was measured after the intervention using 
questionnaire 2 (Table 7.7). The results are presented below.  
 
7.5.2.1 Pregnancy planning 
Knowledge scores were 100% for six items: (1) speaking to a HCP about medication, (2) quitting 
smoking, (3) pre-conception HbA1c value, (4) use of hormonal contraception, (5) choices of 
contraception and (6) safety of over the counter medication (n=11, 100%). The lowest post-
intervention score was recorded for the suitability of all insulin during pregnancy (n=4, 36.4%).  
 
7.5.2.2 Pregnancy-related risks 
For knowledge of risks, scores of a 100% were achieved for five items: (1) high blood glucose levels 
during pregnancy and maternal problems, (2) high blood glucose levels during pregnancy and fetal 
problems, (3) women having control over the baby’s health, (4) being able to have a healthy baby and 
(5) risk of having a large baby (n=11, 100%). Knowledge of miscarriage in women with DM (n=9, 
81.8%) was also high, post-intervention.  
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Table 7.7 Knowledge of PCC: correct answers post-intervention 
 
 
Knowledge statement 
Correct 
response 
Post-
intervention no 
of participants 
correct (n=11) 
Post- 
intervention 
% of 
participants 
correct 
Knowledge of Pregnancy Planning 
1. Women who are planning a pregnancy should discuss medication 
use with a healthcare provider 
T 11 100 
2. Women who are planning a pregnancy should stop smoking T 11 100 
3. Before becoming pregnant, ideally your HbA1c should be below 
6.5% (48.0 mmol/mol) 
T 11 100 
4. Women with diabetes cannot use hormonal contraception  
 
F 11 100 
5. Women with diabetes have very limited choices of contraception F 11 100 
6. Women with diabetes should take folic acid daily when planning a 
pregnancy 
T 10 90.9 
7. Women who are planning a pregnancy should stop drinking alcohol T 10 90.9 
8. All over the counter drugs are safe and can be taken by women with 
diabetes who are planning a pregnancy 
F 11 100 
9. If you have Type 2 diabetes and are planning to become pregnant 
you may need to change from tablets to injections of  insulin  
T 6 54.5 
10. Women with diabetes should take the same amount of folic acid as 
all other women planning a pregnancy  
F 8 72.7 
11. All insulin are suitable for use during pregnancy 
 
F 4 36.4 
Knowledge of Pregnancy-related Risks 
12. High blood glucose levels during pregnancy do not increase the risk 
of problems for the mother 
F 11 100 
13. High blood glucose levels during pregnancy do not increase the risk 
of problems for the baby 
F 11 100 
14. Women with diabetes have little control over the health of their baby F 11 100 
15. Chances of a woman having a healthy baby increase as she 
improves her health prior to conception 
T 10 90.9 
16. Women with diabetes can have a healthy baby 
 
T 11 100 
17. Blood glucose levels before pregnancy can affect the health of the 
baby 
T 10 90.9 
18. Women with diabetes have an increased risk of having a large baby 
making delivery more difficult 
T 11 100 
19. Women with diabetes do not have an increased risk of having a 
baby with birth defects 
F 7 63.6 
20. Women with diabetes have an increased risk of miscarriage T 9 81.8 
 
 Post app responses (scored as correct and incorrect). Three possible responses: true, false, not sure.  
 
7.5.3 Section three: Patient activation measure (PAM)  
Post PADI app intervention results showed that all the participants’ responses clustered around agree 
or strongly agree. Thus all (n=11) participants who completed questionnaire 2 agreed or strongly 
agreed with 12 out of the 13 PAM items (Figure 7.4).  
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Figure 7.4 Participants’ response to the PAM items post-intervention 
 
7.5.3.1 Total post- intervention PAM score 
PAM had improved following the intervention whereby the majority (n=10, 91%) were now at level 4, 
with only one (9%) participant at level 3. Mean and standard deviation for the post-intervention PAM 
score was 48.5 ± 3.2 and the participants’ scores ranged from 43 to 52 (range= 9).  
 
7.5.4 Comparison of PADI app intervention results pre and post-intervention 
Results of the pre- and post-intervention questionnaires were compared to explore feasibility and 
preliminary estimates of the intervention.  
RHAB: The PADI app intervention had a positive effect on four out of the five RHAB constructs. That 
is, perceived benefits of PCC (9.47±.94 vs 9.55±.93, mean difference= +0.29) and self-efficacy to seek 
PCC (12±1.62 vs 12.55±1.81, mean difference= +0.6) increased pre to post-intervention. See Table 
7.8 below for a summary of beliefs and attitudes associated with preventing an unplanned pregnancy 
and seeking PCC. 
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1. When all is said and done, I am the person who is
responsible for taking care of my health
2. Taking an active role in my health care is the most
important thing that affects my health
3. I am confident I can help or reduce problems associated
with my health
4. I know what each of my prescribed medicine does
5. I am confident that I can tell whether I need to go to the
doctor or whether I can take care of a health problem…
6. I am confident that I can tell a doctor concerns I have
even when he or she does not ask
7. I am confident that I can follow through on medical
treatments I may need to do at home
8. I understand my health problems and what causes them
9. I know what treatments are available for my health
problems
10. I have been able to maintain (keep up with) lifestyle
changes, like eating right or exercising
11. I know how to prevent problems with my health
12. I am confident I can figure out solutions when new
problems arise with my health
13. I am confident that I can maintain lifestyle changes, like
eating right and exercising, even during times of stress
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Table 7.8 Summary of beliefs and attitudes associated with preventing an unplanned pregnancy and seeking PCC  
 
 
 
 
Questionnaire 
Measures 
 
Possible 
scale 
range 
Pre-intervention attitudes Post-intervention attitudes  
Mean 
difference 
 
P* 
 
Effect size Mean & 
standard 
deviation 
Median Mean & 
standard 
deviation 
Median 
Susceptibility 4-20 11.53 ± 3.17 12 9.18 ± 2.60 9 -2.4 0.07 0.34 
Benefit 2-10 9.47 ± .94 10 9.55 ± .93 10 0.1 0.29 0.20 
Barriers 2-10 4.94 ± 2.14 4 4.27 ± 2.24 3 -0.7 0.32 0.19 
Self-efficacy 3-15 12 ± 1.62 12 12.55 ± 1.81 12 0.6 0.18 0.25 
Outcome 
expectations 
4-20 15.1 ± 3.72 16 15.1 ± 3.72 13 Nil 0.75 0.06 
 *Pre-intervention scores versus post-intervention score by Wilcoxon signed rank test 
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Perceived susceptibility to unplanned pregnancies and complications (11.53±3.17 vs 
9.18±2.60, mean difference = -2.4) and perceived barriers to seeking PCC (4.94±2.14 vs 
4.27 ± 2.24, mean difference = -0.7) decreased pre to post-intervention.  
There was however no change with regards to outcome expectations which remained the 
same pre and post intervention (15.1 ± 3.72).  
A Wilcoxon signed-rank test revealed that there may be a trend towards significance in 
perceived susceptibility following the PADI app intervention (pre-intervention median, Md = 
12; post-intervention Md= 9), z=-1.79, P= 0.07, with a medium effect size (r=0.34). Apart 
from outcome expectations, there were modest but no significant changes in other measures 
which also had small effect sizes (see Table 7.8).  
 
In addition, the Cronbach alpha coefficient for the RHAB constructs (Table 7.9) ranged from 
0.4 to 0.7 (pre-intervention) and 0.6 to 0.9 (post-intervention), indicating acceptable internal 
consistency that compares closely to those found in previous studies which used the RHAB 
(Charron-Prochownik et al. 2006; Holmes et al. 2012). Thus, indicating that the 
questionnaire used was a reliable method to measure the included theoretical constructs.  
 
Table 7.9 Cronbach alpha for each theoretical construct within the RHAB  
RHAB Theoretical Construct Pre-intervention Post-intervention 
Cues to action 0.6 0.8 
Perceived susceptibility 0.6 0.6 
Perceived benefits 0.5 0.7 
Perceived barriers 0.5 0.9 
Self-efficacy 0.4 0.8 
Outcome expectations 0.7 0.6 
 
PCC Knowledge 
The PADI app intervention also had a positive effect on knowledge of PCC which resulted in 
considerable variation in knowledge scores pre to post intervention especially with regards to 
pregnancy planning (Table 7.10). Compared to pre-intervention where scores of 100% were 
obtained for two items (speaking to HCP about medication and quitting smoking), post-
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intervention results showed scores of 100% for six items (speaking to a HCP about 
medication, quitting smoking, pre-conception HbA1c value, use of hormonal contraception, 
choices of contraception and safety of over-the-counter medication).  
 
Furthermore, increase in knowledge scores were recorded for all other items pre to post 
intervention including higher dose of folic acid, daily intake of folic acid, and avoidance of 
alcohol and safety of insulin during pregnancy. 
 
Table 7.10 Knowledge of PCC: correct answers pre and post-intervention 
 
 
Knowledge statement 
Correct 
response 
Pre-
intervention no 
and % of 
participants 
correct (n=17) 
Post- 
intervention 
no (%) of 
participants 
correct 
(n=11) 
Knowledge of Pregnancy Planning 
1. Women who are planning a pregnancy should discuss medication 
use with a healthcare provider 
T 17 (100) 11 (100) 
2. Women who are planning a pregnancy should stop smoking T 17 (100) 11 (100) 
3. Before becoming pregnant, ideally your HbA1c should be below 
6.5% (48.0 mmol/mol) 
T 16 (94) 11 (100) 
4. Women with diabetes cannot use hormonal contraception  
 
F 16 (94) 11 (100) 
5. Women with diabetes have very limited choices of contraception F 15 (88) 11 (100) 
6. Women with diabetes should take folic acid daily when planning a 
pregnancy 
T 14 (82) 10 (91) 
7. Women who are planning a pregnancy should stop drinking alcohol T 13 (77) 10 (91) 
8. All over the counter drugs are safe and can be taken by women with 
diabetes who are planning a pregnancy 
F 12 (71) 11 (100) 
9. If you have Type 2 diabetes and are planning to become pregnant 
you may need to change from tablets to injections of  insulin  
T 7 (41) 6 (55) 
10. Women with diabetes should take the same amount of folic acid as 
all other women planning a pregnancy  
F 6 (35) 8 (73) 
11. All insulin are suitable for use during pregnancy 
 
F 1 (6) 4 (36) 
Knowledge of Pregnancy-related Risks 
12. High blood glucose levels during pregnancy do not increase the risk 
of problems for the mother 
F 17 (100) 11 (100) 
13. High blood glucose levels during pregnancy do not increase the risk 
of problems for the baby 
F 17 (100) 11 (100) 
14. Women with diabetes have little control over the health of their baby F 17 (100) 11 (100) 
15. Chances of a woman having a healthy baby increase as she 
improves her health prior to conception 
T 17 (100) 10 (91) 
16. Women with diabetes can have a healthy baby 
 
T 16 (94) 11 (100) 
17. Blood glucose levels before pregnancy can affect the health of the 
baby 
T 16 (94) 10 (91) 
18. Women with diabetes have an increased risk of having a large baby 
making delivery more difficult 
T 16 (94) 11 (100) 
19. Women with diabetes do not have an increased risk of having a 
baby with birth defects 
F 12 (71) 7 (64) 
20. Women with diabetes have an increased risk of miscarriage T 8 (47) 9 (82) 
 
 
The Wilcoxon signed rank test indicated a statistically significant increase in knowledge of 
participants following the PADI app intervention, z= -2.67, P = .008, with a large effect size 
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(r= .57). The median score on the knowledge of PCC questionnaire increased from pre-
intervention (Md= 82, IQR=41-94) to post intervention (Md = 100; IQR= 72-100).  
 
Knowledge of risks also increased, compared to pre-intervention whereby four scores of 
100% were achieved, post-intervention results had five scores of 100%. Moreover, an 
increase was recorded in knowledge of miscarriage post-intervention (82%) which when 
compared to pre-intervention (47%), was one of the highest post-intervention scores (100% 
being the highest score). Although the median score increased from pre- to post-
intervention, overall, increase in knowledge of risks was not found to be significant pre-
intervention (Md=94; IQR=82.5-100) to post-intervention (Md= 100; IQR=86.35-100); P= 
0.92, z= 0.11, with a very small effect size (r= .03). 
 
Patient activation measure (PAM) 
Furthermore, positive effects were also recorded in PAM levels pre-to post intervention 
(Table 7.11). Of the (n=11) participants who completed questionnaire 2, two (18.2%) had 
increased their PAM levels from 2 to 4, three (27.3%) from 3 to 4 and five (45.5%) who were 
already at level 4 had increased PAM scores post intervention. Only one participant 
remained at the same level of activation (level 3) pre and post intervention.  
 
There was also an increase in total PAM scores (44.7±4.3 vs 48.5±3.2, mean difference= 
+3.8), pre to post intervention (Table 7.11).   
 
Table 7.11 Summary of PAM score pre and post-intervention 
 
Possible 
scale 
range 
Pre-intervention Post-intervention 
Cronbach 
alpha 
Mean & 
standard 
deviation 
Range 
(Min-Max) 
Cronbach 
alpha 
Mean & 
standard 
deviation 
Range 
(Min-Max) 
13-52 0.86 44±4.3 14 
(37-51) 
0.87 48.5±3.2 9 
(43-52) 
 
 
A Wilcoxon Signed Rank Test indicated a statistically significant increase in patient 
activation measure (PAM) following the app intervention, z= -2.73, P = 0.006, with a large 
effect size (r=.52). The Median score on the PAM scale increased from pre-intervention 
(Md= 45; IQR=41-48) to post intervention (Md =48; IQR=46-52). The Cronbach alpha scores 
for the 13-item PAM (Table 11) remained consistently high pre- (0.86) to post-intervention 
(0.87).
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7.5.5 Section four: Satisfaction with intervention   
This section presents participants’ rating and feedback regarding the PADI app intervention. All 
(n=11) participants who completed questionnaire 2 rated the PADI app in terms of their overall 
satisfaction with the app and its functionalities. Participants rated the app from 0-100, where 
0=not satisfied at all and 100=completely satisfied.  
The average app rating based on the scores of all (n=11) participants = 71.8 (range 25-90). A 
small number of participants (n=2, 18.2%) rated the app ≤50 while the majority (n=9, 81.8%) 
gave it a rating above 60 (Figure 7.5). Satisfaction with the intervention is further explored in the 
user experience interviews, the findings of which are presented later in this chapter.  
 
Figure 7.5 Overall app satisfaction rating  
Content analysis showed that the six participants who included comments found the 
informational content useful and informative. Five were however interested in improved 
functionality of the blood glucose diary while one wanted an improvement to the general app 
features. In summary, they suggested (a) integration of the app with other diabetes 
management technology; (b) increased interactivity via logging and tracking other parameters 
such as insulin, downloading and/emailing blood glucose readings and using free text to make 
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notes of blood glucose readings; (c) synchronisation of blood glucose data between devices 
(e.g. iPad and iPhone) and (d) using notifications twice a day to enter blood glucose reading.  
 
7.5.6 Questionnaire completion 
Missing data was identified for the preconception knowledge (K) section of the pre-intervention 
questionnaire (Questionnaire 1). Three women with T1DM did not answer question 4: If you 
have Type 2 diabetes and are planning to become pregnant you may need to change from 
tablets to injections of insulin. Perhaps the women with T1DM did not find the question relevant 
to them. Although this shows that missing data did occur, this was low as all other questions 
were completed. The post-intervention questionnaire (Questionnaire 2) had no missing data.   
 
7.6 Summary  
17 participants enrolled at baseline and 11 completed the study and post-intervention 
questionnaire. Participants were recruited between December and March 2017. The majority of 
participants had T1DM, were educated and planning a pregnancy in the near future (next one 
year or 1-5 years). The recruitment target of 12 was achieved and exceeded in order to allow for 
loss due to follow up. However, there was some attrition during the study, with only 65% (n=11) 
of participants remaining at the end of the 3-month study.  
 
The aim of the study was to test the feasibility of the PADI app intervention and establish 
preliminary intervention effects. Evaluation of the pre and post PADI-app intervention indicated 
an improvement in overall knowledge, attitudes to PCC and PAM. After the 3-month PADI app 
intervention, there was a positive change in women’s perceived benefits of PCC and self-
efficacy (self-confidence to use contraception to prevent an unplanned pregnancy and seek 
PCC). There was also reduction in perceived susceptibility to unplanned pregnancies and 
complications, and barriers to seeking PCC. Knowledge of PCC, that is, pregnancy planning 
and risks, as well as PAM improved. These preliminary findings appear to suggest that the PADI 
app can be used to provide PCC, potentially improve PCC knowledge, attitudes and PAM. 
Furthermore, the overall app satisfaction rating showed that while participants identified areas 
for future development of the app, they were satisfied with the app-based PCC intervention.   
 
The findings from the user experience interviews are presented in the next section. 
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7.7 Section 2: User experience interviews 
Women’s views and experiences of the PADI app were explored using semi-structured 
interviews and are presented using a thematic analysis.  
7.8 Demographic profile 
Participants comprised of (n=6) women with DM who participated in the 3-month intervention 
and agreed to be interviewed (Table 7.12). Semi-structured telephone interviews took place 
from April to July 2017 and lasted about 20-30 minutes. Participants were geographically 
dispersed across the United Kingdom, America and Canada. The average age of participants 
was 31 years, and all had T1DM.  
Table 7.12 Participants descriptive table 
No Identifier Age (years) Diabetes 
mellitus type 
& duration 
(years) 
Educational 
qualification  
Occupation Planning a 
pregnancy 
1. P11 24 Type 1 (>5) Higher 
degree (M.Sc 
or PhD) 
Researcher > 5 years 
2. P12 36 Type 1 (>5) First degree Nurse < 1 year 
3. P13 33 Type 1 (>5) Higher 
degree (M.Sc 
or PhD) 
Researcher < 1 year 
4. P14 32 Type 1 (>5) Higher 
degree (M.Sc 
or PhD) 
Town planner < 1 year 
5. P15 20 Type 1 (>5) A levels Student > 5 years 
6. P16 39 Type 1 (>5) First degree Administrator < 1 year 
 
7.8.1 Findings 
Three main themes were identified from the analysis (described in chapter 5):  
 Feasibility and acceptability of the PADI app  
 Engagement with the PADI app  
 Future development of the PADI app.  
All themes had two or more sub-themes as shown in Table 7.13 below. 
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Table 7.13 Themes and sub-themes 
 Main theme 
 
Sub-theme 
 
1. 
 
Feasibility and acceptability of 
the PADI app 
Acceptability of the PADI app 
 
Experiences and behavioural effects of the PADI app 
 
 
2. 
 
Engagement with the PADI app 
 
Usage  
 
Factors affecting usage 
 Functionality 
 Personal factors 
 
3. 
 
Future development of the PADI 
app 
 
Improvement to informational content 
 
Improvement to blood glucose diary 
 
Improvement to the general app features 
 
 
7.9 Feasibility and acceptability of the PADI app 
Generally, the PADI app was viewed as an ideal means of providing PCC because of its 
accessibility and portability. Participants highlighted the scarcity of PCC information for women 
with DM, and considered the app to be a comprehensive and informative source of PCC which 
incorporated self-management of blood glucose (SMBG) functions. Participants felt that the 
PADI app helped to improve PCC knowledge especially regarding folic acid and blood glucose 
control. The acceptability of the PADI app and subsequent behavioural effects of the PADI app 
use are explored in more detail below.  
7.9.1 Acceptability of the PADI app 
Participants’ views and attitudes towards the PADI app were positive. Having the PCC 
information delivered via a mobile app was perceived as advantageous as women always had 
their phones with them. 
 It’s helpful to have it on the mobile phone because usually you have your mobile phone with you 
wherever you go. [P12, 36 years] 
Women (n=5) reported that they preferred the PADI app to traditional leaflets because of the 
convenience, mobility and portability associated with the app. They acknowledged that leaflets 
were generally obtained during visits to the GP surgery or diabetes clinics which limited access. 
Furthermore, those who picked up such leaflets rarely carried them around, hence, having the 
PADI app available at all times removed these constraints and made it easier for women to 
access PCC information.   
 I did like that you can have it with you wherever, because although it’s kind of the same 
information that you could get at a brochure at the GP’s office, you’re not always going to have that 
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brochure with you when you want to refer to something, whereas if it’s on your phone you always have it 
with you and it’s easy to go and double check and to just have that information on hand wherever you 
are. [P11, 24 years] 
In addition to the informational content, the app also contained a diary for monitoring of blood 
glucose (BG) levels. Most participants (n=5) felt that it was useful to have a diary within the app 
that recorded and displayed trends as this was considered beneficial to the management of 
diabetes, as noted below. 
 I think it would be very good for monitoring. I mean, I’m very particular. My HbA1C is 6.3, so I 
monitor quite closely my blood glucose anyway. But I think the blood glucose diary is crucial. [P14, 32 
years] 
Participants believed that having the PADI app on their phone was of immense benefit 
especially as it condensed the PCC information and blood glucose diary in a single app within 
their smartphones. It thus precluded the need to carry a book for logging blood glucose readings 
which is not only bulky but also inconvenient. This integration was perceived as a strength of 
PADI app. 
I like it. I’ve carried around a book but I either don’t have a pen or my handbag is too small for it 
or I’ve left it at home and it’s very rare that I leave my phone behind, so it’s always there and I can … 
always put it [BG readings] in and if I don’t have an internet connection the majority of the information is 
there for me and I just like the fact that it’s like having all the information in a book but in a tiny place on 
your phone. [P16, 39 years] 
 
They further reported that the app used a supportive approach to inform women planning a 
pregnancy about the target HbA1c value and the benefits of having BG levels within the 
recommended range. One woman reported taking the app along to clinic consultations so that 
target HbA1c and BG levels could be discussed with HCPs in line with the PADI app PCC 
checklist.  
 I did speak to the diabetes team and had the HbA1c taken and then we had a bit of a discussion 
about it. They were quite blunt about it and it was a little bit kind of scary I guess but they were both telling 
the truth but they weren’t as nice … but your app kind of made them go, “Oh well that’s the preferred level 
you need to be at,” not the, ‘You’ve got to be there otherwise you can’t.’ [P16, 39 years] 
 
This participant further noted not feeling very supported during the clinic visit which reinforced 
the need for the positive language used within the app. Furthermore, as previous experiences 
with HCPs had left women feeling discouraged, the need for reassurance during PCC and 
pregnancy was emphasised by participants who reported that the PADI app specifically 
designed for women with DM made them feel supported.  
 I think that you feel alone and everyone else who is pregnant without diabetes doesn’t have to 
worry about all these things, so to have this app is like comforting and inclusive and it’s nice. [P13, 33 
years] 
Furthermore, the positive intervention language used within the PADI app and the perceived 
benefits of the app content was reported to appeal to participants. Although PADI is a PCC app, 
participants noted that they would carry on using it beyond preconception and throughout the 
duration of their pregnancies due to its useful information and functionality.  
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 It’s got a very good content, I think it would be very beneficial … it’s something that would be 
great to have throughout your pregnancy. [P14, 32 years] 
Thus, the use of a mobile app as an intervention tool for PCC was perceived as acceptable to 
women with DM. One woman summed this up by noting that: “Overall, I think it’s a wonderful 
idea.” [P15, 20 years] 
  
7.9.2 Experiences and behavioural effects  
Generally, women found the PADI app content educational and informative. They felt that the 
app provided detailed PCC information, covered a wide range of topics and provided a sufficient 
amount of tips and advice. All participants were of the opinion that the app was a good source of 
PCC information and should be recommended to all women with T1DM as in their experiences 
some HCPs lacked PCC knowledge.  
 I loved the about pre-pregnancy planning. I think that as a person with type 1 diabetes you don’t 
get that. Even the people you go see don’t know that much and … I think this would be great to give to 
patients so that they understand. So I definitely loved the information in it. [P13, 33 years] 
 Overall, I felt that it had all the information I would want [P15, 20 years].  
Five participants reported that they were able to learn from the PADI app and felt that it 
improved their knowledge and awareness of PCC. They felt that improved knowledge in turn 
reduced any previous anxieties that they had about planning and having a healthy pregnancy. 
 I’m much more knowledgeable on it, learning about things and being prepared for everything. I 
can be a little more calm because I know of things. [P13, 33 years] 
 
Women were generally aware of the need to maintain good blood glucose levels in pregnancy, 
but the rationale and importance of this behaviour was not always clear. The PADI app thus 
helped participants to understand why optimised BG levels before and during pregnancy were 
important. It also provided information regarding the risks of poorly controlled DM during 
pregnancy to both the woman and baby, and signposted users to available resources (such as 
reputable websites and their own diabetic team) that could be consulted for more information.  
 Just greater emphasis on blood sugar control, which I knew was an issue but knowing specifically 
how important it is from the app, it’s definitely made a big impact and knowing what research resources 
are available to me. [P15, 20 years] 
 
Furthermore, the inclusion of a BG diary facilitated monitoring and allowed participants to reflect 
on their own behaviour, which was enlightening for some. For example, a woman in the study 
recognised that she did not always prioritise blood glucose level monitoring and acknowledged 
that using the PADI app helped to improve this. She was also seeing the benefits of regular 
SMBG since using the diary to monitor and visualise blood glucose (BG) levels— her blood 
glucose levels were improving. 
Because I think it drops priority for a while and because I’ve been helping you it’s made it come 
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up to a higher priority and it’s made me think about it more and my levels are coming down, so that’s 
quite impressive. [P16, 39 years] 
 
Participants reported that the PADI app served as a good source of PCC information and its 
content could help other women planning a pregnancy stay informed, and adopt behaviours that 
would increase the likelihood of having a healthy pregnancy and baby. The mere presence of 
the PADI app on a woman’s phone was reported by one participant to provide the motivation to 
initiate and continue with healthy behaviours, as noted below: 
   I think that just having the app and seeing it on my phone would kind of remind me like, yes, I’m 
taking steps to make sure I’m healthy, my baby is healthy. [P15, 20]. 
The PADI app thus highlighted the significance of seeking PCC to all participants while 
providing participants with handy resources and details regarding which HCPs to contact when 
planning a pregnancy. Participants reported that the app intervention enabled them to recognise 
the importance of pregnancy planning and involving their healthcare team. Going forward, they 
reported that they would do things differently by seeking PCC and contacting a HCP about their 
pregnancy intentions.  
 I think when I do decide I would like to become pregnant I definitely would seek preconception 
care. I’d probably go to my GP and look for other resources. Yes, I think the app and being part of this 
study just opened my mind as to what care is out there and where I can search for more care and more 
support. [P11, 24 years] 
In addition to informing women in the study of the merits of seeking PCC, the PADI app was 
reported to have facilitated actual engagement with HCPs, especially the diabetes consultant. 
For example, it encouraged women planning a pregnancy (in less than one year) to take the 
initiative in order to improve their preconception health by requesting a prescription for 5mg folic 
acid.  
 I thought it was very useful actually … Things like about taking the extra folic acid, I was actually 
showing that to my doctor and said, “Well actually it says that we need the 5mg rather than the normal 
[4µg]” so I’ve had that prescribed now. [P16, 39 years] 
The PADI app was a feasible and acceptable means of providing PCC information that resulted 
in raised PCC awareness and other behavioural effects. However, despite the acceptance of 
the PADI app, engagement was moderate and several factors affected usage of the app.   
7.10 Engagement with the PADI app  
7.10.1 Usage 
Most of the participants liked the app and its functionalities and all reported that they had used 
the PADI app to access PCC information. Most reported using it periodically mainly to record 
blood glucose levels, for example; 
 So I read everything that you wrote about like the planning … but like the blood glucose 
monitoring, when you have it everywhere else, to put it somewhere else was just not… I just did not keep 
up with it. [P13, 33 years] 
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 I only did it maybe once a day but not very often because it was just a lot of clicking that I would 
have to do to get there. [P15, 20 years] 
 
Women who were more frequent users, and reported using it daily, explained how they found it 
more convenient to use at a particular time, such as early morning or late evening. 
 I only put my blood glucose in, in the mornings. [P14, 32 years] 
 I would generally use it around about teatime. [P16, 39 years] 
These findings were reflected in the software log of activity data, which, although was limited, 
confirmed all study participants had used the PADI app at least once, and that usage varied 
substantially (range from 1 to 8 sessions/day of use). A number of factors were reported to 
influence the app usage and these are discussed in more detail below.  
7.10.2 Factors affecting usage 
Participants cited various factors related to functionality (e.g. usability, SMBG functions and 
inadequate interactivity) and personal issues (prior knowledge, usefulness, not planning a 
pregnancy, memory/time issues and competing priorities) that influenced their app usage. The 
main barrier reported related to the limitations associated with the SMBG function.  
7.10.2.1 Functionality factors 
Usability of the intervention 
The interview findings revealed that all of the (n=6) participants found the PADI app 
straightforward to download and install onto their mobile phones, as shown in the data extract 
below. 
 Yes, it was very easy to download, so that wasn’t a problem at all. [P12, 36 years] 
Furthermore, all participants noted that they had no difficulty registering their details (username 
and password) and subsequently logging into the app, describing the process as “perfect [and] 
very easy” [P14, 32, UK]. Participants further reported that it was easy to navigate the different 
sections of the app and generally liked the user interface (UI), noting that it was simple, 
attractive and intuitive.  
 Quite easy to use. It looks nice, it was quite self-explanatory. [P16, 39 years] 
All participants reported that the PADI app was easy to learn, noting that the simple design of 
the UI allowed them to easily find information and operate the PADI app. For example, while 
talking about the organisation of the different components within the PADI app, one participant 
noted that “the title of different things were quite clear ... it was quite simply laid out” [P12, 36 
years].  
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Another participant agreed with this view and stated: “Yes, it’s a very simple app.” [P13, 33 
years] 
One participant experienced technical problems with the diary and as a result, was unable to log 
her readings on one day. However, the majority (n=5) of women had not experienced any 
technical problems with regards to the PADI app or diary during the study.  
 There was no problem technically with the application at all. [P15, 20 years] 
Majority of participants were pleased with the overall PADI app and its functionalities, and noted 
that they will be sharing or recommending it to other women with DM.  
 I think it’s a brilliant app … and anyone I do know I will be recommending it to them. [P14, 32 
years] 
 
 Self-monitoring of blood glucose (SMBG) functions  
Participants reported that they found using the PADI app to input their blood glucose data 
straightforward and easy. However, the blood glucose diary was in UK units of measurement 
(mmol/l) and participants from other countries e.g. Canada/USA use mg/dl as their unit of 
measurement and had to convert their blood glucose readings into mmol/l. One of the 
participants pointed out that although the diary was simple to use, she struggled with this 
conversion. 
 I mean, it wasn’t that it was complicated, it was just that having to convert the units … so it was 
easy, it was just somewhat time consuming. [P15, 20 years] 
 
Other perceived limitations of the diary affected its use. For example, the blood glucose diary 
had a graph that displayed trends and a reminder built into the app, but some participants felt 
that it was still limited in its functionality as it did not have the capacity to log insulin, exercise 
and carbohydrate intake, and estimate HbA1c. They compared it to their existent diary and 
reported that it was not as comprehensive in its functionalities, as shown below. 
 No, because I use a different glucose diary … The diary I use you can log the different foods you 
eat, you can log exercise, you can log how much insulin or other medications you take and so it’s a bit 
more comprehensive and so that’s the one I use. [P11, 24 years] 
Participants wanted simple and fast functionality with minimum effort on their part and reported 
that manual entry of BG levels was inconvenient. The diary also lacked the facility to download 
or email BG readings. Participants reported that they already had to write down numbers for 
clinic appointments and having to enter their numbers into the app as well was a factor affecting 
continued usage.   
 My biggest thing was it was something else to do. I wear a Dexcom already, I have a pump, I 
upload it and if my provider wants numbers, I have to write those down on their sheets. And then to have 
another thing, I mean, I did it for two or three days, putting it in the beginning … I felt like it was just 
double work, like it was already being recorded on my phone, the Dexcom readings were there. So to 
then record a blood sugar number, what’s the point when I have 24hrs a day of blood sugar numbers 
recorded? [P13, 33 years] 
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Furthermore participants’ ownership of more sophisticated technology further affected use of the 
diary for SMBG. For example, some women already used advanced technology such as 
continuous glucose monitors (CGMs), BG meters (BGMs) and pumps that displayed and gave 
them a breakdown of their readings. These were considered primary devices because they read 
the blood glucose levels directly and indicated when participants were likely to experience hyper 
or hypoglycaemia. Although the PADI app provided a breakdown of blood glucose readings and 
worked out average BG levels, it was still considered a secondary device because participants 
had to manually transfer readings from their primary devices into the app.  
 I didn’t feel that it was really beneficial for me because I’m using an insulin pump and my own 
blood glucose meter does give me a lot of the information and the downloads and the working out of what 
my average levels are, which times of the day I’m mainly maybe at risk of having high blood sugar … so I 
have got that already, so I didn’t really feel that the app gave me any additional benefits. [P12, 36 years].  
This made the entry of data time-consuming and a slow process. Furthermore, the diary within 
the app was also compared to other commercial apps in terms of functionality and 
comprehensiveness and this determined whether or not participants switched from their existent 
diary to the app. These participants (n=4) who owned sophisticated blood glucose management 
devices however acknowledged that if they didn’t already have access to their existing 
technologies, they would have used the PADI app diary more often. They further acknowledged 
that the diary would be a useful feature for many women as not everyone had access to such 
advanced monitoring technologies.  
 It depends on the technology that the person has set up. For me, because I have the ability to 
export my blood sugar data to like an easier application, it would not be helpful for me, but for somebody 
whose blood sugar meter maybe doesn’t track it or doesn’t export it like that then for sure it would be very 
helpful. [P15, 20 years] 
 
This view was supported by two participants who did not own pumps, CGMs or BGMs that 
recorded their readings, provided a breakdown and showed trends. They thus found the PADI 
app diary useful and did not mind inputting their glucose readings into the app, as shown below:  
I think it’s really useful … I’m happy to do it manually. [P14, 32 years] 
Inadequate interactivity  
Furthermore, for participants who were not planning a pregnancy in the near future (more than 1 
year) and for whom pregnancy planning was not a priority, the diary was the only feature in the 
app that they could frequently interact with. Although they reported that they often dipped in and 
out of the app, the absence of other add-on features, such as a food or medication diary, limited 
their continued engagement.   
 I mean, aside from the [blood glucose] diary, I didn’t really have a reason to look through the 
information or to use the app very often unless I kind of was flipping through my phone and thought “oh 
maybe I’ll take a look and see what it says.” [P11, 24 years] 
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7.10.2.2 Personal factors 
Prior knowledge and usefulness 
Despite the recognition of the app’s usefulness as an informative resource, two participants who 
reported being very knowledgeable about PCC either from hearing about it from HCPs from an 
early age or personal research felt that the app contained generic information that was available 
elsewhere and therefore was not considered personally useful.  
 Personally for me it was just not very beneficial, I felt that a lot of the information I knew already 
and that’s probably because I have been trying to get pregnant for kind of the last four years, so I had a 
lot of time to get the information already, so I didn’t really feel I’ve found a lot of new information. [P12, 36 
years] 
This view was supported by another participant who had been living with diabetes for twelve 
years and was already very familiar with PCC information via diabetes team and online 
resources. Both participants were of the opinion that the PADI app was useful but felt that due 
to their good PCC knowledge, the app would be of more benefit to other women with DM who 
were not as knowledgeable, especially people with T2DM and those that are newly diagnosed. 
Despite having prior PCC knowledge, one participant thought women with DM should take the 
same dose of folic acid as those without DM. Although the app use helped to correct this 
misconception, the relevance of the app to less knowledgeable women was maintained. 
 I thought the information was useful, I did learn a few things from just reading through the 
different sections … like the folic acid intake, I didn’t know that we were supposed to take more than non-
diabetics … I have always known that in order to have a baby my blood glucose needs to be within a 
certain range. I’ve always known that having lots of highs and lows can impact the health of my baby. It 
wasn’t really anything new. But I think for someone that’s newly diagnosed, I think it would have been 
helpful. [P11, 24 years] 
 
All participants reported that they had previously received PCC advice from HCPs. However, 
they reported having inadequate folic acid knowledge, indicating that the information regarding 
5mg folic acid dosage for women with DM was clearly not provided by some HCPs. Thus, nearly 
all participants (n=5) reported that they got to know about this by using the PADI app. 
So about the folic acid, it would never have occurred to me that I needed anything different. It’s 
one of the main things that I found out about … So it was interesting to know that you need to take more 
than you generally hear about. It wasn’t something that I had been aware of at all. [P16, 39 years] 
Apart from being informative, participants also found the educational aspect of the app useful 
because as one participant reported, for somebody who is already thinking about pregnancy, it 
focuses the mind. [P14, 32 years] 
Additionally, participants found the links to external resources (i.e. Diabetes UK support forum) 
very useful as it enabled them to discover and talk to other people in similar situations. This 
form of social support was reported to allow participants to connect with other women with DM, 
share their experiences, ask questions and learn from the experiences of others regarding 
pregnancy planning and pregnancy. 
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Being able to log in to forums about pregnant diabetics …   and be able to hear about other 
people in the same situations … It’s some of the most useful things I’ve seen … I used it via the app and 
read some of the things that came up. [P16, 39 years] 
 
The educational aspect of the app was deemed to be comprehensive by all women and most 
were happy with the PADI app’s content and functionality. Furthermore, links (to websites and 
videos) were used within the informational content of the app to provide more information about 
a specific topic. They reinforced the information in the app, and should participants want more 
information, these links provided easy access to external websites (such as NICE and Diabetes 
UK). Participants reported using these links to seek additional information, as shown in the data 
below. 
The information was very good and the fact that it’s got links to things was also very good. Rather 
than having to search it for yourself, you could press the link and go straight there and that was really 
good. [P16, 39 years] 
 
Not planning a pregnancy 
Women who were not planning a pregnancy in the short-term such as in the next one year, did 
not use the app regularly because they did not perceive accessing the information via the PADI 
app as a priority during the study intervention, as shown in the quote below.  
 I’m also not planning pregnancy at the moment, so the information wasn’t really on my mind all 
the time. [P11, 24 years]. 
In addition to not planning a pregnancy, participants had to deal with a lot of things on a daily 
basis, including life in general and the complexity of managing a long-term condition, which 
caused them to forget to use the app. 
 I wasn’t actually trying to get pregnant but because of all the other things in life I forgot. [P14, 32 
years] 
 
The role of memory and time  
Participants reported that the app could easily fit into their day-to-day routine as it did not take 
up much time. Despite this, they reported that they still did not use the diary to record BG levels 
immediately after taking their readings because they forgot, or did not have time, as shown in 
this quote below. 
 It would be quite easy to fit in if I made sure that I did it. I was struggling a bit to find- find the 
time’s not quite the right word but I think if I set my mind to it … it would only be another minute when I 
wasn’t taking my readings … sometimes I forgot and I’d think “oh I don’t have the time now, I’ll do it later 
on.”  [P16, 39 years] 
 
Participants reported that taking the readings using their meters and recording it in the diary 
often did not occur at the same time, causing them to skip some days or transfer the readings 
from their meters at a later more convenient time. Time constraint and memory therefore 
affected the frequency of use. 
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 I definitely missed a lot of days. [P15, 20 years] 
 
 It was two or three times a week I would say. I’d sit down every couple of days, maybe 
occasionally slightly longer and put in the ones from my meter, I’d put them in. [P16, 39 years] 
 
Competing priorities 
Other aspects in participants’ lives could influence their engagement with the app. The main 
commitments such as work and diabetes management interfered with participants’ use of the 
PADI app and caused them to deviate from using it regularly.  
 I think I would have used it a lot more if my alarm hadn’t have been going off and I hadn’t been 
rushing out the door and then just work and then suddenly it was the next day. [P14, 32 years] 
 
 It’s very hard as a diabetic when you have to wake up in the morning and you have to remember 
to do your blood and to do your insulin and that’s on top of all the other stuff going on inside of your head. 
So it’s another layer that you have to remember. [P14, 32 years] 
 
7.11 Future development of the intervention 
An aspect that emerged from the interviews with women within the study was the need for 
further refinement of the intervention in terms of the PCC information, diary and general app 
features. 
 
7.11.1 PCC information 
Participants noted the usefulness of the information contained in the app and made a number of 
suggestions for future improvements. They stated that not every woman who downloads the 
app would have received PCC advice, and therefore would want to find out as much as possible 
about PCC and diabetes and pregnancy in order to feel more confident before embarking on a 
pregnancy.  
 I mean, it’s okay as it is but … I think more would be even better. Someone downloading this app 
wants as much information as they can, are nervous about their diabetes and their pregnancy and so I 
think more is good. [P13, 33 years] 
On this basis, they provided some suggestions that will further strengthen the app, such as 
more information on medications to avoid while planning and during pregnancy. They noted that 
while the app contained the common ones such as antihypertensive, antimalarial and drugs that 
control cholesterol, it might be helpful to include information on other medicines such as 
antidepressants as people may be unsure as to their safety for use in pregnancy. One 
participant noted that she was able to find more information about medications to avoid by using 
links and resources provided within the app but noted that more information about this within the 
app would be of immense benefit to women.  
I didn’t realise that an antidepressant was going to be an issue and it isn’t necessarily going to be 
because obviously it’s better if you are not on medication but if you are seriously depressed while you are 
pregnant then that’s more dangerous than if you are taking the antidepressants … It was nice to find out 
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that perhaps I ought to look into that and discuss it with the doctor at the very least rather than just 
stopping it or not knowing about it. [P16, 39 years] 
Participants, especially those planning a pregnancy, further reported that there was a general 
lack of clear direction and information about pregnancy (from healthcare and online resources) 
especially what women with DM should do when they first find out that they are pregnant. They 
thus wanted the app to help fill this gap by incorporating a section on steps to take after a 
pregnancy is confirmed, including who to contact and what the process entailed in order to help 
simplify the process that might otherwise be confusing for new expectant mothers.  
 When you find out your pregnant, what do you do? I think find out your pregnant first steps, 
contact your GP or something which sounds so stupid but actually as a diabetic they told me to contact 
the antenatal clinic which I did but there’s lots of different people you need to talk to and I didn’t know. So 
I think that would be useful. Or ‘think you might be pregnant, contact your GP,’ or, ‘contact your diabetic 
team’ or what to expect, that kind of thing. [P14, 32 years] 
 
7.11.2 Blood glucose diary 
Most participants (n=5) strongly recommended that the BG diary be enhanced and refined in 
order to reduce user burden and increase efficiency. One of those recommendations pertained 
to automation of the diary, as shown in the quote below;  
 It was easy enough. It would be brilliant if you could link it into a sugar monitor or from a 
Bluetooth sort of monitor or something so that it could automatically go in. That would make it much 
easier, because that would save so much time. [P16, 39 years] 
Participants however recognised the challenge in automatic transfer of BG readings between 
the diary and the various data collection software and diabetes management technology on the 
market e.g. BGMs and CGMs.    
 I think that it could be a lot better integration from the other data collection but I know that that’s a 
big challenge in terms of the software and also the model … I know [it] is a very tall order. [P15, 20 years] 
 
Asides from integration, participants reported that they would have used it more regularly if it 
had the capacity to log other information pertaining to their daily lives (such as insulin, diet, 
carbs, mood, exercise or sleep). Rather than using separate apps for these activities, they 
suggested if this could be done collectively via the PADI app it would make it easier to pick up 
trends and make adjustments. They also felt that increased flexibility within the diary with 
regards to download or email facilities might increase engagement and the ability to make notes 
within the app would be particularly useful.  
 I think potentially having more ability to log different circumstances within your glucose diary, 
being able to log information and make notes [about] your GP appointments. [P11, 24 years] 
Furthermore, all women in the study reported that adding a free text option within the diary 
would help to increase the diary’s appeal and be of immense benefit even to those already 
using sophisticated technology to manage their diabetes. They noted that this would aid in their 
reflection, analysis and management of BG levels.  
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 I mean, one feature that I could see would be of benefit to other people in my situation would be 
kind of a free text option that you can write this is why it [blood glucose level] might have been high so 
that a certain blood sugar could have made more sense. I think that’s one of the things that I would have 
found beneficial. [P12, 36 years] 
7.11.3 General app features 
Participants suggested further improvement that could be made to the app. They recognised the 
importance of personalising the app or tailoring it to better meet the needs of women at different 
stages of the pregnancy planning journey. For example, some women may be planning a 
pregnancy over the next six months, whereas for others this may be several years in the future. 
Participants felt that, personalising it from the start would help make the information more 
relevant to the individual.   
Perhaps if you put in how far in the future you want to be pregnant and it brought up more 
relevant things, that could be a very useful thing, so like if I want to get pregnant in six months then 
maybe you need to think about folic acid, that kind of feature maybe a good one, or “now’s the time to go 
and get your HbAC1” But perhaps a reminder to book in to get that done or something like that. [P16, 39 
years] 
The need for personalisation and increased feedback was supported by another participant who 
suggested adding more resources on lifestyle modification especially diet and exercise. It was 
felt that that tailored advice with examples of foods to eat and exercises to do would enable 
people to better modify their behaviours.  
 I think everyone knows that you should be active and you should do exercise and you should eat 
healthy but it might be nice to have some concrete tips on how to do so rather than just saying ‘cut down 
on this’ or ‘exercise 30 minutes a day’. Saying ‘go for a walk after dinner, for dinner have this and this’ 
would be more useful. [P11, 24 years]  
 
Furthermore, participants reported that women would benefit from the use of motivational 
messages (push notifications) that also acted as reminders for pre-pregnancy activities such as 
folic acid supplementation and HbA1c check. They noted that these motivational messages 
were especially important because of the challenges women with DM go through with regards to 
managing DM and, as such would serve both as a source of encouragement and reminder to 
help keep them on track.  
 Little notifications of more motivation. But I think that it’s hard, especially during pregnancy. It’s 
the hardest thing I’ve ever done. I mean, to add to it, I think someone once said to me, “People with 
diabetes, well type 1 diabetes aren’t looking for more, they are looking for less, for much less.” … we 
want less, so that would be like motivation, just doing reminders so that you don’t have to remind yourself, 
things like that. [P13, 33 years] 
Participants felt that apart from the periodic motivational messages, they would also benefit from 
the use of daily reminders to enter their BG reading and that such reminders were best sent in 
the morning or evening (when participants entered their readings into the diary). They reported 
that this would enable them record their readings more regularly and use the app more often.  
 So my recommendation would be that it should have in the morning a reminder or a notification or 
some kind of alert to make you think about it, so to enter your blood glucose levels. I think that would be 
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really helpful … and I think that would be something that I personally would have benefitted quite a bit 
from. [P14, 32 years] 
Other suggestions include adding personal tips from women with DM who have had a baby, 
ovulation / fertility tracker and a period tracker.  
7.12 Summary of key findings 
This section has presented the findings from the user experience interviews with six participants 
(aged 20-39 years). All participants had T1DM, were educated and planning a future pregnancy. 
Participants’ views and experiences regarding the 3-month PADI app use were explored to 
ascertain acceptability and factors affecting use.  
Overall, participants found the PADI app to be a feasible and acceptable means of providing 
PCC information. The provision of information via an app made it easy to access PCC while the 
incorporation of a blood glucose diary reduced the hassle of recording it separately. Participants 
found the PADI app visually appealing and easy to use, and appreciated the positive language 
used within the PADI app. The app’s content was viewed as comprehensive, useful and 
informative while its capacity to serve as a source of support and information from 
preconception to pregnancy was recognised. Furthermore, there were accounts of positive 
experiences and behavioural effects including improved PCC awareness, pregnancy planning, 
willingness to seek PCC before pregnancy and actual engagement with HCPs regarding PCC.  
However, participants’ usage of the app was modest and episodic. Engagement with the app 
was affected by various functionality and personal factors. For example, usability 
(attractiveness, ease of use and satisfaction) and usefulness facilitated the app usage while 
limitations of the SMBG function, competing priorities and memory/time constraints had a 
detrimental effect on app usage. For majority of participants, the main factor affecting regular 
usage was the limitations of the SMBG function. Suggestions for improvement were made 
including personalisation, automation of the blood glucose diary, use of reminders, motivational 
messages and a reflective notepad.  
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7.2 Software log of activity 
This section explores the download, usage and interaction with the app during the intervention 
period (January-June 2017). The (n=17) women recruited into the study at baseline (pre-
intervention) joined at different time points during the intervention period. Although the app was 
not actively publicised, other users still found and downloaded it. The launch of the app into 
Google Play (android app store) and iTunes (Apple / iOS app store) following development may 
be the reason why the app usage log revealed >17 downloads within the intervention period. 
From January when the recruitment started until June 2017, a total of 38 iOS (n=14) and 
Android (n=24) users from 11 countries had downloaded and installed the app. Figure 7.6 and 
7.7 below show app installation data by country for the two mobile platforms (iOS and Android).  
 
 
Figure 7.6 iOS installations 
 
Figure 7.6 shows that the (n=14) iOS users who downloaded the app were based in America 
(n=6) and UK (n=8), and both countries had similar rates of download. The usage log also 
showed that android users (n=24) across 11 countries downloaded and installed the app within 
the same intervention period, as shown in Figure 7.7 below.  
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Key: GB-United Kingdom, US-America, CA-Canada, KR-South Korea, DE-Germany, IR-Iran,  
IN-India, NL-Netherlands, CH-Switzerland, RS-Serbia, AE-United Arab Emirates 
Figure 7.7 Android installations 
 
Figure 7.7 also showed the following number of downloads: UK (n=6), Iran (n=4), India (n=4) 
and America (n=3). All other (n=7) countries, had one download each.  
 
7.2.1 App usage data 
Usage data for the android platform was not available due to a limitation with data provided by 
this platform. Thus, usage data was only provided for the iOS platform. According to the 
available app logs, while the (n=8) users in the US engaged in one session on average, the 
(n=6) iOS users in the UK engaged in five sessions on average. Every time a user opened the 
app, it was counted as a new session. It is possible that the study participants used the app 
more often than other users, but because data could not be collected for the individual (n=17) 
participants, usage could not be verified. Moreover, frequency of usage varied substantially 
amongst users with a range from 1 to 8 sessions/day. The components of the app visited, i.e. 
informational pages or blood glucose diary, and the duration of sessions could not be 
determined. The usage data however showed that users in the UK used the app more 
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frequently than those in the US, as shown in Figure 7.8 below.  
 
Figure 7.8 iOS session data 
 
Furthermore, because usage data was not available for the android platform, usage sessions 
could not be compared across platforms. However, some participants may have been more 
active users of the app than others. Usage log further showed that the app was used 
intermittently, rather than daily. At the time of data compilation, a total of (n=7) devices in 
America were used actively, while (n=15) devices in the UK were used actively to access the 
app (Figure 7.9).  
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Thus, everyone who installed the app used it at least once. The data also showed that there 
were more active devices being used to access the app in the UK (n=15) compared to the 
number of users (n=6), indicating that perhaps women were using at least ≥2 mobile devices to 
access the app.  
 
7.2.2 Summary of key findings 
Participants’ use of the app can best be described as episodic with periods of action and 
inaction. Although data from the app usage log was limited, it corroborated participants’ report 
regarding engagement with the app. Some of the highlighted factors hindering engagement may 
have been responsible for the modest use of the app as shown in the usage log. Furthermore, 
participants in America and Canada reported that they were not able to fully utilise the blood 
glucose diary due to the burden of converting blood glucose units. This may have been 
responsible for the low usage sessions amongst users in the US. Nevertheless, participants 
found the app to be a feasible and acceptable means of providing PCC, with high usability, 
benefits and user satisfaction rating. Furthermore, the various suggestions for app improvement 
could improve users’ long-term engagement, usage and interaction with the app. This is 
especially important as the app is currently being used in 11 (developed and developing) 
countries. 
 
The discussion of the phase 1 and 2 study findings forms the focus of chapter 8.  
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8. Chapter 8: Discussion  
8.1 Overview 
This chapter commences with a discussion of the study findings in relation to the literature. A 
critical review of the study methodology, strengths and limitations are presented, followed by a 
critical evaluation of the research process. The study’s contribution to knowledge, methodology 
and theory are discussed. A number of recommendations and implications for practice are 
provided, and a conclusion of the main issues is then presented. Each of these topics are 
discussed in depth in the subsequent sections.  
 
8.2 Discussion of the findings in relation to the literature 
The results provide preliminary evidence that the PADI app could be successfully used to 
provide PCC information to women with DM. Phase 1 study findings highlighted current gaps in 
service provision and indicated that the PADI app was acceptable to both women with DM and 
HCPs and was seen as an opportunity to improve the provision of PCC. Phase 2 findings 
showed that the PADI app was considered a useful and comprehensive source of PCC 
information by the participants who used it for three months and may help improve knowledge 
and attitudes to PCC and PAM, however, usage was modest and affected by functionality and 
personal factors.  
 
A discussion of the key issues identified from the results is presented using the following sub-
headings: ‘Improving access to PCC,’ ‘Using eHealth to improve PCC behaviours,’ and 
‘Acceptability of the PADI app’. 
Improving access to PCC   
The findings from this study and the literature suggest that current approaches to providing 
preconception care (PCC) do not meet the needs of women with DM (Holmes et al., 2017; 
Murphy et al., 2010b; Spence et al., 2010; Nwolise et al., 2016). Service provision was reported 
to be fragmented and inconsistent, with variability in services across different healthcare 
settings. Consequently, many women with DM lacked knowledge and awareness of the risks 
associated with pregnancy and/or the need for careful planning (CEMACH, 2007; Spence et al., 
2010; Earle et al., 2017). Furthermore, according to the New Statesman (2018), the UK health 
system is under immense pressure with demand growing at four percent and funding at only 
one percent. Inadequate funding for PCC services in primary and secondary care trusts may 
affect their capacity to provide PCC, and although guidelines (CEMACH, 2007; NICE, 2015; 
NHS Digital, 2016) recommend annual PCC information be given to all women of childbearing 
age, this may not be achieved without adequate funding and staff capacity. PCC significantly 
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improves the pregnancy outcomes of women and the inadequacy in service provision gives 
cause for concern because organogenesis takes place within the first 6-8 weeks of pregnancy, 
while teratogenic changes tend to occur before many women realise that they are pregnant 
(Murphy et al., 2010b; Neff et al., 2014; Egan et al., 2016; van Voorst et al., 2015). Hence, a 
more innovative and sustainable PCC solution is needed.  
 
Phase 1 participants (HCPs and women) believed that PCC provided via eHealth technology, 
specifically via a smartphone app, could provide a more flexible and convenient way to access 
PCC and improve pregnancy planning. eHealth is increasingly being used to transform health 
service delivery and improve access to care (May et al., 2005; Townsend et al., 2015). It is 
currently used around the world to prevent and monitor diseases, provide health education and 
encourage self-management; it has ensured that patients can access healthcare from a variety 
of locations, not just at the hospital or clinic (WHO, 2011). Although some eHealth technologies 
(DVDs and CD-ROMs) have been used to provide PCC to women with DM, they are now 
considered outdated and offer limited scope to women without computers and DVD players 
(Nwolise et al., 2016; Tripp et al., 2014). Hence, there have been calls for more consideration to 
be given to contemporary means of providing PCC, such as smartphone apps (Nwolise et al., 
2016; Earle et al., 2017; O’Higgins et al., 2014; Hughes et al., 2016). The PADI app, 
successfully developed during phase 1, was subsequently used in phase 2 to provide consistent 
and comprehensive PCC available to participants 24/7 and accessible from any geographical 
location, thereby overcoming issues of access in service provision.  
Evidence from this study suggests that the PADI app can be used to support PCC service 
provision. This is of significance given that traditional PCC services, which rely on face-to-face 
consultations and/or information leaflets, are hindered by the inherent problems within the 
current UK health system (Temple et al., 2006; Murphy et al., 2010b; Egan et al., 2016). An 
increased demand for services combined with staff shortages and delayed or cancelled clinics 
result in reduced access and/or opportunities to receive care (Health Education England, 2017). 
This has negative implications for the PCC of women with DM because HCPs may not be 
available during women’s times of need, as highlighted in this study. The successful use of the 
PADI app, in phase 2, to provide uninterrupted access to PCC across three countries 
demonstrates its capacity to meet the PCC needs of women with DM. Hence, the PADI app 
could help overcome the existent barriers of traditional PCC practice identified in this study, 
including demand-side (childcare issues, inadequate PCC awareness, lack of pregnancy 
planning and time constraints) and supply-side barriers (HCP attitudes, busy clinics, inadequate 
knowledge and fragmented advice), consistent with the literature (Earle et al., 2017; Yehuda et 
al., 2016; Spence et al., 2010; O’Higgins et al., 2014). The findings of this study also indicate 
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agreement with the literature (Calvillo et al., 2013; Jurascio et al., 2015) regarding app use to 
extend the reach of health interventions and overcome problems associated with traditional 
face-to-face care.  
This study has shown that mobile apps are being increasingly used by patients, HCPs and 
healthcare organisations to access up-to-date information, connect with HCPs and patient 
groups, and improve health outcomes in line with the literature (WHO, 2012b; Townsend et al., 
2015; Silva et al., 2015). eHealth, specifically the smartphone app, is instrumental in making 
care more accessible, particularly where resources are scarce, and in encouraging individuals 
to be more actively involved in their healthcare (May et al., 2005; DH, 2012; Townsend et al., 
2015). Hence, national and international initiatives (DH, 2012; NHS, 2014; NHS Scotland, 2014; 
WHO, 2012a, 2012b) support their use for giving patients more control over their health and 
care, and providing cost-effective patient-centred care. Evidently, healthcare systems need to 
more fully embrace technological innovations, such as the PADI app, in order to improve PCC 
accessibility and health outcomes, and lower healthcare costs.  
The PADI app, reported by study participants to have increased their awareness of, and 
signposted them to, PCC information, can be used to reduce the disparities in PCC access. 
Several studies (CEMACH, 2007; Murphy et al., 2010b; Steel et al., 2015) have recognised that 
PCC services, mainly located in NHS hospitals, are more accessible to T1DM women receiving 
care from a multidisciplinary team within specialist diabetes clinics. This disparity has been 
attributed to inefficiency in the primary—secondary care referral pathway (NHS Digital, 2016) 
and general practitioners’ inadequate understanding of the importance of PCC for women with 
DM (Earle et al., 2017). Hence for women with T2DM, fragmented DM and PCC services make 
it difficult to access PCC; many therefore lack awareness of PCC services or how to access 
them and as a result conceive without adequate pregnancy preparations, as highlighted in this 
study and relevant literature (Murphy et al., 2010b; Egan et al., 2015; CEMACH, 2007). As the 
current care configuration is unlikely to change given the financial crisis facing the NHS, 
variations and gaps in care could be reduced by maximising eHealth (NHS, 2014) in order to 
increase the availability of information via smartphone apps.  
Improved, flexible and convenient PCC access such as that provided via the PADI app is vital to 
reducing high-risk pregnancies and resultant healthcare costs. Globally, healthcare systems are 
struggling with an increased demand associated with the growing burden of chronic diseases 
including DM (IDF, 2017; New Statesman, 2018). It is evident that the increasing numbers of 
women with DM of childbearing age who get pregnant, especially young and T2DM women, 
outstrip current PCC coverage (CEMACH, 2007; Murphy et al., 2010b; Egan et al., 2016). 
Women of childbearing age increasingly rely on smartphone apps because of their advanced 
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functionalities (including internet access combined with photos, videos and geo-positioning 
capacity), mobility, ease-of-use and portability (Eng and Lee, 2013; Silva et al., 2015; 
Derbyshire and Dancey, 2013; Hebden et al., 2012; Tripp et al., 2014). Apps also have 
significant advantage over desktop computers, laptops and DVD players. For example, the need 
to have access to a computer affects intervention uptake and usage, whereas, a smartphone 
app provides a nearly continuous access between the intervention and patients (Renton et al., 
2014; Stiles-Shields et al., 2017). Ninety percent of the time spent on mobile phones is spent on 
apps, which are preferred over web or computer-based applications (Kollmann et al., 2007; 
Quinn et al., 2011), making the PADI app a valuable tool for giving more women access to PCC.  
Facilitating access to PCC via an app is not without its challenges. These include inequality of 
access between those with smartphones and those without. However, evidence shows that in 
developed countries, smartphone use is ingrained in daily life; for example, ninety-one percent 
of adults in the UK aged eighteen to forty-four own a smartphone (Deloitte Report, 2016). 
Ownership in developing countries is also increasing rapidly and projected to reach the rates of 
developed countries by 2021 (Pew Research Center, 2016). This provides evidence for a 
reverse digital divide, whereby people from low-income populations and resource-poor settings 
are amongst the fastest growing users of mobile phone technology (Bull, 2011; Donner, 2008). 
Furthermore, a decline in price has contributed to the unprecedented increase in the number of 
mobile phone users in both developed and developing countries (Lambert and Littlefield, 2009; 
WHO, 2011b). This penetration of mobile phones could facilitate access to PCC for women who 
are unreachable via traditional face-to-face channels, e.g. those from lower socio-economic 
groups, and developing countries. This access has positive implications for addressing some of 
the disparities and inadequacies in PCC both in the UK and the wider international community 
(NHS Digital, 2016; WHO, 2013).  
Using eHealth to improve PCC behaviours 
In line with the study by Holmes et al. (2012), phase 2 findings indicated that women who 
received PCC via eHealth were more likely to plan their pregnancy and seek PCC. This finding 
is supported by Spence et al. (2010) and Earle et al. (2017), who suggest that knowledge and 
attitudes influence women’s PCC behaviours. Evidence is increasing that contemporary eHealth 
innovations, aimed at improving PCC knowledge, can successfully change PCC behaviours and 
improve pregnancy outcomes for women in general. For example Van Dijk  et al. (2016), using 
the Smarter Pregnancy mHealth platform in a sample of 1,275 couples contemplating 
pregnancy in the Netherlands, observed improvement in nutrition and lifestyle after 6 months. 
Gardiner et al. (2013) found that seventy-three percent of behaviours that were contemplative, 
progressed to an action or maintenance stage after women used the Gabby PCC system for 
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two months. Other PCC interventions include Healthy Pregnancy 4 All, in the Netherlands, 
which uses the ZwangerWijzer internet questionnaire to assess risks and modify behaviours 
(Denktaş et al., 2014). Although the effectiveness of the PADI app in changing behaviours 
requires further study, preliminary results indicate that the app addressed the key determinants 
of behaviour change, i.e. knowledge, attitudes and self-efficacy, which, according to Michie et 
al. (2005; 2008), is necessary for a meaningful behaviour change to occur.  
 
Educational interventions, such as the PADI app, are premised on the philosophy of equipping 
people with the knowledge, skills and confidence to improve their health, and empowering 
individuals to develop a sense of responsibility over their own health to enable them to practise 
healthy behaviours. For an individual to engage in healthy behaviours, they need to acquire 
knowledge because knowledge improves attitude, and attitude (positive or negative) determines 
the likelihood of behaviour change (Kalua and Nyasulu, 2007; Strecher and Rosenstock, 1997). 
The PADI app’s capacity to change behaviour was underpinned by the Expanded Health Belief 
Model (EHBM), and it can be inferred that the PCC knowledge acquired through the PADI app 
positively influenced attitudes (i.e. improved benefits, self-efficacy, and reduced barriers), which 
then increased the likelihood of behaviour change. This is supported by Van Dijk et al. (2016, 
2017), who argue that PCC education provided via mobile technology can improve both health 
literacy and behaviours. The findings relating to the PADI app are indicative, yet they are 
consistent with other eHealth PCC studies, which have demonstrated the effectiveness of 
eHealth technologies in promoting behaviour change (Holmes et al., 2012; Charron-Prochownik 
et al., 2008, 2013; Fischl et al., 2010).  
 
Health education, which is a recognised prerequisite to improved knowledge and behaviour 
(Kalua and Nyasulu, 2007; Prestwich et al., 2018), was a core component of the PADI app 
intervention. Phase 2 results indicated an increase in the overall knowledge related to 
pregnancy planning, particularly the intake of 5mg of folic acid, lifestyle modification, 
contraception use, HbA1c target and rationale for blood glucose optimisation. Participants’ 
knowledge of risks, particularly miscarriage and macrosomia, also improved. Other educational 
mHealth interventions have reported success in improving reproductive health knowledge and 
changing women’s risk behaviours. For example, Smarter Pregnancy improved folic acid intake 
and lifestyle (healthy diet, physical activity, smoking and alcohol cessation) in pre-pregnant 
women (Van Dijk et al., 2016); Text4two significantly reduced gestational weight gain in 
overweight or obese pregnant women by improving self-monitoring and lifestyle (Willcox et al., 
2017). In addition, the Waiting Room app improved contraception and family planning 
knowledge (Gilliam et al., 2014), while the systematic review by Chen and Mangone (2016) 
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highlighted the role of apps in preventing unplanned pregnancy in young women. The PADI app 
intervention also contributed to an increase in PAM, which researchers (Hibbard and Gilburt, 
2014; Rask et al., 2009) have highlighted has a direct relationship with adoption of healthy 
preventive behaviours, e.g. blood glucose optimisation, as well as adherence to rigorous 
regimens. Hence, the PADI app has shown promise as a behaviour change instrument.  
Phase 2 participants, who used the app, reported involving or being willing to involve their HCPs 
in pregnancy planning and preconception health checks. This finding supports the argument by 
Janz et al. (1995) and Fischl et al. (2001) that the ability to make reproductive health decisions 
and initiate discussions with HCPs constitute key modifying factors that affect women’s intention 
to seek PCC and plan pregnancies. They are considered motivational cues, which contribute to 
behaviour change, according to the EHBM (Stretcher and Rosenstock, 1997). This argument is 
supported by Kalua and Nyasulu (2007), who note that although knowledge influences attitudes, 
it does not guarantee a desirable behaviour; other modifying factors that enable an individual to 
engage in healthy behaviours have to be present. The improved interaction between young 
women with DM and their HCPs in relation to PCC observed in the READY-girls eHealth 
intervention (Fischl et al., 2010), supports the finding in this study. Hence, the PADI app could 
facilitate PCC discussion with healthcare professionals, which has positive implications for PCC 
uptake.  
 
Phase 2 participants also reported feeling supported by the PADI app intervention, and 
experiencing reduced anxiety, along with improved motivation and confidence to plan their 
pregnancies. These findings support the qualitative study by McCorry et al. (2012) in that 
women need to know why pregnancy planning is important and must feel confident that they 
can effectively plan their pregnancies in order to avoid unnecessary anxiety. Apps are becoming 
widely accepted as effective tools for empowering patients, changing behaviours and increasing 
quality of life (DigitalHealth.London, 2017). The systematic review by Zhao et al. (2016) 
highlighted their role in encouraging healthy behavioural changes in several areas including 
diabetes, weight and medication management as well as their contribution to general lifestyle 
improvement. A literature review on the use of technology to empower patients found that health 
literacy, remote access to healthcare and self-management mechanisms were the most valued 
means of achieving patient empowerment and behaviour change (Solomon et al., 2012; Calvillo 
et al., 2013). Bridging knowledge gaps is a vital step towards improving maternal and child 
health outcomes (Knight-Agarwal et al., 2015); knowledgeable, competent and confident 
women are more likely to take responsibility for their health and that of their babies-to-be. 
Hence, the PADI app has the potential to improve pregnancy planning and outcomes in women 
with DM.  
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Acceptability of the PADI app 
Phase 1 findings suggested that the PADI app intervention would be acceptable and feasible to 
deliver to women planning a pregnancy. Phase 2 participants similarly felt that there was 
significant value in using mobile technology to deliver PCC, as they were comfortable accessing 
PCC via the PADI app, noting that the intervention was both relevant and beneficial to women 
with DM. Acceptability reflects participants’ views of the intervention’s suitability, 
appropriateness for addressing the problem and convenience for use in daily life (Sidani and 
Braden, 2011). In order to ensure that the PADI app was acceptable to the target audience 
(HCPs and women with DM), a co-design approach was adopted. This involvement of service 
users and HCPs in intervention design and development enhances the intervention’s 
acceptability by highlighting the components most acceptable (to the target population) for 
addressing the identified problem (Sidani and Braden, 2011). A similar approach was used by 
Tonkin-Crine et al. (2011), who used GPs as co-designers of an online intervention to promote 
prudent antibiotics prescribing across Europe; the involvement of GPs in the formative stage led 
to the development of an intervention that was acceptable and successful across five countries. 
Hence, co-design ensures that participants’ expectations are closely matched to the intervention 
and promotes the likelihood of success (Steen et al., 2011).  
 
Participants’ input facilitated the successful development of a mobile health intervention that 
was consistent with, and responsive to, participants’ preferences and needs. Phase 1 
participants identified vital design and content features that were used to inform the 
development of the app, such as efficiency, usefulness, simplicity, relevant content (pregnancy 
planning, contraception, lifestyle modification and SMBG function) and an attractive user 
interface. They noted that these features would promote its use in practice. The importance of 
participants’ input and acceptability of a technological intervention is demonstrated in 
Greenhalgh et al. (2017), who contrasted the level of uptake between two similar eHealth 
technologies designed to help relatives, friends and HCPs organise tasks and visits for people 
with health and care needs. In contrast to the web portal developed based on an employee’s 
past caring experience, which did not consider the training and ongoing support needs of end 
users and was used by less than five families, a smartphone app (with linked web portal) 
developed and piloted with families, took into consideration the various needs of end users 
during the development stage and as a result was accepted, downloaded and used by over one 
thousand families. Catwell and Sheikh (2009) concluded that eHealth interventions, which are 
not acceptable and ‘fit for purpose’, are unlikely to be adopted by HCPs or users and at risk of 
implementation failure. The acceptability of the PADI app intervention to service users and 
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HCPs (who will deliver the intervention in practice) is therefore important to its uptake and 
adoption by users and healthcare organisations.  
 
The study findings suggest that in line with the literature (McLean, 2011; Sidani and Braden, 
2011), phase 2 participants accepted the app because they found it simple, informative and 
useful. The acceptability of the PADI app contributed to the high satisfaction rating and 
achievement of preliminary intervention effects, such as improved knowledge and attitudes, and 
self-management ability or PAM. This reflects the argument that while those who view an 
intervention as unacceptable tend to withdraw from it, participants who accept the intervention 
rate it favourably, use it and experience its beneficial effects (Hibbard et al., 2009; Kowinsky et 
al., 2009; Sidani, 2008), which include reduced health service use, costs to the healthcare 
system and burden to individuals and society (Eckert and Hintze, 2000; Naber and Kasper, 
2000). Acceptance of the PADI app by service users is important because it demonstrates that 
the users considered the app to be useful and worth an investment of their time. As Groshek et 
al. (2015) pointed out, a HCP’s recommendation of an app is no guarantee that the end user will 
find it of value. In addition, an intervention that is perceived as providing limited benefits, difficult 
to understand or fit into normal daily practice would not appeal to HCPs (Murray et al., 2010; 
Mair et al., 2012). This highlights the importance of HCP and patient input, support and 
acceptability of the PADI app from the outset.  
The early testing of the app (phase 2) provided the opportunity to identify aspects of the PADI 
app that need improvement in order to enhance the intervention’s acceptability, usage and 
effectiveness in the future. Guidelines for developing eHealth interventions for behaviour 
change (Mummah et al., 2016; Whittaker et al., 2012; Yardley et al., 2015) recommend testing 
technological innovations early, in order to analyse usage behaviour, understand user 
experiences and highlight any design faults or limitations. This is particularly important in terms 
of avoiding low-quality and potentially harmful interventions being made available to the public 
(Mummah et al., 2016; Catwell and Sheikh, 2009). In line with the literature (Krebs and Duncan, 
2015; Milward et al., 2017; Scott et al., 2017), phase 2 of this study suggested that despite 
acceptability and a high user satisfaction rating, the engagement with the app was episodic and 
affected by personal factors (e.g. pregnancy intention, memory, time and competing priorities) 
and functionality (e.g. manual data input). Although Dennison et al. (2013) found that users 
prefer to engage with health apps periodically, an increased engagement through the repeated 
use of digital health technology, e.g. apps and websites, is associated with improved health 
outcomes (Hoj et al., 2017; Funk et al., 2010; Strecher et al., 2008). Thus, as highlighted by the 
phase 2 participants and relevant literature (Short et al., 2015; Chomutare et al., 2011), 
automation, an improved self-monitoring capacity, notifications and the personalisation of health 
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apps may be vital for sustaining engagement and realising the optimal effects of the PADI app. 
For this to be realised, further development is required.  
Evidence in this study and the literature (Murray et al., 2011; Mair et al., 2007; Milward et al., 
2017; Wu et al., 2017; Zapata et al., 2015) indicates that possible factors affecting the 
implementation of eHealth technology within the NHS include at the individual level, the cost of 
the eHealth technology, user acceptance and support of HCPs, and at the organisational level, 
cost, organisational support and financial viability. For women with DM, cost was also a 
potential barrier to the PADI app uptake. Cost is a recognised barrier to healthcare in developed 
and developing countries, whether provided face-to-face or remotely via mobile apps (Jacobs et 
al., 2011; Fu et al., 2013; Aaltonen et al., 2015; Stiles-Shields et al., 2017). Hence, although 
ownership of a smartphone was necessary, no cost was associated with the app and it was free 
to download from Google Play and iTunes stores. This ensured that women in all eleven 
countries, where the app had been downloaded and used, received the same level of PCC 
support at no extra cost. Other mHealth studies have also identified the cost of the data 
package, in addition to internet accessibility, as a barrier to app usage (Stiles-Shields et al., 
2017); hence after the initial PADI app download, the information pages did not require an 
active internet connection and could be accessed in areas without third and fourth generation 
(i.e. 3G and 4G) mobile broadband internet. 
Although this feasibility study did not explore, in detail, the implementation of the PADI app, 
these preliminary findings form the platform for future work, and proponents (Whittaker et al., 
2012; Murray et al., 2010) recommend planning for implementation early. The normalisation 
process theory (NPT) was used as a framework to guide the app development and study, in 
order to improve the potential for successful implementation in future. According to Bull (2011), 
implementation is important because when health promotion interventions reach the target 
population, even modest effects can translate into a reduction in mortality and morbidity. For 
example, the preconception counselling DVD implemented across healthcare services in 
Northern Ireland demonstrated improved maternal and child health outcomes (Holmes et al., 
2017). Hence, as the ultimate goal of the PADI app is to improve pregnancy outcomes for 
women with DM, it is imperative that the PADI app is implemented and normalised into 
healthcare practice, in order for it to maximise its clinical and public health impact (Pagoto and 
Bennett, 2013; DigitalHealth. London, 2017).  
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8.3 Discussion of methodology 
Overall, this feasibility study was successful in that each research question was answered (i.e. 
research question, RQ, 1 was answered in Chapter 2; RQ 2 and 3 were answered in Chapter 6 
while RQ 3 to 7 were answered in Chapter 7). The mixed methods research (MMR) approach 
enabled the use of different data collection methods (i.e. focus group, interviews and 
questionnaires) in answering the research questions (Chapter 1, section 1.5). The MMR 
facilitated the collection of data on the views and experiences of women and HCPs regarding 
PCC, app content, feasibility of the PADI app and women’s experiences of using the app. Data 
regarding the preliminary effects, i.e. knowledge and attitudes towards PCC and PAM, as well 
as app satisfaction rating were also collected. The insights gained from the user experience 
interviews highlighted likely reasons for the variability observed in the app usage and allowed 
insight into how participants used the app.  
 
The MMR approach used is especially of benefit in mHealth studies, where it is recognised that 
one method alone is likely to be insufficient to answer the research questions (Whittaker et al., 
2012; Mummah et al., 2016). The researcher’s pragmatic approach allowed the incorporation of 
different research paradigms and approaches to data collection and analysis while researching 
a multi-faceted and complex technological intervention. Thus, by not taking a post-positivist or 
constructivist view, more informative, complete and useful research findings were achieved 
(Johnson et al., 2007; Tashokkori and Teddlie, 2010; Creswell and Plano-Clarke 2011). 
Challenges were nevertheless experienced in recruiting women with DM of reproductive age 
from healthcare settings. The recruitment of patients into the study was initially facilitated by 
HCPs in three local NHS hospitals. Other studies (Holmes et al. 2012; Earle et al. 2017) also 
experienced similar difficulties in recruiting women with DM from healthcare settings. However, 
this method of recruitment proved unsuccessful and there were delays in identifying participants 
who met the inclusion criteria and were willing to participate. Furthermore, the researcher aimed 
to recruit women with T2DM from one GP surgery, which was later unable to support the study 
due to time constraints. The protocol was subsequently revised, and an amendment was 
submitted for ethical approval, in order to allow the researcher to recruit participants for phase 1 
and 2 via social media. Although the amendment was approved by the ethics committee and 
recruitment via this means was successful, these recruitment challenges caused a five-month 
delay. 
 
 
 
  
196 
 
8.3.1 Study strengths 
This is the first study to design and explore the acceptability and feasibility of a Preconception 
and Diabetes Information (PADI) app for women with DM. The content of the PADI app was 
informed by phase 1 study findings, and incorporated service users and HCPs views. The 
quality of this process is a strength of the study. The acceptability of the PADI app by women 
with DM and HCPs, in terms of content and mode of delivery, as a feasible means of providing 
PCC has positive implications for future PCC delivery.  
 
The PADI app was developed using a systematic approach in line with the recommendations by 
the MRC (Craig et al., 2008), and mHealth development and evaluation frameworks (Whittaker 
et al., 2012; Mummah et al., 2016). The exploratory study (phase 1) provided insight into service 
users’ and HCPs’ expectations regarding the app, which was developed using an iterative 
approach. In phase 2, the feasibility study evaluated the data collection tools, overall user 
satisfaction (rating > 70%) and preliminary intervention effects, while the interviews explored 
experience, usability and satisfaction. App usage behaviour, which is important for the 
development of more effective apps (Yardley et al., 2016), was also examined.  
Apps that go through iterative development cycles involving patients and HCPs are more likely 
to be effective (Cai et al., 2013; Mummah et al., 2016). The PADI app development went 
through two cycles of pre-testing with patients, HCPs, researchers and members of the public 
before being released for further evaluation. Feedback was obtained from participants 
throughout the PADI app development to ensure that the final app met users’ needs, was easy 
to use and provided evidence-based guidance. Patients further tested it for three months to 
establish the app’s feasibility and provided additional feedback regarding their experience and 
suggestions for future app improvement.  
This study used a behavioural theory, the expanded health belief model, as a theoretical 
framework to underpin the PADI app intervention content in line with recommendations for 
mHealth studies (Yardley et al., 2015; Baker et al., 2014; Riley et al., 2011; Mummah et al., 
2016). Furthermore, NPT was used to guide the feasibility study design and promote the app’s 
potential for implementation. Many commercially-developed apps do not use behavioural 
theories or conduct efficacy tests, while researcher-developed apps do not incorporate the 
expertise of commercial app developers who are more adept at developing attractive apps 
(Pagoto and Bennett, 2013). This study used both methods via a co-design approach, which 
resulted in an app that is both potentially effective and attractive.  
The completion rate for the PADI app intervention was good at 65%, all (n=17) participants 
completed the pre-intervention questionnaire, while (n=11, 65%) participants completed the 
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post-intervention questionnaire. The number of missing responses was low with only one 
question in the pre-intervention questionnaire having (n=3) missing responses, indicating that 
the questionnaire was acceptable for measuring demographic, knowledge, reproductive health 
and self-management status.  
Despite challenges with recruitment, nineteen participants (10 women with DM and 9 HCPs) 
were recruited in phase 1. Seventeen participants were also successfully recruited into the 
feasibility study, which exceeded the recruitment target (n=12). The log of activity also showed 
that a total of 38 iOS (n=14) and Android (n=24) users from eleven countries downloaded and 
installed the app during this time, highlighting international interest. The majority of phase 2 
participants reported that they had a good experience and enjoyed participating in the study as 
it was easy, beneficial, enlightening and timely.  
 
8.3.2 Study limitations 
While this study contributes to our understanding of the use of mobile phone apps in the PCC of 
women with DM, there are a number of limitations. The preliminary findings suggest that the 
PADI app can improve knowledge and attitudes to PCC and PAM, but as a feasibility study the 
aim was not to detect statistical changes. Hence, the findings are indicative and should be 
interpreted with caution.  
 
Due to challenges associated with the recruitment of women with DM from healthcare settings, 
the participants for phase 1 were recruited solely via social media platforms, which may bias the 
sample to digitally-literate individuals, who would be open and perhaps more likely to use 
smartphone apps as opposed to the general population of women with DM. Phase 2 
participants were mostly recruited via social media and it is possible that the more motivated 
and highly-educated women responded to the invitation to participate in this study. This may 
help explain the high rate of participants (88%), who previously reported receiving PCC pre-
intervention.  
 
This study was self-funded by the researcher and non-financial incentives (e.g. giving 
participants an opportunity to contribute to the app development and sharing the study findings 
with them) were used to promote participation. The use of financial incentives may have aided 
recruitment, uptake and retention. The financial constraint also limited the type and amount of 
data that was collected via the software log of activity and as a result, the frequency of app 
usage for each participant in the study could not be determined.  
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8.3.3 Critical evaluation of the research process 
As a researcher, it is important to reflect on and critically evaluate the research process. Overall, 
the study was successful in that the study objectives were met, the intervention was acceptable 
to participants and the majority of participants found the intervention feasible to implement 
within healthcare. Recruitment was also successful, however, the challenges and delays, 
particularly during phase 1, meant that the recruitment was not a straightforward or smooth 
process. Hence, a multi-modal recruitment approach should be employed in future studies. That 
is, in addition to placing adverts on social media sites and approaching patients during clinic 
visits, potentially eligible patients in general practices and NHS hospitals should receive a letter 
of invitation from their HCPs.  
 
Although some concerns have been expressed about the use of MMR and mixing qualitative 
and quantitative research perspectives within a single study (Greene, 2008; Mertens, 2012), the 
researcher has demonstrated that the chosen methodology and methods worked well together 
and were the appropriate choice to address the research topic and answer the research 
questions. Furthermore, the use of MMR improved the researcher’s time and project 
management skills because conducting and analysing both forms of data was time and labour-
intensive. The large volumes of qualitative and quantitative data had to be carefully transcribed, 
coded, organised, analysed and interpreted. 
This study gives a clear and detailed account of each stage of the research process starting 
with the intervention design, development of the data collection tools, ethical approval, data 
collection and app development. At each stage, records of what helped or hindered the process 
were kept. For example, difficulties and delays were experienced by the researcher in obtaining 
R&D approvals from the study sites. This highlighted the importance of establishing and 
maintaining a close relationship with the site gatekeepers, such as R&D managers and the 
clinical team.  
Adherence to the intervention was low and the use of the mobile app was moderate, which 
support findings from a previous qualitative research study exploring users’ engagement with 
health apps (Dennison et al., 2013). A solution may be the improvement of the intervention. 
Suggestions, such as personalisation to make it more relevant to women at various pregnancy 
planning stages, incorporation of other add-on features to increase interactivity and refinement 
of the diary may promote engagement in future studies.  
During this study, the researcher achieved a steep learning curve. Undertaking research within 
a clinical setting, in an unfamiliar geographical area and country (having just moved to Surrey 
for my PhD) were challenging aspects of the research process. However, this study allowed the 
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researcher to appreciate the complexities of the research process and the experience is one 
that I have immensely benefitted from. This vital experiential learning will be applied to future 
research projects.  
The project has allowed me to work with HCPs and researchers, and to experience the 
academic and practical side of developing and testing the feasibility of an mHealth intervention. 
Working with women with DM has been an interesting and rewarding aspect of the study. I have 
always been interested in health education and improvement, and during the course of the 
research, I realised the difference the PADI app intervention could make to the lives of women 
with DM who are planning a pregnancy. All of these have increased my passion for research in 
this area.  
 
8.4 Contribution to knowledge, methodology and theory 
This section outlines the contribution this study has made to the body of knowledge, 
methodology and theory, each of which is discussed below. 
 
a. Contribution to knowledge 
This is the first study to design and use a smartphone app for the PCC of women with DM and 
adds to the small body of evidence on the use of eHealth for PCC. Various researchers have 
called for the development of alternative means of providing PCC, other than face-to-face care 
(Hughes et al., 2016; Earle et al. 2017) but few studies have explored the use of technology for 
the PCC of women with DM (Charron-Prochownik et al., 2008, 2013; Fischl et al., 2010; Holmes 
et al., 2012, 2017). Moreover, none have taken advantage of the ubiquity and acceptance of 
smartphones among women of reproductive age to develop an app-based intervention tailored 
specifically to women with DM. The PADI app, an alternative means for providing PCC, which 
combines PCC information with SMBG functions, was therefore successfully developed and its 
feasibility and acceptability explored.  
 
This is the first study to include the views and opinions of key stakeholders (i.e. women with DM 
and HCPs) regarding the desired PCC app content and features. In this study, the input from 
HCPs and women with DM was specifically used to inform the content of the PADI app 
intervention so that it addressed current shortfalls in PCC service provision. Participants used 
the app for 3 months and their feedback provided insight into its functionality and the personal 
factors that hinder app usage and need consideration in future app development.  
This study has enhanced understanding regarding the role of mobile apps for PCC in women 
with DM and provided insight into their use for promoting PCC awareness, patient activation and 
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behaviour change. These study findings suggest that knowledge and attitudes to PCC, and 
PAM can be improved via eHealth technology. This is consistent with the few studies that have 
used technology to effectively increase knowledge and change behaviours towards PCC 
(Charron-Prochownik et al., 2008, 2013; Fischl et al., 2010; Holmes et al., 2012).  
This study highlights the importance of the co-design approach in the iterative development of 
mHealth interventions. The study found that it was important for a PCC mobile app to be 
efficient, affordable, comprehensive, user-friendly, useful and attractive in order to be 
acceptable to service users and HCPs. This adds to the growing literature in this area. 
Furthermore, as highlighted in the literature (Yardley et al., 2016), the credibility of the PADI app 
intervention was enhanced by the professional visual appearance of the app, provision of 
additional supportive evidence via links and videos, up-to-date content and opportunities to 
provide additional feedback either via the app or email to the researcher.  
This study recruited women from a number of countries, thus highlighting international interest, 
as issues related to PCC access are not specific to the UK. The diffusion and pervasive nature 
of mobile phone technology means that interventions, such as the PADI app, can be delivered 
to women with DM irrespective of geographical locations or demographic factors. mHealth apps 
have been deemed one of the most effective tools for changing behaviours and improving 
outcomes and can be scaled up at a relatively low cost compared to face-to-face methods 
(Zhao et al., 2016). The use of mobile phone technology to improve patients’ health and care is 
supported by national and international health initiatives (WHO, 2012, 2013; NHS, 2014; UN, 
2015).  
The study findings have been disseminated in various ways including presentations at national 
and international conferences. A selection of these conference presentations is presented 
below: 
Faculty of Health and Medical Sciences (FHMS) Festival of Research & Doctoral 
College Conference, University of Surrey (April/June, 2015). Poster and oral pitch presentation: 
Planning a holiday or planning a pregnancy: exploring alternative strategies for providing 
preconception care for women with diabetes. 
 
FHMS Festival of Research, University of Surrey (June, 2016). Poster: Preconception 
care educational interventions for women with diabetes: a narrative review.  
 
3rd European Congress on Preconception Health and Care, Uppsala, Sweden (February, 
2016). Poster: Feasibility study of a smartphone application for the preconception care of 
women with diabetes. 
 
Festival of Research & Doctoral College Conference, University of Surrey (June/July, 
2017). Poster: Perceptions of the feasibility of a preconception and diabetes information (PADI) 
app for women with type 1 or 2 diabetes mellitus.  
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Three articles have been published in peer reviewed journals and these have supported the 
wider dissemination of the study and its findings within the field of eHealth and healthcare 
practice. A copy of each of the articles below can be found in Appendix 15: 
Robinson A., Nwolise C. and Shawe J. (2016) Contraception for women with diabetes: 
Challenges and solutions. Open Access J Contracept, 7: 11-18. Doi: 10.2147/OAJC.S56348 
 
Nwolise C. H., Carey N. and Shawe J. (2016) Preconception care education for women with 
diabetes: A systematic review of conventional and digital health interventions. J Med Internet 
Res, 18(11): e291. Doi: 10.2196/jmir.5615 
Nwolise C. H., Carey N. and Shawe J. (2017) Exploring the acceptability and feasibility of a 
preconception and diabetes information app for women with pregestational diabetes: A mixed-
methods study protocol. Digital Health, 3: 1-11. Doi: 10.1177/2055207617726418 
 
b. Contribution to research methodology 
A lack of studies using a mixed methods approach in this field was highlighted in Chapter 2, 
especially in terms of reporting both the effect of eHealth PCC interventions and in-depth patient 
experience.  
 
This study offers a significant contribution to methodology in this area as it is the first to use a 
combination of qualitative methods to inform the intervention development, a feasibility study to 
explore the effect of the PADI app intervention, and qualitative methods to explore the 
experience of the app use. Additional information regarding app use is also provided via the 
software log of activity.  
The use of mixed methods added rigour and credibility to the study, and enabled the 
examination of processes and outcomes (Plano-Clarke, 2010; Craig et al., 2008). This facilitated 
an extensive understanding of the PADI app intervention as well as how it can best be 
optimised to yield maximum benefit.  
 
c. Contribution to theory 
The need for studies to adopt a less clinically-oriented and a more theoretical approach in this 
area of research was highlighted in Chapter 2. Furthermore, theory-based strategies have been 
known to produce changes in health behaviour interventions, yet very few studies in the 
literature have incorporated these into mHealth interventions. Thus, the Expanded Health Belief 
Model (EHBM), a behaviour change theory, was used to predict and understand the behaviour 
change mechanism of the PADI app intervention. This theory proposes that behaviour is 
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influenced by an individual’s attitudes, i.e. favourable or unfavourable evaluative reaction 
towards PCC, exhibited in their beliefs or intended behaviours (Myers, 1999). 
 
The PADI app intervention, incorporating health education, social support, self-monitoring of 
blood glucose levels and instructions, contributed to knowledge improvement. Knowledge may 
have influenced attitudes (including self-efficacy/confidence), which in combination could have 
altered intention and increased the likelihood of planning a pregnancy and seeking PCC, 
according to the EHBM. These findings support other PCC studies that have used technology, 
underpinned by the EHBM, to change behaviours (Charron-Prochownik et al., 2008, 2013; 
Fischl et al., 2010; Holmes et al., 2012). However, this study makes a valuable contribution to 
theory in that it is the first study to use the EHBM to understand the mechanism of action of a 
PCC mobile app for women with DM.  
For patients to adhere to adopted behaviours, they need to be activated (Hibbard and Gilburt, 
2014), i.e. have the knowledge, skills and confidence to manage their preconception health 
behaviours. It has been recognised that patients with higher levels of activation are more likely 
to be engaged in their health, motivated to adopt healthy behaviours and take actions that result 
in their health promotion (Hibbard and Gilburt, 2014; Mosen et al., 2007; Rask et al., 2009). A 
similar pattern of behaviour was evident in the results of this feasibility study. Although this 
study used a small sample, the findings support other PAM research in people with DM which 
indicates that educational interventions can increase the PAM (Shah et al., 2015; Solomon et 
al., 2012). The relevance of patient activation to PCC is one that has not been studied in 
previous PCC research. Hence, this study has made a useful contribution to theory by showing 
that mHealth PCC has the capacity to increase the PAM, which can help to facilitate the uptake 
of PCC services with the ultimate goal of improving pregnancy outcomes.  
Additionally, the use of normalisation process theory (NPT) in mHealth PCC intervention 
development is one that has not been previously undertaken. This study has therefore made a 
contribution to theory in this area by showing that the use of NPT to guide intervention 
development helped to promote the app’s acceptability and potential for implementation. It also 
shaped the feasibility study and contributed to the development of a useful and simple 
intervention that is relevant to service users and HCPs.  
 
8.5 Recommendations  
The findings from this study provide insight into the role of the PADI app for PCC, its 
acceptance, use and feasibility. The results have confirmed and extended knowledge and 
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understanding in this area. Given the study findings, strengths and limitations, a number of 
recommendations have been made. These are presented below: 
 
 
8.5.1 Recommendations for future research  
 
1. The current study focused on the development, feasibility and acceptability of the PADI app. 
In line with the MRC, and mHealth development and evaluation framework (Craig et al., 
2008; Whittaker et al., 2012; Mummah et al., 2016), further piloting using an RCT over a 
longer period of time is needed, followed by an evaluation study to determine clinical 
effectiveness. 
 
2. Pregnancy planning with an emphasis on optimising glycaemic control before pregnancy 
reduces the risk of adverse outcomes (Wahabi et al., 2010; Murphy et al., 2010). Hence, in 
future studies, it would be useful to evaluate the effect of the PADI app intervention on the 
clinical measures used to monitor diabetes control, e.g. HbA1c, pregnancy planning 
indicators, e.g. folic acid intake, pregnancy outcomes, in addition to PCC knowledge and 
attitudes. This would provide evidence of the clinical effect on patient outcomes.  
 
3. The PADI app needs to be further developed to include personalised information in order to 
improve and sustain engagement, positive behaviour change and outcomes. It would also 
be useful to explore women’s experiences of using a more personalised PADI app.  
 
4. The app analytics functionality also needs to be optimised to enable it to provide 
comprehensive app usage data particularly in terms of frequency and duration of app usage, 
features used as well as the number and type of informational pages visited by each 
participant.  
 
5. The findings in this study and in the relevant literature (Mulvaney et al., 2011, Milward et al., 
2017, Tatara et al., 2013) support the use of automation to reduce user burden, improve 
clinical outcomes, e.g. HbA1c, and promote compliance and long-term app usage. Hence, 
the blood glucose (BG) diary should be automated and BG measurements for different 
countries should be included in order to improve efficiency.  
 
6. T2DM is more prevalent in people from minority ethnic groups, hence, areas with a large 
representation of ethnic communities should also be targeted to ensure that the sample is 
more ethnically diverse and balanced in terms of the type of DM. This will ensure that the 
next version of the PADI app is refined to best meet the needs of women with T1 and T2DM. 
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8.5.2 Recommendations for practice 
 
1. In order to overcome the inadequacies associated with the traditional model of PCC (i.e. 
face-to-face and use of leaflets), it is recommended that healthcare organisations that care 
for women with DM, e.g. NHS hospitals and general practices, consider adopting and 
integrating technology-based PCC, such as the PADI app (subject to resources, further 
development and evaluation), into routine healthcare. In addition, national policy-makers 
should encourage and support this implementation, which is in line with the current 
government policy on improving patients’ access to information and reducing complications 
via smartphones and apps (NHS, 2014).  
 
2. Technology-based PCC, such as the PADI app, has the potential to enhance the patient-
provider relationship. However, HCPs’ attitudes towards PCC and pregnancy encourage or 
discourage women from seeking PCC. In order to prevent dissatisfaction and the 
perceived lack of support towards PCC and pregnancy planning, there is a need for more 
awareness and training of the HCPs who care for women with DM in relation to PCC, 
diabetes and pregnancy. In addition, the importance of a supportive approach that focuses 
on success and the normalisation of pregnancy in women with DM should be emphasised. 
This could be achieved by reviewing current diabetes education and training, to ensure it is 
fit for purpose and focuses on positivity.  
 
3. PCC policies, funding and guidelines for women with DM need to be reviewed to take into 
consideration the increase in the prevalence of DM among women of childbearing age, 
and pregnancies in younger women and those with T2DM. The PCC referral pathways 
between primary and secondary care need to be strengthened. This could be achieved by 
providing additional PCC training to GPs and practice nurses so that they understand the 
need for PCC especially in the case of women with DM. Furthermore, PCC and 
contraception responsibility need to be more clearly delineated and communicated to 
service providers, and PCC services for women with DM, audited to ensure equity in 
provision and receipt of PCC.  
 
8.6 Conclusions 
eHealth is increasingly being used to improve access to healthcare around the world. The 
findings presented in this thesis demonstrate that a smartphone application is an acceptable 
way of providing PCC to women with DM and can help overcome current shortfalls in PCC 
service provision. 
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Studies using smartphone app to provide PCC to women with DM are scarce; hence, this study 
has developed and tested the feasibility and acceptability of a preconception and diabetes 
information (PADI) app, for women with DM. As such it provides a unique contribution to 
knowledge, which can influence future PCC service delivery and lead to healthy outcomes of 
pregnancy for women with DM. 
 
Findings from the study showed a high level of interest, acceptance and support from 
healthcare professionals and women with DM regarding the use of the PADI app for PCC. This 
is important given that acceptance by women with DM and healthcare professionals, will be key 
to successful adoption and implementation of the PADI app in routine practice. 
 
Preliminary results also indicate that the PADI app may help improve knowledge, attitudes and 
behaviours towards PCC, which has positive implications for pregnancy planning and PCC 
uptake. However, in order to realise the full potential of the PADI app intervention, further 
development and evaluation is required.  
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first author and year first full 
report of study was published 
e.g. Smith 2001) 
 
Country in which the study 
conducted 
 
Economic level of the country in 
which the study conducted 
(e.g. low income, lower-middle 
income or upper-middle 
income) 
 
Notes:   
 
2. Eligibility 
 
Study Characteristics Review Inclusion Criteria 
 
Location in text   
(pg /fig/table) 
 
 
Type of study 
 
  
Participants 
 
  
Types of intervention 
 
  
Types of outcome measures 
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3. Population and setting 
 
 Description 
Include comparative information for each group (i.e. intervention and 
controls) if available 
Location in text 
(pg /fig/table) 
Population description 
(from which study 
participants are drawn) 
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4. Methods 
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10. Conclusion and other information 
 Description as stated in report/paper Location in text 
(pg & ¶/fig/table) 
Key conclusions of study 
authors 
  
References to other relevant 
studies 
  
Notes: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
236 
 
 
 
 
Appendix 2 
 
QUALITY ASSESSMENT TOOL 
FOR QUANTITATIVE STUDIES 
 
 
 
COMPONENT RATINGS 
 
1 SELECTION BIAS 
 
(Q1) Are the individuals selected to participate in the study likely to be representative of the 
target population? 1 Very likely 
2  Somewhat likely  
3  Not likely  
4  Can’t tell 
 
(Q2)   What percentage of selected individuals agreed to participate?  
1  80 - 100% agreement  
2  60 – 79% agreement  
3  less than 60% agreement  
4  Not applicable  
5  Can’t tell  
 
      
RATE THIS SECTION STRONG MODERATE  WEAK  
See dictionary 1 2 3  
      
 
 
 
1. STUDY DESIGN 
 
Indicate the study design  
1  Randomized controlled trial  
2  Controlled clinical trial  
3  Cohort analytic (two group pre + post)  
4  Case-control  
5  Cohort (one group pre + post (before and after))  
6  Interrupted time series  
7  Other specify ____________________________  
8  Can’t tell 
 
Was the study described as randomized? If NO, go to Component C.    
 No Yes     
If Yes, was the method of randomization described? (See dictionary)    
 No Yes     
If Yes, was the method appropriate? (See dictionary)     
 No Yes     
       
 RATE THIS SECTION STRONG MODERATE  WEAK  
       
 See dictionary 1 2 3  
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3. CONFOUNDERS 
 
(Q1) Were there important differences between groups prior to the 
intervention? 1 Yes 
2  No  
3  Can’t tell 
 
The following are examples of confounders:  
1 Race  
2  Sex  
3  Marital status/family  
4  Age  
5  SES (income or class)  
6  Education  
7  Health status  
8  Pre-intervention score on outcome measure 
 
(Q2) If yes, indicate the percentage of relevant confounders that were controlled (either in 
the design (e.g. stratification, matching) or analysis)? 
                                      1  80 – 100% (most)  
2  60 – 79% (some)  
3  Less than 60% (few or none)  
4  Can’t Tell  
 
RATE THIS SECTION STRONG MODERATE  WEAK  
      
See dictionary 1 2 3  
      
 
D) BLINDING 
 
(Q1) Was (were) the outcome assessor(s) aware of the intervention or exposure status of 
participants? 1 Yes 
2  No  
3  Can’t tell 
 
(Q2) Were the study participants aware of the research 
question? 1 Yes  
2  No  
3  Can’t tell   
RATE THIS SECTION STRONG MODERATE  WEAK  
      
See dictionary 1 2 3  
      
 
E) DATA COLLECTION METHODS 
 
(Q1)   Were data collection tools shown to be valid?  
1  Yes  
2  No  
3  Can’t tell 
 
(Q2)   Were data collection tools shown to be reliable?  
1  Yes  
2  No  
3  Can’t tell   
RATE THIS SECTION STRONG MODERATE  WEAK  
      
See dictionary 1 2 3  
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F) WITHDRAWALS AND DROP-OUTS 
 
(Q1) Were withdrawals and drop-outs reported in terms of numbers and/or reasons per group?  
                              1 Yes  
2  No  
3  Can’t tell  
4  Not Applicable (i.e. one time surveys or interviews) 
 
(Q2) Indicate the percentage of participants completing the study. (If the percentage differs by 
groups, record the lowest).  
 1 80 -100%    
 2 60 - 79%    
 3 less than 60%    
 4 Can’t tell    
 5 Not Applicable (i.e. Retrospective case-control)   
      
 RATE THIS SECTION STRONG MODERATE WEAK  
       
 See dictionary  1 2 3 Not Applicable 
     
G) INTERVENTION INTEGRITY    
 (Q1)   What percentage of participants received the allocated intervention or exposure of interest? 
 1 80 -100%    
 2 60 - 79%    
 3 less than 60%    
 4 Can’t tell    
 
(Q2) Was the consistency of the intervention measured?  
1 Yes  
2  No  
3  Can’t tell 
 
(Q3) Is it likely that subjects received an unintended intervention (contamination or co-
intervention) that may influence the results?  
                              1 Yes  
2 No  
3 Can’t tell 
 
H) ANALYSES 
 
(Q1)   Indicate the unit of allocation (circle one)  
 community organization/institution practice/office individual 
(Q2) Indicate the unit of analysis (circle one)   
 community organization/institution practice/office individual 
 
(Q3) Are the statistical methods appropriate for the study design?  
                        1 Yes  
2  No  
3  Can’t tell 
 
(Q4) Is the analysis performed by intervention allocation status (i.e. intention to treat) rather 
than the actual intervention received?  
1 Yes  
2  No  
3  Can’t tell 
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GLOBAL RATING 
 
COMPONENT RATINGS  
Please transcribe the information from the gray boxes on pages 1-4 onto this page. See dictionary on how to rate this section. 
 
 
A SELECTION BIAS STRONG  MODERATE  WEAK  
        
  1 2 3  
        
B STUDY DESIGN STRONG  MODERATE  WEAK  
        
  1 2 3  
        
C CONFOUNDERS STRONG  MODERATE  WEAK  
        
  1 2 3  
        
D BLINDING STRONG  MODERATE  WEAK  
        
  1 2 3  
        
E DATA COLLECTION 
STRONG 
 
MODERATE 
 
WEAK 
 
 
METHOD 
   
       
        
  1 2 3  
        
F WITHDRAWALS AND 
STRONG 
 
MODERATE 
 
WEAK 
 
 
DROPOUTS 
   
       
      
  1 2 3 Not Applicable 
        
 
GLOBAL RATING FOR THIS PAPER (circle one): 
 
1 STRONG (no WEAK ratings) 
2 MODERATE (one WEAK rating) 
3 WEAK (two or more WEAK ratings) 
 
With both reviewers discussing the ratings: 
 
Is there a discrepancy between the two reviewers with respect to the component (A-F) ratings? 
 
No Yes 
 
If yes, indicate the reason for the discrepancy 
 
1 Oversight  
2 Differences in interpretation of criteria  
3 Differences in interpretation of study 
 
Final decision of both reviewers (circle one): 1. STRONG  
2. MODERATE  
3. WEAK
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Quality Assessment Tool 
for Quantitative Studies 
Dictionary 
 
The purpose of this dictionary is to describe items in the tool thereby assisting raters to score study quality. Due to 
under-reporting or lack of clarity in the primary study, raters will need to make judgements about the extent that bias 
may be present. When making judgements about each component, raters should form their opinion based upon 
information contained in the study rather than making inferences about what the authors intended. 
 
A) SELECTION BIAS 
(Q1) Participants are more likely to be representative of the target population if they are randomly selected from a 
comprehensive list of individuals in the target population (score very likely). They may not be representative if they are referred 
from a source (e.g. clinic) in a systematic manner (score somewhat likely) or self-referred (score not likely). 
(Q2) Refers to the % of subjects in the control and intervention groups that agreed to participate in the study before they were 
assigned to intervention or control groups. 
 
B) STUDY DESIGN 
In this section, raters assess the likelihood of bias due to the allocation process in an experimental study. For observational 
studies, raters assess the extent that assessments of exposure and outcome are likely to be independent. Generally, the type of 
design is a good indicator of the extent of bias. In stronger designs, an equivalent control group is present and the allocation 
process is such that the investigators are unable to predict the sequence. 
 
Randomized Controlled Trial (RCT) 
An experimental design where investigators randomly allocate eligible people to an intervention or control group. A rater should 
describe a study as an RCT if the randomization sequence allows each study participant to have the same chance of receiving each 
intervention and the investigators could not predict which intervention was next. If the investigators do not describe the 
allocation process and only use the words ‘random’ or ‘randomly’, the study is described as a controlled clinical trial. 
See below for more details. 
Was the study described as randomized? 
Score YES, if the authors used words such as random allocation, randomly assigned, and random assignment. Score NO, if no 
mention of randomization is made. 
Was the method of randomization described? 
Score YES, if the authors describe any method used to generate a random allocation sequence. 
Score NO, if the authors do not describe the allocation method or describe methods of allocation such as alternation, case record 
numbers, dates of birth, day of the week, and any allocation procedure that is entirely transparent before assignment, such as 
an open list of random numbers of assignments. 
If NO is scored, then the study is a controlled clinical trial. 
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Was the method appropriate? 
Score YES, if the randomization sequence allowed each study participant to have the same chance of receiving each intervention 
and the investigators could not predict which intervention was next. Examples of appropriate approaches include assignment of 
subjects by a central office unaware of subject characteristics, or sequentially numbered, sealed, opaque envelopes. 
Score NO, if the randomization sequence is open to the individuals responsible for recruiting and allocating participants or 
providing the intervention, since those individuals can influence the allocation process, either knowingly or unknowingly. 
If NO is scored, then the study is a controlled clinical trial. 
 
Controlled Clinical Trial (CCT) 
An experimental study design where the method of allocating study subjects to intervention or control groups is open to 
individuals responsible for recruiting subjects or providing the intervention. The method of allocation is transparent before 
assignment, e.g. an open list of random numbers or allocation by date of birth, etc. 
 
Cohort analytic (two group pre and post) 
An observational study design where groups are assembled according to whether or not exposure to the intervention has 
occurred. Exposure to the intervention is not under the control of the investigators. Study groups might be non- equivalent or 
not comparable on some feature that affects outcome. 
 
Case control study 
A retrospective study design where the investigators gather ‘cases’ of people who already have the outcome of interest and 
‘controls’ who do not. Both groups are then questioned or their records examined about whether they received the intervention 
exposure of interest. 
 
Cohort (one group pre + post (before and after) 
The same group is pretested, given an intervention, and tested immediately after the intervention. The intervention group, by 
means of the pretest, act as their own control group. 
 
Interrupted time series 
A time series consists of multiple observations over time. Observations can be on the same units (e.g. individuals over time)  or on 
different but similar units (e.g. student achievement scores for particular grade and school). Interrupted time series analysis 
requires knowing the specific point in the series when an intervention occurred. 
 
C) CONFOUNDERS 
By definition, a confounder is a variable that is associated with the intervention or exposure and causally related to the outcome of 
interest. Even in a robust study design, groups may not be balanced with respect to important variables prior to the intervention. 
The authors should indicate if confounders were controlled in the design (by stratification or matching) or in the analysis. If the 
allocation to intervention and control groups is randomized, the authors must report that the groups were balanced at baseline 
with respect to confounders (either in the text or a table). 
 
D) BLINDING 
(Q1) Assessors should be described as blinded to which participants were in the control and intervention groups. The purpose of 
blinding the outcome assessors (who might also be the care providers) is to protect against detection bias. 
 
(Q2) Study participants should not be aware of (i.e. blinded to) the research question. The purpose of blinding the participants is 
to protect against reporting bias. 
  
242 
 
E) DATA COLLECTION METHODS 
Tools for primary outcome measures must be described as reliable and valid. If ‘face’ validity or ‘content’ validity has been 
demonstrated, this is acceptable. Some sources from which data may be collected are described below:  
Self reported data includes data that is collected from participants in the study (e.g. completing a questionnaire, survey, 
answering questions during an interview, etc.). 
Assessment/Screening includes objective data that is retrieved by the researchers. (e.g. observations by 
investigators). 
Medical Records/Vital Statistics refers to the types of formal records used for the extraction of the data. 
Reliability and validity can be reported in the study or in a separate study. For example, some standard 
assessment tools have known reliability and validity. 
 
F) WITHDRAWALS AND DROP-OUTS 
Score YES if the authors describe BOTH the numbers and reasons for withdrawals and drop-outs. Score NO if 
either the numbers or reasons for withdrawals and drop-outs are not reported. 
The percentage of participants completing the study refers to the % of subjects remaining in the study at the final data collection 
period in all groups (i.e. control and intervention groups). 
 
G) INTERVENTION INTEGRITY 
The number of participants receiving the intended intervention should be noted (consider both frequency and intensity). For 
example, the authors may have reported that at least 80 percent of the participants received the complete intervention. 
The authors should describe a method of measuring if the intervention was provided to all participants the same way. As well, the 
authors should indicate if subjects received an unintended intervention that may have influenced the outcomes. For example, co-
intervention occurs when the study group receives an additional intervention (other than that intended). In this case, it is possible 
that the effect of the intervention may be over-estimated. 
Contamination refers to situations where the control group accidentally receives the study intervention. This could result in an 
under-estimation of the impact of the intervention. 
 
H) ANALYSIS APPROPRIATE TO QUESTION 
Was the quantitative analysis appropriate to the research question being asked? 
 
An intention-to-treat analysis is one in which all the participants in a trial are analyzed according to the intervention to which they 
were allocated, whether they received it or not. Intention-to-treat analyses are favoured in assessments of effectiveness as they 
mirror the noncompliance and treatment changes that are likely to occur when the intervention is used in practice, and because of 
the risk of attrition bias when participants are excluded from the analysis. 
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Component Ratings of Study: 
For each of the six components A – F, use the following descriptions as a roadmap. 
A) SELECTION BIAS 
Strong: The selected individuals are very likely to be representative of the target population (Q1 is 1) and there is greater than 80% 
participation (Q2 is 1). 
Moderate: The selected individuals are at least somewhat likely to be representative of the target population (Q1 is 1 or 2); and there 
is 60 - 79% participation (Q2 is 2). ‘Moderate’ may also be assigned if Q1 is 1 or 2 and Q2 is 5 (can’t tell). 
Weak: The selected individuals are not likely to be representative of the target population (Q1 is 3); or there is less than 60% 
participation (Q2 is 3) or selection is not described (Q1 is 4); and the level of participation is not described (Q2 is 5). 
 
B) DESIGN 
Strong: will be assigned to those articles that described RCTs and CCTs. 
Moderate: will be assigned to those that described a cohort analytic study, a case control study, a cohort design, or an interrupted 
time series. 
Weak: will be assigned to those that used any other method or did not state the method used. 
 
C) CONFOUNDERS 
Strong: will be assigned to those articles that controlled for at least 80% of relevant confounders (Q1 is 2); or (Q2 is 1). Moderate: will 
be given to those studies that controlled for 60 – 79% of relevant confounders (Q1 is 1) and (Q2 is 2). Weak: will be assigned when 
less than 60% of relevant confounders were controlled (Q1 is 1) and (Q2 is 3) or 
control of confounders was not described (Q1 is 3) and (Q2 is 4). 
 
D) BLINDING 
Strong: The outcome assessor is not aware of the intervention status of participants (Q1 is 2); and the study participants are not 
aware of the research question (Q2 is 2). 
Moderate: The outcome assessor is not aware of the intervention status of participants (Q1 is 2); or the study participants are not 
aware of the research question (Q2 is 2); or blinding is not described (Q1 is 3 and Q2 is 3). 
Weak: The outcome assessor is aware of the intervention status of participants (Q1 is 1); and the study participants are aware of 
the research question (Q2 is 1). 
 
E) DATA COLLECTION METHODS 
Strong: The data collection tools have been shown to be valid (Q1 is 1); and the data collection tools have been shown to be 
reliable (Q2 is 1). 
Moderate: The data collection tools have been shown to be valid (Q1 is 1); and the data collection tools have not been shown to be 
reliable (Q2 is 2) or reliability is not described (Q2 is 3). 
Weak: The data collection tools have not been shown to be valid (Q1 is 2) or both reliability and validity are not 
described (Q1 is 3 and Q2 is 3). 
 
F) WITHDRAWALS AND DROP-OUTS - a rating of: 
Strong: will be assigned when the follow-up rate is 80% or greater (Q2 is 1). 
Moderate: will be assigned when the follow-up rate is 60 – 79% (Q2 is 2) OR Q2 is 5 (N/A). 
Weak: will be assigned when a follow-up rate is less than 60% (Q2 is 3) or if the withdrawals and drop-outs were not described (Q2 is 
4). 
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Appendix 3  
 
 
 
 
 
 
 
26 August 2015 
 
Miss Chidiebere Nwolise 
Postgraduate research student 
University of Surrey 
5th Floor, Duke of Kent Building 
School of Health Sciences, University of Surrey 
GU2 7TE 
 
 
Dear Miss Nwolise 
NRES Committee East Midlands - Derby 
The Old Chapel 
Royal Standard Place 
Nottingham 
NG1 6FS 
Telephone:  01158839390 
 
Study title: Feasibility Study Of A Smartphone Application (App) for 
the Preconception Care Of Women With Type 1 or Type  
2 Diabetes: A Mixed Methods Study 
REC reference: 15/EM/0358 
Protocol number: N/A 
IRAS project ID: 178530 
 
Thank you for your letter of 25th August 2015, responding to the Proportionate Review 
Sub-Committee’s request for changes to the documentation for the above study. 
 
The revised documentation has been reviewed and approved by the sub-committee. 
 
We plan to publish your research summary wording for the above study on the HRA website, 
together with your contact details. Publication will be no earlier than three months from the   
date of this favourable opinion letter. The expectation is that this information will be published 
for all studies that receive an ethical opinion but should you wish to provide a substitute   
contact point, wish to make a request to defer, or require further information, please contact   
the REC Assistant, Tad Jones, NRESCommittee.EastMidlands-Derby@nhs.net. Under very 
limited circumstances (e.g. for student research which has received an unfavourable opinion),   
it may be possible to grant an exemption to the publication of the study. 
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above 
research on the basis described in the application form, protocol and supporting documentation 
as revised. 
 
Conditions of the favourable opinion 
 
The favourable opinion is subject to the following conditions being met prior to the start of the
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study. 
 
Management permission or approval must be obtained from each host organisation prior to the 
start of the study at the site concerned. 
 
Management permission (“R&D approval”) should be sought from all NHS organisations 
involved in the study in accordance with NHS research governance arrangements. 
 
Guidance on applying for NHS permission for research is available in the Integrated Research 
Application System or at http://www.rdforum.nhs.uk. 
 
Where a NHS organisation’s role in the study is limited to identifying and referring potential 
participants to research sites (“participant identification centre”), guidance should be sought 
from the R&D office on the information it requires to give permission for this activity. 
 
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation. 
 
Sponsors are not required to notify the Committee of approvals from host organisations. 
 
Registration of Clinical Trials 
 
All clinical trials (defined as the first four categories on the IRAS filter page) must be registered   
on a publically accessible database. This should be before the first participant is recruited but no 
later than 6 weeks after recruitment of the first participant. 
 
There is no requirement to separately notify the REC but you should do so at the earliest 
opportunity e.g. when submitting an amendment. We will audit the registration details as part of 
the annual progress reporting process. 
 
To ensure transparency in research, we strongly recommend that all research is registered but 
for non-clinical trials this is not currently mandatory. 
 
If a sponsor wishes to request a deferral for study registration within the required timeframe, 
they should contact hra.studyregistration@nhs.net. The expectation is that all clinical trials will 
be registered, however, in exceptional circumstances non registration may be permissible with 
prior agreement from NRES. Guidance on where to register is provided on the HRA website. 
 
It is the responsibility of the sponsor to ensure that all the conditions are complied with 
before the start of the study or its initiation at a particular site (as applicable). 
 
Ethical review of research sites 
 
The favourable opinion applies to all NHS sites taking part in the study, subject to management 
permission being obtained from the NHS/HSC R&D office prior to the start of the study (see 
“Conditions of the favourable opinion” above). 
 
Approved documents 
 
The documents reviewed and approved by the Committee are:
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Document Version Date 
Evidence of Sponsor insurance or indemnity (non NHS Sponsors 
only) [Public Liability Certificate 2014-2015] 
 28 July 2015 
Evidence of Sponsor insurance or indemnity (non NHS Sponsors 
only) [Public Liability Certificate 2015-2016] 
 24 August 2015 
GP/consultant information sheets or letters [GP information letter] 1 24 August 2015 
Interview schedules or topic guides for participants [Intervention 
patient interview schedule] 
1 28 July 2015 
Interview schedules or topic guides for participants [Patient focus 
group schedule] 
1 28 July 2015 
Interview schedules or topic guides for participants [Stakeholder 
focus group schedule] 
1 28 July 2015 
IRAS Checklist XML [Checklist_28072015]  28 July 2015 
IRAS Checklist XML [Checklist_24082015]  24 August 2015 
Letters of invitation to participant [Invitation letter for focus group 
participants] 
1 28 July 2015 
Letters of invitation to participant [Invitation letter for intervention 
patients] 
1 28 July 2015 
Non-validated questionnaire [PCC-MA Feasibility questionnaire] 1 28 July 2015 
Non-validated questionnaire [PCC-MA Feasibility questionnaire] 2 24 August 2015 
Other [2nd Supervisor Jill Shawe CV] 1 28 July 2015 
Other [Letter of response]  24 August 2015 
Participant consent form [Patient Focus Group Consent Form] 3 28 July 2015 
Participant consent form [Stakeholder consent form] 3 28 July 2015 
Participant consent form [Intervention patient consent form] 3 28 July 2015 
Participant consent form [Patient Focus Group Consent Form] 4 24 August 2015 
Participant consent form [Healthcare Professional consent form] 4 24 August 2015 
Participant consent form [Intervention patient consent form] 4 24 August 2015 
Participant information sheet (PIS) [Intervention patient information 
sheet] 
3 28 July 2015 
Participant information sheet (PIS) [Patient focus group information 
sheet] 
3 28 July 2015 
Participant information sheet (PIS) [Stakeholder focus group 
information sheet] 
3 28 July 2015 
Participant information sheet (PIS) [Intervention patient information 
sheet] 
4 24 August 2015 
Participant information sheet (PIS) [Patient focus group information 
sheet] 
4 24 August 2015 
Participant information sheet (PIS) [Healthcare Professional focus 
group information sheet] 
4 24 August 2015 
REC Application Form [REC_Form_28072015]  28 July 2015 
Research protocol or project proposal [PCC-MA Feasibility Study 
Project Protocol] 
1 28 July 2015 
Summary CV for Chief Investigator (CI) [Postgraduate Researcher 
Chidiebere Nwolise CV] 
1 28 July 2015 
Summary CV for student [Postgraduate Researcher Chidiebere 
Nwolise CV] 
1 28 July 2015 
Summary CV for supervisor (student research) [1st Supervisor 1 28 July 2015 
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15/EM/0358 Please quote this number on all correspondence 
 
 
Nicola Carey CV]   
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for Research 
Ethics Committees and complies fully with the Standard Operating Procedures for Research 
Ethics Committees in the UK. 
 
After ethical review 
 
Reporting requirements 
 
The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
 
 Notifying substantial amendments 
 Adding new sites and investigators 
 Notification of serious breaches of the protocol 
 Progress and safety reports 
 Notifying the end of the study 
 
The HRA website also provides guidance on these topics, which is updated in the light of 
changes in reporting requirements or procedures. 
 
Feedback 
 
You are invited to give your view of the service that you have received from the National 
Research Ethics Service and the application procedure. If you wish to make your views known 
please use the feedback form available on the HRA website: 
http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance 
 
We are pleased to welcome researchers and R & D staff at our NRES committee members’ 
training days – see details at http://www.hra.nhs.uk/hra-training/ 
 
 
 
With the Committee’s best wishes for the success of this project. 
Yours sincerely 
Mrs Janet Mallett 
Chair 
 
Email: NRESCommittee.EastMidlands-Derby@nhs.net 
 
Enclosures: “After ethical review – guidance for researchers” [SL-AR2] 
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Copy to: Dr Sophie Wehrens 
 
Sarah Martin, Royal Surrey County Hospital 
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Appendix 4  
  
 
 
 
Miss Chidiebere Nwolise 
School of Health Sciences 
Faculty of Health and Medical Sciences 
Research Integrity & Governance 
Office (RIGO) 
Senate House 
Guildford, Surrey GU2 7XH UK 
 
T: +44 (0)1483 68 9103 /2051 
F: +44 (0)1483 68 3791 
 
ethics @surrey.ac.uk 
www.surrey.ac.uk 
 
01 September 2015 
 
Confirmation of sponsorship by the University of Surrey 
 
Dear Miss Nwolise, 
 
Study title: Feasibility Study of a Smartphone Application (app) for the Preconception Care of 
Women with Type 1 or Type 2 Diabetes: A Mixed Methods Study. 
NHS REC reference: 15/EM/0358 
University of Surrey reference: SPON/2015/003/FHMS 
 
I am writing to confirm that the above study has satisfied the requirements of the University of 
Surrey Research Integrity and Governance Office. We are pleased to confirm that the University of 
Surrey, as a recognised Sponsor under the Department of Health’s Research Governance Framework 
for Health and Social Care, agrees to act as a Sponsor for your study on the basis of the 
documentation listed in the NHS REC Favourable Ethical Opinion letter of 26 August 2015. 
 
Your study does not require review by a University of Surrey Ethics Committee. Permission to start 
recruitment is given provided that you comply with the conditions listed in your NHS REC Favourable 
Ethical Opinion letter and any additional condition letter(s). These conditions include, but are not 
limited to: 
 
- Management permission or approval must be obtained from each host organisation prior to 
the start of the study at the site concerned. 
- All clinical trials must be registered on a publically accessible database before the first 
participant is recruited but no later than 6 weeks after recruitment of the first participant. 
 
Ongoing sponsorship by the University is further subject to satisfactory reporting of the following to 
the Research Integrity and Governance Office as well as the NHS REC where they request this: 
 
- Submitting substantial and notifying minor amendments 
- Adding new sites and investigators 
- Notification of serious breaches of the protocol 
- Serious Adverse Events and Suspected Unexpected Serious Adverse Reactions 
- Progress and safety reports 
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- Notifying the end or early termination of the study or extension of the study beyond the 
expected end date 
 
Please also ensure that you and your study staff are familiar and act in accordance with the 
University of Surrey’s Code on Good Research Practice and the Ethical Principles and Procedures for 
Teaching and Research. 
Yours sincerely, 
 
Dr Sophie Wehrens 
Research Integrity and Governance Officer Copy to. 
Dr Nicola Carey, Professor Jill Shawe 
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Appendix 7 
  
 
Research & Development Department 
 
R&D Ref: 2016CHN01SP 
 
Chidiebere Hope Nwolise 
Postgraduate Researcher 
University of Surrey 
Date: 17th June 2016 
 
 
 
St Peter’s Hospital 
Guildford Road 
Chertsey 
Surrey 
KT16 0PZ 
Tel: 0193-272-3534 
Fax: 0193-272-2841 
 
Dear Chidiebere, 
 
 
Letter of NHS Permission at ASPH 
 
Full Study Title: Feasibility Study Of A Smartphone Application (App) for 
the Preconception Care Of Women With Type 1 or Type 2 
Diabetes: A Mixed Methods Study. 
IRAS Project ID: 178530 
REC Ref: 15/em/0358 
 
Thank you very much for submitting your study for R&D review. I am very pleased to inform 
you that the Director of R&D has approved your study and the R&D office has no objection 
to your proceeding with this study. However, the R&D Office would highly appreciate to 
receive final report of your study and any dissemination(s) from this work. 
 
Please make sure you are using the latest version of all documents and are following the 
latest procedures. 
 
We wish you success with your research! 
 
If you wish to discuss further, please do not hesitate to contact me. 
Yours sincerely,  
 
Freda Gomes 
R&D Support Manager 
E-Mail: Freda.Gomes@asph.nhs.uk 
 
 
 
Cc: Prof Jill Shawe, Professor and Lead Maternal & Family Health, University of Surrey 
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Dr Isaac John, Deputy Director of R&D, ASPH 
Dr Martha Wrigley, R&D Manager, ASPH 
 
Appendix 5 
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Appendix 8 – Phase 1 
 
 
Healthcare Professional Information Sheet  
 
Feasibility study of a smartphone application (App) for the preconception care (PCC) of 
women with Type 1 or Type 2 diabetes. 
 
My name is Chidi Nwolise and I would like to invite you to take part in a research project that is 
being undertaken as part of a PhD study at the University of Surrey. Your participation in the 
project is entirely voluntary. Before you decide to participate it is important that you understand 
why the research is being done and what it will involve. Please take the time to read the 
following information carefully. Talk to others about the study if you wish. If there is anything that 
is not clear, or you would like to know about, please contact me using the contact details 
provided at the end of this sheet. Thank you for reading this information. 
 
What is the purpose of the study? 
Preconception care enables women to prepare themselves to become as healthy as possible 
before pregnancy and achieve the best outcomes for both themselves and their baby. It involves 
adopting actions that support a healthier lifestyle such as stopping smoking and decreasing 
alcohol intake, improving blood glucose levels, taking folic acid (supplements) and using 
contraception until stable glycaemic control (HbA1c) is attained. Despite this, preconception 
care services are only accessed by a small number of women. In line with recent changes in 
technology, smartphone applications (Apps) are increasingly being used to improve health in a 
number of areas. However, little is known about the use or acceptability of Apps in the 
preconception care of women with diabetes.   
 
Aim of the study 
This study seeks to develop, test and explore the usage of a smartphone application (App) to 
promote knowledge and awareness of preconception care in women with diabetes.  
   
Why have I been chosen? 
You have been chosen because you are a healthcare professional involved in the care of 
women with diabetes. In order to ensure the mobile App that is developed best meets the 
preconception care needs of women with diabetes, it is important that a wide range of expert 
views are sought. The information collected will be used to help inform the development of the 
App. 
 
Do I have to take part? 
No, you do not have to participate. If you decide to participate, you are free to withdraw at any 
time without giving a reason. If you withdraw from the study, data collected would be used in the 
study but no further data will be collected or any other research procedures carried out. There 
will be no impact on your employment status if you decide not to participate.  
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What will my involvement require? 
If you decide to participate, you will be asked to take part in a discussion which will last no more 
than 1 hour. This will take place at a place and time convenient for you. The discussion will be 
audio recorded. You will be asked to discuss your views and opinions regarding the use and 
acceptability of an App for preconception care of women with diabetes, and information that 
should be included to improve the health outcomes of women and their babies.  
 
What are the possible benefits of taking part? 
The discussions will give you an opportunity to contribute to the development of a preconception 
care mobile App (PCC-MA) for use by women with diabetes, but otherwise you are unlikely to 
benefit directly from taking part in the study. If you take part, you may be helping to develop an 
alternative means of providing preconception care information to this high-risk group of women.  
 
Are there any disadvantages or risks in taking part in the research? 
It is unlikely that there will be any, I just need a little of your time to discuss issues regarding the 
content of the preconception care mobile App (PCC-MA). 
  
Will the information you provide be passed on to anybody else? 
All information provided will be treated as strictly confidential in accordance with the Data 
Protection Act 1998. The audio recording from the discussion will only be identified by a unique 
code number, not by your name, your organisation’s name or the name of the service you 
provide. Although what you have said may be quoted in study reports and publications, no 
material from which you or your service could be identified will be published.  
 
What will happen to the results of the study? 
The findings will be included in my PhD thesis, presented at conferences and submitted to 
medical journals for publication. A written report of the study findings will be sent to you at the 
end of the study. Research data will be securely stored for at least 10 years in line with 
university policy.   
   
Who has reviewed the project? 
The study has been reviewed and received a favourable ethical approval by East Midlands - 
Derby National Research Ethics Service (NRES). 
 
What if there is a problem with the study? 
If you have any concern or complaint about the way you have been dealt with during the course 
of the study, you can contact the researcher (Chidi Nwolise), the study supervisor (Dr Nicola 
Carey) or the Patients Advice and Liaison Service (PALS) using the details below.  
 
Contacts for further information 
If you are interested in taking part in this study or if you have any questions about it, please 
contact Chidi Nwolise using the contact details below. 
 
Miss Chidi Nwolise  
(PhD Researcher) 
Dr Nicola Carey 
(Supervisor)  
Patients Advice and Liaison 
Service  
School of Health Sciences 
Faculty of Health & Medical 
Sciences 
School of Health Sciences 
Faculty of Health & Medical 
Sciences 
(PALS Service) 
Royal Surrey County Hospital 
Egerton Road, Guildford 
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University of Surrey University of Surrey GU2 7XX 
Tel: 01483 686717 Tel: 01483 684512 Tel: 01483 402757 
Email: c.nwolise@surrey.ac.uk  Email: n.carey@surrey.ac.uk Email: rsc-tr.PALS@nhs.net  
 
Thank you for taking the time to read this Information Sheet. 
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Phase 1 
 
 
Patient Information Sheet  
 
Feasibility study of a smartphone application (App) for the preconception care (PCC) of 
women with Type 1 or 2 diabetes 
 
 
My name is Chidi Nwolise and I would like to invite you to take part in a research project that is 
being undertaken as part of a PhD study at the University of Surrey. Your participation in the 
project is entirely voluntary. Before you decide to participate it is important that you understand 
why the research is being done and what it will involve. Please take the time to read the 
following information carefully. Talk to others about the study if you wish. If there is anything that 
is not clear, or you would like to know about, please contact me using the contact details 
provided at the end of this sheet. Thank you for reading this information. 
 
What is the purpose of the study? 
Preconception care enables women to prepare themselves to become as healthy as possible 
before pregnancy and achieve the best outcomes for both themselves and their baby. It involves 
adopting actions that support a healthier lifestyle such as stopping smoking and decreasing 
alcohol intake, improving blood glucose levels, taking folic acid (supplements) and using 
contraception until stable glycaemic control (HbA1c) is attained. Despite this, preconception 
care services are only accessed by a small number of women. In line with recent changes in 
technology, smartphone applications (Apps) are increasingly being used to improve health in a 
number of areas. However, little is known about the use or acceptability of Apps in the 
preconception care of women with diabetes.   
 
Aim of the study 
This study seeks to develop, test and explore the usage of a smartphone application (App) to 
promote knowledge and awareness of preconception care in women living with diabetes.   
 
Why have I been chosen? 
You have been chosen because you are a woman with type 1 or 2 diabetes, aged between 18-
45 years.  
 
Do I have to take part? 
It is up to you whether or not to take part in this research. You are free to withdraw from the 
research at any time and without giving a reason. If you choose to withdraw from the study, data 
collected would be used in the study but no further data will be collected or any other research 
procedures carried out. Your decision about this will not affect the standard of care you will 
receive. 
 
What will happen to me if I take part? 
You will be asked to take part in a discussion which will last no more than 1 hour. This will take 
place at a place and time convenient for you. The discussion will be audio-recorded. You will be 
asked about your understanding of preconception care, and how diabetes affects pregnancy. 
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You will be asked about your thoughts and feelings of using an App for preconception care. This 
information will be used to inform the content and features of the App.  
 
Will my taking part in the study be kept confidential? 
All information collected during the course of the research will be kept strictly confidential and 
secured against unauthorised access in accordance with the Data Protection Act 1998. 
Identification codes will be assigned to the data to protect your anonymity. 
  
What are the possible benefits of taking part? 
The App is an educational tool that will educate and provide information on preconception care 
and risks involved in unplanned pregnancies, benefits of pregnancy planning for both the 
woman and child. Furthermore, if you take part, you will be contributing to the development of a 
tool that may be of benefit to women with diabetes, to raise awareness of preconception care, 
educate and aid in pregnancy planning. 
  
Are there any disadvantages or risks in taking part in the research? 
It is unlikely that there will be any, I just need a little of your time to discuss issues regarding the 
content of the preconception care mobile App (PCC-MA). 
 
What will happen to the results of the study? 
At the end of the study, the results will be included in my PhD thesis, published in academic 
journals and presented at conferences. You will not be identified in any report or publication. A 
written report of the study findings will be sent to you at the end of the study. Research data will 
be securely stored for at least 10 years in line with university policy. 
 
Who is organising and funding the study? 
The study is being organised by the University of Surrey and self-funded by the researcher. You 
will not be paid for taking part in this study.  
 
Ethical Review 
The study has been reviewed and received a favourable ethical approval by East Midlands - 
Derby National Research Ethics Service (NRES). 
 
What if there is a problem? 
If you have any concern or complaint about the way you have been dealt with during the course 
of the study or if you have an issue with the care you have received, you can contact the 
researcher (Chidi Nwolise), the study supervisor (Dr Nicola Carey) or the Patient Advice and 
Liaison Service (PALS) using the details given below.  
 
Contacts for further information 
If you are interested in taking part in this study or if you have any questions about it, please 
contact Chidi Nwolise using the contact details below: 
 
Miss Chidi Nwolise  
(PhD Researcher) 
Dr Nicola Carey 
(Supervisor)  
Patient Advice and Liaison 
Service  
 
School of Health Sciences 
Faculty of Health & Medical 
Sciences 
School of Health Sciences 
Faculty of Health & Medical 
Sciences 
(PALS service) 
Royal Surrey County Hospital 
Egerton Road, Guildford 
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University of Surrey University of Surrey GU2 7XX 
Tel: 01483 686717 Tel: 01483 684512 Tel: 01483 402757 
Email: c.nwolise@surrey.ac.uk  Email: n.carey@surrey.ac.uk Email: rsc-tr.PALS@nhs.net  
 
Thank you for taking the time to read this Information Sheet. 
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Phase 2 
 
 
Intervention Patient Information Sheet  
 
Feasibility study of a smartphone application (App) for the preconception care (PCC) of 
women with Type 1 or 2 diabetes 
 
 
My name is Chidi Nwolise and I would like to invite you to take part in a research project that is 
being undertaken as part of a PhD study at the University of Surrey. Your participation in the 
project is entirely voluntary. Before you decide to participate it is important that you understand 
why the research is being done and what it will involve. Please take the time to read the 
following information carefully. Talk to others about the study if you wish. If there is anything that 
is not clear, or you would like to know about, please contact me using the contact details 
provided at the end of this sheet. Thank you for reading this information. 
 
What is the purpose of the study? 
Preconception care enables women to prepare themselves to become as healthy as possible 
before pregnancy and achieve the best outcomes for both themselves and their baby. It involves 
adopting actions that support a healthier lifestyle such as stopping smoking and decreasing 
alcohol intake, improving blood glucose levels, taking folic acid (supplements) and using 
contraception until stable glycaemic control (HbA1c) is attained. Despite this, preconception 
care services are only accessed by a small number of women. In line with recent changes in 
technology, smartphone applications (Apps) are increasingly being used to improve health in a 
number of areas. However, little is known about the use or acceptability of Apps in the 
preconception care of women with diabetes.   
 
Aim of the study 
This study seeks to develop, test and explore the usage of a smartphone application (App) to 
promote knowledge and awareness of preconception care in women living with diabetes.   
 
Why have I been chosen? 
You have been chosen because you are a woman with type 1 or 2 diabetes, aged between 18-
45 years. You have also had diabetes for more than 6 months, own a smartphone and have 
indicated that you are planning a future pregnancy (in the next 5 years) or want children 
sometime in the future.  
 
Do I have to take part? 
It is up to you whether or not to take part in this research. You are free to withdraw from the 
research at any time and without giving a reason. Your decision about this will not affect the 
standard of care you will receive. If you choose to withdraw from the study or lose capacity to 
consent during the study, data collected with consent would be retained and used in the study. 
No further data will be collected or any other research procedures carried out.  
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What will happen to me if I take part? 
The researcher will answer any questions you may have and if you decide to take part in the 
study, she will ask you to sign a consent form. During this process you will be asked if you are 
willing to participate in any of the following:  
 
 Receive a demonstration from the researcher, explaining how to download and use the 
preconception care mobile App. You will be asked to regularly use the preconception 
care App by viewing the information on preconception care, diabetes and recording your 
blood glucose levels in the diary for 3 months. It is anticipated that you will use the App 
for around 5 minutes a day. 
 Completing a questionnaire at the beginning and 3 months later after you have used the 
App. This should take about 15 minutes to complete each time and include questions 
about your reproductive health and preconception care. Once complete, please either 
hand the questionnaire to the researcher or post it back using the stamped envelope 
provided.   
 An optional interview after you have used the App for 3 months. You will discuss your 
experiences of using the App including its usefulness for preconception care, as well as 
your ideas of how to improve it with the researcher. This will last no more than 20-30 
minutes and will be audio-recorded. You can indicate if you would like to participate in an 
interview on the consent form. 
 Having the researcher look at the data you have entered via the App for research 
purposes.  
 
You may decide that you are happy to participate in some of these activities but not others. This 
is OK, just let the researcher know or indicate this on the consent form. 
   
Will my taking part in the study be kept confidential? 
All information collected during the course of the research will be kept strictly confidential and 
secured against unauthorised access in accordance with the Data Protection Act 1998. 
Identification codes will be assigned to the data to protect your anonymity. 
  
What are the possible benefits of taking part? 
The App is an educational tool that will educate and provide information on preconception care 
and risks involved in unplanned pregnancies, benefits of pregnancy planning for both the 
woman and child. Furthermore, if you take part, you will be contributing to the development of a 
tool that may be of benefit to women with diabetes, to raise awareness of preconception care, 
educate and aid in pregnancy planning. 
  
Are there any disadvantages or risks in taking part in the research? 
It is unlikely that there will be any, I just need a little of your time to use the App (periodically for 
3 months) and answer some questions.  All participants of this study are at low risk of hazards 
or harm.  
 
What will happen to the results of the study? 
At the end of the study, the results will be included in my PhD thesis, published in academic 
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journals and presented at conferences. You will not be identified in any report or publication. A 
written report of the study findings will be sent to you at the end of the study. Research data will 
be securely stored for at least 10 years in line with university policy.  
 
Ethical Review 
The study has been reviewed and received a favourable ethical approval by East Midlands - 
Derby National Research Ethics Service (NRES).  
 
What if there is a problem? 
If you have any concern or complaint about the way you have been dealt with during the course 
of the study or if you have an issue with the care you have received, you can contact the 
researcher (Chidi Nwolise), the study supervisor (Dr Nicola Carey) or the Patient Advice and 
Liaison Service (PALS), using the details given below.  
 
Contacts for further information 
If you are interested in taking part in this study or if you have any questions about it, please 
contact Chidi Nwolise using the contact details below. 
 
 
Miss Chidi Nwolise  
(PhD Researcher) 
Dr Nicola Carey 
(Supervisor) 
Patient Advice and 
Liaison Service  
School of Health Sciences Senior Lecturer 
School of Health Sciences 
PALS Service 
Faculty of Health & 
Medical Sciences 
Faculty of Health & 
Medical Sciences 
Royal Surrey County 
Hospital, Egerton Road 
University of Surrey University of Surrey GU2 7XX 
Tel: 01483 686717 Tel: 01483 684512 Tel: 01483 402757 
Email: 
c.nwolise@surrey.ac.uk  
Email: 
n.carey@surrey.ac.uk 
Email: rsc-
tr.PALS@nhs.net  
 
 
Thank you for taking the time to read this Information Sheet. 
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Appendix 9 – Phase 1 
 
Healthcare Professional Consent Form 
 
Feasibility study of a smartphone application (App) for the preconception care (PCC) 
of women with Type 1 or 2 diabetes 
 
 
Name of Researcher: Chidi Nwolise 
Please initial each 
box 
 
 I confirm that I have read and understood the Information Sheet (version 4, 24/08/15) provided for 
the above study and have had the opportunity to ask questions and have these answered to my 
satisfaction.   
 
 I understand that my participation is voluntary and that I am free to withdraw at any time without 
giving a reason or affecting my medical or legal rights. If I withdraw from the study, data collected 
would be retained and used in the study. No further data will be collected or any other research 
procedures carried out. 
 
 I confirm that I have been given adequate time to consider my participation and freely consent to 
participating in the study.    
 
 I agree to being involved in a discussion and for these to be audio-recorded and used for research 
purposes.      
 
 I agree to anonymous quotations (taken from discussion data) to be used in publications.   
 
 I agree to receive a written report of the study findings at the end of the study. This is 
optional.  
          YES  
             
 NO 
                                                                  
 I consent to my personal data, as outlined in the accompanying information sheet, being used for 
this study. I understand that all personal data relating to volunteers is held and processed in the 
strictest confidence, and in accordance with the Data Protection Act (1998). 
 
 I agree to respect the privacy of other participants in the study.  
 
 I agree to take part in the above study. 
 
 
            
Name of Participant   Date    Signature 
            
Name of Person taking consent  Date    Signature 
 
 269 
 
 
Phase 1 
 
Patient Consent Form  
 
Feasibility study of a smartphone application (App) for the preconception care (PCC) 
of women with type 1 or 2 diabetes 
 
Name of Researcher: Chidi Nwolise 
Please initial each 
box 
 I confirm that I have read and understood the Information Sheet (version 4, 24/08/15) provided for 
the above study and have had the opportunity to ask questions and have these answered to my 
satisfaction.   
 
 I understand that my participation is voluntary and that I am free to withdraw at any time without 
giving a reason or affecting my medical or legal rights. If I withdraw from the study, data collected 
would be retained and used in the study. No further data will be collected or any other research 
procedures carried out. 
 
 I understand that relevant sections of my medical notes and data collected during the study, may 
be looked at by individuals from the University of Surrey, from regulatory authorities or from the 
NHS Trust, where it is relevant to my taking part in this research. I give permission for these 
individuals to have access to my records. 
 
 I agree to comply with any instruction given to me during the study and to cooperate fully with the 
investigators.  
 
 I confirm that I have been given adequate time to consider my participation and freely consent to 
participating in the study.    
 
 I agree to being involved in a discussion and for this to be audio-recorded and used for research 
purposes.      
 
 I agree to anonymous quotations (taken from discussion data) to be used in publications.   
 
 I agree to receive a written report of the study findings at the end of the study. This is              
optional.                                                                                                                YES                       
                                                                                                                                                 
                             NO                
                                                                                                  
 I consent to my personal data, as outlined in the accompanying information sheet, being used for 
this study. I understand that all personal data relating to volunteers is held and processed in the 
strictest confidence, and in accordance with the Data Protection Act (1998). 
 
 I agree to respect the privacy of other participants in the study.                                                                                       
 
 I agree to take part in the above study.                                                                          
            
Name of Participant   Date    Signature 
            
Name of Person taking consent  Date    Signature 
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Phase 2 
Intervention Patient Consent Form  
 
Feasibility study of a smartphone application (App) for the preconception care (PCC) of 
women with Type 1 or 2 diabetes 
 
Name of Researcher: Chidi Nwolise 
Please initial each 
box 
 
 I confirm that I have read and understood the Information Sheet (version 4, 24/08/15) provided for 
the above study and have had the opportunity to ask questions and have these answered to my 
satisfaction.   
   
 I understand that my participation is voluntary and that I am free to withdraw at any time, without 
giving a reason or affecting my medical or legal rights. If I withdraw from the study, data collected 
would be retained and used in the study. No further data will be collected or any other research 
procedures carried out. 
 
 I understand that relevant sections of my medical notes and data collected during the study, may 
be looked at by individuals from the University of Surrey, from regulatory authorities or from the 
NHS Trust, where it is relevant to my taking part in this research. I give permission for these 
individuals to have access to my records. 
 
  I agree to my General Practitioner being informed of my participation in the study. 
 
 I agree to receiving a demonstration regarding the download and use of the preconception care 
mobile App.    
 
 I agree to complete 2 questionnaires at the beginning and 3 months after using the mobile App. 
 
 I agree to participate in an interview and for this to be audio recorded, and used for             
research purposes. Participation in the interview is optional.                             YES  
                                                                                         
                                                                                                                                    NO    
      
 I agree to receive a written report of the study findings at the end of the study. This is             
optional.                                                                                                               YES 
                                                            
                                                                                                                                    NO  
   
 I agree to having a researcher look at the data entered via the preconception care mobile App for 
research purposes.  
 
 I consent to my personal data, as outlined in the accompanying information sheet, being used for 
this study. I understand that all personal data relating to volunteers is held and processed in the 
strictest confidence, and in accordance with the Data Protection Act (1998). 
 
 I agree to take part in the above study. 
 
            
Name of Participant   Date    Signature 
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Name of Person taking consent  Date    Signature 
   
 
If you are willing to participate in an interview please provide your contact details below 
 
Contact details: 
 
 
Name ………………………………………………………………………………………………… 
 
Address ……………………………………………………………………………………………… 
 
…………………………………………………………………………………………………………. 
 
…………………………………………………………………………………………………………. 
 
Postcode …………………………………………………………………………………………….. 
 
Home Telephone ……………………………………………………………………………………. 
 
Mobile Telephone ………………………………………………………………………………….. 
 
Email …………………………………………………………………………………………………. 
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Appendix 10- Phase 1 
 
Healthcare Professional Schedule 
Title of Project: Feasibility study of a smartphone App for preconception care of 
women with Type 1 or 2 diabetes 
 
1. Introduce self and project. Recap ethical issues such as confidentiality, anonymity, audio-
recording of session, obtain consent and signed consent form. 
 
2. Lets talk about preconception care (PCC)  
 
Prompts 
 
What do you think about PCC and diabetes? 
What do you think about diabetes and pregnancy? 
What is the relevance of PCC to women living with diabetes? 
What information do you think these women need to know about PCC? 
What information do you think they need to know about pregnancy planning? 
What advice would you give on how to minimise pregnancy-related risks?  
What are the most important points about diabetes, pregnancy and PCC that women need to be 
aware of? 
Is there any other information you think women with diabetes should be aware of? 
 
3. Lets talk about the smartphone App 
 
Prompts 
 
What do you think about the use of information technology (IT) to promote PCC? 
What do you think about the use of a smartphone App for PCC in practice? 
What do you think about adding self-monitoring features such as a blood glucose diary to the 
App? 
Do you have suggestions for any other add-ons that may promote self-management?  
How frequently should women record their blood glucose readings in the diary? 
Do you have further suggestions on components or information you want incorporated in the 
App? 
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Phase 1  
 
Patient Schedule 
Title of Project: Feasibility study of a smartphone App for preconception care of 
women with type 1 or 2 diabetes 
 
1. Introduce self and project. Recap ethical issues such as confidentiality, anonymity, audio-
recording of session, obtain consent and signed consent form. 
 
2. Lets talk about preconception care (PCC) and diabetes 
 
Prompts 
 
What do you understand about preconception care? 
What do know about PCC and diabetes? 
What do you know about diabetes and pregnancy? 
What do you know about diabetes and folic acid intake? 
What do you know about diabetes and family planning/contraception? 
If you needed information on PCC, where would you get it? 
If you needed information about diabetes and pregnancy, where would you get it? 
If you needed contraception/family planning advice, where would you get it? 
If you needed folic acid where would you get it? 
 
3. Lets talk about the smartphone App 
 
Prompts 
 
What do you know about smartphone Apps? 
What do you think about using an App for preconception care? 
What do you think about the title of the App? 
How do you think the App in general could be made more interesting? 
How do you think the information pages could be made more visually appealing? 
What do you think about adding self-monitoring features such as a blood glucose diary to the 
App and what other features would you like to see included?  
Do you have any suggestions about preferred number of times to record blood glucose readings 
in the diary? 
Do you have any other suggestions on how to improve the App? 
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Phase 2 
 
Title of Project: Feasibility study of a smartphone App for preconception care of 
women with type 1 or 2 diabetes 
Intervention Patient Interview Schedule 
1. Introduce self and project. Recap ethical issues such as confidentiality, anonymity, audio-
recording of interviews, obtain consent and signed consent form. 
 
2. Let’s talk about your experience of using the smartphone App 
Prompts 
Can you tell me how you got on with using the App over the last few months? 
How did you find navigating the pages and finding information? 
What do you think about the content and functionality of the App? 
Do you have any suggestions of how the App could be improved?  
 
3. Let’s talk about the use of the App for preconception care (PCC) 
Prompts 
How did you find using an App for PCC? 
How did you find the information on preconception care (PCC)? 
How did you find the general information pages, checklists, videos and external links? 
Is there any other information that you would have liked included in the App? 
 
4. Let’s talk about the features of the App 
Prompts 
Can you tell me what you think about the add-on features of the App, such as blood glucose 
diary? 
What was your experience of using the included diary to record your blood glucose? 
Would this help you in the management of your diabetes? 
 
5. Tell me about your experience of being in the study 
Prompts  
How did you find the overall experience of being in the preconception care mobile App (PCC-
MA) feasibility study? 
Is there anything you would do differently following your participation in the study? 
Is there anything that I haven’t asked about regarding the use of the App for PCC of women with 
diabetes that you think would be helpful? 
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Appendix 11 – Phase 1 Healthcare Professional interview 
Coding Summary By Source 
Feasibility study 
 
 
Classification  Aggregate  Coverage  Number Of 
Coding 
References 
 Reference 
Number 
 Coded By 
Initials 
 Modified On 
Internals\\Interviews\\HCP7 
Node 
Nodes\\Accessibility of care or services\Limitations, constraints and challenges of PCC or barriers to 
PCC provision 
  No  0.1014  4  
         1  CHB  04/06/2016 05:47 
And then the other side, a lot of women don’t like every time they come being asked if they are planning to get pregnant, you know. I 
mean even without diabetes, “oh you know, are you gonna have little ones soon?” and they are like “go away” you know.  
Can you imagine having that every time? But kind of unfortunately it’s so important that it has to be mentioned. I think our doctors kind of 
try and you know just mention it. You know, and kind of say look just give me the nod if we are to go for this but if not, you know the drill. 
Yeah. So, it’s all a bit complicated but all positive 
  2  CHB  04/06/2016 05:46 
But yeah the women appreciate not being dragged up to a hospital every 5 minutes. You know the parking here is appalling and you know 
they’ve got other things going on. Yeah and pregnancy and preconception is supposed to be a lovely healthy time isn’t it, you don’t want to 
associate it with always being at a hospital, kind of almost gives you the impression that you are ill. Yeah. That’s it really.  
  3  CHB  04/06/2016 05:51 
I mean to get patient information leaflets done by the hospital, there is so many forms and things you have to do and go through. I must 
admit we, it sounds awful, it’s something I wanted to do, I wanted to do an up to date information for our ladies but actually having the 
time to research it, write it and put it through the hospital systems and all that, without being funny there is no chance. No, we are 
struggling just to see patients at the moment which is when diabetes UK brought out a lovely booklet for gestational diabetes, and actually 
what I’m trying to do is gather leaflets from all round, that companies have made and we are gonna try and look at them as an antenatal 
team and see which one we are happy giving out. But again that’s another piece of paper and also  the lady’s got to come in and engage 
with us to get it 
  4  CHB  04/06/2016 05:55 
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Yeah. I think some people don’t tell you they are planning a pregnancy because they don’t want a lecture and the– you know, the Spanish 
inquisition, sort of thing.  
Yeah. A lot of ladies won’t tell people that they are trying for a baby because you don’t know how long it’s going to take, the pressure, you 
just keep it quiet don’t you? You don’t tell people till you’ve had your 12 weeks scan and everything is ok. I know we are healthcare 
professionals but there’s got to be an element to that as well. You go to your diabetes team and say oh you are trying for a baby and then 
you go back a year later and they go “oh you are not pregnant yet?” you know, so yeah.  
 
Nodes\\Accessibility of care or services\Provision of Care 
  No  0.0136  1  
         1  CHB  04/06/2016 05:17 
It’s so important and generally you know it can be just taking time to get their control good, getting them onto folic acid, you know. Yeah 
and especially ladies with type 2, younger age and women having babies later. You’ve got the risks that they might be on tablets that they 
shouldn’t be on for the pregnancy and that’s kind of a key thing 
Reports\\Coding Summary By Source Report  
 
Classification  Aggregate  Coverage  Number Of 
Coding 
References 
 Reference 
Number 
 Coded By 
Initials 
 Modified On 
Nodes\\Accessibility of care or services\Satisfaction in care provided or dissatisfaction 
  No  0.0300  2  
         1  CHB  03/07/2016 19:29 
It’s so important and generally you know it can be just taking time to get their control good, getting them onto folic acid, you know. Yeah 
and especially ladies with type 2, younger age and women having babies later. You’ve got the risks that they might be on tablets that they 
shouldn’t be on for the pregnancy and that’s kind of a key thing 
  2  CHB  04/06/2016 05:25 
we’ve had you know–  I have been doing antenatal for 5, 6 years maybe and you know we’ve got so many of our type 1’s, type 2’s having 
healthy beautiful children, several, you know so they are coming back for their second and third pregnancies which is lovely. Yeah, we are 
very lucky here that we’ve got some midwives that try and pair up with us, you know, see our ladies, so they get a bit of continuity. Yeah.  
 
Nodes\\Accessibility of care or services\Variation in PCC provision 
  No  0.0306  1  
         1  CHB  04/06/2016 05:54 
and especially with more and more ladies with type 2, you know, now becoming pregnant, we do tend to miss them because they are 
managed in primary care whereas we are very pregnancy focused. You know, there is all these ladies who aren’t getting that and if a GP 
rang me and said “oh my lady is type 2, she wants to get pregnant”, I would be like “oh that’s great, when is she coming to have a chat with 
me?”  
You know what I mean, we make ourselves so accessible but kind of it doesn’t happen and the type 2 ladies do tend to have quite poor 
control when they conceive so you know those first 12 weeks of organ forming can be– you can miss them before the lady realises she is 
pregnant and then they’ve had awful control, they haven’t had their folic acid, you know, yeah 
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Nodes\\Expertise and knowledge about PCC for women with DM\Knowledge of PCC & PCC 
practices\Importance of PCC or pregnancy planning 
  No  0.0437  1  
         1  CHB  04/06/2016 23:23 
But kind of, you want to address the diabetes and you want to address the pregnancy but you also want to combine it because it is the 
whole package and some ladies are focused just on the diabetes whereas actually they are having this pregnancy and you know that’s the 
key, that’s what it’s about. The diabetes is important but you know, so it’s not– I guess not purely diabetes-driven, you know kind of linking 
it back to positive message of you know, yes ladies with pre-existing diabetes are at risk of all these problems you know. I mean it’s still 
appalling— maternal death, preeclampsia, intrauterine death, still births, you know early miscarriage, but kind of getting the preconception 
in there you know kind of reduces all the various risks so much. It’s so important and generally you know it can be just taking time to get 
their control good, getting them onto folic acid, you know. Yeah and especially ladies with type 2, younger age and women having babies 
later. You’ve got the risks that they might be on tablets that they shouldn’t be on for the pregnancy and that’s kind of a key thing 
 
Nodes\\Expertise and knowledge about PCC for women with DM\Knowledge of PCC & PCC 
practices\Information Seeking practices 
  No  0.0498  2  
         1  CHB  04/06/2016 04:55 
 
Classification  Aggregate  Coverage  Number Of 
Coding 
References 
 Reference 
Number 
 Coded By 
Initials 
 Modified On 
 
 2  CHB  04/06/2016 05:53 
but actually hopefully, you know,  if you are thinking of getting pregnant you might google things at home first and you know rather than us 
meeting a lady when she is pregnant but now to get in there with PCC 
  3  CHB  04/06/2016 05:54 
So you would kind of hope the lady or her partner or someone will be like “well hang on if you are gonna be doing this, do a bit of research” 
and kind of google, and the internet and apps is the way forward, 
 
 Nodes\\Expertise and knowledge about PCC for women with DM\Self-management, motivation and 
responsibility  
  No  0.0078  1  
         1  CHB  04/06/2016 06:59 
and also it’s always about teaching.  
You don’t want someone always relying on you to adjust things for them, but you want them to become independent and develop their 
own knowledge sort of thing. 
 
 278 
 
 
Nodes\\Feasibility and acceptability of a smartphone app for PCC 
  No  0.0627  3  
         1  CHB  05/06/2016 20:35 
I guess you must be able to get general apps and things for planning a pregnancy so maybe, I’m assuming I haven’t looked to see what is 
kind of out there to kind of combine that with the diabetes which I suppose is where you are coming from to kind of fill that gap. 
  2  CHB  04/06/2016 06:12 
I don’t see why not, even within our hospital, there are so many different groups and people you have to go through. Preconception might 
be easier because you are talking more about just a certain group of healthcare professionals, the obstetrics and the diabetes, but to be 
recommended as a hospital you know again I don’t know if it’s the patient safety group or if it would be the information governance team. 
It probably wouldn’t have to go through infection control but you know. I must admit I wouldn’t know, you know what I mean but there’s 
got to be various groups and things that it would have to go through and I guess sometimes with a lot of things we seem to trial things in 
the hospital, get feedback and then kind of launch them. Yeah. 
  3  CHB  04/06/2016 06:14 
I couldn’t do it professionally except the hospital was happy. Because when I’m sitting in my uniform I am representing the hospital. If I 
was, you know, down the park and someone didn’t know what I did and you know I was speaking to someone, I might say “oh, there is an 
app.” But as I say when you’ve got a registration you’ve always got to be careful what you do because you are accountable 24 hours a day 
and all that. But generally as long as my hospital and my team, antenatal team were happy, I would be happy to, because again it’s helping 
benefit women.  
 
Nodes\\Feasibility and acceptability of a smartphone app for PCC\Facilitators or barriers to PCC-MA 
acceptance 
  No  0.0942  4  
         1  CHB  04/06/2016 06:10 
I guess the way to meet most people would be for the app to be free, you’ve got to put it out there haven’t you? 
You know, or, yeah. Or at least very you know what I mean. If the app was £20 pounds, you’d be like no chance, so- 
 Reports\\Coding Summary By Source Report  
 
Classification  Aggregate  Coverage  Number Of 
Coding 
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 2  CHB  04/06/2016 06:13 
Every hospital is struggling financially. We are leasing resources and various things, so I must admit generally if there is a cost, combined 
generally it’s- yeah.  
Oh definitely, definitely. but apart from that, kind of– the reason we do this job or we work in a hospital is to make a difference and 
improve things with people so from that side of things you know people would be interested in everything. It’s just we’ve also got the 
constraint of, I mean there is a constraint on time, you’ve seen X and I, you know don’t know where to start but also we keep looking at 
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actually this is important, this is what we are focusing on and since we got that done, we will you know kind of change, people still want to 
drive things forward and improve care, yeah. 
  3  CHB  04/06/2016 06:18 
Kind of the things we’ve gone over to be honest. I never give out a leaflet or anything unless I’ve looked at. This might seem extreme but 
even the needles we supply, X and I have tested them on ourselves to check because we, not just as a healthcare professional but also as a 
person you want the best for your patients. So if it provided the information and kind of everything else and the hospital are happy then I’d 
be happy to have posters up, you know what I mean. You could, kind of, we have a meeting where we meet with the GPs and the diabetes 
leads in the area, it would be presented there, and kind of everything. If it kind of had the backing you know what I mean, we do our best 
to use it. ‘Cause as I say, it makes sense.   
  4  CHB  04/06/2016 06:19 
If it say, if it got mixed in with gestational diabetes, sometimes you look at leaflets and it will talk about gestational diabetes and checking 
for ketones and DKA, and I’m thinking hang on that’s not appropriate–  this is the company trying to get more of their ketones strips used. 
I’m like well actually no, I’m not scaring my ladies by giving them the wrong information. If there was an app, I would download it and have 
a look at it and make sure I was happy, but if it was relevant and up to date, yeah, I don’t see a problem.  
  
Nodes\\Feasibility and acceptability of a smartphone app for PCC\Opinion of PCC-MA 
  No  0.0485  1  
         1  CHB  04/06/2016 05:59 
I think it’s a brilliant idea. Easy to access, you know, you’ve got the information there so it’s something you can discreetly look at on your 
phone. It’s not like you are sitting there with a textbook on diabetes and pregnancy. It’s just something people could look up when they 
are, you know, commuting on the train, standing in the post office for an hour, they can look at their app which would make it kind of, a lot 
easier for ladies to look up things. Yeah, I think it would be good. I’ve got an app on geography, I’m trying to improve my knowledge on 
maps and stuffs but actually having it on my phone, you know what I mean, I must say I can’t remember the last time I did but it’s there 
and I can just do it. I have got a book of maps somewhere in my house but to go and find it or the time you know, you could play on the 
app and I don’t quite know how it relates but apps often has quizzes and questionnaires, you know something interactive whereas general 
leaflets and textbooks don’t and of course the updating bit, for it to be really relevant. I mean NICE guidelines have just updated so that’s 
kind of put so many things are now wrong– leaflet information out there. Yeah, I think an app is a lovely idea.  
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Nodes\\IT awareness\Appreciation of tech use in healthcare 
  No  0.1784  4  
         1  CHB  04/06/2016 04:50 
Kind of, I think it’s a good thing. It’s always important to make sure what you are looking at is up to date. Kind of, I mean actually that’s 
where textbooks and things fall down, isn’t it. I mean you can buy a textbook and it’s already out of date or things like that. If you– A lot of 
apps and things, you know, you go on your phone and it’s like there is an update available. So actually you kind of feel competent that 
you’ve got the latest information and things, that’s quite nice. With like computers in the last few years, in the trust in general, have been 
used so much more. We’ve got so many more PCs and lots of things on the desktops and information is very accessible to everyone which 
is kind of important because you can’t always, or you rarely can get anyone on the end of the phone nowadays. You know what I mean, so 
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there is always the information and support there even if it’s a random time and I guess that comes into your own life as well. You might be 
looking up something for yourself and it’s not, you know it’s so much easier to do at 10 o’ clock at night when you’ve finished for the day 
than it is you know while you are trying to work and stuff. So I guess it makes it a lot more accessible and probably not so daunting either.  
You know, kind of phoning someone up and asking things, things you might think you ought to know can be a bit embarrassing and put you 
off whereas  if you just look it up, you know at least it will give you the confidence when you then go and speak to someone like a 
healthcare professional. Does that kind of make sense?  
  2  CHB  04/06/2016 04:59 
If you are that way inclined, brilliant. The fact that we can upload metres nowadays is a god-send because we can literally– you know we 
have Diasend® and we upload and then we can print graphs, we can print charts and it’s so much better at being visual. You know if you 
say to a patient well your sugars are high in the morning you know, they might go “well they are low at night” but if you can kind of go well 
look yeah this is what’s happening and its happening because of this. You know if people can understand why you are suggesting things, 
then they are much more likely to you know comply or do it 
  3  CHB  05/06/2016 19:30 
So kind of from that point of view, brilliant, and if its written down you know you can always refer back to what it says in black and white 
whereas when you tell people things they only take down 10% or something of what you say and you know, kind of here you might see 
these ladies you know once or twice or something and you want to get all the information in. We give them so many bits of paper, you 
know when I start my ladies on insulin and things but I do know, then you’ve got loads of bits of paper to go through whereas an app on 
your phone or an e-reader or something, it just, it feels easier to do. At least it does for me, you know what I mean, I can literally dip in and 
out when I’ve got the time rather than thinking, oh I’ve got 10 minutes, oh the paper’s at home. You know it’s generally with you isn’t it, so 
you can log on wherever you are and I guess kind of a lot of my ladies, it’s not, I mean it is them that’s going through the pregnancy but its 
them and their partner you know.  
The partners are very involved, you know, want to know about their ladies’ diabetes and want to know how it’s going to affect them and 
their babies. You know it’s– So actually it’s something their partners as well can look at with them which will improve their experience 
generally. 
  4  CHB  05/06/2016 20:35 
Then, the ladies could always use various apps and things to track their blood glucose levels you know, record them and you can get meters 
that do bolus advice, how you calculate your rapid acting insulin, you can get those on phones, you know some people have the blood 
glucose metre and then the app on their phones, kind of thing and I guess you must be able to get general apps and things for planning a 
pregnancy so maybe, I’m assuming I haven’t looked to see what is kind of out there to kind of combine that with the diabetes which I 
suppose is where you are coming from to kind of fill that gap. But apart from that, I guess you’ve got the technology to be able to keep in 
touch with your nurses and people. A lot of our ladies are busy, you know they are working and raising other kids so being able to do things 
via email and being able to download the information and send it easily and quickly to us. We are in a very time-constrained world, aren’t 
we? Everyone’s got so much to do. 
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Nodes\\IT awareness\Appreciation of tech use in healthcare\Technology use for diabetes 
  No  0.0240  1  
         1  CHB  09/06/2016 13:39 
If you are that way inclined, brilliant. The fact that we can upload metres nowadays is a god-send because we can literally– you know we 
have Diasend® and we upload and then we can print graphs, we can print charts and it’s so much better at being visual. You know if you 
say to a patient well your sugars are high in the morning you know, they might go “well they are low at night” but if you can kind of go well 
look yeah this is what’s happening and its happening because of this. You know if people can understand why you are suggesting things, 
then they are much more likely to you know comply or do it 
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Nodes\\IT awareness\Interaction with technology 
  No  0.0108  1  
         1  CHB  05/06/2016 20:04 
I mean at work it’s always the computer, the bleep, faxes, email, things like that. At home the only other things really are things like, I guess 
various apps on the phone and ipad, things like that. Yeah, I am not very technology-based I am afraid. No. That’s about it.  
 
Nodes\\Technology-assisted PCC intervention\Intervention content or content of Smartphone app 
  No  0.0404  1  
         1  CHB  04/06/2016 06:09 
Apart from that I guess it’s important to cover their general health, checking what medications they are on, their control. You know we 
meet ladies who aren’t actually monitoring their blood sugars, they might be on metformin monotherapies and just the metformin and 
generally you don’t test but of course if you are planning a pregnancy, you should be testing and everything, making sure they know what 
their targets are, know who to contact sort of thing, where they could go for more information, maybe direct them to diabetes UK, or 
something, somewhere you know is reliable. So diet, meds, general health, what else? I guess the usual prepregnancy information as well 
because you don’t want people thinking they’ve got to have an app for their diabetes preconception and an app for preconception 
generally, you know. So it would be covering things that they just generally should be considering and then having their diabetes side in 
there as well, like relating it, putting it in and then just the general things  
 
Nodes\\Technology-assisted PCC intervention\Intervention content or content of Smartphone 
app\Assessments, check-ups and vaccinations 
  No  0.0040  1  
         1  CHB  04/06/2016 05:27 
if they have got any problems with their eyes and kidneys they need checking out before they conceive 
 
Classification  Aggregate  Coverage  Number Of 
Coding 
References 
 Reference 
Number 
 Coded By 
Initials 
 Modified On 
Nodes\\Technology-assisted PCC intervention\Intervention content or content of Smartphone 
app\Contraception 
  No  0.0314  1  
         1  CHB  04/06/2016 05:22 
Yeah and especially ladies with type 2, younger age and women having babies later. You’ve got the risks that they might be on tablets that 
they shouldn’t be on for the pregnancy and that’s kind of a key thing, we had GP training here the other week and that was kind of a key 
thing saying, actually yes we’ve got all these wonderful drugs but any woman who could potentially conceive you’ve got to think of that 
you know and Dr X says you are either on folic acid or you are on the pill, you know [laughter]. Those are your options sort of thing. So, if 
you are not trying to prevent a pregnancy, in theory you are trying for a pregnancy. Yeah so especially now we tend to put in like ACE 
inhibitors a lot earlier and things like that, you know. It’s got to be so careful for these women 
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Nodes\\Technology-assisted PCC intervention\Intervention content or content of Smartphone 
app\Diabetes complications 
  No  0.0296  1  
         1  CHB  04/06/2016 05:08 
you want to address the diabetes and you want to address the pregnancy but you also want to combine it because it is the whole package 
and some ladies are focused just on the diabetes whereas actually they are having this pregnancy and you know that’s the key, that’s what 
it’s about. The diabetes is important but you know, so it’s not– I guess not purely diabetes-driven, you know kind of linking it back to 
positive message of you know, yes ladies with pre-existing diabetes are at risk of all these problems you know. I mean it’s still appalling— 
maternal death, preeclampsia, intrauterine death, still births, you know early miscarriage, but kind of getting the preconception in there 
you know kind of reduces all the various risks so much.  
 
Nodes\\Technology-assisted PCC intervention\Intervention content or content of Smartphone 
app\Folic acid & supplementation 
  No  0.0417  3  
         1  CHB  04/06/2016 05:20 
It’s so important and generally you know it can be just taking time to get their control good, getting them onto folic acid, you know. 
  2  CHB  04/06/2016 05:22 
Yeah and especially ladies with type 2, younger age and women having babies later. You’ve got the risks that they might be on tablets that 
they shouldn’t be on for the pregnancy and that’s kind of a key thing, we had GP training here the other week and that was kind of a key 
thing saying, actually yes we’ve got all these wonderful drugs but any woman who could potentially conceive you’ve got to think of that 
you know and Dr X says you are either on folic acid or you are on the pill, you know [laughter]. Those are your options sort of thing. So, if 
you are not trying to prevent a pregnancy, in theory you are trying for a pregnancy. Yeah so especially now we tend to put in like ACE 
inhibitors a lot earlier and things like that, you know. It’s got to be so careful for these women 
  3  CHB  04/06/2016 05:27 
I guess it’s providing the information that women need to think about and consider such as being on the folic acid, you know, 
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Nodes\\Technology-assisted PCC intervention\Intervention content or content of Smartphone 
app\Good diabetes control 
  No  0.0072  2  
         1  CHB  04/06/2016 05:20 
It’s so important and generally you know it can be just taking time to get their control good, getting them onto folic acid, you know. 
  2  CHB  04/06/2016 05:28 
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you know, getting the good control sort of thing. 
 
Nodes\\Technology-assisted PCC intervention\Intervention content or content of Smartphone 
app\Medication review 
  No  0.0314  1  
         1  CHB  04/06/2016 05:22 
Yeah and especially ladies with type 2, younger age and women having babies later. You’ve got the risks that they might be on tablets that 
they shouldn’t be on for the pregnancy and that’s kind of a key thing, we had GP training here the other week and that was kind of a key 
thing saying, actually yes we’ve got all these wonderful drugs but any woman who could potentially conceive you’ve got to think of that 
you know and Dr X says you are either on folic acid or you are on the pill, you know [laughter]. Those are your options sort of thing. So, if 
you are not trying to prevent a pregnancy, in theory you are trying for a pregnancy. Yeah so especially now we tend to put in like ACE 
inhibitors a lot earlier and things like that, you know. It’s got to be so careful for these women 
 
Nodes\\Technology-assisted PCC intervention\Supportive approach or intervention language 
  No  0.0613  1  
         1  CHB  04/06/2016 06:25 
If it started with, you know, ladies with diabetes are more likely to have a still–, you know what I mean, that never goes down well with me 
because it’s important the ladies know definitely and it’s– but at the same time it’s kind of saying these risks are– can be reduced. It is 
possible, that’s why we want preconception care and we would look after you during your pregnancy. Ladies with diabetes should be able 
to enjoy their pregnancies and have a healthy pregnancy just the same as any other lady, yeah. But sometimes you start reading and it’s 
just all doom and gloom and I think if that’s the first thing you read, you immediately switch off. You think I can’t deal with that, you know, 
because I mean how would that make you feel? Yeah, so kind of like giving all the information but I guess in a positive way.  
Not kind of going all don’t worry you will be fine but at the same time going actually, no this is how it’s dealt with, this is how it’s controlled, 
you know. Giving the ladies a bit of knowledge is power and a bit of positivity like actually this is fine. I need to get my sugar sorted, I need 
my folic acid you know what I mean. Actually I want this baby and I can do the best I can by getting my preconception sorted. You don’t 
want to scare the ladies off before you’ve even started and I guess you know an app would be brilliant in kind of saying to them or saying in 
there that actually there is always someone you know like me on the end of the phone sort of thing, yeah. But no, apart from that glad to 
use an app. 
 
Nodes\\Technology-assisted PCC intervention\Suggestions 
  No  0.0756  3  
         1  CHB  04/06/2016 05:58 
So you would kind of hope the lady or her partner or someone will be like “well hang on if you are gonna be doing this, do a bit of research” 
and kind of google, and the internet and apps is the way forward, definitely, and it’s something that could be advertised in like a poster, up 
in the GP surgery, you know, do you have diabetes? Are you planning to get pregnant? Look at it. It’s out there kind of thing.  
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 2  CHB  04/06/2016 06:02 
I guess in not so much in our area but if you were looking at it being kind of UK wide, you would also want it in different languages, you 
know what I mean. Like in the London area, a lot of South East Asian ladies and things and kind of, we find this with some of our things, you 
know, like the dietary information such as low carbs whereas actually some ethnic groups you know they are very focused on you know 
different cooking methods. 
 
Like actually I’ve got one lady who has rice all day, but that’s what they do. So we are busy focusing on the evening meal and you are like 
“what did you have for breakfast?” and she is like “rice” and you are like “rice?” and she says “yes rice.” I have got friends from the 
Philippines and it’s the same, they have rice for breakfast and you are like, “ok”. So you know my other ladies I’m like “oh change your 
cereal to low GI, change your bread to brown” and when you are presented with rice, you are like “could you try brown rice?” It’s not like 
you can substitute it with much else, so yeah kind of there will be some groups that would need it in their own language, maybe some 
tweaks or even if it was a general app that says, is your diet like this or do you follow a more traditional diet.  
That’s where maybe speaking to someone who works with ladies from South East Asia, you know things like that might help sort of thing. 
Yeah.    3  CHB  04/06/2016 23:04 
I guess the way to meet most people would be for the app to be free, you’ve got to put it out there haven’t you? 
 
Nodes\\Technology-assisted PCC intervention\User engagement 
  No  0.0021  1  
         1  CHB  04/06/2016 06:01 
Relevant up to date information, easy to read language, 
 
Nodes\\Technology-assisted PCC intervention\User engagement\Design of PCC-MA 
  No  0.0291  3  
         1  CHB  04/06/2016 06:26 
Relevant up to date information, easy to read language, 
  2  CHB  04/06/2016 06:10 
you know it’s so much easier to read kind of either bullet points or short paragraphs rather than just an essay, you know. Some people are 
visual, aren’t they for their learning, so just making it memorable what they are reading. 
  3  CHB  04/06/2016 06:11 
 That’s it really, being updated, not just being put out there but if you are providing information that is kind of, it’s not medical as such but 
it’s so important, it’s also kind of important to make sure that its updated and if it’s not, to put some info about when it was stopped so at 
least the women know when it was last updated or they know that things do change so please speak to your healthcare professional. But 
no that’s about it I think. 
 285 
 
 
Reports\\Coding Summary By Source Report  
Classification  Aggregate  Coverage  Number Of 
Coding 
References 
 Reference 
Number 
 Coded By 
Initials 
 Modified On 
Nodes\\Technology-assisted self-monitoring 
  No  0.0239  1  
         1  CHB  04/06/2016 05:36 
Then, the ladies could always use various apps and things to track their blood glucose levels you know, record them and you can get meters 
that do bolus advice, how you calculate your rapid acting insulin, you can get those on phones, you know some people have the blood 
glucose metre and then the app on their phones, kind of thing and I guess you must be able to get general apps and things for planning a 
pregnancy so maybe, I’m assuming I haven’t looked to see what is kind of out there to kind of combine that with the diabetes which I 
suppose is where you are coming from to kind of fill that gap. 
 
Nodes\\Technology-assisted self-monitoring\Blood glucose diary or log with data visualisation 
  No  0.0239  1  
         1  CHB  09/06/2016 15:46 
Then, the ladies could always use various apps and things to track their blood glucose levels you know, record them and you can get meters 
that do bolus advice, how you calculate your rapid acting insulin, you can get those on phones, you know some people have the blood 
glucose metre and then the app on their phones, kind of thing and I guess you must be able to get general apps and things for planning a 
pregnancy so maybe, I’m assuming I haven’t looked to see what is kind of out there to kind of combine that with the diabetes which I 
suppose is where you are coming from to kind of fill that gap. 
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Phase 1 Patient interview 
 
Internals\\Interviews\\Patient2 
Node 
 Nodes\\Accessibility of care or services\Limitations, constraints and challenges of PCC or barriers to 
PCC provision 
  No  0.0293  1  
          1  CHB  05/06/2016 00:58 
 I think sometimes people go in, obviously with preconception people go in with good intentions but obviously if like it takes a while to get 
pregnant or whatever, they can lose interest which is, you know is obviously a bit alarming because especially with diabetics, you need to 
maintain and check, you need to maintain you know looking after yourself and obviously like supplementations and all things like that 
  
 Nodes\\Accessibility of care or services\Provision of Care 
  No  0.0935  2  
          1  CHB  05/06/2016 12:15 
 I am– I have recently charted over to the adolescence clinic from like child, child clinic. I go to the hospital I think once every 6 months to 
see my consultant and a dietician but I do have contact quite regularly with my diabetes nurse and the dietician. If like I have got any 
problems with the pump or whatever I just give them a ring and, I pretty much get an appointment that day to go in and sort out any 
problems. 
   2  CHB  05/06/2016 12:17 
 Well when I was placed on an insulin pump, the consultant–  I had like a 3 month review catch up with the consultant and she said that the, 
the pump was like the best thing to be on when like obviously it comes to like thinking about starting a family and things. But, I don’t know, 
I don’t know whether it’s because I’m like still a student they think– I haven’t really had any like advice or anything about like conceiving or 
like leaflets with diabetes or anything on it. My mother is a pharmacist as well so she is obviously like quite aware of the importance of 
obviously supplementation and things and because I think I am a dietetic student, I’m probably more aware of the importance of diabetes 
control but like with conception and things, but I have never, I’ve never had any like any particular input from my care team. I’ve never–  
nothing more than what I have learned myself.  
 
  
 Nodes\\Accessibility of care or services\Satisfaction in care provided or dissatisfaction 
  No  0.0522  1  
          1  CHB  05/06/2016 12:24 
 No, I think– Now I’ve decided to take part in this like study thing with you and discussing it. ‘Cause it’s like I’ve thought about it a lot more 
over the weekend. Like, when like you google it and things, there doesn’t seem to be much out there about like preconception especially 
with diabetes. Because obviously, it’s– it needs to be tightly controlled, you know your blood sugar and things. But there doesn’t seem to 
be much. I don’t know whether it’s just the healthcare team I’m with necessarily, but I would have thought that being like a 22 year old 
female, they would have like warned– like talked more to me about it, and like the importance of it but there doesn’t, doesn’t seem to be 
much literature and things on that.   
 
 Classification  Aggregate  Coverage  Number Of 
Coding 
References 
 Reference 
Number 
 Coded By 
Initials 
 Modified On 
 287 
 
 
 Nodes\\Expertise and knowledge about PCC for women with DM\Knowledge of PCC & PCC 
practices\Diabetes and pregnancy 
  No  0.0278  1  
          1  CHB  05/06/2016 12:19 
 Well, I don’t really know too much about it. I, I know obviously about the importance of like folic acid supplementation because that’s just a 
topic I’ve just covered now myself in university. I know, I know about like the importance of controlling your blood sugars and having 
HbA1c of a certain range before conceiving and things but nothing, I don’t really know too much on the subject.  
  
 Nodes\\Expertise and knowledge about PCC for women with DM\Knowledge of PCC & PCC 
practices\Importance of PCC or pregnancy planning 
  No  0.0501  1  
          1  CHB  05/06/2016 01:01 
 I think for me is probably highlighting how little I know about this area of diabetes. I think maybe it’s different for different people, given 
perhaps that I’m a student. Maybe my diabetes team don’t look at me as being of childbearing age because I’m still a student, maybe all 
these things would become more relevant to me in a few years’ time when I graduate you know things like that. But I still think, this 
conversation today has highlighted to me the importance of knowing things beforehand. I think, I think people need to be aware of 
preconception advice, maybe not only when they are planning to have– like get pregnant then. Just in general, I think it’s a good thing to 
know just in general 
  
 Nodes\\Expertise and knowledge about PCC for women with DM\Knowledge of PCC & PCC 
practices\Information Seeking practices 
  No  0.1112  4  
          1  CHB  05/06/2016 00:41 
 Well when I was placed on an insulin pump, the consultant–  I had like a 3 month review catch up with the consultant and she said that the, 
the pump was like the best thing to be on when like obviously it comes to like thinking about starting a family and things. But, I don’t know, 
I don’t know whether it’s because I’m like still a student they think– I haven’t really had any like advice or anything about like conceiving or 
like leaflets with diabetes or anything on it. My mother is a pharmacist as well so she is obviously like quite aware of the importance of 
obviously supplementation and things and because I think I am a dietetic student, I’m probably more aware of the importance of diabetes 
control but like with conception and things, but I have never, I’ve never had any like any particular input from my care team. I’ve never–  
nothing more than what I have learned myself.  
 
   2  CHB  05/06/2016 12:24 
 Usually I, I usually google. I google quite a lot of things, I know. Dr Google in all things [laughter]. But, I- If it’s something that’s obviously 
diabetes-related or affecting my health, I go to the doctor or more specifically to do with my diabetes, I probably phone my nursing team or 
try and get an appointment with my consultant specifically.  
   3  CHB  05/06/2016 12:25 
 Probably the internet.  
   4  CHB  05/06/2016 00:49 
 Yeah, it’s nice like information is all concentrated in one place. Like I know, like if I’m not sure of what I’m eating and I’m not really sure on 
like the calories or carbohydrate content of foods, I usually just whip my phone out and have a quick look for that information which is 
quite handy.  
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 Nodes\\Expertise and knowledge about PCC for women with DM\Knowledge of PCC & PCC 
practices\Knowledge gaps, uncertainty & misconceptions 
  No  0.1851  4  
          1  CHB  05/06/2016 12:19 
 Well, I don’t really know too much about it. I, I know obviously about the importance of like folic acid supplementation because that’s just a 
topic I’ve just covered now myself in university. I know, I know about like the importance of controlling your blood sugars and having 
HbA1c of a certain range before conceiving and things but nothing, I don’t really know too much on the subject.  
   2  CHB  05/06/2016 00:45 
 No, I think– Now I’ve decided to take part in this like study thing with you and discussing it. ‘Cause it’s like I’ve thought about it a lot more 
over the weekend. Like, when like you google it and things, there doesn’t seem to be much out there about like preconception especially 
with diabetes. Because obviously, it’s– it needs to be tightly controlled, you know your blood sugar and things. But there doesn’t seem to 
be much. I don’t know whether it’s just the healthcare team I’m with necessarily, but I would have thought that being like a 22 year old 
female, they would have like warned– like talked more to me about it, and like the importance of it but there doesn’t, doesn’t seem to be 
much literature and things on that.   
   3  CHB  05/06/2016 12:38 
 Well considering I don’t really have much in–, I have never been told much information on it. Anything really, anything that’s relevant to 
me, to my age, my condition, the thing, I know people, just getting the message across to people in different ways. But to me, shock tactics 
work. So like when I realised like, only recently I got spoken to about diabetic retinopathy and things like that and it was only when the 
message was delivered to me like in a shock [category?]. When you realise you know this can happen to you, then I think, I think that’s the 
best way, for me personally anyways, it’s the best way to get the message across and relay the importance of it and how things can and 
things do go wrong with, like obviously an unplanned pregnancy in diabetics.  
   4  CHB  05/06/2016 12:58 
 I think for me is probably highlighting how little I know about this area of diabetes. I think maybe it’s different for different people, given 
perhaps that I’m a student. Maybe my diabetes team don’t look at me as being of childbearing age because I’m still a student, maybe all 
these things would become more relevant to me in a few years’ time when I graduate you know things like that. But I still think, this 
conversation today has highlighted to me the importance of knowing things beforehand. I think, I think people need to be aware of 
preconception advice, maybe not only when they are planning to have– like get pregnant then. Just in general, I think it’s a good thing to 
know just in general 
  
 Nodes\\Expertise and knowledge about PCC for women with DM\Knowledge of PCC & PCC 
practices\Understanding of PCC 
  No  0.0237  2  
          1  CHB  05/06/2016 12:21 
 I suppose it would be things like controlling blood sugars, giving up alcohol and things, making sure you’ve got a good diet like folic acid and 
supplementation and giving up smoking, all the normal things really. 
   2  CHB  05/06/2016 12:20 
 Mainly family planning, I think of like obviously planned pregnancy rather than an unexpected or unplanned pregnancy. 
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 Nodes\\Expertise and knowledge about PCC for women with DM\Importance of PCC 
  No  0.1024  2  
          1  CHB  09/06/2016 14:40 
 No, I think– Now I’ve decided to take part in this like study thing with you and discussing it. ‘Cause it’s like I’ve thought about it a lot more 
over the weekend. Like, when like you google it and things, there doesn’t seem to be much out there about like preconception especially 
with diabetes. Because obviously, it’s– it needs to be tightly controlled, you know your blood sugar and things. But there doesn’t seem to 
be much. I don’t know whether it’s just the healthcare team I’m with necessarily, but I would have thought that being like a 22 year old 
female, they would have like warned– like talked more to me about it, and like the importance of it but there doesn’t, doesn’t seem to be 
much literature and things on that.   
   2  CHB  05/06/2016 01:01 
 I think for me is probably highlighting how little I know about this area of diabetes. I think maybe it’s different for different people, given 
perhaps that I’m a student. Maybe my diabetes team don’t look at me as being of childbearing age because I’m still a student, maybe all 
these things would become more relevant to me in a few years’ time when I graduate you know things like that. But I still think, this 
conversation today has highlighted to me the importance of knowing things beforehand. I think, I think people need to be aware of 
preconception advice, maybe not only when they are planning to have– like get pregnant then. Just in general, I think it’s a good thing to 
know just in general 
  
 Nodes\\Expertise and knowledge about PCC for women with DM\Self-management, motivation and 
responsibility or women's desire to adopt healthy behaviours 
  No  0.0548  1  
          1  CHB  06/07/2016 05:21 
 Well considering I don’t really have much in–, I have never been told much information on it. Anything really, anything that’s relevant to 
me, to my age, my condition, the thing, I know people, just getting the message across to people in different ways. But to me, shock tactics 
work. So like when I realised like, only recently I got spoken to about diabetic retinopathy and things like that and it was only when the 
message was delivered to me like in a shock [category?]. When you realise you know this can happen to you, then I think, I think that’s the 
best way, for me personally anyways, it’s the best way to get the message across and relay the importance of it and how things can and 
things do go wrong with, like obviously an unplanned pregnancy in diabetics.  
  
 Nodes\\Feasibility and acceptability of a smartphone app for PCC 
  No  0.0501  1  
          1  CHB  05/06/2016 13:50 
 I think for me is probably highlighting how little I know about this area of diabetes. I think maybe it’s different for different people, given 
perhaps that I’m a student. Maybe my diabetes team don’t look at me as being of childbearing age because I’m still a student, maybe all 
these things would become more relevant to me in a few years’ time when I graduate you know things like that. But I still think, this 
conversation today has highlighted to me the importance of knowing things beforehand. I think, I think people need to be aware of 
preconception advice, maybe not only when they are planning to have– like get pregnant then. Just in general, I think it’s a good thing to 
know just in general 
  
 Nodes\\Feasibility and acceptability of a smartphone app for PCC\Facilitators or barriers to PCC-MA 
acceptance 
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  No  0.1410  4  
          1  CHB  05/06/2016 00:52 
 I think it’s probably the best way to get information across to people like myself who obviously haven’t been informed of like the 
importance of preconception especially in diabetes. I think if it, if it was like user friendly, not too overpowering but delivers like the main, 
the key information points needed. Like the absolute importance of supplementation, the importance of blood glucose control, the effect 
of not having blood glucose control. So, that delivered the key messages in a simple way that was, that got the message across to people 
who may not be, as, like understand the medical terms. Key importance really. I think it’s a good idea. To get the message out there is 
better than– to have some understanding is more important than having no understanding.   
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 2  CHB  05/06/2016 00:56 
 I think visual aids are a big thing. I think sometimes if apps have too much like detailed information, like, too much words and things that 
can be quite off-putting. My friend’s mum is trying to get pregnant, she like, keeps track of, like, like through visual ways, she’s got like an 
app that shows how the baby is developing and things like that and she finds it quite motivating. So she said to me, when you can see 
what’s going on inside your body through an app is more motivating. Which I think would be a good thing for diabetics, if they can 
understand–  if they can see the baby developing through visual aids, more so than information, I think it keeps people motivated obviously 
to look after themselves and keeps them interested and on top of like healthcare. 
   3  CHB  05/06/2016 12:56 
 Just that its relevant and easy to use obviously, people don’t want to spend hours at a time putting–  inputting information into an app. if it 
was something that was quick and easy, just simple to use like obviously on the go and things then. Simplicity and ease of use more than 
anything really.  
   4  CHB  05/06/2016 12:57 
 If it was too expensive, if it was slow running, if it was giving out like too much wordy information, things like that.  
  
 Nodes\\Feasibility and acceptability of a smartphone app for PCC\Opinion of PCC-MA 
  No  0.0560  1  
          1  CHB  05/06/2016 12:36 
 I think it’s probably the best way to get information across to people like myself who obviously haven’t been informed of like the 
importance of preconception especially in diabetes. I think if it, if it was like user friendly, not too overpowering but delivers like the main, 
the key information points needed. Like the absolute importance of supplementation, the importance of blood glucose control, the effect 
of not having blood glucose control. So, that delivered the key messages in a simple way that was, that got the message across to people 
who may not be, as, like understand the medical terms. Key importance really. I think it’s a good idea. To get the message out there is 
better than– to have some understanding is more important than having no understanding.   
  
 Nodes\\IT awareness\Appreciation of tech use in healthcare 
  No  0.0902  3  
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 1  CHB  05/06/2016 12:26 
 Yeah, I use 2 apps mainly- I use my Fitness Pal® to like calculate foods and keep track of what I’m eating. I use the Carb and Cal® app too for 
obviously when I need to estimate carbohydrate intake. 
   2  CHB  05/06/2016 00:49 
 Yeah, it’s nice like information is all concentrated in one place. Like I know, like if I’m not sure of what I’m eating and I’m not really sure on 
like the calories or carbohydrate content of foods, I usually just whip my phone out and have a quick look for that information which is 
quite handy.  
   3  CHB  05/06/2016 00:56 
 I think visual aids are a big thing. I think sometimes if apps have too much like detailed information, like, too much words and things that 
can be quite off-putting. My friend’s mum is trying to get pregnant, she like, keeps track of, like, like through visual ways, she’s got like an 
app that shows how the baby is developing and things like that and she finds it quite motivating. So she said to me, when you can see 
what’s going on inside your body through an app is more motivating. Which I think would be a good thing for diabetics, if they can 
understand–  if they can see the baby developing through visual aids, more so than information, I think it keeps people motivated obviously 
to look after themselves and keeps them interested and on top of like healthcare. 
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 Nodes\\IT awareness\Appreciation of tech use in healthcare\Technology use for diabetes 
  No  0.0352  2  
          1  CHB  09/06/2016 13:52 
 Yeah, I use 2 apps mainly- I use my Fitness Pal® to like calculate foods and keep track of what I’m eating. I use the Carb and Cal® app too for 
obviously when I need to estimate carbohydrate intake. 
   2  CHB  09/06/2016 13:52 
 Yeah, it’s nice like information is all concentrated in one place. Like I know, like if I’m not sure of what I’m eating and I’m not really sure on 
like the calories or carbohydrate content of foods, I usually just whip my phone out and have a quick look for that information which is 
quite handy.  
  
  Nodes\\IT awareness\Interaction with technology 
  No  0.0887  5  
          1  CHB  05/06/2016 12:25 
 Mainly my phone or my iPad or my laptop.  
   2  CHB  05/06/2016 12:25 
 Well [laughter] I have practically got my phone glued to my hands. When I’m in Uni, I mostly use my laptop and my phone. So yeah, I have 
always got some sort of device on me. But like, if I need to know, if like something comes to mind that I want to think of, it’s usually my 
phone that I tend to use. 
   3  CHB  05/06/2016 00:47 
 Yeah, I use 2 apps mainly- I use my Fitness Pal® to like calculate foods and keep track of what I’m eating. I use the Carb and Cal® app too for 
obviously when I need to estimate carbohydrate intake. 
   4  CHB  05/06/2016 20:07 
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 I think I find that mobile apps are more specific to like a certain subject. Like obviously, the Carb and Cal are specific for calculating carbs, 
my Fitness Pal I use that to track my exercise and obviously what I’m eating and obviously like social media. Like Instagram and things like 
that, which are more specific. I find apps focus on one area rather than a broad range of things if that makes sense. 
   5  CHB  05/06/2016 12:28 
 Yeah, it’s nice like information is all concentrated in one place. Like I know, like if I’m not sure of what I’m eating and I’m not really sure of 
like the calories or carbohydrate content of foods, I usually just whip my phone out and have a quick look for that information which is 
quite handy.  
  
 Nodes\\Technology-assisted PCC intervention\Intervention content or content of Smartphone app 
  No  0.0549  1  
          1  CHB  05/06/2016 12:39 
 Well considering I don’t really have much in–, I have never been told much information on it. Anything really, anything that’s relevant to 
me, to my age, my condition, the thing, I know people, just getting the message across to people in different ways. But to me, shock tactics 
work. So like when I realised like, only recently I got spoken to about diabetic retinopathy and things like that and it was only when the 
message was delivered to me like in a shock [category?]. When you realise you know this can happen to you, then I think, I think that’s the 
best way, for me personally anyways, it’s the best way to get the message across and relay the importance of it and how things can and 
things do go wrong with, like obviously an unplanned pregnancy in diabetics.  
 
 Classification  Aggregate  Coverage  Number Of 
Coding 
References 
 Reference 
Number 
 Coded By 
Initials 
 Modified On 
 Nodes\\Technology-assisted PCC intervention\Intervention content or content of Smartphone 
app\Antenatal care 
  No  0.0199  1  
          1  CHB  05/06/2016 12:40 
 I think it’s good to obviously include preconception information but then also continuing into the pregnancy because obviously it’s 
important to plan as a diabetic for pregnancy but also to provide like ongoing support to people and unto the early and later stages of 
pregnancy.  
  
 Nodes\\Technology-assisted PCC intervention\Intervention content or content of Smartphone 
app\Folic acid & supplementation 
  No  0.0243  3  
          1  CHB  05/06/2016 12:17 
 My mother is a pharmacist as well so she is obviously like quite aware of the importance of obviously supplementation and things 
   2  CHB  05/06/2016 12:18 
 I know obviously about the importance of like folic acid supplementation because that’s just a topic I’ve just covered now myself in 
university. 
   3  CHB  05/06/2016 12:20 
 293 
 
 
 making sure you’ve got a good diet like folic acid and supplementation 
  
 Nodes\\Technology-assisted PCC intervention\Intervention content or content of Smartphone 
app\Good diabetes control 
  No  0.0343  3  
          1  CHB  05/06/2016 12:17 
 and because I think I am a dietetic student, I’m probably more aware of the importance of diabetes control but like with conception and 
things, but I have never, I’ve never had any like any particular input from my care team. I’ve never–  nothing more than what I have learned 
myself.  
   2  CHB  05/06/2016 12:18 
 I know, I know about like the importance of controlling your blood sugars and having HbA1c of a certain range before conceiving and things 
   3  CHB  05/06/2016 12:19 
 I suppose it would be things like controlling blood sugars 
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 Nodes\\Technology-assisted PCC intervention\Intervention content or content of Smartphone 
app\Lifestyle modification 
  No  0.0032  2  
          1  CHB  05/06/2016 12:19 
 giving up alcohol and things 
   2  CHB  05/06/2016 12:20 
 giving up smoking 
  
 Nodes\\Technology-assisted PCC intervention\User engagement 
  No  0.1508  5  
          1  CHB  05/06/2016 12:29 
 I like that, because I use them quite regularly and I like that they are easy to use and I know how to work it and things like that. It’s not like 
very complicated, I know like especially the Carb and Cal it’s got– it’s got a large database, so there is a lot of information in one place 
rather than going to google for instance to have to search and to find something that’s relevant to what I’m looking for, the Carb and Cal 
especially uses like pictures and stuff which is easy to visualise. It’s quite user friendly, it’s quite– its suits me for what I need.  
   2  CHB  05/06/2016 00:50 
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 No. not really. Sometimes, it can be quite limited in the information. I mean there’s a lot on apps and things but sometimes if you are 
looking for something a little bit more then you will need to like search, do your search. But generally, for what I use apps and things for is 
pretty much things that I need.  
   3  CHB  05/06/2016 00:51 
 A wide variety of information available, user friendly, not too much information like no information overload, yes, easy to use. Obviously, I, 
sometimes I buy apps, but I–  yes, and use it and things, as long as it’s not like too expensive I don’t mind paying 2 or 3 pounds for an app if 
I know I’m going to get good use out of it.  
   4  CHB  05/06/2016 00:51 
 No not really. Just, it’s easy to use, runs well. It’s got the information I need, and it’s all relevant but not too over-powering.  
   5  CHB  05/06/2016 12:41 
 I think visual aids are a big thing. I think sometimes if apps have too much like detailed information, like, too much words and things that 
can be quite off-putting. My friend’s mum is trying to get pregnant, she like, keeps track of, like, like through visual ways, she’s got like an 
app that shows how the baby is developing and things like that and she finds it quite motivating. So she said to me, when you can see 
what’s going on inside your body through an app is more motivating. Which I think would be a good thing for diabetics, if they can 
understand–  if they can see the baby developing through visual aids, more so than information, I think it keeps people motivated obviously 
to look after themselves and keeps them interested and on top of like healthcare. 
  
 Nodes\\Technology-assisted PCC intervention\User engagement\Comprehensiveness 
  No  0.0612  2  
          1  CHB  05/06/2016 12:28 
 Yeah, it’s nice like information is all concentrated in one place. Like I know, like if I’m not sure of what I’m eating and I’m not really sure on 
like the calories or carbohydrate content of foods, I usually just whip my phone out and have a quick look for that information which is 
quite handy.  
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 2  CHB  09/06/2016 15:29 
 I like that, because I use them quite regularly and I like that they are easy to use and I know how to work it and things like that. It’s not like 
very complicated, I know like especially the Carb and Cal it’s got– it’s got a large database, so there is a lot of information in one place 
rather than going to google for instance to have to search and to find something that’s relevant to what I’m looking for, the Carb and Cal 
especially uses like pictures and stuff which is easy to visualise. It’s quite user friendly, it’s quite– its suits me for what I need.  
  
 Nodes\\Technology-assisted PCC intervention\User engagement\Design of PCC-MA 
  No  0.1098  2  
          1  CHB  05/06/2016 00:54 
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 Well considering I don’t really have much in–, I have never been told much information on it. Anything really, anything that’s relevant to 
me, to my age, my condition, the thing, I know people, just getting the message across to people in different ways. But to me, shock tactics 
work. So like when I realised like, only recently I got spoken to about diabetic retinopathy and things like that and it was only when the 
message was delivered to me like in a shock [category?]. When you realise you know this can happen to you, then I think, I think that’s the 
best way, for me personally anyways, it’s the best way to get the message across and relay the importance of it and how things can and 
things do go wrong with, like obviously an unplanned pregnancy in diabetics.  
   2  CHB  05/06/2016 12:51 
 I think visual aids are a big thing. I think sometimes if apps have too much like detailed information, like, too much words and things that 
can be quite off-putting. My friend’s mum is trying to get pregnant, she like, keeps track of, like, like through visual ways, she’s got like an 
app that shows how the baby is developing and things like that and she finds it quite motivating. So she said to me, when you can see 
what’s going on inside your body through an app is more motivating. Which I think would be a good thing for diabetics, if they can 
understand–  if they can see the baby developing through visual aids, more so than information, I think it keeps people motivated obviously 
to look after themselves and keeps them interested and on top of like healthcare. 
  
 Nodes\\Technology-assisted self-monitoring 
  No  0.1124  2  
          1  CHB  05/06/2016 12:52 
 Maybe like reminders. Like I know of some, if you haven’t used it– an app for a while they give like notifications to like remind you that you 
know it’s still here, you can still use me sort of thing. I think that’s a good thing to have, to like, because I think sometimes people go in, 
obviously with preconception people go in with good intentions but obviously if like it takes a while to get pregnant or whatever, they can 
lose interest which is, you know is obviously a bit alarming because especially with diabetics, you need to maintain and check, you need to 
maintain you know looking after yourself and obviously like supplementations and all things like that so having reminders and like 
notifications and things would be a good thing to include. 
   2  CHB  05/06/2016 12:53 
 Personally because I use a handset that comes with my pump, I tend to keep track of my blood glucose and things through that, if there 
could be a way of maybe like linking the two technologies together. I obviously, when I was first diagnosed, that was 15, 16 years ago or 
whatever it was, I- we- used to have a diary, and having a diary of pages and pages of numbers had no relevance but like now obviously 
with the way technology has advanced, on my handset I can see like breakdowns of my blood glucose readings over the last day, weeks, 
months which is quite handy, because you can see you know how it’s going and have like graphs and pie charts and things which is more 
handy than obviously pages of useless numbers. I suppose yes, if there was a way of maybe putting like weekly averages in or like daily 
averages.  
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 Nodes\\Technology-assisted self-monitoring\Blood glucose diary or log with data visualisation 
  No  0.0583  1  
          1  CHB  09/06/2016 15:49 
 Personally because I use a handset that comes with my pump, I tend to keep track of my blood glucose and things through that, if there 
could be a way of maybe like linking the two technologies together. I obviously, when I was first diagnosed, that was 15, 16 years ago or 
whatever it was, I- we- used to have a diary, and having a diary of pages and pages of numbers had no relevance but like now obviously 
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 with the way technology has advanced, on my handset I can see like breakdowns of my blood glucose readings over the last day, weeks, 
months which is quite handy, because you can see you know how it’s going and have like graphs and pie charts and things which is more 
handy than obviously pages of useless numbers. I suppose yes, if there was a way of maybe putting like weekly averages in or like daily 
averages.  
  
 Nodes\\Technology-assisted self-monitoring\Reminders 
  No  0.0537  1  
          1  CHB  09/06/2016 15:48 
 Maybe like reminders. Like I know of some, if you haven’t used it– an app for a while they give like notifications to like remind you that you 
know it’s still here, you can still use me sort of thing. I think that’s a good thing to have, to like, because I think sometimes people go in, 
obviously with preconception people go in with good intentions but obviously if like it takes a while to get pregnant or whatever, they can 
lose interest which is, you know is obviously a bit alarming because especially with diabetics, you need to maintain and check, you need to 
maintain you know looking after yourself and obviously like supplementations and all things like that so having reminders and like 
notifications and things would be a good thing to include. 
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Phase 2 Patient interview 
 
 Internals\\P16 
 Node 
 Nodes\\Engagement with the intervention\Adherence 
  No  0.0542  5  
          1  CHB  23/08/2017 11:05 
 I had a similar app on an old phone and it’s no longer supported. You’d log in your details of what your scores were, you know what I mean, 
in a similar way to the app that you’ve got. So I found it quite simple to do, but sometimes I’d forget to put them in, so I’d sit down at the 
end of the week and put them all in rather than perhaps doing it at the same time, because I wouldn’t always have my phone next to me 
when I took readings. 
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 2  CHB  23/08/2017 11:05 
 I didn’t use it every day, but I would have been able to 
   3  CHB  23/08/2017 11:06 
 It was two or three times a week I would say. I’d sit down every couple of days, maybe occasionally slightly longer and put in the ones from 
my meter, I’d put them in. 
   4  CHB  23/08/2017 11:07 
 I would generally use it around about teatime.  
   5  CHB  23/08/2017 11:08 
 Sometimes I would use it at the time I took the readings but more often it was around teatime because I’d sit down after I’d driven home 
from work and just have a bit of a sit down and then I’d sit there and fill it in. 
  
 Nodes\\Engagement with the intervention\Barriers to usage 
  No  0.0603  4  
          1  CHB  23/08/2017 11:06 
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 Sometimes I forgot and I’d think oh I don’t quite have the time now, I’ll do it later on. 
   2  CHB  23/08/2017 11:07 
 I’m not sure. I’m a bit rubbish at it at the moment. I think when I do get pregnant then I will be more motivated to make sure that I’m 
sticking to targets and things like that. 
   3  CHB  23/08/2017 11:07 
 I had a lot of things going on at the time as well, so it wasn’t quite at the top of my priority list. 
 
 
I had a wedding to plan, I had the end of my university year to hand in assignments for, I was doing a sponsored swim and I had to fit all 
these things in and just kind of forgot I guess occasionally. 
   4  CHB  23/08/2017 11:09 
 It wasn’t difficult to use. I would suggest if I’d been more… I’m trying to think of the right word. It wasn’t… Ooh I’ve lost all my words, I’m 
terribly sorry. It would be quite easy to fit in if I made sure that I did it. I was struggling a bit to find… find the time’s not quite the right word 
but I think if I set my mind to it, it would be quite easy for it to fit in, it would only be another minute when I wasn’t taking my readings, so. 
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 Nodes\\Engagement with the intervention\Barriers to usage\Priorities 
  No  0.0188  1  
          1  CHB  23/08/2017 11:12 
 I had a lot of things going on at the time as well, so it wasn’t quite at the top of my priority list. 
 
  
I had a wedding to plan, I had the end of my university year to hand in assignments for, I was doing a sponsored swim and I had to fit all 
these things in and just kind of forgot I guess occasionally. 
  
 Nodes\\Feasibility and acceptability of intervention\ PCC Support  
  No  0.0424  2  
          1  CHB  23/08/2017 11:26 
 I did speak to the diabetes team, yes, and had the HbA1 thing - I can never say that right - taken and then we had a bit of a discussion about 
it. They were quite blunt about it and it was a little bit kind of scary I guess but they were both telling the truth but they weren’t as nice… 
nice is not quite the right word but your app kind of made them go, “Oh well that’s the preferred level you need to be at,” not the, ‘You’ve 
got to be there otherwise you can’t.’ So I just spoke to them.  
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   2  CHB  23/08/2017 11:27 
 I didn’t really feel very supported but I guess it was more of a question of I wasn’t at the time saying I’m trying to get pregnant, it was more 
of a “you’ve got to do this before you can start,” so it wasn’t very supportive at that point. 
  
 Nodes\\Feasibility and acceptability of intervention\Acceptability of intervention\Benefits of a mobile phone-
based PCC intervention 
  No  0.0270  1  
          1  CHB  23/08/2017 11:32 
 I like it. I’ve carried around a book but I either don’t have a pen or my handbag is too small for it or I’ve left it at home and it’s very rare that 
I leave my phone behind, so it’s always there and I can, if I remember, always put it in and it’s always there and if I don’t have an internet 
connection the majority of the information is there for me and I just like the fact that it’s like having all the information in a book but in a 
tiny place on your phone. 
  
 Nodes\\Feasibility and acceptability of intervention\Acceptability of intervention\Views and attitudes towards 
app use for PCC 
  No  0.0270  1  
          1  CHB  23/08/2017 11:32 
 I like it. I’ve carried around a book but I either don’t have a pen or my handbag is too small for it or I’ve left it at home and it’s very rare that 
I leave my phone behind, so it’s always there and I can, if I remember, always put it in and it’s always there and if I don’t have an internet 
connection the majority of the information is there for me and I just like the fact that it’s like having all the information in a book but in a 
tiny place on your phone. 
Reports\\Coding Summary By Source Report  
 
 Classification  Aggregate  Coverage  Number Of 
Coding 
References 
 Reference 
Number 
 Coded By 
Initials 
 Modified On 
 Nodes\\Feasibility and acceptability of intervention\Practicality or Usability\Ease of use 
  No  0.0178  2  
          1  CHB  23/08/2017 11:11 
 Quite easy to use. It looks nice, it was quite self-explanatory 
   2  CHB  23/08/2017 11:14 
 It was quite simple to do. As I said, I didn’t have a lot of motivation to do it straightaway, so occasionally it took me a while, but that’s my 
fault for not doing it at the time. So I would say it’s easy, I was just making my own life hard. 
  
 Nodes\\Feasibility and acceptability of intervention\Practicality or Usability\Experience with user interface 
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  No  0.0036  1  
          1  CHB  23/08/2017 11:11 
 Quite easy to use. It looks nice, it was quite self-explanatory 
  
 Nodes\\Feasibility and acceptability of intervention\Usefulness of intervention content 
  No  0.0104  1  
          1  CHB  23/08/2017 11:35 
 I think I will… I’m trying to think of the words, in general, take better care of me and keep taking readings and trying to take my… just being 
in better control of my diabetes. 
  
 Nodes\\Feasibility and acceptability of intervention\Usefulness of intervention content\Usefulness of diary 
  No  0.0368  2  
          1  CHB  23/08/2017 11:30 
 I think it probably did, yes. I think, in a small part is, because I was testing it for you, it made me do it more, but being able to see what it 
says and it’s actually in front of me rather than having to scroll through on the meter and stuff, it definitely makes me think about it more 
and the fact that I need to put in the readings might remind me a little bit better to take the readings and things like that. 
   2  CHB  23/08/2017 11:36 
 Because I think it drops priority for a while and because I’ve been helping you it’s made it come up to a higher priority and it’s made me 
think about it more and my levels are coming down, so that’s quite impressive. 
Reports\\Coding Summary By Source Report  
 
 Classification  Aggregate  Coverage  Number Of 
Coding 
References 
 Reference 
Number 
 Coded By 
Initials 
 Modified On 
 Nodes\\Feasibility and acceptability of intervention\Usefulness of intervention content\Usefulness of PCC 
content 
  No  0.1001  4  
          1  CHB  23/08/2017 11:11 
 The information was very good and the fact that it’s got links to things was also very good. Rather than having to search it for yourself, you 
could press the link and go straight there and that was really good. 
   2  CHB  23/08/2017 11:19 
 I thought it was very useful actually. I’m not sure it would be very useful to somebody who was thinking about it five years down the line 
but maybe six months or a year before it would be better suited than in four or five years because it was all just a ‘ooh I might remember 
that,’ whereas things like about taking the extra folic acid, I was actually showing that to my doctor and said, “Well actually it says that we 
need the 5mg rather than the normal,” so I’ve had that prescribed now. 
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   3  CHB  23/08/2017 11:20 
 finding out about the other things and being able to log in to forums about pregnant diabetics and see what had to be said because my 
sugar level is slightly too high than what the doctors are recommending and I just wanted to see what other people had and whether it 
would be awful if it was one above what they’d asked for or not. Just being able to log in to these forums and be able to hear about other 
people in the same situations.  
   4  CHB  23/08/2017 11:23 
 I found it very useful actually. I actually sat and read quite a lot of it one night when I couldn’t sleep and found out a lot of things that I 
perhaps wouldn’t have known before or things like that. So about the folic acid, it would never have occurred to me that I needed anything 
different. It’s one of the main things that I found out about rather than the actual while I’m pregnant stage because obviously I’m not at 
that stage yet. So it was interesting to know that you need to take more than you generally hear about. It wasn’t something that I had been 
aware of at all. 
  
 Nodes\\Feasibility and acceptability of intervention\Usefulness of intervention content\Usefulness of PCC 
content\Usefulness of links and videos 
  No  0.0589  4  
          1  CHB  23/08/2017 11:11 
 The information was very good and the fact that it’s got links to things was also very good. Rather than having to search it for yourself, you 
could press the link and go straight there and that was really good. 
   2  CHB  23/08/2017 11:20 
 finding out about the other things and being able to log in to forums about pregnant diabetics and see what had to be said because my 
sugar level is slightly too high than what the doctors are recommending and I just wanted to see what other people had and whether it 
would be awful if it was one above what they’d asked for or not. Just being able to log in to these forums and be able to hear about other 
people in the same situations.  
   3  CHB  23/08/2017 11:21 
 It was, yes. Logging in is not quite the right word but I used it via the app and read some of the things that came up. 
   4  CHB  23/08/2017 11:23 
 I didn’t think any of it was too short, no, and it wasn’t too long and I think the fact that it got links so you could find out more was probably 
the perfect way for it to be, so if you did want to hear more you could go on and have a look. 
Reports\\Coding Summary By Source Report  
 
 Classification  Aggregate  Coverage  Number Of 
Coding 
References 
 Reference 
Number 
 Coded By 
Initials 
 Modified On 
 Nodes\\Feasibility and acceptability of intervention\Usefulness of intervention content\Utility of app 
intervention 
  No  0.0104  1  
          1  CHB  23/08/2017 11:35 
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 I think I will… I’m trying to think of the words, in general, take better care of me and keep taking readings and trying to take my… just being 
in better control of my diabetes. 
  
 Nodes\\Future development of the intervention\Improvement to app features 
  No  0.0645  3  
          1  CHB  23/08/2017 11:30 
 I don’t think so. I don’t know whether… perhaps if you put in how far in the future you want to be pregnant and it brought up more 
relevant things, that could be a very useful thing, so like if I want to get pregnant in six months then maybe you need to think about folic 
acid, that kind of feature maybe a good one, or “now’s the time to go and get your [HbA1c]”. I can’t say it. [Laughs] I get it wrong every 
time and when I think about it. But perhaps a reminder to book in to get that done or something like that. 
   2  CHB  23/08/2017 11:31 
 Because obviously you need to do different things at different times before you get pregnant and it could become more specific when you 
actually are or “here are the favourite bits for this time in your journey” I guess is one way to put it. 
   3  CHB  23/08/2017 11:33 
 I don’t… Oh I just thought that maybe there could be a space so you could put in local numbers, for instance, like I’d put in my diabetic 
consultant’s number or some local places where perhaps I’d need to go, like see the pregnancy team at the hospital or the diabetic nurse, 
perhaps put their- a space to put notes maybe or contact details for people.  
  
 Nodes\\Future development of the intervention\Improvement to diary 
  No  0.0442  2  
          1  CHB  23/08/2017 11:28 
 It was easy enough. It would be brilliant if you could link it into a sugar monitor or from a Bluetooth sort of monitor or something so that it 
could automatically go in. That would make it much easier, because that would save so much time, and my monitor is tiny and fiddly and 
getting to go through the… if you leave it too long it will go back to the beginning again and then you have to scroll through. 
   2  CHB  23/08/2017 11:33 
 I don’t… Oh I just thought that maybe there could be a space so you could put in local numbers, for instance, like I’d put in my diabetic 
consultant’s number or some local places where perhaps I’d need to go, like see the pregnancy team at the hospital or the diabetic nurse, 
perhaps put their- a space to put notes maybe or contact details for people.  
  
 Nodes\\Future development of the intervention\Improvement to PCC content 
  No  0.0361  1  
          1  CHB  23/08/2017 11:24 
 Yes, I think the more commons ones were in there and perhaps a thing to say ‘discuss anything you’re on with the doctor’ would be very 
useful because I didn’t realise that an antidepressant was going to be an issue. And it isn’t necessarily going to be because obviously it’s 
better if you are not on medication but if you are seriously depressed while you are pregnant then that’s more dangerous than if you are 
taking the antidepressants. It was nice to find out that oh well, perhaps I ought to look into that and discuss it with the doctor at the very 
least rather than just stopping it or not knowing about it. 
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Reports\\Coding Summary By Source Report  
 Classification  Aggregate  Coverage  Number Of 
Coding 
References 
 Reference 
Number 
 Coded By 
Initials 
 Modified On 
 Nodes\\Future development of the intervention\Satisfaction with study 
  No  0.0239  1  
          1  CHB  23/08/2017 11:33 
 I quite enjoyed it actually. I feel like I’ve helped Diabetes UK for instance and helped you and I feel good for having done it and it’s given me 
more information that I perhaps wouldn’t have looked at. I would have got round to it at some point but because it was in front of me and 
it was important to be helping you then I’ve looked at it and got all the knowledge I need probably at the right time as well. 
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Appendix 12 
 
 Feasibility study of a Smartphone Application (App) 
for the preconception care of women with diabetes 
 
 
PATIENT QUESTIONNAIRE 
 
 
 
Instructions: Thank you for agreeing to complete this questionnaire. It is 
designed to assess your knowledge and attitudes to reproductive health 
and preconception care. The questionnaire will take about 15 minutes to 
complete. Please answer every question. 
 
 
 
To return the questionnaire, either hand it to the researcher who gave it to 
you or post it back in the envelope provided.  
 
 
 
 
Pre-conception Care Mobile App (PCC-MA) 
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This section is designed to explore your knowledge about how diabetes affects 
pregnancy. Please read each statement and mark the option that best describes your 
opinion. Please respond to all of the questions 
 
QUESTION 
 
 
1. Have you ever discussed how diabetes affects pregnancy with your regular diabetes 
health care provider?  
If Yes, please state who you discussed this with.  
 
 
  
2. Has a health care professional (doctor, nurse, etc) ever told you that you should get 
special medical care and advice before you become pregnant or plan for a 
pregnancy?  
     This is called preconception care or pregnancy planning 
     If Yes, please state who told you.  
 
 
 
3. Has anyone else (partner, friends, family, colleagues, etc) told you that you should 
get preconception care (special medical care and advice) before you become 
pregnant or plan for a pregnancy? 
If Yes, please state who told you.  
 
 
 
4. Has a healthcare professional (doctor, nurse, etc) told you that you should use some 
type of contraception to prevent a pregnancy? 
If Yes, please state who told you.  
 
 
 
5. Has anyone else (partner, friends, family, colleagues, etc) told you that you should 
use some type of contraception to prevent a pregnancy? 
If Yes, please state who told you. 
 
 
 
Please continue questions on next page 
 
Yes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Section 1                         Knowledge of Reproductive Health  
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Assuming you are sexually 
active or think back to when 
last you were: 
Not at all A little Somewhat A moderate 
amount 
A lot 
6. How much do/did you worry 
that you could become 
pregnant? 
 
     
7. How much do/did you worry 
that you could catch a 
sexually transmitted infection 
(eg HIV/AIDS)? 
 
     
8. How much do/did you worry 
that you could develop health 
problems if you become 
pregnant? 
     
 
9. How much do/did you worry 
that if you become pregnant 
your baby could develop 
health problems? 
 
     
When planning a pregnancy: 
 
Not at all A little Somewhat A moderate 
amount 
A lot 
10. Would having blood sugar 
levels in the normal range (3.5-
7.5 mmol/l) before becoming 
pregnant improve your 
chances of having a healthy 
baby? 
 
     
11. Would seeking preconception 
care (special medical care and 
advice) improve your chances 
of having a healthy baby? 
 
     
12. How difficult do you think it 
would be to seek 
preconception care (special 
medical care and advice)? 
     
13. How difficult do you think it 
would be, to follow the 
preconception care advice 
given by a health professional 
(e.g attending retinal 
screening)? 
     
 
 307 
 
 
How confident am I that I could: 
 
Not at all A little Somewhat A moderate 
amount 
A lot 
14. Get preconception care 
(special medical care and 
advice) before I get pregnant. 
 
     
15. Change my insulin, 
medication and diet to keep 
my blood sugar levels in 
normal range, even if I am not 
yet pregnant, but planning a 
pregnancy. 
     
16. Delay becoming pregnant until   
my blood sugar levels are 
within the normal range. 
     
 
 
Would you say that getting 
preconception care (special 
medical care and advice): 
Not at all A little Somewhat A moderate 
amount 
A lot 
17. Would help you get normal 
blood sugar levels? 
     
18. Would help you understand 
how diabetes affects 
pregnancy? 
 
     
19. Would help you decide what 
contraception method to use? 
 
     
20. Would help you prevent an 
unplanned pregnancy? 
     
 
 
 
This section is designed to assess your knowledge of preconception care (special medical care 
and advice about pregnancy planning). Please read each statement and mark the option that 
best describes your opinion. Please respond to all of the statements 
STATEMENT True False Not  sure 
1. Women with diabetes have very limited choices of 
contraception 
   
 
2. Women with diabetes cannot use hormonal contraception  
   
 
3. All insulin are suitable for use during pregnancy 
 
   
Section 2             Knowledge of preconception care 
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STATEMENT 
4. If you have Type 2 diabetes and are planning to become 
pregnant you may need to change from tablets to injections 
of  insulin  
  
 
True 
 
False 
 
Not sure 
5. Women with diabetes should take folic acid daily when 
planning a pregnancy 
 
6. Women with diabetes should take the same amount of folic 
acid as all other women planning a pregnancy  
 
   
7. Before becoming pregnant, ideally your HbA1c should be 
below 6.5% (48.0 mmol/mol) 
 
   
8. Blood glucose levels before pregnancy can affect the health 
of the baby 
   
    
9. High blood glucose levels during pregnancy do not increase 
the risk of problems for the mother 
 
   
10. High blood glucose levels during pregnancy do not increase 
the risk of problems for the baby 
 
   
11. Women with diabetes have an increased risk of having a 
large baby making delivery more difficult 
 
   
12. Women with diabetes do not have an increased risk of 
having a baby with birth defects 
 
13. Women with diabetes have an increased risk of miscarriage  
   
    
14.  All over the counter drugs are safe and can be taken by 
women with diabetes who are planning a pregnancy 
 
   
15.  Women who are planning a pregnancy should discuss 
medication use with a healthcare provider 
 
   
16.  Women who are planning a pregnancy should stop smoking 
 
   
17.  Women who are planning a pregnancy should stop drinking 
alcohol 
 
   
18.  Women with diabetes have little control over the health of 
their baby 
 
   
19.  Chances of a woman having a healthy baby increase as she 
improves her health prior to conception 
 
   
20.  Women with diabetes can have a healthy baby    
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Below are some statements that people sometimes make when they talk about their health. 
Please indicate how much you agree or disagree with each statement as it applies to you 
personally by marking your answer. Your answers should be what is true for you and not just 
what you think others want you to say. 
If the statement does not apply to you, mark N/A (Not Applicable) 
STATEMENT Disagree 
strongly 
Disagree Agree Agree 
strongly 
N/A 
1. When all is said and done, I am the 
person who is responsible for taking 
care of my health 
 
     
2. Taking an active role in my health 
care is the most important thing that 
affects my health 
 
     
3. I am confident I can help or reduce 
problems associated with my health 
 
     
4. I know what each of my prescribed 
medicine does 
 
     
5. I am confident that I can tell whether 
I need to go to the doctor or whether 
I can take care of a health problem 
myself 
 
     
6. I am confident that I can tell a doctor 
concerns I have even when he or 
she does not ask 
 
     
7. I am confident that I can follow 
through on medical treatments I may 
need to do at home 
 
     
8. I understand my health problems and 
what causes them 
 
     
9. I know what treatments are available 
for my health problems 
 
     
10. I have been able to maintain (keep 
up with) lifestyle changes, like eating 
right or exercising 
     
Section 3                 About Your Health 
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STATEMENT 
 
Disagree 
strongly 
 
Disagree 
 
Agree 
 
Agree 
strongly 
 
N/A 
11. I know how to prevent problems with 
my health 
 
     
12. I am confident I can figure out 
solutions when new problems arise 
with my health 
 
     
13. I am confident that I can maintain 
lifestyle changes, like eating right 
and exercising, even during times of 
stress 
     
 
 
 
This section is designed to provide some basic information about who took part in the study 
1. What month and year were you born? 
______ / ______ (Please write month/year) 
2. Current marital status 
 Married/ living with partner 
 Divorced/separated 
 Single (never married) 
 Widowed 
 
3. Please look down the list starting from the top and tick the first educational qualification you 
come to that you have (Please tick one box) 
 
 Higher degree (M.Sc or PhD) 
 First degree (B.Sc) 
 Other diplomas  
 A / AS / S levels 
 O level / GCSE/ NVQ 
 Other academic qualifications  
 None of these qualifications 
 
4. What is your ethnic group? 
Choose one section from (a) to (e) then tick the appropriate box to indicate your cultural 
background. 
a) White d) Black or Black British 
 British  Caribbean 
 Irish  African 
 Any other White background  Any other Black background 
 
 
Section 4                                      General Information 
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b) Mixed e) Chinese or other ethnic group 
 White and Black Caribbean  Chinese 
 White and Black African  Any other 
 White and Asian  
 Any other mixed background 
 
c) Asian or Asian British 
 Indian 
 Pakistani 
 Bangladeshi 
 Any other Asian background 
 
5. Is English your first language? 
 Yes 
 No (Please give details   ________________________________ 
 
6. Diabetes type 
Type 1 
Type 2 
 
7. How long is it since you were diagnosed with diabetes? 
  Less than 1 year 
 1-5 years 
 Over 5 years 
 
8. Are you currently employed?    
 Employed full time/part-time    Student 
 Full time home-maker 
 Unemployed 
 
9. Currently considering or planning to have children? 
 In less than 1 year 
 In 1-5 years 
 Over 5 years 
 Do not know/unsure 
 Do not want children 
 My family is complete 
 
10. Have you had any pregnancies that were not carried to term?  
 Yes     
 No  
 
If yes, what was the cause? Please tick all that apply 
 Miscarriage  
 Ectopic pregnancy (pregnancy in tube) 
 Still birth (i.e birth of a baby that is not alive, past 24 weeks’ pregnancy)  
 Fetal/congenital abnormalities 
 
Please continue on to next page 
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Please indicate if you would like to receive a summary of the overall results of 
this survey. Please note that this information will be separated and stored 
separately immediately upon receipt.  
 
 
Yes      No 
 
If yes, please provide your contact details in the space provided 
 
Name …………………………………………………………………………… 
Address ………………………………………………………………………… 
…………………………………………………………………………………… 
Postcode ……………………………………………………………………….. 
Email ……………………………………………………………………………. 
 
Thank you for completing this questionnaire, your help with this study is much 
appreciated. 
 
To return the questionnaire, please hand it back to the researcher who gave it to 
you or post it back in the enclosed Freepost envelope. 
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Questionnaire 2 
 
 
 
Feasibility study of a Smartphone Application (App) 
for the preconception care of women with diabetes 
 
 
PATIENT QUESTIONNAIRE 2 
 
 
 
Instructions: Thank you for agreeing to complete this questionnaire. It is 
designed to assess your knowledge and attitudes to reproductive health 
and preconception care. The questionnaire will take about 15 minutes to 
complete. Please answer every question. 
 
 
 
To return the questionnaire, either hand it to the researcher who gave it to 
you or post it back in the envelope provided.  
 
 
 
Pre-conception Care Mobile App (PCC-MA) 
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This section is designed to explore your knowledge about how diabetes affects 
pregnancy. Please read each statement and mark the option that best describes your 
opinion. Please respond to all of the questions 
 
QUESTION 
 
1. Since using the app, have you discussed how diabetes affects pregnancy with 
your regular diabetes health care provider?  
If Yes, please state who you discussed this with.  
 
2. Since using the app, has a health care professional (doctor, nurse, etc) told you 
that you should get special medical care and advice before you become 
pregnant or plan for a pregnancy?  
     This is called preconception care or pregnancy planning 
     If Yes, please state who told you.  
 
3. Since using the app, has anyone else (partner, friends, family, colleagues, etc) 
told you that you should get preconception care (special medical care and 
advice) before you become pregnant or plan for a pregnancy? 
If Yes, please state who told you.  
 
 
4. Since using the app, has a healthcare professional (doctor, nurse, etc) told you 
that you should use some type of contraception to prevent a pregnancy? 
If Yes, please state who told you.  
 
 
5. Since using the app, has anyone else (partner, friends, family, colleagues, etc) 
told you that you should use some type of contraception to prevent a pregnancy? 
If Yes, please state who told you. 
 
 
 
 
Please continue questions on next page 
 
 
Yes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No 
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Assuming you are sexually 
active or think back to when last 
you were: 
 
Not at all A little Somewhat A moderate 
amount 
A lot 
6. How much do/did you worry 
that you could become 
pregnant? 
 
     
7. How much do/did you worry 
that you could catch a sexually 
transmitted infection (eg 
HIV/AIDS)? 
 
     
8. How much do/did you worry 
that you could develop health 
problems if you become 
pregnant? 
     
 
9. How much do/did you worry 
that if you become pregnant 
your baby could develop 
health problems? 
 
     
When planning a pregnancy: Not at all A little Somewhat A moderate 
amount 
A lot 
10. Would having blood sugar 
levels in the normal range  
(4.0 - 7.5 mmol/l) before 
becoming pregnant improve 
your chances of having a 
healthy baby? 
 
     
11. Would seeking preconception 
care (special medical care and 
advice) improve your chances 
of having a healthy baby? 
 
     
12. How difficult do you think it 
would be to seek 
preconception care (special 
medical care and advice)? 
 
     
13. How difficult do you think it 
would be, to follow the 
preconception care advice 
given by a health professional 
(e.g attending retinal 
screening)? 
     
Please continue questions on next page 
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How confident am I that I 
could: 
Not at all A little Somewhat A moderate 
amount 
A lot 
14. Get preconception care 
(special medical care and 
advice) before I get pregnant. 
     
15. Change my insulin, 
medication and diet to keep 
my blood sugar levels in 
normal range, even if I am 
not yet pregnant, but 
planning a pregnancy. 
     
16. Delay becoming pregnant 
until   my blood sugar levels 
are within the normal range. 
     
 
 
Would you say that getting 
preconception care (special 
medical care and advice): 
 
Not at all A little Somewhat A moderate 
amount 
A lot 
17. Would help you get normal 
blood sugar levels? 
 
     
18. Would help you understand 
how diabetes affects 
pregnancy? 
 
     
19. Would help you decide what 
contraception method to use? 
 
     
20. Would help you prevent an 
unplanned pregnancy? 
     
 
 
 
This section is designed to assess your knowledge of preconception care (special medical care 
and advice about pregnancy planning). Please read each statement and mark the option that 
best describes your opinion. Please respond to all of the statements 
STATEMENT True False Not  sure 
1. Women with diabetes have very limited choices of contraception    
2. Women with diabetes cannot use hormonal contraception     
3. All insulin are suitable for use during pregnancy    
Section 2             Knowledge of preconception care 
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STATEMENT 
 
4. If you have Type 2 diabetes and are planning to become 
pregnant you may need to change from tablets to injections of  
insulin  
  
True False Not sure 
5. Women with diabetes should take folic acid daily when planning 
a pregnancy 
 
6. Women with diabetes should take the same amount of folic acid 
as all other women planning a pregnancy  
 
   
7. Before becoming pregnant, ideally your HbA1c should be below 
6.5% (48.0 mmol/mol) 
 
   
8. Blood glucose levels before pregnancy can affect the health of 
the baby 
   
    
9. High blood glucose levels during pregnancy do not increase the 
risk of problems for the mother 
 
   
10. High blood glucose levels during pregnancy do not increase the 
risk of problems for the baby 
 
   
11. Women with diabetes have an increased risk of having a large 
baby making delivery more difficult 
 
   
12. Women with diabetes do not have an increased risk of having a 
baby with birth defects 
 
13. Women with diabetes have an increased risk of miscarriage  
   
    
14.  All over the counter drugs are safe and can be taken by women 
with diabetes who are planning a pregnancy 
 
   
15.  Women who are planning a pregnancy should discuss 
medication use with a healthcare provider 
 
   
16.  Women who are planning a pregnancy should stop smoking 
 
   
17.  Women who are planning a pregnancy should stop drinking 
alcohol 
 
   
18.  Women with diabetes have little control over the health of their 
baby 
   
19. Chances of a woman having a healthy baby increase as she 
improves her health prior to conception 
   
20.  Women with diabetes can have a healthy baby    
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Below are some statements that people sometimes make when they talk about their health. 
Please indicate how much you agree or disagree with each statement as it applies to you 
personally by marking your answer. Your answers should be what is true for you and not just 
what you think others want you to say. 
If the statement does not apply to you, mark N/A (Not Applicable) 
STATEMENT Disagree 
strongly 
Disagree Agree Agree 
strongly 
N/A 
1. When all is said and done, I am the 
person who is responsible for taking 
care of my health 
     
2. Taking an active role in my health 
care is the most important thing that 
affects my health 
     
3. I am confident I can help or reduce 
problems associated with my health 
     
4. I know what each of my prescribed 
medicine does 
     
5. I am confident that I can tell whether 
I need to go to the doctor or whether 
I can take care of a health problem 
myself 
     
6. I am confident that I can tell a doctor 
concerns I have even when he or 
she does not ask 
     
7. I am confident that I can follow 
through on medical treatments I may 
need to do at home 
     
8. I understand my health problems 
and what causes them 
 
     
9. I know what treatments are available 
for my health problems 
 
     
10. I have been able to maintain (keep 
up with) lifestyle changes, like eating 
right or exercising 
 
     
Section 3                 About Your Health 
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STATEMENT Disagree 
strongly 
Disagree Agree Agree 
strongly 
N/A 
11. I know how to prevent problems with 
my health 
 
     
12. I am confident I can figure out 
solutions when new problems arise 
with my health 
 
     
13. I am confident that I can maintain 
lifestyle changes, like eating right 
and exercising, even during times of 
stress 
     
 
 
On a scale from 0 [not satisfied at all] to 100 [completely satisfied] how satisfied were you with 
the overall app? 
 
 
 
Please list any other suggestions for app improvement  
 
………………………………………………………………………………………………… 
 
………………….……………………………………………………………………………… 
 
………………………………………………………………………………………………… 
 
Do you have any additional comments?  
 
………………………………………………………………………………………………… 
 
………………………………………………………………………………………………… 
 
………………………………………………………………………………………………… 
 
………………………………………………………………………………………………… 
 
Thank you for completing this questionnaire, your help with this study is much 
appreciated. 
 
To return the questionnaire, please post it back in the envelope provided.  
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Appendix 13 - Full list of suggested app content 
Content / 
Frequency 
Illustrative Quote 
 
#1. Antenatal 
Care (HCPs, n=4) 
 Informing them they have to have more regular check-ups, they’ve got to monitor 
their fetal movements and everything … Inform anybody if there is anything that is of 
concern. [HCP2] 
#2. Assessments,  
Vaccinations &  
Check-ups 
(HCPs, n=5) 
 Type 1 diabetes will require ophthalmic assessments, checking kidney function is 
also good practice … because it’s an autoimmune condition, and so you want to 
make sure that they don't have coexisting underactive thyroid. [HCP5] 
 There are certain tests that you should have. A lot of women don’t know what 
checks they should be having and obviously if they are not given that information, 
then that might be quite useful. [P3] 
#3. Contraception 
(HCPs, n=3) 
 You are either on folic acid or you are on the pill, those are your options [HCP7] 
#4. Diabetes and 
pregnancy 
information 
(HCPs, n=3); 
women, n=5) 
 It will be useful if it extended to … when you did become pregnant, that information 
is quite useful as well … and also its important that there is the general information 
and then if you needed more information, links to where you can go … so it would be 
good to have the basics and if you wanted more complicated stuffs, it would link into 
it. [P9] 
 Making sure that … their diabetes is well controlled and that they are healthy going 
into pregnancy and that they try and maintain that during the pregnancy, so that they 
continue to get support from their midwives and the diabetes consultants, so it’s an 
ongoing process. [HCP4] 
#5. Frequently 
asked questions 
(FAQs, women, 
n=2) 
 If you could put frequently asked questions or maybe upload questions and if you 
had any kind of queries you could look them up in the app … that would be quite 
useful. [P6] 
#6. Folic acid 
supplementation 
(HCPs, n=6; 
women, n=3) 
 A lot of ladies with diabetes need to be on 5mg of folic acid, rather than the 400 
microgrammes that is readily available over the counter, so they need to go ask for it 
be specifically prescribed. [HCP6] 
 Letting people know that they need to start folic acid because … people don’t know 
this.” [P5] 
#7. Foods to eat 
or avoid (HCPs, 
n=3; women, n=6) 
 Just the general advice that you will give them about avoiding certain foodstuffs e.g 
non-pasteurised. [HCP4] 
 If there was anything that I should or shouldn’t eat. I think that changes year on year 
doesn’t it? I think when I had one of my children, you could eat eggs and when I had 
the next one, you couldn’t or the other way around. [P3] 
#8. Good blood 
glucose control 
(HCPs, n=8; 
women, n=5) 
 I think the main thing is, with diabetes, your control has got to be absolutely optimal 
in order to achieve a pregnancy in the first place and it’s vital that in order to make 
sure the baby grows within the right parameters that your blood sugar is kept 
absolutely perfect and the HbA1c is good throughout the pregnancy. [HCP2] 
 Just to make women aware of the dangers of not keeping their levels within range. 
[P8] 
#9. 
Hypoglycaemia 
(HCPs, n=3; 
women (n=2) 
 
 I think it’s being clear about the targets pre and post prandially … so it’s having all 
those, the targets there but then it’s the means to get there but not go too low that 
you are risking hypos all the time. [HCP8] 
 Positive support around the benefits of maintaining blood glucose levels … hypo 
risks, obviously I know sort of certainly in the first trimester of pregnancy, you are 
much more likely to have a lot of hypos. [P7] 
#10. Lifestyle 
modification 
(HCPs, n=7) 
 They have to know of lifestyles factors that will improve their health status, so avoid 
things like smoking, excessive alcohol intake, be advised that they take folic acid, 
yes, healthy diet in general, exercise, so it’s more of health promotion together with 
their specific medical needs, yeah. [HCP5] 
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#11. Medication 
compliance 
(HCPs, n=4) 
 Also making sure that they are taking their medications, to help maintain their sugars 
within acceptable range. [HCP5] 
#12. Medication 
review (HCPs, 
n=5) 
 Some of the medication does have to be changed because some of the medications 
they can’t take during pregnancy, so things like, the prime one is the ACE inhibitor 
that they may take for hypertension and renoprotection, and a lot of the hypertension 
medication, you shouldn’t take during pregnancy, and their insulin requirements may 
change. [HCP4] 
#13. Obstetric 
complications 
(HCPs, n=5) 
 To be aware that their medical condition puts them at greater risk with the pregnancy 
and the delivery, there is higher instance of stillbirth, higher instance of having a 
baby- being induced and having a baby early, there is higher instance of overweight 
babies. [HCP2] 
#14. PCC 
education 
(women, n=5) 
 I think just the awareness and education for women … There should be more 
education especially pre-pregnancy and during pregnancy. [P8] 
 I think the educational side because I think it’s not something that I know of 
personally, it’s not something I know much about. [P1] 
#15. Rapport with 
HCPs (clinicians, 
n=8) 
 An app would be brilliant in saying to them or saying in there that actually there is 
always someone like me on the end of the phone. [HCP7] 
 And if they have problem, yes they can have someone to talk to. [HCP3] 
#16. Social 
support (women, 
n=4) 
 Letting them know of other people they could talk to … just trying to get people’s 
own experiences and advice of what they’ve gone through and how they’ve handled 
it, and the emotional support as well … being able to communicate freely and 
confidentially with other people. [P9] 
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Appendix 14 – Additional PADI app snapshots 
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Abstract: Diabetes mellitus (DM), the most common of metabolic disorders, is a global 
public health concern. Numbers are rising with 383 million adults currently diagnosed with 
DM and another 175 million as yet undiagnosed. The rise in cases includes increasing numbers 
of women of a reproductive age whose reproductive health and contraception need careful 
consideration. Unintended pregnancy with poor glycemic control at the time of conception 
increases the chance of adverse pregnancy outcomes including stillbirth, congenital abnormali-
ties, and perinatal mortality. In order to minimize complications, safe and effective contracep-
tion is paramount for all women with DM. This is a challenge as women have been found to be 
reticent to ask for advice, appear to lack understanding of risks, and are less likely to be using 
contraception than women without DM. The World Health Organization has developed Medical 
Eligibility Criteria to guide contraceptive choice. Women with DM without complications can 
choose from the full range of contraceptive methods including hormonal contraception as the 
advantages of use outweigh any risk. Women with diabetic complications may need specialist 
advice to assess the risk–benefit equation, particularly in respect of hormonal contraception. 
Women should be aware that there is no restriction to the use of oral and copper intrauterine 
emergency contraception methods. There is a need for an integrated approach to diabetes and 
reproductive health with improved communication between women with DM and their health 
care providers. Women need to be aware of advice and services and should make their own 
choice of contraception based on their needs and associated risk factors. Practitioners can offer 
nonjudgmental guidance working in partnership with women. This will enable discussion of 
risks and benefits of contraceptive methods and provision of advice dedicated to improving 
overall health and well-being.
Keywords: diabetes mellitus, gestational diabetes, contraception, education, preconception 
counseling
Introduction
Diabetes mellitus (DM), the most common of metabolic disorders,1 is a global public 
health concern. Three hundred and eighty three million adults are currently diagnosed 
with DM and another 175 million are estimated to be living with the condition but are 
as yet undiagnosed.2 By 2035, numbers are set to increase by 55% with 592 million 
people becoming affected worldwide.2 The rise in cases includes increasing numbers 
of women of reproductive age whose reproductive health and contraceptive needs must 
be carefully considered as DM has serious implications for pregnancy. It is the most 
common medical condition complicating pregnancy and affects up to 10% of women 
of a reproductive age in developed countries.3
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There are three main types of DM (Table 1). Type 1 DM 
is an autoimmune, chronic condition occurring in both adults 
and children, often before 40 years of age, and accounting 
for ∼10% of cases in adults and 98% of cases in children.4 
In type 1 DM, the primary beta cells of the pancreas do not 
produce insulin resulting in hyperglycemia. The propensity 
to develop autoimmune diseases, such as diabetes, may be 
familial. Treatment involves careful glucose monitoring and 
administration of insulin.
Type 2 DM, accounting for ∼90% of cases in adults and 
2% of cases in children,4 is sometimes known as mature 
onset diabetes. This occurs when the amount of insulin 
produced by the pancreatic beta cells is insufficient or if the 
body develops a resistance to the insulin produced. As this 
condition is often associated with obesity, treatment involves 
diet and exercise, oral medication, and occasionally insulin. 
Recently, more cases of type 2 DM have been diagnosed in 
younger age groups due to increasing obesity.1
Gestational DM (GDM) develops during pregnancy in 
women without previously diagnosed DM. It is caused by 
increased blood glucose levels in pregnancy and is treated 
with diet or insulin. GDM usually disappears after preg-
nancy but women are at risk of developing type 2 DM in 
the future.
This paper will review some of the challenges for women 
with DM in relation to contraception and will suggest solu-
tions guided by current evidence.
Methods
To update previous searches for new primary research and 
reviews, we searched MEDLINE (754 articles), PsycINFO 
(95 articles), CAB Abstracts (451 articles), CINAHL 
(174 articles), Maternity and Infant Care (49 articles), Web 
of Science (53 articles), British Nursing Index (35 articles), 
Embase (150 articles), and ScienceDirect (76 articles) from 
2008 to 2015. The following terms were used for MEDLINE 
and Maternity and Infant Care; these terms were amended 
for the other databases.
“Contraception”, “birth control”, “intrauterine device/
IUD”, “Levonorgestrel intrauterine system/IUS”, “vagi-
nal ring”, “barrier method”, “hormonal contraception”, 
“contraceptive implant”, “family planning”, “reproductive 
health”, “contraceptive counseling”, “hormonal contracep-
tion”, “sterilization”, “contraceptive injection”, “diabetes”, 
“diabetes mellitus”, “type 1 diabetes”, “type 2 diabetes”, 
“women with diabetes”.
The terms were searched separately and in combination. 
References given in the listed papers were searched for papers 
that did not appear on any of the databases searched. The 
search was limited to studies in the English language. Articles 
that addressed the issues of contraception use in women with 
diabetes were qualified for inclusion in the review. The search 
yielded 1,837 results; most of these were duplicates due to the 
combination of search terms within the different databases. 
The titles and abstracts of 1,837 studies were screened, 
and those articles whose eligibility could not be determined 
from their titles and abstracts alone were read in full. The full 
text of 28 studies was read and 17 studies were found to be 
relevant. The relevant studies included reviews and primary 
quantitative and qualitative research studies.
Facing the challenges
DM can lead to numerous complications with long-term 
health implications on vascular, neurological, renal, and 
ophthalmic functions.5 From a reproductive perspective, poor 
glycemic control at the time of conception and during preg-
nancy increases the chance of adverse pregnancy outcomes 
including stillbirth, congenital abnormalities, and perinatal 
mortality.6 Neonates born to women with DM are “five times 
as likely to be stillborn, three times as likely to die in their first 
months of life, and twice as likely to have a major congenital 
anomaly”.7 The UK Mothers and Babies: Reducing Risk 
through Audits and Confidential Enquiries across the UK 
(MBRRACE) report8 highlights other risks associated with 
diabetes and pregnancy, namely, hypoglycemia and diabetic 
ketoacidosis, and the importance of preconception advice 
and glycemic control with an HbA
1c
 ,10%.
In order to minimize complications, safe and effec-
tive contraception to prevent unintended pregnancy and 
preconception care is paramount for all women with DM.9 
Monitoring and improving maternal health whilst encourag-
ing adequate inter-pregnancy spacing and the use of effective 
contraception forms an integral part of pre-pregnancy care.1 
This is a challenge for health care professionals as only half 
Table 1 Prevalence of diabetes
Prevalence of diabetes (2014)2,4
Adults aged 20–79 
years worldwide
387 million people were affected in 2014. This 
figure was calculated to rise to 592 million by 20352
Undiagnosed  
type 2 diabetes
179 million people were calculated to have 
undiagnosed type 2 Diabetes4
Type 1 and type 2 
diabetes
Type 1 diabetes – 10% of those affected 
Type 2 diabetes – 90% of those affected4
Global estimations The international Diabetes Federation (iDF) 
documents the countries with the highest number 
of diabetic patients: People’s Republic of China, 
india, USA, Russia, Brazil2
Open Access Journal of Contraception 2016:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
13
Contraceptive methods for women with diabetes
of the women with DM plan their pregnancies,7 and they can 
be reticent to ask for advice;10 a US National survey found 
that women with DM were less likely to be using contracep-
tion than women without DM.11
Lack of understanding about the high risks for unplanned 
pregnancy and diabetes and the need for effective contracep-
tion among women with DM are of concern. Cartwright et al12 
published findings of an audit involving 100 women attending 
a diabetic clinic in UK. Findings revealed that two-thirds of 
women were not able to remember discussing pregnancy or 
contraception with a health care provider. The most common 
method of contraception (65%) was the use of condoms and 
some women were unsure about suitable contraception. Those 
having had a pregnancy exhibited no additional knowledge 
regarding risks associated with pregnancy and DM.
Murphy et al13 explored the experiences of women with 
DM who did not attend pre-pregnancy care in the UK. Twenty-
nine pregnant women with type 1 and type 2 DM participated 
in a qualitative study. Data were collected via semi-structured 
interviews and coded as part of thematic analysis. Women 
were found to have difficulty complying with contraceptive 
advice and the majority were not using reliable contraception 
prior to becoming pregnant. With regard to preconception 
health, although some women had experienced previous 
miscarriage, fetal anomaly, and stillbirth, they had however 
been reluctant to attend preconception care due to previous 
negative experiences, becoming pregnant quickly, having 
concerns relating to fertility, or simply due to practicalities 
associated with attending services.
The prevalence of DM is rising rapidly in the Middle 
Eastern countries and the developing world,2 and two stud-
ies from Iran have identified low use of contraception by 
women with DM.14,15 A mixed method cross-sectional study 
involving 200 women identified many pregnancy-related 
abnormalities and a lack of confidence in using contracep-
tives, with many women not using any form of contraception. 
Similar findings and low use of modern contraceptive meth-
ods with women mainly using coital withdrawal method were 
found in Iranian women with type 2 DM, hypertension, or 
obesity.15 Although the results of these studies may not be 
generalizable to different demographic communities, the 
importance of educating women with DM from all groups 
of society needs to be emphasized.
The challenge is to support women with type 1 and type 2 
DM in making a choice of contraception based on their indi-
vidual needs and associated risk factors.16 No restrictions for 
use of any contraceptive apply to women with GDM, but their 
propensity to develop type 2 DM may need consideration. 
Young people with unstable DM are of particular concern as 
they need reliable contraception in order to prevent high-risk 
unintended pregnancies.
Providing contraceptive solutions
Guidance about contraception needs to be offered holistically 
and a trusting relationship between practitioner and client is 
advocated.17 The importance of avoiding unintended pregnancy 
should be an integral part of diabetes education from adoles-
cence onward discussed by diabetes health care providers.9 
Choice of contraception should be made on the preference of 
the woman and individual risk factors identified such as the 
presence of vascular, nephropathy, neuropathy, or retinal dis-
ease.1,18 Choosing a safe and reliable method of contraception 
for a woman with DM needs careful consideration and practi-
tioners need to make reference to the WHO Medical Eligibility 
Criteria for Contraceptive Use18 as outlined in Table 2.
Efficacy must be assured and the chosen method must not 
induce diabetic-related risks such as thromboembolic and cardio-
vascular complications.19 Those with poorly controlled diabetes 
and obese women may need to be targeted as they often fall 
victim to associated risks by not seeking advice and support.1
Combined hormonal contraception
Combined hormonal contraception (CHC) methods include 
the administration of estrogen and progestogen. Examples 
of CHC include combined contraceptive pills, transdermal 
contraceptive patches, combined vaginal rings, and com-
bined injectable contraception. Historically, women with 
diabetes were denied CHC due to concerns about the effect 
on carbohydrate and lipid metabolism.20 Recent data high-
light the safety of CHC not only in relation to women with 
DM without complications, but in not inducing diabetes in 
otherwise healthy individuals.1,20,21
A recent review of evidence1 emphasized that CHC con-
taining less than 35 µg of ethinyl-estradiol did not alter blood 
glucose concentrations and insulin secretion. In relation to 
Table 2 wHO Medical eligibility Criteria for Contraceptive Use 
(2015)
Category  With clinical judgment
1 Use method in any circumstance
2 Generally use method
3 Use of method not usually recommended unless other 
more appropriate methods are not available or not 
acceptable
4 Method not to be used
Note: Reprinted from wHO. WHO Medical Eligibility Criteria for Contraceptive Use; 
Geneva: 2015. Available from: http://www.who.int/reproductivehealth/publications/
family_planning/mec-wheel-5th/en/. Accessed August 19, 2015.18 Copyright © 2015.
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diabetic retinopathy, macular edema, and nephropathy, there 
was no increase in risk or acceleration of disease in women 
taking oral CHC.1,19 The WHO Medical Eligibility Criteria for 
Contraceptive Use18 states (Table 3) that for any diabetic patient 
without cardiovascular or microvascular complications, advan-
tages of using the method generally outweigh the theoretical 
or proven risks, and Category 2 applies for CHC.
The results of a Cochrane review of randomized con-
trolled trials by Visser et al21 was inconclusive in determining 
whether hormonal contraception affected carbohydrate and 
lipid metabolism and long-term complications in women with 
DM. The French Society of Endocrinology expert group,22 
however, undertook a comprehensive review of evidence and 
pathophysiological data, as to the safe contraceptive options 
for diabetic women with risk factors, and concluded that from 
a hormonal perspective extreme caution is recommended as 
risk factors often do not occur in isolation. Gourdy1 in his 
review supports this and suggests that CHC with estrogens 
and progestogen should be avoided whatever their route of 
administration in women with DM who have microvascular 
complications such as severe retinopathy (ischemic or prolif-
erative), active macular edema, or nephropathy with persistent 
proteinuria. In cases of DM complicated by cardiovascular or 
microvascular disease, the risks of prescribing CHC outweigh 
any advantages and a WHO Medical Eligibility Criteria 
(MEC) 3/418 would be awarded.1,22,23 CHC is also unlikely 
to be suitable for women with risk factors such as smoking, 
obesity, or hypertension due to increased risk of venous throm-
boembolism, myocardial infarction, and stroke.17,23
Progestogen oral hormonal 
contraception
The progestogen-only pill (POP) is regarded as a safe option 
for women with DM of any age with or without complications. 
Advantages of using the method generally outweigh the theo-
retical or proven risks (WHO MEC 218). The POP needs to be 
taken within a daily set time period but compliance is likely 
to be good if scheduled with routine insulin or oral hypogly-
cemic medication. Desogestrel has the benefit of inhibiting 
ovulation in 97% of cases and a 12 hours dosing period,24 
and therefore may be a more reliable choice especially for 
younger people with DM.
Long-acting reversible 
contraception
Long-acting reversible contraceptives (LARC) are not 
memory-dependent and have high efficacy, which can 
make them a good choice for women with DM. Methods 
include copper intrauterine device (IUD), intrauterine 
system (IUS), progestogen-only injectable contraceptives, 
progestogen-only subdermal implants, and combined vaginal 
ring. The combined vaginal ring has been included under 
CHC within this review. Despite their safety and effective-
ness, LARCs are generally underutilized with only 15.5% 
of women worldwide using IUDs, and only 3.4% using 
subdermal implants.25 In the UK in 2008–2009, only 12% 
of women aged 16–49 years used LARC compared to 25% 
of women who used COC and 25% whose male partners 
used condoms.26
Goldstuck and Steyn27 published a systematic review 
focusing on the efficacy of the IUD and IUS for women with 
DM. Four hundred and ninety nine articles were screened and 
seven studies met the inclusion criteria. Analysis resulted in 
the reassurance that the copper IUD and IUS were suitable 
for women with type 1 and type 2 DM, although the IUS 
needed further monitoring from a metabolic perspective in 
relation to type 2 DM. WHO MEC18 agrees that the IUD is 
entirely suitable for women with type 1 or type 2 DM with no 
restriction for use, and the advantages of using IUS generally 
outweigh the theoretical or proven risks.
A Cochrane review by Visser et al21 focused on evidences 
from randomized controlled trials relating to hormonal as 
opposed to nonhormonal contraception in diabetic patients. 
Results concluded that there was limited evidence relating to 
the effect of hormonal contraception on diabetes. Although 
the quality of the data was inconclusive, it identified the POP 
and the IUS as not being contraindicated for women with 
DM, whereas the CHC was identified as having a negligible 
effect on glucose stability.
Progestogen-only injectable contraceptives, such as 
medroxyprogesterone acetate and norethindrone enanthate, 
are suitable for women with DM without complications.26 
Concerns regarding possible negative effect on lipid 
Table 3 Contraceptive methods and diabetes
Condition CHC POP DMPA/
NET-EN
IMP Cu 
IUD
IUS
History of gestational 
diabetes
1 1 1 1 1 1
Nonvascular disease 
 i. Noninsulin dependent 
ii. insulin dependent
 
2 
2
 
2 
2
 
2 
2
 
2 
2
 
1 
1
 
2 
2
Neuropathy/retinopathy/
neuropathy
3/4 2 3 2 1 2
Other vascular disease 3/4 2 3 2 1 2
Abbreviations: CHC, combined hormonal contraception; Cu iUD, copper 
intrauterine device; DMPA/NeT-eN, medroxyprogesterone acetate/Norethisterone 
enanthate; iMP, implants; POP, progestogen-only pill; iUS, intrauterine system.
Note: Reprinted from wHO. WHO Medical Eligibility Criteria for Contraceptive Use; 
Geneva: 2015. Available from: http://www.who.int/reproductivehealth/publications/
family_planning/mec-wheel-5th/en/. Accessed August 19, 2015.18 Copyright © 2015.
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metabolism due to hypoestrogenic effects and reduced 
HDL levels mean that for women with complications, risk 
outweighs benefit (MEC 3/4), and POPs would only be 
administered following specialist advice.18 Injectable meth-
ods may also cause a possible delay returning to fertility,26 
which may be unacceptable to women with DM who may 
prefer to have families as soon as possible before complica-
tions of DM arise.
Progestogen-only subdermal implants containing 
etonogestrel are suitable for women with diabetes, as per 
WHO MEC guidelines.18 Implants release a constant dose 
of progestogen reducing the potential for metabolic variation 
and maintaining steady blood-lipid ratios.28
Barrier and natural methods of 
contraception
Barrier methods include a range of contraceptives includ-
ing diaphragms, cervical caps, as well as male and 
female condoms. Some involve using spermicide such as 
nonoxynol-9; however, there appear to be no studies contrain-
dicating the use of spermicide from a diabetic perspective. 
The decision to use a barrier method comes down to personal 
acceptability and efficacy; a male condom, for example, is 
98% effective with proper use, a female condom 95%, and 
a diaphragm with spermicide is 92%–96% effective.29 Using 
barrier methods alone may be too unreliable in preventing 
pregnancy for women with DM, especially if she is trying to 
lose weight or reduce her HbA
1c
 levels.26 Male and female 
condoms may be best used to prevent sexually transmitted 
infections, in conjunction with a more effective contraceptive 
such as hormonal methods or IUD.
Fertility awareness methods, although effective for 
some couples striving for a non-hormonal, more “natural” 
method of contraception, may not be a suitable choice 
for women with DM. In healthy women with a regular 
menstrual cycle and contemporaneous use, natural family 
planning is rated as being 99% effective.29 Women with DM 
have a potentially increased incidence of erratic menstrual 
cycles30 that may affect efficacy and lead to an increased 
failure rate.31
Male and female sterilization
The failure rate for female sterilization is one in 200 and 
one in 2,000 for men following a vasectomy.29 Since both 
procedures involve an operative intervention, however, minor, 
glycemic control needs consideration since it can affect the 
chances of acquiring a postoperative infection.32 In addition, 
the chances of hypoglycaemia and ketoacidosis occurring, 
increase post surgery complications.33 Guidance from a 
diabetic physician regarding the safest operative location 
as well as prophylactic antibiotics are advisable if a couple 
decides that sterilization is the right choice.18
Emergency contraception
Emergency contraception provides all women with addi-
tional choice for prevention of pregnancy. The global rate of 
unplanned pregnancy in 2012 was 53 per 1,000 women aged 
between 15 years and 44 years.34 Emergency contraception 
may be required for multiple reasons including failure to 
use a contraceptive correctly and following sexual abuse 
or rape. Women with DM at risk and not wanting to be 
pregnant are advised to seek emergency contraception at 
the earliest opportunity. From a diabetic perspective, there 
are no contraindications to taking emergency progestogen-
only contraceptive pills within the recommended time frame 
or to the use of the copper-bearing IUD within 5 days of 
unprotected intercourse or when ovulation is known, no 
more than 5 days after ovulation.35 According to the WHO 
MEC guidelines,18 the benefit of using emergency con-
traception outweighs the risk, even where there is severe 
vascular disease.
Key solutions
Our review has highlighted that women with DM need to use 
a reliable method of contraception in order to avoid high-risk 
unintended pregnancies. Women without complications can 
choose from the full range of methods that are available;18 
however, studies have shown that they are less likely to use 
contraception or to seek advice.10,11 To improve pregnancy 
outcomes, women with DM need to be made aware of fertil-
ity and contraception advice services available within both 
acute and primary care.
Taking the earlier discussions into account, it is of con-
cern that not all women with DM appear to understand the 
importance of contraceptive and/or preconception well-being 
from a diabetic perspective. Contraception messages in the 
diabetic female population need to be reinforced.12–15
There is a need for a more integrated approach to diabe-
tes and reproductive health with improved communication 
between women with DM and their health care providers.13 
Diabetes health professionals need to discuss contraception 
with women and referral to a contraceptive specialist for 
advice may be advisable.22,36
UK guidelines16 emphasize that women should choose 
their own contraceptive method, based on guidelines and 
taking account of any risks. In order to make appropriate 
choices, women with DM need to be provided with up-to-
date research-based evidence regarding suitable methods. 
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The effectiveness of barrier methods and oral contraception 
is often compromised due to inconsistent use,26 and LARC 
methods, if suitable, will provide better efficacy.26
Women with DM need to plan any pregnancies and use 
reliable contraception until their diabetic health care provider 
confirms a satisfactory HbA
1c
 result, ideally below 6.5%.9 
Women should be advised to maintain their “fasting blood 
glucose between 3.5 and 5.9 mmol/L and their 1-hour post-
prandial blood glucose below 7.8 mmol/L if this is safely 
achievable”.37 They do, however, need to be aware of the 
potential risk of hypoglycemic episodes and the appropri-
ate treatment required. Women with an HbA
1c
 level above 
86 mmol/mol (10%) are advised not to become pregnant 
due to associated risks.9 Before discontinuing contraception, 
a comprehensive drug assessment should be made to review 
and change medication that is potentially teratogenic, such as 
ACE inhibitors and certain insulins.9,38 In addition, women 
should be offered a renal assessment including measure-
ment of microalbuminuria and retinal assessment to exclude 
progressive disease.9,38
Support and education prior to pregnancy, therefore, 
benefits by ensuring an optimal pre-pregnancy weight, 
stabilizing glycemic control, ensuring safety of medication, 
and providing baseline levels for monitoring retinal and 
renal functions.9,38 Delay of pregnancy to achieve favorable 
glycemic control has been found to prevent poor maternal 
and neonatal outcomes,6 and in most cases, maintaining 
an optimal inter-pregnancy interval reduces adverse birth 
outcomes and decreases maternal morbidity from a physical 
and psychological perspective.39,40
Monitoring and improving health while encouraging 
adequate use of effective contraception forms an integral part 
of contraceptive care. Follow-up for women with DM using 
hormonal contraception is based on routine clinical practice 
of blood pressure and body mass index measurements, but 
baseline lipid profiles may need assessment, especially if 
injectable contraception is used, and blood glucose levels 
as relevant.19
In conclusion, the prevalence of DM in women of repro-
ductive age is rising. Effective contraception is required 
in order to prevent unintended pregnancy as uncontrolled 
glucose levels at conception leads to poor maternal and 
perinatal outcomes. Contraceptive choices need to be made 
by women in conjunction with evidence-based research 
(Table 4). Women with DM without complications have 
multiple choices for contraception and those with complica-
tions may need specialist advice. Communication between 
health professionals and women with DM needs improving in 
relation to promoting reproductive health and contraception. 
A trusting, nonjudgmental approach and a positive relation-
ship are important. This will enable the discussion of risks 
and benefits of contraceptive methods and provision of advice 
dedicated to improving overall health and well-being.
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Abstract
Background: Worldwide, 199.5 million women have diabetes mellitus (DM). Preconception care (PCC) education starting
from adolescence has been recommended as an effective strategy for safeguarding maternal and child health. However, traditional
preconception care advice provided by health care professionals (HCPs) within clinic settings is hindered by inadequate resources,
suboptimal coverage, and busy clinics. Electronic health (eHealth), which is instrumental in solving problems around scarce
health resources, could be of value in overcoming these limitations and be used to improve preconception care and pregnancy
outcomes for women with DM.
Objective: The objectives were to: (1) identify, summarize, and critically appraise the current methods of providing PCC
education; (2) examine the relationship between PCC educational interventions (including use of technology as an intervention
medium) on patient and behavioral outcomes; and (3) highlight limitations of current interventions and make recommendations
for development of eHealth in this field.
Methods: Electronic databases were searched using predefined search terms for PCC education in women with type 1 or 2 DM
for quantitative studies from 2003 until June 2016. Of the 1969 titles identified, 20 full papers were retrieved and 12 papers were
included in this review.
Results: The reviewed studies consistently reported that women receiving educational interventions via health care professionals
and eHealth had significantly improved levels of glycosylated hemoglobin (P<.001) with fewer preterm deliveries (P=.02) and
adverse fetal outcomes (P=.03). Significant improvements in knowledge (P<.001) and attitudes toward seeking PCC (P=.003)
were reported along with reduced barriers (P<.001).
Conclusions: PCC has a positive effect on pregnancy outcomes for women with DM. However, uptake of PCC is low and the
use of eHealth applications for PCC of women with DM is still in its infancy. Initial results are promising; however, future research
incorporating mobile phones and apps is needed. Clearly, there is much to be done if the full potential of eHealth PCC to improve
obstetric outcomes for women with DM is to be realized.
(J Med Internet Res 2016;18(11):e291)   doi:10.2196/jmir.5615
KEYWORDS
preconception care; education; diabetes mellitus; women; review; smartphone; mobile applications; technology
Introduction
Electronic health (eHealth) is transforming health care delivery
[1-9] and increasingly being used to promote healthy behaviors
in people with diabetes mellitus (DM) [10-17]. eHealth is the
cost-effective and secure use of information and communication
technologies (ICT) in support of health and health-related fields,
including health education, knowledge, and research [1]. eHealth
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plays an instrumental role in improving access to health care,
particularly where resources are scarce, and encourages
individuals to actively connect with health care services [6,18].
eHealth technologies include consumer health informatics, the
Internet, and mobile devices [19]. The Internet has emerged as
a popular source of health care information that may replace
face-to-face consultations, strengthen patient participation, and
supplement health care [20].
A recent report on Internet use [21] identified that of the average
5.6 hours spent on the Internet per day, 51% of time was spent
accessing it via mobile devices compared with computers or
laptops (42%) and other connected devices (7%). By providing
individuals with increased access to information anytime and
anywhere, eHealth delivered via mobile phones has significant
potential to transform health care delivery. Evidence suggests
that 90% of the world’s population own a mobile phone, and
over a third of the 7.1 billion mobile devices in use are now
smartphones [22,4,23-26] that run third-party apps. Apps are
programs designed to enhance smartphone functionality and
their increased popularity has resulted in proliferation of
educational, decision support, and patient monitoring apps
[24]. In 2010, over 200 million health apps were downloaded
with estimates suggesting that this figure will have risen to 1.7
billion by 2017 [22].
eHealth technologies can be used to maximize preventative
health care for people with chronic conditions such as DM.
Worldwide 415 million people have DM, of which 199.5 million
are women [27]. DM is now of increasing concern in the field
of women’s health and the most common preexisting medical
condition complicating pregnancy [28,29]. Poorly-controlled
DM at conception coupled with unplanned pregnancy is a major
contributor to morbidity and mortality including miscarriages,
maternal and perinatal death, and congenital malformations
[29,30-36]. It is therefore recommended that women optimize
their health via preconception care (PCC) [29,36-42]. Women
are also encouraged to achieve a target glycosylated level of
hemoglobin (HbA1c; average blood glucose level over the past
2-3 months) of <7% before and during the first trimester of
pregnancy to reduce obstetric risks [29,36,38-41]. However,
less than 50% of women with DM receive PCC advice
[34,43,44] with fragmented and suboptimal services being
reported [45-47]. As a result, women with DM have insufficient
knowledge of the risks associated with pregnancy to themselves
or their baby [12,48,49]. International clinical guidelines
[29,38-41] recommend PCC education from adolescence for
all women with DM as an effective strategy to facilitate behavior
change and improve pregnancy outcomes. However, barriers
such as inadequate resources, busy clinics, time, and distance
to health facilities [48,50] can inhibit and restrict the extent to
which women engage in PCC. Hence, eHealth could be of value
in overcoming these limitations and extending the reach of
health interventions.
While rapid advances in eHealth technology create a new
opportunity to improve knowledge and health outcomes, to date
there is no extant literature appraising and quantifying the impact
of different methods of PCC provision for women with DM.
Therefore, a systematic literature review was undertaken to (1)
identify, summarize, and critically appraise the current methods
of providing PCC education; (2) examine the relationship
between PCC educational interventions (including use of
technology as an intervention medium) on patient and behavioral
outcomes; and (3) highlight limitations of current practice and
make recommendations of eHealth in this field.
Methods
Search Strategy
A systematic approach was used to search the literature for
relevant articles. The review was limited to human studies
conducted between 2003 and June 2016 to reflect current and
emerging trends in design and conduct of PCC interventions
for women with DM. The reviewed literature drew on a wide
range of evidence. The following databases were searched:
Medline, Embase, Web of Science, Maternity and Infant Care,
Cumulative Index to Nursing and Allied Health, CAB Abstract,
British Nursing Index, PsycINFO, Scopus, Science Direct, and
Google Scholar.
The keywords “preconception care,” “education,” “counseling,”
“diabetes,” “pregnancy outcomes,” “knowledge,” “behavior
change,” “birth defects,” and “women” were used in various
combinations when searching the databases (see Multimedia
Appendix 1 for full text of search string). Additionally, reference
lists of retrieved articles, reviews, and related articles were
hand-searched for potentially relevant papers. Emphasis was
placed on primary research. No language restriction was applied
to the search.
Study Selection
The titles, abstracts, and full papers were screened by CHN and
checked by NC and JS. Articles were excluded if there was an
agreement that the article met 1 or more of the following
exclusion criteria: did not contain any human data; contained
no original data (ie, was a commentary, meeting abstract, or
editorial); population of interest was not women with DM; and
did not assess impact of a PCC educational intervention. The
search protocol included identification of potentially relevant
articles, screening of identified papers based on their titles and
abstracts, examination of full text of potentially relevant studies
for eligibility, and application of the inclusion criteria to select
the studies included in the review. For the study to be included
in the literature review, the following inclusion criteria were
applied.
• Women of reproductive age with preexisting type 1 diabetes
mellitus (T1DM) or type 2 diabetes mellitus (T2DM) not
pregnant at the time of the PCC intervention.
• PCC interventions including but not limited to education,
advice, or counseling on use of folic acid, insulin therapy,
glycemic control, screening for diabetes complications,
contraception use, and blood glucose monitoring.
• Comparator was standard care in all studies except the one
[12] in which the intervention group also served as the
control.
• Studies reporting maternal and neonatal outcomes and
knowledge and attitudes toward PCC.
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• Quantitative studies, that is randomized controlled trials,
before and after studies, and observational (cohort,
cross-sectional and case control) studies.
Data Abstraction
The data was subsequently extracted by CHN and checked by
NC and JS for accuracy and completeness. The reviewers were
not masked to the articles’ authors, journals, or institutions.
Quality Assessment
Assessment was initially performed by CHN and results agreed
by NC and JS. The quality of reviewed studies was assessed
using a modified version of the EPHPP quality assessment tool
for quantitative studies which was developed by the Effective
Public Health Practice Project (EPHPP), Canada. It contains
summary judgments and an accompanying dictionary that
increases standardization of the study quality assessment [51,52].
This tool includes items on selection bias, study design,
confounders, blinding, data collection, and withdrawals and
dropouts. Each of these 6 aspects of quality received a score
out of 3 to make up a total score of 18. The studies were given
a rating out of 18, and the quality of the evidence was graded
as strong (rating> 14), moderate (rating 7-13), or weak (rating
1-6).
Synthesis
Meta-analysis of the data was not appropriate because there was
great diversity in the interventions, research designs
(methodology), and outcome measures. In this review, the main
focus was on extracting data on descriptions of interventions
(study design, samples, and intervention overviews), outcome
measures, and examinations of the effectiveness of interventions.
The results are presented as a narrative summary.
Results
Search Results
A total of 1969 articles were identified from the literature search
and the titles and abstracts of 864 articles were screened for
eligibility. After excluding 844 articles that did not meet the
eligibility criteria, 20 full text articles were selected for detailed
review, of which 12 met the eligibility criteria (Figure 1).
The 12 included studies evaluated 2 categories of PCC health
education delivery in use for women with DM: health education
provided by health care professionals (HCPs; n=8) and health
education using eHealth technologies (CD-ROMs and DVDs;
n=4). Of the included studies, 8 were found to investigate the
effect of PCC education on maternal and child health outcomes,
whereas 4 focused on use of eHealth technology for PCC of
women with DM. Of the 12 included articles, 1 study discussed
their findings in 2 articles [53,54]. Hence, 12 articles of 11
studies were included.
Figure 1. Preferred reporting items for systematic reviews and meta-analyses (PRISMA) flowchart of included studies. PCC: preconception care.
Study Characteristics
The summary characteristics of reviewed articles are given in
Multimedia Appendix 2. All studies provided face-to-face or
eHealth PCC education to women with DM. Women were
recruited from specialist and primary care diabetes clinics. Of
the included studies, 8 focused on the effect of a PCC
intervention on maternal and child outcomes [43,44,53-58] and
4 on improving knowledge and changing attitudes toward PCC
[10,11,12,13]. Timing and duration of intervention for some
studies was not specified [12,44,55-58]. Follow-up periods
ranged from 3 months to 12 years.
All studies were carried out in clinical settings, except one [12],
undertaken in women’s homes. Most of the studies were
observational [43,44,53-58], with data collected from medical,
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pregnancy and birth records, or databases. Of the included
studies, 4 [10-13] used previously validated and reliable
questionnaires. Although data collection methods were different
for the face-to-face and eHealth PCC studies, there was
consistency in findings and methods of data collection used
within each category. Sample sizes ranged from n=58 to n=680.
All studies, except one [12], had a separate intervention and
control group. All studies were carried out in developed country
settings (United States, n=3; United Kingdom, n=5; France,
n=1; Spain, n=1; Finland, n=1; and Republic of Ireland, n=1),
highlighting increased prioritization of PCC for women with
DM in these countries. Studies which adopted eHealth for PCC
of women with DM were based in either United States (n=3)
[10,11,13] or United Kingdom (n=1) [12], perhaps reflecting
the increasing use of ICT to support PCC service provision in
these countries.
Study Quality
Studies varied with respect to their quality (See Multimedia
Appendix 2). Of the included studies, 3 had a rating above 14
[11,13,43] and 9 were rated between 7-13 [10,12,44,53-58]. All
studies used appropriate study designs, namely, randomized
controlled trials, before and after, and cohort studies but lacked
details on blinding and allocation concealment. Although small
sample sizes [10,11,12], selection bias [10,12,58], and
confounding [12,56,57] were underlying issues of weakness
within most studies, these were acknowledged and addressed
by the authors.
Findings
Of the included articles, 12 of them reporting on 11 studies
(n=12) were grouped into 2 main categories based on their mode
of PCC health education delivery: (1) evaluation of PCC
education provided by HCPs (n=8) and (2) evaluation of PCC
education provided via eHealth technology (n=4).
Evaluation of PCC Education Provided by HCPs
PCC education traditionally provided in clinical settings by
health care professionals is associated with positive maternal
and child health outcomes. An overview of the interventions,
outcome measures, and their effects are described in the
following points.
Maternal Health Outcomes
Of the included studies, 2 [56,57] explored the effect of a PCC
educational intervention on levels of glycosylated hemoglobin
(HbA1c). Boulot et al [56] assigned women with T1DM and
T2DM to either an intervention group (n=175) where they
received the PCC education before conception, or to a control
group (n=360) receiving standard care. Results showed that the
educational intervention was effective in enabling more women
in the intervention group attain HbA1c <8%. Intervention
participants had improved HbA1c in the first trimester with a
significantly lower number of women with T1DM (4.3% vs
55%) and T2DM (2.9% vs 27.9%) having HbA1c >8%
compared with those in the control group (P<.001). A similar
study by Galindo et al [57] in Spain included women with both
T1DM and T2DM. The intervention group (n=15) received
preconception counseling, whereas the control group (n=112)
only presented to medical care when pregnant. Although Galindo
et al [57] did not set out to measure the effect of a PCC
intervention on maternal HbA1c, the intervention group had
significantly improved HbA1c (<7%) compared with those in
the control group (P=.02).
Another UK study [53,54] considered the effect of PCC
education on maternal HbA1c, spontaneous abortion, preterm
deliveries, and gestational age at presentation for prenatal care.
Statistically significant differences were found in intervention
participants who had improved and sustained HbA1c (6.5% vs
7.6%; P<.001) throughout pregnancy, presented earlier for
prenatal care (6.6 vs 8.3 weeks; P<.001), less spontaneous
abortions (P=.06), and preterm deliveries (P=.02).
Furthermore, 2 other studies [43,44] reported the effects of PCC
education on HbA1c, gestational age at presentation for prenatal
care, and folic acid intake in women with T1DM and T2DM.
During the 3-year study period by Murphy et al [43], women
who received a structured education program were assigned to
the intervention group (n=181) and those who did not, to a
control group (n=499). Women in the intervention group with
increased intake of 5mg folic acid before conception (P<.001)
had significantly improved HbA1c values (6.9% vs 7.6%;
P<.001), and an earlier date of presentation for prenatal care
compared with those in the control group (6.7 vs 7.7 weeks;
P<.001). The role of PCC education in promoting healthy
preconception behaviors and pregnancy planning was also
explored by Tripathi et al [44] who assigned women receiving
PCC counseling to the intervention group (n=240) and those
who did not, to the control group (n=297). Results showed that
participants receiving the intervention had significantly
improved and sustained levels of HbA1c (≤7% vs >7%) 3
months before conception (P=.002) and during the first trimester
of pregnancy (P<.001), higher rates of folic acid intake 3 months
before pregnancy (P<.001), and presented earlier for prenatal
care (≤8 weeks vs >8 weeks; P=.001).
Additionally, 2 recent studies [55,58] reinforced the benefits of
PCC education on HbA1c and pregnancy outcomes. Neff et al
[55] assigned women with T1DM to the intervention group
where they received health education (n=70) while those in the
control group received standard care (n=394). Intervention
participants had significant improvements to HbA1c <7% (6.9%
vs 7.8%; P<.001) and earlier prenatal care presentation (6±2
weeks vs 8±6 weeks; P<.001) compared with those who received
standard care. However, the effect on rates of spontaneous
abortion or preterm delivery was not found to be statistically
significant (P=.12, P=.46 respectively). Kekalainen et al [58]
also found statistically significant differences in the intervention
group who had improved and sustained HbA1c (7.1% vs 9.1%;
P<.001) and reduced adverse pregnancy outcomes (P=.06).
Child Health Outcomes
Boulot et al [56] demonstrated that women with T1DM who
received PCC education had significantly lower rates of perinatal
mortality and congenital malformation (P<.005) compared to
those in the control group. Furthermore, women with DM whose
HbA1c was > 8% in the first trimester had double the risk of
developing adverse fetal outcomes such as perinatal mortality
(P<.005), congenital malformation (P<.01), and preterm delivery
(P<.005).
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Additionally, 5 further studies [43,53,54,57,58] reported similar
findings. Temple et al [53,54] found that women who received
a PCC educational intervention had significantly reduced risk
of adverse outcomes (including malformations, stillbirths, and
neonatal death) compared with those receiving standard care
(P=.03). Similarly, Murphy et al [43] and Kekalainen et al [58]
found that the intervention group participants experienced a
significant reduction in congenital malformations compared
with those in the control group (P=.009; P=.001). Galindo et al
[57] also found a positive relationship between increase in
maternal HbA1c levels (>7%) and the occurrence of fetal
malformations. Additionally, Tripathi et al [44] and Neff et al
[55] found a significant association between lack of
preconception care education and increased risk of adverse fetal
outcomes (P=.03).
Most studies (n=7) reported low levels of PCC uptake, range
12% [57] to 48.5% [56], amongst women with DM.
Evaluation of PCC Education Provided via eHealth
Technology
Low levels of PCC uptake among women with DM have elicited
interest in use of multimedia technologies such as CD-ROMs
and DVDs as an intervention tool for PCC education.
Four studies [10-13] investigated the effect of eHealth
technology on knowledge and PCC behaviors.
Charron-Prochownik et al [10] developed and used an interactive
computer program (CD-ROM) to promote PCC knowledge.
Adolescent girls with T1DM were randomized to receive the
3-month CD-ROM intervention (n=37) or standard care (n=16).
Significant improvement in knowledge (P<.05), perceived
benefits (P=.04), and reduced barriers to seeking PCC (P=.01)
were reported in intervention participants. An RCT by Fischl
et al [11], which lasted 9 months, similarly used an interactive
CD-ROM to deliver PCC health education. Adolescent girls
with T1DM were randomized to either the intervention group
(n=43) where they watched 2 CD-ROMs, read a book, and met
with a nurse for counseling or standard care (n=45). Compared
with those receiving standard care, intervention participants had
significantly improved knowledge and perceived benefits of
PCC (P<.001), reduced barriers to seeking PCC (P<.001), and
increased intention to initiate PCC discussion with health care
professionals (P<.001). The effect on intention to use
contraception was not significant (P=.10).
A UK study by Holmes et al [12] aimed to explore whether an
educational DVD would improve PCC knowledge and behavior.
Women with T1DM and T2DM (n=97) who viewed the contents
of the DVD individually in their homes showed a significant
increase in perceived benefits and attitudes to contraceptive use
(P=.001), receiving PCC (P=.003), knowledge of pregnancy
planning (P<.001), and pregnancy-related risks (P<.001).
Finally, Charron-Prochownik et al [13] assessed the long-term
effect (12 months) of an educational DVD on knowledge and
attitudes to PCC in adolescent girls with T1DM and T2DM.
Participants who were randomized to receive the intervention
(n=51) demonstrated a significant increase in PCC knowledge
(P=.001), and intention to discuss PCC and contraception with
health care professionals (P=.03, P=.003), compared with those
in the control group who received standard care (n=58).
Discussion
Principal Findings
The reviewed evidence suggests that educationally-based PCC
(delivered by health care professionals) is effective in improving
maternal and child health. The evidence is consistent across
studies, but with few robust controlled studies of PCC
educational interventions for women with DM. Studies are
generally of moderate quality, with only one assessed as high
quality [43]. The inadequacy in traditional PCC education in
meeting the needs of women with DM has been widely
recognized [43,44,48,56-58], but alternative means of providing
PCC remains underresearched. This review highlights the
potential capacity of eHealth technologies to help improve
coverage and access to PCC.
PCC should ideally be provided to all women with DM [29,34].
However, evidence presented in this review confirms that PCC
uptake is still <50% [44,55-57], in line with the low PCC uptake
reported in the 2007 confidential enquiry into maternal and child
health (CEMACH) in women with DM [34]. Women who do
not receive PCC also have poor levels of glycemic control,
higher rates of unplanned pregnancy, and adverse pregnancy
outcomes [29,30,43,53,54,56-58]. It is therefore worrying that
PCC service provision and uptake has not increased at the same
rate as the prevalence of DM in women of reproductive age.
PCC provided predominantly in a health care setting by a HCP
also excludes the 55% (3.1 billion) of the developing world’s
population in rural areas who do not have adequate access to
health care [59]. PCC provision is therefore almost nonexistent
for many women in the developing world who have increased
risk of adverse maternal and fetal outcomes [37]. This underlines
the shortcoming of traditional PCC practice. We have reached
the age of personalized medicine [23]. The growing popularity
and effectiveness of eHealth technologies for health promotion
in several areas including obesity and smoking cessation
[4,15-17,60-62], makes its use in PCC of women with DM
timely, warranting further exploration.
eHealth technologies hold great promise in terms of helping to
deliver preconception health education that increases knowledge
and supports behavior change [10-13]. This review highlights
the potential of these technologies to empower women with
DM to make informed reproductive health decisions. The
ultimate goal is to prevent unplanned pregnancies and reduce
adverse maternal and fetal outcomes. Behavioral interventions
must reach the target population to achieve success [62]; in this
lies a weakness of the reviewed eHealth intervention studies
which have used technology that is now dated and offers limited
scope to the many women who do not have access to computers
and/or DVD players [10-13].
Challenges of eHealth PCC
This review highlights that adoption of eHealth in this field is
slow and use of ICT for PCC is still very limited. For example,
between 2008 and 2016, only 4 studies examined the effect of
eHealth PCC using multimedia technology—CD-ROMs and
DVDs, with none examining the use of the Internet or mobile
phones. Computers or ICT has been used by some reviewed
studies to provide health education within clinic settings
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[10,11,13]. However, people are now proactive in seeking health
information and increasingly prefer to do things in the privacy
of their homes and in their own time. Developments in
technology mean that increasingly health programs can be
delivered to people outside the traditional clinic setting,
improving access for hard to reach populations across the world,
as reflected in the recently agreed goals of the United Nations
sustainable development plan [63].
The majority of studies (n=11) involved women traveling to
clinics to physically receive the PCC educational intervention.
However, constraints such as inadequate resources, time, and
distance to health facilities have been shown to inhibit women’s
ability to adequately access such PCC interventions [48,50],
and for many women around the world, this has negative
implications for PCC uptake. Furthermore, no studies were
carried out in developing countries; reflecting the existent
inequality in PCC service provision. Mobile technologies can
be used to extend the reach of PCC interventions given that
90% of the world’s population now have access to a mobile
phone [25]. Moreover, evidence of a reverse digital divide
confirms that low income populations and those living in
resource-poor settings are among the fastest growing users of
mobile phones [64,65].
Bull [64] argues that if more people can be reached with health
promotion interventions then even “modest” effects will translate
into greater impact on morbidity and mortality. Contemporary
eHealth technologies have the capacity to take an intervention
that works on a small scale to a larger audience. From this
review, which demonstrates the efficacy of PCC health
education, it is apparent that the challenge lies in translating
“what works” to a wider audience. We have a unique
opportunity to overcome this challenge in eHealth PCC using
mobile phones.
Way Forward for eHealth PCC
Mobile phones represent an underutilized resource that could
be developed to support eHealth interventions for women with
DM. Mobile phone ownership in developed countries has
outstripped the population, with an average phone ownership
of 1.16 mobile phones per person [25]. In developing countries,
mobile communications technology is the fastest growing sector
of the telecommunications industry with over a billion mobile
phones [65,66]. Smartphones in particular, have the capacity
of both computers and the Internet [24]. Their significant
advantage over desktop computers, laptops, and DVD players
make them a valuable tool for giving more women access to
PCC [46]. They offer the opportunity to penetrate a larger
population, are easily accessible, technologically advanced,
utilize existing features (eg, geo-positioning technology; Internet
access with photos, videos, and voice-recording capabilities),
are mobile and convenient to use [4,22,23,67].
Many of the advanced functionalities of smartphones are aided
by software applications or apps which hold great potential in
helping to deliver cost-effective health interventions
[4,16,17,22,23,67]. 90% of the time spent on mobile phones is
spent on apps and in terms of usability, they are preferred over
Web or computer-based applications [14,68]. Incorporating
health education interventions into apps could help reduce
barriers to adoption and facilitate increased acceptance of the
intervention [4,24,69]. The innovative integration of
smartphones or apps and PCC health education could help
reduce the widespread burden caused by unplanned pregnancies
in women with DM.
This is the first review to incorporate the use of eHealth
technologies for PCC of women with DM into a discussion of
PCC interventions. It highlights the benefits and limitations of
each mode of delivery, and recommends use of smartphones
and apps for maximizing the impact of future PCC interventions.
Limitations
A number of limitations should be noted. All reviewed studies
were conducted in developed countries and their generalizability
is limited to the geographical locations and health care settings
in which the studies have been conducted. Various research
methodologies were used in this review, and study quality was
mainly moderate. Methodological weaknesses present in the
study designs (small sample sizes, selection bias, confounding,
and short follow-up periods) require caution in interpreting the
results.
Conclusions
PCC education has a positive effect on pregnancy outcomes for
women with DM. However, uptake of PCC is low and the use
of eHealth apps for PCC of women with DM is still in its
infancy. eHealth apps have the potential to improve access to
PCC around the world, particularly in developing countries
where women have increased risk of adverse maternal and fetal
outcomes. Further research utilizing smartphones and apps is
urgently needed as these technologies are increasingly being
used around the world to provide health care information and
support. Clearly, there is much to be done if full potential of
eHealth PCC to improve obstetric outcomes for women with
DM is to be realized.
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Research Protocol
Exploring the acceptability and feasibility of
a preconception and diabetes information
app for women with pregestational diabetes:
A mixed-methods study protocol
Chidiebere Hope Nwolise, Nicola Carey and Jill Shawe
Abstract
Background: Women with diabetes are at increased risk of adverse maternal and fetal outcomes. Preconception care can
improve pregnancy outcomes and is paramount to minimise complications, but, current provision is sub-optimal. Mobile
technology, particularly smartphones and apps have the potential to improve preconception care provision but research is
lacking in this area. The need to use modern technologies to improve preconception care knowledge and awareness led to
the development of a preconception and diabetes information app in Stage A of this study.
Objective: The aim of this paper, Stage B of the study, is to explore the feasibility and acceptability of the Preconception and
Diabetes Information app to improve preconception care knowledge and attitudes in women with diabetes, and explore the
potential for wider implementation.
Methods: A mixed-methods study design adopting a quasi-experimental approach will assess women’s knowledge and
attitudes related to preconception care, and level of patient activation (knowledge and confidence for self-management of
health) before and after the three-month intervention period. A log of activity will be used to determine engagement with
the app and semi-structured interviews will explore women’s experiences.
Conclusions: This is the first study to explore the acceptability and feasibility of a preconception and diabetes information
app for women with diabetes. The app has potential to change the way preconception care is delivered, improve pregnancy
outcomes and be widely implemented both in developed and developing countries. This is important given the considerable
shortfalls in current preconception care services in the United Kingdom and around the world.
Keywords
Preconception care, education, diabetes mellitus, women, smartphones, mobile applications, mobile health, technology
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Introduction
Diabetes mellitus (DM) has been deemed a global
emergency.1,2 Worldwide, 415 million adults have
DM and by 2040, this is predicted to rise to 642 million
adults.2 There are two main types of DM that aﬀect
women before pregnancy: Type 1 (the pancreas does
not produce any insulin) and Type 2 (the amount of
insulin produced by the pancreas is insuﬃcient or the
body develops a resistance to insulin produced).1,2 DM
is the most common pre-existing medical condition that
can complicate pregnancy creating considerable risks
both for mother and child.35 Poorly controlled DM
together with unplanned pregnancy increases the risk
of maternal and fetal complications. In addition to the
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increased risk of fetal and maternal death, common
complications include miscarriage, birth defects,
preterm labour and birth injury,36 the risks of which
can be minimised through preconception care (PCC).
This is targeted medical care and advice about preg-
nancy planning which can improve pregnancy out-
comes by increasing knowledge and supporting
women to adopt healthy behaviours, e.g. blood glucose
monitoring and folic acid use before pregnancy.3,5,712
Clinical guidelines recommend that PCC is provided to
all women with DM once they reach adoles-
cence.3,6,13,14 However, evidence suggests that PCC is
hindered by poor implementation of clinical guide-
lines,11,15,16 provider- and patient-level barriers,10,12,16
sub-optimal uptake10,17 and inadequate knowledge of
PCC.8,12 These have negative implications for women
with DM around the world, especially those in develop-
ing countries who are at greatest risk of adverse preg-
nancy outcomes.18
There is therefore a need to adopt more innovative
approaches to delivering PCC. Evidence suggests that
while PCC delivered by multimedia, i.e. compact discs
with read-only memory (CD-ROMs) and digital video
discs (DVDs)1922 is feasible and eﬀective in raising
awareness of PCC in women with DM,12 these multi-
media technologies are now outdated. Consequently
they oﬀer limited scope to the many women without
access to computers or DVD players who increasingly
rely on apps delivered by smartphones to access health
information.23 The smartphone is the most popular
mobile device, with over a billion users worldwide.23
It is technologically advanced, easily accessible,
mobile and oﬀers the opportunity to penetrate a
larger population.23,24 In most developed countries,
smartphones are ingrained into daily life while in
developing economies, usage is proliferating rapidly
and is expected to approach levels seen in developed
countries.24 Most smartphone functionalities are aided
by apps (software designed to run on smartphones),
and in a recent qualitative study, women with DM sug-
gested development of a PCC app to help convey PCC
education, increase knowledge of diabetes and preg-
nancy and improve PCC uptake.8
The increasing availability of health information in
easily accessible digital format is rapidly changing the
health education and information paradigm.25 There is
some evidence to suggest that apps can help improve
women’s knowledge of family planning and contracep-
tion26 and to reduce body mass index (BMI).27 They
have also contributed to healthy behavioural changes in
other areas  medication management, diet control,
physical activity, lifestyle improvement, smoking cessa-
tion and diabetes management.28 The acceptance,
coverage and eﬀectiveness of apps in improving
knowledge and enhancing behaviour change, coupled
with the need for increased PCC awareness and
uptake in women with DM, led to the development of
a Preconception and Diabetes Information (PADI) app
in Stage A of this study. The PADI app is designed to
provide ﬂexible and easy access to information about
PCC, blood glucose monitoring and support for
women with DM to optimise their health from precon-
ception to early pregnancy. This paper presents Stage B
of the study, the primary aim of which is to test the
feasibility and acceptability of the PADI app and
explore its potential for wider implementation.
Methods
Study design
A mixed-methods2931 study design incorporating sev-
eral data-collection methods will be used to explore the
feasibility of the PADI app for women with Type 1 DM
(T1DM) and Type 2 DM (T2DM). A longitudinal
quasi-experimental approach with two data collection
points, at the beginning and end of three months of app
usage (Figure 1), will be used to assess women’s know-
ledge and attitudes to PCC. The quasi-experiment will
not involve an external control group, outcomes will be
measured before participants receive the intervention
and again after the intervention, and any changes in
measurement compared within the individuals over a
period of time to determine the impact of the interven-
tion.32,33 A log of activity will be used to determine
engagement with the app, a simple visual scale will
measure satisfaction and semi-structured interviews
will explore women’s experiences of app usage.
Conceptual framework
The Normalisation Process Theory (NPT)34 provides the
theoretical basis for this study. The NPT provides a
framework that is useful for assessing and enhancing
the implementation potential of technological interven-
tions. It addresses the factors for successful implementa-
tion and integration of health interventions into routine
practice, a process known as normalisation. The four
components of the NPT (Table 1) were considered
before and during the development of the app, and
incorporated into the design of this feasibility study.
Ethical review
Favourable ethical opinion was obtained from United
Kingdom National Research Ethics Service (UK
NRES) Committee East Midlands-Derby; REC refer-
ence 15/EM/0358; IRAS project ID: 178530.
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Figure 1. Study flow diagram.
Table 1. Components of the Normalisation Process Theory.
Component Related Questions
1. Coherence or sense-making (the meaning the intervention
makes to participants)
Is the intervention easy to understand and what benefits will it bring and to
whom?
2. Cognitive participation or engagement (commitment made by
participants)
Will the target user groups see it as a good idea and will they be prepared to
invest time, energy and work into it?
3. Collective action (effort invested in the intervention by
participants)
How will the intervention affect the work of user groups, will it promote or
impede their work, and what effect will it have on health services, e.g.
consultation time?
4. Reflexive monitoring (appraisal of the intervention by
participants)
How will users perceive use of the intervention, can users contribute feed-
back about the intervention, and is there room for the intervention to be
improved following user experience?
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Recruitment
Participants will be recruited from two National Health
Service (NHS) hospitals in the South of England and via
social media (i.e. Twitter). Eligible participants who
attend the outpatient clinics at the hospitals will be
approached by a member of the healthcare team when
they come for their clinic appointments and asked if they
are willing to speak to a researcher (CHN) about testing
the PADI app. A Twitter advert will be sent out inviting
eligible participants to contact the study researcher if
they are interested in taking part in the study. If partici-
pants indicate interest, they will be asked to provide the
researcher (CHN) with their contact details. Potentially
eligible participants will receive an introduction to the
study face to face, by mail or telephone. It will be made
clear in all information provided to participants that
they do not have to participate in the study and that
they can withdraw from the study at any time without
prejudicing their care. All potentially eligible participants
will be screened for eligibility against the following inclu-
sion criteria:
. Woman of reproductive age (1845 years) with
T1DM or T2DM.
. Diagnosis of diabetes by a healthcare professional
for more than six months.
. Currently are not pregnant, but are planning a
future pregnancy (in the next ﬁve years) or want
children sometime in the future.
. Own a smartphone (iOS or Android).
Those who meet the inclusion criteria will be provided
with a written participant information sheet (PIS)
informing them about the study. They will be given
the opportunity to ask questions and written consent
to participate in the study will be obtained prior to
study commencement. Only eligible participants who
provide written informed consent will be enrolled in
the study.
Sample
A purposive sample of patients with T1DM and T2DM
will be recruited into the study, from two NHS hos-
pitals in the South of England and via social media.
For feasibility studies, a sample size of 12 is considered
suﬃcient.35 Participants for the intervention phase will
comprise (n¼ 1520) women with DM, with attrition
(or drop-outs) estimated at 20%.36 Figure 1 provides a
ﬂowchart of participants through the study.
Intervention
All eligible participants enrolled in the study will
receive the intervention. It is anticipated that
participants will utilise the PADI app for at least ﬁve
minutes a day, 35 minutes a week and seven hours over
three months to (1) access preconception information
and (2) record their blood glucose level.
PADI app development
A co-design approach was used to develop the PADI
app (Figure 2) to help ensure that it met the needs of
women and that its content was appropriate and
acceptable.3740 The PADI development team included
women with DM (app development working group),
healthcare professionals (expert advisory group) and a
digital agency (Netsells Ltd).
Content development. The PADI app content was based
on a series of focus groups and interviews with the
expert advisory group and app development working
group, the majority of whose members were supportive
of using technology to support PCC. The app content
was also informed by previous research in this area
(Holmes et al.21) and the ﬁndings from a recent sys-
tematic review.10
Expert advisory group
The expert advisory group comprised doctors (general
practitioner, obstetrician, endocrinologist) and nurses
(research and specialist) who suggested including the
following information: importance of planning preg-
nancy and using contraception until stable HbA1c is
achieved, pregnancy-related risks for the woman and
baby, and general health advice for the preconception
period.
App development working group
The app development working group included women
of childbearing age with T1DM and T2DM, age range
2243 years, with and without prior pregnancies. They
expressed desire for easily accessible and comprehen-
sive PCC information that was provided using positive
and supportive language.
Both groups were of the opinion that the informa-
tion should extend beyond preconception to include
diabetes and pregnancy, particularly what to expect
during pregnancy and delivery. They suggested includ-
ing a blood glucose diary, reminder and graph to help
women track and visualise their blood glucose levels in
the run up to pregnancy, and wanted a PCC app that
was attractive, simple and user friendly.
PADI app design and prototype development. The app
design was discussed with the app developer
(Netsells), which then created wireframes, a visual
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guide representing the skeletal framework of the app.
The wireframes were used to detail the app layout,
prioritise components and determine how the app
screens will link together. They took into account the
functionality of the screen, content, layout, app behav-
iour and sequencing of the app’s function. The output
of the wireframe work was then used to create an initial
prototype, a design model of the ﬁnal user interface
(UI), which gave the ﬁrst detailed impression of how
the UI or app screens would look and work. The app
prototype was designed to provide a series of informa-
tional pages and a place to submit and view blood glu-
cose readings by day, week and month. This initial
design output, however, highlighted potential usability
issues regarding the layout, colours and navigation.
The prototype was then revised several times to
ensure that the ﬁnal UI was simple, user friendly and
attractive.
PADI was developed both in Swift (programming
language for iOS) and Java (android development lan-
guage) in order to run both on Apple’s iOS and
Google’s Android platforms. An application program-
ming interface (API) was also developed to allow the
storage and retrieval of individual records of informa-
tion. The API routine connects PADI to Netsells’
remote server and along with the creation of user
accounts, allows authentication with the data in the
database. The API was developed using one of the
most popular programming languages for web applica-
tion backend development, Hypertext Preprocessor
(PHP) framework Laravel.41 The resulting prototype
was tested by Netsells in-house to ensure optimal func-
tionality before being released for further testing. The
ﬁnal prototype was presented to a selection of partici-
pants (healthcare professionals, women with DM,
researchers and members of the public) to test the full
 
Women
PADI app prototype 
Developer HCPs 
Piloting / testing with 
 
 
HCPs Women Public Researchers 
Consensus 
Yes No 
Final development and 
trial of app with  
women  
Figure 2. Diagrammatic representation of PADI app development process.
PADI: Preconception and Diabetes Information; HCPs: healthcare providers.
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app functionality for a period of 14 days and provide
feedback. The piloting comprised two cycles of
feedback and resulted in minor textual changes, modi-
ﬁcation of the blood glucose diary, and rectiﬁcation of
an error with the graphical display of blood glucose
readings. This process was deemed complete when the
modiﬁcations made were tested by participants and
their needs satisﬁed.
Features of the final PADI app. Screenshots of the ﬁnal app
(Figure 3) show the following features: Planning for
pregnancy and blood glucose diary with graphical dis-
play and reminder. The core aspects of these features
and their purpose within the app are shown in Table 2.
Outcome measures
As a feasibility study evaluating the process and/
acceptability of the intervention to users there is no
primary outcome measure.45,46 The study will explore
women’s satisfaction and experiences of using the
PADI app, and provide preliminary outcome estimates,
i.e. knowledge of preconception care, patient activation
measure (PAM) and attitudinal change to PCC.
Evaluative semi-structured interviews and log of activ-
ity after the three months of app use will seek to explore
perceived acceptability, utility and usability of the app.
Data collection
Background information. Information will be collected on
participants’ demographics and baseline characteristics.
A section containing questions aimed at capturing these
background data will be included in the patient
questionnaires (Q1) administered on enrolment.
Patient questionnaires. These will be administered at two
time points, on enrolment (at baseline) and following
Figure 3. Screenshots of the final Preconception and Diabetes Information (PADI) app.
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three months of PADI app usage, and will be informed
by previously validated tools involving PAM,47,48
reproductive health and diabetes instrument
(RHAB)49 and knowledge of PCC.21 These evaluative
questionnaires will be used to compare PAM, know-
ledge and attitudes to PCC before (pre-) and after
(post)-intervention. At the end of the study, partici-
pants will be required to repeat the initial questionnaire
(but without background information) (Q2).
Software log of activity. This will provide information on
the frequency of use of the app for accessing informa-
tional pages and for self-monitoring activities, i.e. log-
ging of blood glucose. This will be used to demonstrate
uptake/utilisation of PADI’s features. PADI has inbuilt
analytics that support collection of these data, which
will be stored on a secure server accessible only to
the app development company who will then ensure
secure transfer to the researcher (CHN) to allow data
analysis.
Patient interviews. Semi-structured face-to-face or tele-
phone interviews will be undertaken at the end of the
study, 4060 minutes with the ﬁrst six to eight partici-
pants30 from the intervention who consent to being
interviewed. Interviews will explore their experience of
using PADI and from this, common themes will be
identiﬁed regarding acceptability, impediments to regu-
lar usage and suggestions for improvement.40 The inter-
view schedule (Appendix) was informed by previously
published protocols for exploring participant experi-
ence of using an app.50
Table 2. Preconception and Diabetes Information (PADI) app feature description.
Features Aspects of the feature Purpose
Planning for pregnancy drafted in
line with National Institute for
Clinical Excellence (NICE) pre-
conception care (PCC)
guidelines3
This feature comprises 13 sections with information
on the various aspects of preparing for pregnancy
and what to expect during pregnancy and deliv-
ery. In addition to textual information, it contains
videos and uniform resource locators (URLs) that
users can click on to view more information on a
specific topic. These URLs take users out of the app
and to reliable external websites such as Diabetes
UK,42 NICE guidelines,3 Family Planning
Association (FPA)43 and womenwithdiabetes.-
net.21,44 PADI app icon will remain at the top of the
page and users can use this to navigate back to
their current session in the app.
Promote knowledge of PCC and pregnancy
planning.
Blood glucose diary (repre-
sented both in text format and
through data visualisation)
Blood glucose (BG) readings throughout the day are
recorded. Frequency depends on number of times
BG reading is taken and as advised by a health-
care professional. Users are able to select the
current time of day from a drop-down menu, e.g.
before breakfast. The time of reading is automat-
ically set and users have the option of being
reminded to take their next reading before saving
the BG reading. The list of entries is then dis-
played starting with the oldest to the most recent.
To record and keep track of BG reading.
Reminders These are set when a new reading is added. A noti-
fication is sent to the user’s phone at their set
reminder time. Users have the option to deactivate
set reminders by toggling the switch.
Reminder to take BG reading and help keep a
regular BG reading schedule.
Progress The inputted BG information is further broken
down into daily averages and represented in a
graph. BG readings outside recommended PCC
target range (49 mmol/l) trigger a pop-up fea-
ture and highlights the reading. Clicking on the
pop-up redirects users to the BG management
page within the app. Users can choose how they
want their progress displayed, e.g. today, past
seven days or 30 days.
To display the user’s progress and help monitor
trends.
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Data management and analysis
Microsoft Excel will be used for the organisation, col-
lation and recording of the quantitative data from each
participant. Processing of the questionnaire will be con-
sistent and a clear record of the returned questionnaires
will be kept. Each participant will be assigned a number
and the same number will be used throughout the study
to allow the data on demographic information, know-
ledge and attitudes to PCC and PAM to be correlated.
A coding manual will be developed for each question-
naire and used during the data entry process. The
responses will be assigned numerical codes and rec-
orded in the codebook. The data will then be entered
into Excel spreadsheets and later imported into SPSS
version 22 for analysis. Descriptive statistics will pro-
vide preliminary estimates of key parameters, as recom-
mended for feasibility studies.45,46
Content data from the open questions will be coded
by assigning data to categories and then labelling the
categories. Qualitative data (interviews) will be analysed
using inductive thematic analysis.51 Interviews will be
recorded, transcribed verbatim, and anonymised. QSR
Nvivo 1052 will be used as a data handling management
system for the data collected from the interviews. Nvivo
will be used mainly for the advantages it oﬀers in allow-
ing large volumes of data to be handled with speed,
preparing conceptual maps of coded data, facilitating
exploration of relationships between codes, and aiding
interpretation and theorising.33,51,52
Discussion
This paper presents a mixed-methods protocol that is
designed to examine the acceptability and feasibility of
the PADI app intervention. PADI incorporates both
PCC information and self-monitoring of blood glucose
(SMBG) functions. PCC education has been widely
recommended as an eﬀective strategy to promote
PCC knowledge and encourage behaviour
change.3,6,13,14,18,53 SMBG is a vital part of managing
glycaemic control and optimised glycaemic control is a
core component of PCC. Mobile phones have been
shown to improve glycaemic control in patients with
DM5456 and the eﬀectiveness of technological innov-
ations in improving PCC knowledge and attitude have
been demonstrated.1922 PADI is designed to improve
awareness of PCC and to support women with T1DM
and T2DM adopt behaviours that support a healthy
pregnancy and baby such as regular blood glucose
monitoring, folic acid intake, lifestyle modiﬁcation
and use of contraception until optimum blood glucose
levels are achieved.
Health interventions utilising mobile technologies
oﬀer many advantages including the potential for
wide-scale implementation and dissemination.40 They
are also able to penetrate disadvantaged or resource-
poor settings including developing countries, thereby
expanding the reach of health information to under-
served communities in line with the United Nations
sustainable development goals.57,58 Successful imple-
mentation of a technological innovation, however,
requires careful consideration of several factors.
For example, an intervention that is perceived as pro-
viding limited beneﬁts, diﬃcult to understand or ﬁt into
normal everyday practice would not appeal to health-
care professionals or policy makers.34,40 In order to
maximise beneﬁt, it is important for technological
interventions to be accepted by the target population
and normalised into practice.34,40 While a healthcare
professional may recommend a smartphone app, it is
ultimately up to those concerned to determine if the
app is beneﬁcial and worth an investment of their
time.59 Therefore, to increase PADI’s potential for
wide-scale adoption and implementation, women with
DM and their healthcare providers were involved in its
design and development, and the NPT framework34
was used to optimise the app development and inform
the study design.
This is the ﬁrst study to test the feasibility of a pre-
conception app speciﬁcally developed for women with
DM. Findings of the study will enhance understanding
of the role of apps in PCC of women with DM and
provide insight into their use for promoting PCC
awareness and behaviour change. It is anticipated
that PADI will provide an innovative way of providing
more women with DM with information on PCC. This
is important given the barriers associated with trad-
itional PCC practice8,12,15,17 and the limited technology
that is available to support PCC services.10 Given these
limitations, the PADI app has been designed both for
Apple iOS and Google Android, the two leading mobile
operating systems.60 If this study is successful, it will
provide the platform for a larger study to evaluate a
potentially feasible and easy-to-implement intervention
that can be integrated into healthcare and provide evi-
dence of its eﬀect on patient outcomes. However, for
this study participants will be required to download the
app onto their own phones and need to own a smart-
phone to be eligible to participate. Repeated examin-
ation of preliminary outcomes within three months may
introduce some information bias into the study. Also,
being a feasibility study, the sample size for the quan-
titative phase is quite small, limiting the generalisability
of the study ﬁndings to other contexts and populations.
Conclusion
The prevalence of DM in women of reproductive age is
growing, and improved PCC awareness is urgently
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required to reduce poor maternal and perinatal out-
comes experienced by women with DM, particularly
in low and middle income countries. Mobile technol-
ogy, mainly smartphones and apps, have the potential
to improve PCC and obstetric outcomes for women
with DM around the world, but, research is lacking
in this area. This is the ﬁrst study to explore the accept-
ability and feasibility of a preconception app for
women with DM, and the ﬁndings will inform the
development of a larger study. PADI could be easily
integrated into healthcare, scaled up and adapted into a
sustainable PCC intervention programme which could
be widely implemented, particularly in developing
countries where women have the highest risk of adverse
pregnancy outcomes. This is important given the con-
siderable shortfalls in current PCC provision around
the world and in the United Kingdom.
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Appendix
Semi-structured interview guide
1. Experience of using the smartphone App
How did you get on with using the App over the
last 3 months?
How did you ﬁnd navigating the pages and ﬁnding
information?
Did you have any problems using the app?
If you had problems, what were they?
Was the app easy to use?
2. Use of App for preconception care (PCC)
How did you ﬁnd using an App for PCC?
Did you use the app regularly e.g. 5 minutes/day?
 If no, why not.
How did you ﬁnd the information on preconcep-
tion care (PCC)?
Did you think the links to websites and videos were
helpful?
Did you use any other PCC services whilst in the
study (e.g. GP, other website)?
Is there any other information that you would have
liked included in the App?
3. Acceptability of features provided
What do you think of the blood glucose diary?
How did you ﬁnd inputting blood glucose data?
Did you use the reminders to record your blood
glucose reading?
 If no, why not.
 If yes, were the reminders helpful?
Did you use the progress feature to monitor
trends?
 If no, why not.
 If yes, did it help you in your diabetes
management?
What features did you ﬁnd useful?
Why did you ﬁnd these features useful?
4. Satisfaction with the app
What do you think about the overall content and
functionality of the App?
What did you like about having the PCC informa-
tion delivered via an app?
What did you dislike about having the PCC infor-
mation delivered via an app?
5. Feedback
What improvements can be made to the App?
Do you think any features could be removed or
added to the app?
Is there anything you would do diﬀerently follow-
ing your participation in the study?
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